DDI-DrugBank.d219.s7.p5	cyclosporine digoxin methotrexate lodine like other drug through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine drug methotrexate and increased toxicity 	DDI-mechanism
DDI-DrugBank.d284.s12.p1	drug beta blockers and drug may interfere with the effect of each other when administered concurrently 	DDI-effect
DDI-DrugBank.d44.s2.p5	acellular live and drug should not be administered during drug treatment 	DDI-advise
DDI-DrugBank.d15.s4.p0	in an in vitro study in human liver microsomes inhibition of cyp a hydroxylation of drug by drug m m m i e mg l was 	DDI-mechanism
DDI-DrugBank.d485.s17.p8	benzodiazepines combination drug may decrease the clearance of some drug alprazolam chlordiazepoxide diazepam and increase the clearance of others lorazepam oxazepam temazepam 	DDI-mechanism
DDI-DrugBank.d548.s9.p0	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain drug tricyclic antidepressants tcas such as nortriptyline amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d78.s3.p12	caffeine theobromine grepafloxacin like other drug may inhibit the metabolism of drug and theobromine 	DDI-mechanism
DDI-MedLine.d3.s8.p0	drug significantly decreased the auc ss of drug by but amprenavir had no effect on rifampin pharmacokinetics 	DDI-mechanism
DDI-DrugBank.d561.s9.p0	if a drug is also used the risk of drug toxicity may be increased 	DDI-effect
DDI-DrugBank.d82.s23.p1	in some patients the administration of drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d401.s0.p4	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other drug tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d495.s2.p11	amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats epidural injection drug may potentiate the cns depressive effect of alcohol barbiturates or other drug 	DDI-effect
DDI-DrugBank.d454.s2.p0	drug may enhance the effects of drug therapy	DDI-effect
DDI-DrugBank.d566.s0.p8	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and drug preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d414.s2.p0	drug may increase the ototoxic potential of other drugs such as drug and some cephalosporin antibiotics 	DDI-effect
DDI-DrugBank.d86.s0.p1	the concurrent use of two or more drugs with anticholinergic activity such as an drug eg chlorpromazine an drug eg trihexyphenidyl and or a tricyclic antidepressant eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d414.s0.p0	drug generally should not be given with drug because they reduce its renal clearance and add a high risk of lithium toxicity 	DDI-mechanism
DDI-DrugBank.d483.s1.p0	if drug and an drug are used concomitantly renal function should be carefully monitored because nephrotoxicity may be potentiated 	DDI-effect
DDI-DrugBank.d485.s17.p13	benzodiazepines combination drug may decrease the clearance of some benzodiazepines alprazolam chlordiazepoxide diazepam and increase the clearance of others lorazepam drug temazepam 	DDI-mechanism
DDI-DrugBank.d165.s24.p0	plasma concentrations of drug are reduced when given concurrently with drug 	DDI-mechanism
DDI-DrugBank.d210.s28.p2	adequate monitoring of theophylline plasma concentrations should be considered when therapy with drug is initiated or changed in patients receiving drug 	DDI-advise
DDI-DrugBank.d314.s19.p4	drugs which inhibit cyp a e g ketoconazole drug such as erythromycin have the potential to result in increased plasma concentrations of drug 	DDI-mechanism
DDI-DrugBank.d509.s22.p0	when drug is withdrawn from the combination therapy drug dose should then be reduced 	DDI-advise
DDI-DrugBank.d548.s9.p9	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g propafenone drug should be approached with caution 	DDI-advise
DDI-DrugBank.d180.s1.p4	the pressor effects of catecholamines such as drug or norepinephrine are enhanced by drug 	DDI-effect
DDI-DrugBank.d76.s31.p0	thus patients receiving oral drug and drug tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly 	DDI-advise
DDI-DrugBank.d198.s11.p0	it is recommended not to exceed a single mg drug dose in a hour period when used in combination with drug 	DDI-advise
DDI-DrugBank.d18.s1.p4	injection drug injection like other injectable benzodiazepines produces depression of the central nervous system when administered with ethyl alcohol phenothiazines barbiturates drug and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d40.s14.p0	drugs that may either increase or decrease plasma drug concentrations include drug vaiproic acid and sodium valproate 	DDI-mechanism
DDI-DrugBank.d448.s3.p8	the antihypertensive effects of methyldopa mecamylamine drug and veratrum alkaloids may be reduced by drug 	DDI-effect
DDI-DrugBank.d111.s0.p14	non selective mao inhibitors including tranylcypromine sulfate phenelzine sulfate and pargyline hc concomitant use of drug and non selective drug may cause hypertension 	DDI-effect
DDI-DrugBank.d469.s7.p8	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the aminoglycosides and polymyxins lithium magnesium salts drug and quinidine 	DDI-effect
DDI-DrugBank.d202.s8.p0	administration of drug during therapy with a drug has been shown to produce a stimulating effect in some depressed patients 	DDI-effect
DDI-DrugBank.d122.s0.p1	nephrotoxicity has been reported following concomitant administration of drug with aminoglycoside antibiotics or potent drug such as furosemide 	DDI-effect
DDI-DrugBank.d40.s10.p6	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol drug estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d123.s15.p3	probenecid drug interferes with renal tubular secretion of drug and produces an increase in the level of ciprofloxacin in serum 	DDI-mechanism
DDI-DrugBank.d556.s0.p0	increased nephrotoxicity has been reported following concomitant administration of drug and drug 	DDI-effect
DDI-DrugBank.d494.s1.p0	using drug with drug heart medicine may cause hypercalcemia too much calcium in the blood which could increase the chance of developing an irregular heartbeat 	DDI-effect
DDI-DrugBank.d40.s19.p10	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral contraceptives rifampin quinidine drug vitamin d 	DDI-effect
DDI-DrugBank.d566.s0.p1	drug resin may delay or reduce the absorption of concomitant oral medication such as drug warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d386.s23.p32	if desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug and benzodiazepines e g chlordiazepoxide or drug are additive 	DDI-effect
DDI-DrugBank.d35.s0.p0	interactions may steroidal between drug supplements and drug and other non occur anti biloba drugs and herbs such as garlic allium sativum and ginkgo ginkgo inflammatory	DDI-int
DDI-DrugBank.d35.s0.p0	interactions may occur between drug supplements and drug and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and ginkgo ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p0	interactions may occur early between drug supplements and drug and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and ginkgo fundamental interaction ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p0	interactions may occur between drug supplements and drug and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and ginkgo ginkgo biloba 	DDI-int
DDI-DrugBank.d397.s13.p0	there have been postmarketing reports of drug interactions when drug is coadministered with drug resulting in qt prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation and torsades de pointes most like due to inhibition of hepatic metabolism of cisapride by erythromycin 	DDI-effect
DDI-DrugBank.d5.s20.p7	levodopa and amantadine limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug concurrently with either drug or amantadine 	DDI-effect
DDI-DrugBank.d365.s1.p8	h and h blockers although not reported drug via its metabolism to histamine might decrease the efficacy of h and drug 	DDI-effect
DDI-DrugBank.d165.s29.p0	edema has been reported in patients concomitantly receiving drug and drug 	DDI-effect
DDI-DrugBank.d521.s1.p8	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan drug magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d382.s14.p1	the iv drug dose should be reduced by approximately and the oral methylprednisolone dose should be reduced by approximately when coadministered with drug to achieve exposures of methylprednisolone similar to those obtained when it is given without aprepitant 	DDI-advise
DDI-DrugBank.d219.s23.p1	short term pharmacokinetic studies have demonstrated that concomitant administration of drug and lodine drug capsules and tablets results in reduced protein binding of warfarin but there was no change in the clearance of free warfarin 	DDI-mechanism
DDI-DrugBank.d526.s17.p4	barbiturates drug or rifampin increased metabolic clearance of drug because of the induction of hepatic enzymes 	DDI-mechanism
DDI-DrugBank.d124.s26.p114	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine drug pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d269.s16.p2	calcium channel blockers isolated cases of conduction disturbance rarely with hemodynamic compromise have been observed when drug is co administered with drug 	DDI-effect
DDI-DrugBank.d78.s10.p0	however because some drug have been reported to enhance the effects of drug or its derivatives prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives 	DDI-effect
DDI-DrugBank.d238.s6.p1	plasma levels of several closely related drug have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g drug fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with cmi as well 	DDI-mechanism
DDI-MedLine.d39.s6.p0	exogenous drug also appeared to influence the percentage of drug induced deaths in a dose dependent manner 	DDI-effect
DDI-DrugBank.d365.s1.p7	h and h blockers although not reported drug via its metabolism to histamine might decrease the efficacy of drug 	DDI-effect
DDI-DrugBank.d238.s3.p0	close supervision and careful adjustment of dosage are required when drug is administered with drug or sympathomimetic drugs 	DDI-advise
DDI-DrugBank.d249.s18.p3	protein binding in vitro drug interferes minimally or not at all with the protein binding of salicylic acid decrease in binding tolbutamide prednisolone decrease in binding or drug 	DDI-mechanism
DDI-DrugBank.d565.s22.p0	the depression of cardiac contractility conductivity and automaticity as well as the vascular dilation associated with drug may be potentiated by drug 	DDI-effect
DDI-DrugBank.d485.s17.p10	benzodiazepines combination drug may decrease the clearance of some benzodiazepines alprazolam drug diazepam and increase the clearance of others lorazepam oxazepam temazepam 	DDI-mechanism
DDI-DrugBank.d458.s3.p3	the following drug interactions have been identified involving nizoral tablets and other drugs metabolized by the cytochrome p a enzyme system drug tablets inhibit the metabolism of drug resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite 	DDI-mechanism
DDI-DrugBank.d137.s11.p0	drug could exaggerate the depression of av nodal conduction observed with drug 	DDI-effect
DDI-DrugBank.d131.s10.p10	data from in vitro studies of benzodiazepines other than drug suggest a drug interaction for the following cyclosporine amiodarone nicardipine and drug	DDI-int
DDI-DrugBank.d131.s10.p10	data from in benzodiazepines studies of vitro and than drug suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone nicardipine other drug	DDI-int
DDI-DrugBank.d131.s10.p10	data from in vitro studies of benzodiazepines other than drug suggest a potential drug fundamental interaction for the following ergotamine cyclosporine amiodarone nicardipine and drug	DDI-int
DDI-DrugBank.d131.s10.p10	data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone nicardipine and drug 	DDI-int
DDI-DrugBank.d413.s16.p9	ampicillin amoxicillin an increase in the frequency of skin rash has been reported among patients receiving ampicillin or drug concurrently with drug compared to patients who are not receiving both drugs 	DDI-effect
DDI-DrugBank.d43.s5.p1	drugs whose absorption can be affected by the level of acidity in the stomach drugs such as drug and itraconazole should be administered at least hours prior to dosing with drug 	DDI-advise
DDI-DrugBank.d443.s8.p0	drug may decrease drug anti inflammatory action by competing for the same receptors 	DDI-effect
DDI-DrugBank.d96.s0.p1	drug may decrease emetic response to drug 	DDI-effect
DDI-MedLine.d8.s6.p9	when combined with ofloxacin krm exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or drug and drug 	DDI-effect
DDI-DrugBank.d19.s1.p0	drug should be used with caution in those patients reveiving drug and its congeners 	DDI-advise
DDI-DrugBank.d550.s4.p5	probenecid as with other drug co administration of probenecid with drug resulted in an increase in the plasma exposure of cefditoren with a increase in mean cmax a increase in mean auc and a increase in half life 	DDI-mechanism
DDI-DrugBank.d516.s5.p5	magnesium and drug containing antacids administered concomitantly with drug significantly decreased the bioavailability of lomefloxacin 	DDI-mechanism
DDI-DrugBank.d562.s1.p2	there have been reports of theophylline related side effects in patients on concomitant drug drug therapy 	DDI-effect
DDI-DrugBank.d198.s36.p7	ritonavir and indinavir upon concomitant administration of mg of drug with mg bid drug the cmax and auc of ritonavir were reduced by approximately 	DDI-mechanism
DDI-DrugBank.d223.s24.p0	additionally higher than expected drug levels have been observed when they are begun in patients already taking drug 	DDI-mechanism
DDI-DrugBank.d263.s23.p2	the clinical significance of this reduction is not known hence drug is not recommended to be ingested simultaneously with magnesium aluminum containing drug 	DDI-advise
DDI-DrugBank.d64.s6.p0	drugs that have been reported to diminish oral drug response ie decreased prothrom bin time response in man significantly include drug 	DDI-effect
DDI-DrugBank.d115.s9.p1	particular caution is recommended when administering drug with cyp a substrates that have a narrow therapeutic window e g cyclosporine or drug 	DDI-advise
DDI-DrugBank.d328.s29.p1	plasma exposure auc to drug was increased when coadministered with fluconazole and when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d163.s4.p4	micro dosed progesterone preparations micro dosed drug preparations minipills that do not contain an estrogen may be an inadequate method of contraception during drug therapy 	DDI-effect
DDI-DrugBank.d400.s14.p13	antacids in a single dose study n ingestion of an antacid containing gram of drug with mg of drug increased the cmax and auc of mefenamic acid by and respectively a number of compounds are inhibitors of cyp c including fluconazole lovastatin and trimethoprim 	DDI-mechanism
DDI-DrugBank.d131.s10.p6	data from vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following drug cyclosporine nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p6	data from in vitro studies of benzodiazepines other than drug suggest a drug drug interaction for the following nifedipine cyclosporine amiodarone nicardipine and possible	DDI-int
DDI-DrugBank.d131.s10.p6	data from in vitro discipline of benzodiazepines other than drug suggest a potential drug interaction for the following drug cyclosporine amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p6	data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following drug cyclosporine amiodarone nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d158.s0.p2	urinary acidifying agents these agents ammonium chloride drug etc increase the concentration of the ionized species of the drug molecule thereby increasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d500.s5.p1	the concurrent use of drug and penthrane drug has been reported to result in fatal renal toxicity 	DDI-effect
DDI-DrugBank.d464.s0.p2	drug in combination with other narcotic analgesics general anesthetics drug tranquilizers sedative hypnotics or other cns depressants including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d165.s18.p0	when drug was coadministered with drug rifampin or h antagonists reduced plasma concentrations of itraconazole were reported 	DDI-mechanism
DDI-DrugBank.d567.s12.p9	amiodarone or verapamil the risk of myopathy rhabdomyolysis is increased when either amiodarone or drug is used concomitantly with a closely related member of the drug see warnings myopathy rhabdomyolysis 	DDI-effect
DDI-DrugBank.d249.s13.p0	a direct causal relationship has not been established but physicians should consider the possibility that drug may alter a diabetic patient s response to drug or oral hypoglycemic agents 	DDI-effect
DDI-DrugBank.d170.s5.p15	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids drug hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d187.s14.p3	plasma valproate concentration should be monitored when drug and drug are co administered and appropriate dosage adjustments of valproate should be made 	DDI-advise
DDI-DrugBank.d87.s2.p0	during administration of multiple oral doses of drug to healthy subjects stabilized on a maintenance dose of drug a increase in plasma digoxin levels occurred at six hours postdose 	DDI-mechanism
DDI-DrugBank.d187.s5.p0	furthermore it has been proposed that drug resulted in induction of p iie in the patients liver which in turn resulted in a greater proportion of the ingested drug being converted to the toxic metabolites 	DDI-mechanism
DDI-DrugBank.d338.s1.p7	the action of the drug may be potentiated by anticonvulsants antihistamines alcohol barbiturates monoamine oxidase inhibitors narcotics phenothiazines drug or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d401.s0.p8	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and drug 	DDI-effect
DDI-DrugBank.d237.s8.p0	human pharmacokinetic data indicate that oral drug markedly inhibits the metabolism of drug resulting in a mean eight fold increase in auc of cisapride 	DDI-mechanism
DDI-DrugBank.d170.s5.p22	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and drug may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d260.s3.p8	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and amikacin amphotericin b foscarnet intravenous pentamidine vancomycin and drug is contraindicated 	DDI-advise
DDI-DrugBank.d386.s27.p0	conversely decreases in plasma levels of the drug have been reported upon discontinuation of drug which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 	DDI-mechanism
DDI-DrugBank.d568.s23.p5	although trough citalopram plasma levels were unaffected given the enzyme inducing properties of carbamazepine the possibility that drug might increase the clearance of drug should be considered if the two drugs are coadministered 	DDI-mechanism
DDI-DrugBank.d429.s0.p9	antacids and kaolin antacids and drug can reduce absorption of drug 	DDI-mechanism
DDI-DrugBank.d236.s5.p1	urinary alkalinizing agents drug some thiazides increase the concentration of the non ionized species of the drug molecule thereby decreasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d263.s23.p0	the clinical significance of this reduction is not known hence drug is not recommended to be ingested simultaneously with drug aluminum containing antacids 	DDI-advise
DDI-DrugBank.d462.s5.p3	probenecid the oral combination of drug before intramuscular injection of drug produces an increase in piperacillin peak serum level of about 	DDI-mechanism
DDI-DrugBank.d485.s41.p10	tricyclic antidepressants amitriptyline drug nortriptyline metabolism may be inhibited by drug increasing plasma levels of antidepressant 	DDI-mechanism
DDI-DrugBank.d3.s7.p9	although these results do not indicate a significant interaction between toradol and warfarin or heparin the administration of drug to patients taking drug should be done extremely cautiously and patients should be closely monitored 	DDI-advise
DDI-DrugBank.d484.s0.p35	drug may interact with the follow medicinal drug acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin atorvastatin atromid s atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitor agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin drug prednisolone prelone rifadin rifampin st whoremonger wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p35	drug may interact with the following medications acetaminophen tylenol antibiotics such as reciprocal ohm ampicillin and restoril tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral ritonavir sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin drug prednisolone prelone rifadin rifampin st johns wort pediapred temazepam proteolytic enzyme theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p35	drug may crixivan with the following medications acetaminophen tylenol antibiotics such tetracycline vitamin and as anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor rifampin atromid s wort neoral sandimmune hiv drugs classified and protease inhibitors agenerase interact fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin drug prednisolone prelone rifadin clofibrate st johns cyclosporine temazepam theophylline theo dur as ampicillin c	DDI-int
DDI-DrugBank.d484.s0.p35	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin drug prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d176.s9.p19	antacids in a clinical pharmacology study coadministration of an antacid drug magnesium hydroxide and simethicone with drug reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone suggesting that antacids may impair absorption of fosinopril 	DDI-mechanism
DDI-DrugBank.d419.s5.p2	in common with other broad spectrum antibiotics drug may reduce the efficacy of oral drug 	DDI-effect
DDI-DrugBank.d446.s0.p4	may interact with antidepressants aspirin barbiturates bromocriptine drug supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and	DDI-int
DDI-DrugBank.d446.s0.p4	drug may interact with antidepressants aspirin barbiturates bromocriptine drug supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin estrogen antagonist and warfarin	DDI-int
DDI-DrugBank.d446.s0.p4	barbiturates may interact with antidepressants aspirin drug bromocriptine drug supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p4	drug may interact with antidepressants aspirin barbiturates bromocriptine drug supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d466.s17.p1	these studies indicate that drug or erythromycin co administration enhances drug gastrointestinal absorption 	DDI-mechanism
DDI-DrugBank.d368.s12.p0	drug increases drug excretion and the lithium may be decreased 	DDI-mechanism
DDI-DrugBank.d476.s4.p0	concurrent use of drug increases the metabolic clearance of drug resulting in a shortened elimination half life of zebeta 	DDI-mechanism
DDI-DrugBank.d526.s17.p2	drug phenytoin or rifampin increased metabolic clearance of drug because of the induction of hepatic enzymes 	DDI-mechanism
DDI-DrugBank.d484.s0.p13	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants atorvastatin dilantin phenobarbital tegretol trileptal topamax felbatol antifungals drug nizoral proteolytic enzyme sporanox prelone phenytoin atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease acetaminophen inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and reciprocal ohm vitamin c	DDI-int
DDI-DrugBank.d484.s0.p13	dose may interact with the following medications panadol tylenol antibiotic drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals dose nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified ad as protease inhibitors agenerase indinavir fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone pediapred prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p13	drug may interact the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals drug nizoral sporanox atorvastatin lipitor atromid s cyclosporine sandimmune hiv drugs classified as protease agenerase crixivan fortovase invirase kaletra morphine kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p13	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals drug nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d340.s6.p6	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine drug antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d131.s10.p8	data from in vitro studies of benzodiazepines other than drug suggest a drug interaction for the following ergotamine drug nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p8	data from canvass in vitro studies of benzodiazepines other than stick with drug suggest a possible drug interaction for the following ergotamine cyclosporine drug nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p8	data from nicardipine vitro studies the benzodiazepines other than drug suggest a possible drug interaction for of following ergotamine cyclosporine drug in and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p8	data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following ergotamine cyclosporine drug nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d87.s3.p0	in a study involving healthy subjects receiving drug and drug concurrently plasma flecainide levels were increased about and propranolol levels were increased about compared to control values 	DDI-mechanism
DDI-DrugBank.d558.s28.p0	in patients the concomitant administration of drug with drug was associated with a higher occurrence of torsade de pointes 	DDI-effect
DDI-DrugBank.d450.s6.p5	drug kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs and metoclopramide may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d75.s14.p13	the effects of medicinal products with similar properties such as inotropes milrinone enoximone amrinone drug and cilostazol may be exacerbated by drug 	DDI-effect
DDI-DrugBank.d559.s1.p11	butalbital drug and caffeine may enhance the effects of other narcotic analgesics drug general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d328.s39.p0	coadministration with drug increased exposure of drug auc by 	DDI-mechanism
DDI-DrugBank.d150.s3.p0	drug may enhance the seizure risk in patients taking drug 	DDI-effect
DDI-DrugBank.d531.s79.p1	drug has the potential to decrease plasma concentrations of itraconazole and drug 	DDI-mechanism
DDI-DrugBank.d94.s4.p9	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin drug fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d568.s16.p5	sumatriptan there have been rare postmarketing reports describing patients with weakness hyperreflexia and incoordination following the use of a selective serotonin reuptake inhibitor drug and drug 	DDI-effect
DDI-DrugBank.d324.s16.p0	multiple dose administration of the potent cyp a inducer drug mg every hours q h for days however reduced drug cmax and auc by approximately 	DDI-mechanism
DDI-DrugBank.d328.s18.p0	coadministration with drug mg bid for days resulted in a significant increase in drug plasma levels suggesting that at these doses valdecoxib is a weak inhibitor of d 	DDI-mechanism
DDI-DrugBank.d78.s20.p2	antidiabetic agents disturbances of blood glucose including hyperglycemia and hypoglycemia have been reported in patients treated concomitantly with drug and an drug 	DDI-effect
DDI-DrugBank.d233.s3.p2	use with angiotensln converting enzyme inhibitors the use of drug to control hypertension in patients on drug has been reported to induce severe leukopenia 	DDI-effect
DDI-DrugBank.d140.s11.p0	these increases should be considered when selecting an oral drug for a woman taking drug 	DDI-advise
DDI-DrugBank.d123.s3.p4	glyburide the concomitant administration of drug with the sulfonylurea drug has on rare occasions resulted in severe hypoglycemia 	DDI-effect
DDI-DrugBank.d5.s21.p1	administration of drug tablets to patients receiving either levodopa or drug concurrently should be undertaken with caution using small initial doses and small gradual dose increases 	DDI-advise
DDI-DrugBank.d165.s5.p1	in vitro data suggest that drug when compared to ketoconazole has a less pronounced effect on the biotransformation system responsible for the metabolism of drug 	DDI-mechanism
DDI-DrugBank.d140.s10.p5	oral contraceptives coadministration of drug and an oral contraceptive increased auc values for drug and ethinyl estradiol by approximately and 	DDI-mechanism
DDI-DrugBank.d107.s3.p1	agents causing renin release the antihypertensive effect of drug and enalapril iv is augmented by drug that cause renin release e g diuretics 	DDI-effect
DDI-DrugBank.d241.s3.p49	in clinical trials flolan was used with digoxin diuretics anticoagulants oral vasodilators and supplemental oxygen in a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or drug in whom therapy with drug was initiated apparent oral clearance values for furosemide n and digoxin n were decreased by and respectively on the second day of therapy and had returned to baseline values by day 	DDI-mechanism
DDI-DrugBank.d384.s2.p13	phenytoin phenobarbital the coadministration of phenytoin or drug will not affect plasma concentrations of vitamin d but may reduce endogenous plasma levels of drug ergocalcitriol by accelerating metabolism 	DDI-mechanism
DDI-MedLine.d23.s1.p10	in a comparison of digitalis tolerance in dogs anesthetized with drug innovar vet or pentobarbital the dosage of drug needed to cause ventricular tachycardia was significantly higher as was the ld of ouabain with ketamine or innovar than with pentobarbital 	DDI-effect
DDI-DrugBank.d267.s5.p10	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts drug local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d422.s10.p2	although the interactions observed in these studies do not appear to be of major clinical importance drug should be titrated with caution in patients being treated concurrently with digoxin morphine drug or warfarin 	DDI-advise
DDI-DrugBank.d240.s2.p0	drug can interact with drug increasing the metabolism of chlorpromazine 	DDI-mechanism
DDI-DrugBank.d357.s1.p5	antihypertensive medications and vasodilators the following adverse events were experienced more commonly in patients receiving concomitant drug or drug n compared to patients not receiving these concomitant drugs n hypotension vs myocardial infarction vs serious pneumonia vs serious falls vs and bone and joint injuries vs 	DDI-effect
DDI-DrugBank.d94.s4.p19	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors drug quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d249.s11.p2	there are rare reports however from marketing experiences of changes in effects of insulin or oral drug in the presence of drug that necessitated changes in the doses of such agents 	DDI-effect
DDI-DrugBank.d558.s2.p0	drug at mg bid the usual prescription dose co administered with drug mcg bid for days has been shown to increase dofetilide plasma levels by 	DDI-mechanism
DDI-DrugBank.d144.s1.p19	if treatment with inhibitors of cyp a activity such as ketoconazole intraconazole ritonavir indinavir drug erythromycin etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-DrugBank.d234.s6.p0	the effects of nonbenzodiazepine agonists at benzodiazepine receptors such as drug triazolopyridazines and others are also blocked by drug 	DDI-effect
DDI-DrugBank.d531.s79.p0	drug has the potential to decrease plasma concentrations of drug and ketoconazole 	DDI-mechanism
DDI-DrugBank.d99.s24.p3	discontinuation of cimetidine in well controlled patients receiving drug and drug may decrease the plasma levels and efficacy of the antidepressants 	DDI-mechanism
DDI-DrugBank.d321.s4.p3	cimetidine drug concentrations in bile and cystic fluid were increased about fold in hydatid cyst patients treated with drug mg kg day n compared with albendazole mg kg day alone n 	DDI-mechanism
DDI-DrugBank.d484.s0.p0	drug may interact with the following medications drug tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral saquinavir sporanox atorvastatin atorvastatin lipitor clofibrate atromid s cyclosporine neoral stick with sodium thiopental sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st indinavir johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p0	drug may interact with the following medications drug tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin luminal tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase indinavir fortovase invirase kaletra ritonavir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin light speed	DDI-int
DDI-DrugBank.d484.s0.p0	theophylline may interact with the following classified drug medications antibiotics such as ampicillin and tetracycline peg agenerase phenobarbital tegretol trileptal topamax felbatol antifungals drug anticonvulsants nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs tylenol as protease inhibitors dilantin crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam gris theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p0	drug may interact with the following medications drug tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d276.s2.p5	uricosuric drugs such as probenecid and drug can inhibit renal tubular secretion of drug 	DDI-mechanism
DDI-DrugBank.d172.s20.p0	patients on drug treatment should be closely monitored when drug is introduced or withdrawn 	DDI-advise
DDI-DrugBank.d35.s0.p1	interactions may occur between drug herb supplements and aspirin and other drug and herbs such as tween garlic allium sativum and ginkgo ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p1	interactions occur between drug supplements and aspirin and other and herbs such as garlic allium and biloba	DDI-int
DDI-DrugBank.d35.s0.p1	interactions may occur between drug supplements and such and other drug herbs and aspirin as garlic allium sativum and ginkgo ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p1	interactions may occur between drug supplements and aspirin and other drug and herbs such as garlic allium sativum and ginkgo ginkgo biloba 	DDI-int
DDI-DrugBank.d124.s26.p132	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl drug alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d508.s1.p4	in addition to bleeding associated with drug and vitamin k antagonists drugs that alter platelet function such as acetylsalicylic acid dipyridamole and abciximab may increase the risk of bleeding if administered prior to during or after drug therapy 	DDI-effect
DDI-DrugBank.d446.s0.p7	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin drug nicotine dantrolene somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p7	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin drug dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p7	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin drug dantrolene nicotine supplementation somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p7	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin drug dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d202.s0.p0	steady state serum concentrations of drug are reported to fluctuate significantly when drug is either added or deleted from the drug regimen 	DDI-mechanism
DDI-MedLine.d106.s8.p1	and methaqualone interact pharmacologically with orally administered drug but the effect is clinically significant	DDI-int
DDI-MedLine.d106.s8.p1	drug and methaqualone interact pharmacologically with orally administered drug but the upshot is not clinically significant	DDI-int
DDI-MedLine.d106.s8.p1	drug and methaqualone interact pharmacologically with orally administered drug significant the effect is not clinically but	DDI-int
DDI-MedLine.d106.s8.p1	drug and methaqualone interact pharmacologically with orally administered drug but the effect is not clinically significant 	DDI-int
DDI-DrugBank.d521.s1.p4	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate drug disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d462.s4.p0	due to their similar mechanism of action it is expected that the neuromuscular blockade produced by any of the drug could be prolonged in the presence of drug 	DDI-effect
DDI-DrugBank.d103.s4.p17	corticosteroids methylxanthines and diuretics concomitant treatment with drug steroids or diuretics may potentiate a possible hypokalemic effect of drug 	DDI-effect
DDI-DrugBank.d345.s9.p0	therefore patients on drug should be observed when drug tablets are either added or deleted from a therapeutic regimen 	DDI-advise
DDI-DrugBank.d176.s3.p5	potassium supplements and potassium sparing diuretics drug can attenuate potassium loss caused by drug 	DDI-effect
DDI-DrugBank.d559.s1.p4	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics alcohol general drug tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d82.s35.p1	drug can reduce the antihypertensive effects of captopril and drug 	DDI-effect
DDI-MedLine.d56.s8.p0	exposure of the muscle to drug m markedly increased the drug induced release 	DDI-effect
DDI-DrugBank.d438.s31.p0	this small decrease in excretion of drug by drug is not expected to be of clinical importance 	DDI-mechanism
DDI-DrugBank.d456.s1.p8	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir drug telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d76.s19.p2	diazepam the co administration of drug tablets and drug is generally not advisable 	DDI-advise
DDI-DrugBank.d380.s6.p2	subutex and drug should be prescribed with caution to patients on drug or other drugs that act on the central nervous system regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse 	DDI-advise
DDI-DrugBank.d484.s0.p18	drug may interact the following medications acetaminophen tylenol antibiotics such as and tetracycline dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin drug atromid cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p18	drug may interact with the following medications acetaminophen tylenol antibiotic drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole lipitor lipitor drug atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian molar concentration contin butazolidin prednisolone prednisolone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p18	drug may interact with fortovase following medications kaletra tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital drug trileptal topamax felbatol antifungals gris rifadin nizoral sporanox protease lipitor tegretol atromid s cyclosporine neoral sandimmune hiv drugs classified as atorvastatin inhibitors agenerase norvir the invirase acetaminophen crixivan viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone peg rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p18	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor drug atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d8.s4.p0	drug reduces the clearance of drug 	DDI-mechanism
DDI-DrugBank.d254.s0.p13	other cns depressant drugs e g barbiturates tranquilizers drug and general anesthetics have additive or potentiating effects with drug 	DDI-effect
DDI-DrugBank.d283.s12.p0	therefore drug should be taken at least hour before or hours after a drug to avoid impeding its absorption 	DDI-advise
DDI-DrugBank.d320.s3.p1	although no clinical studies have been conducted it is likely that the metabolism of drug may be affected by the known cyp a inducers such as phenytoin drug rifampin cyp a inhibitors azole antimycotics e g ketoconazole 	DDI-mechanism
DDI-DrugBank.d422.s0.p0	catecholamine depleting drugs e g drug may have an additive effect when given with drug 	DDI-effect
DDI-DrugBank.d175.s6.p2	therefore nitroglycerin or other drug as used for management of angina or other drugs having vasodilator activity should if possible be discontinued before starting drug 	DDI-advise
DDI-DrugBank.d94.s4.p24	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate drug zileuton 	DDI-mechanism
DDI-DrugBank.d340.s11.p0	therefore drug should not be administered concurrently with drug because of the potential for serious and or life threatening cardiac arrhythmias 	DDI-advise
DDI-DrugBank.d318.s2.p4	corticosteroids and drug acth may potentiate drug induced hypokalemia which may predispose the patient to cardiac dysfunction 	DDI-effect
DDI-DrugBank.d123.s3.p3	glyburide the concomitant administration of drug with the drug glyburide has on rare occasions resulted in severe hypoglycemia 	DDI-effect
DDI-DrugBank.d296.s0.p2	drug has additive effects with alcohol and other cns depressants drug sedatives tranquilizers etc 	DDI-effect
DDI-DrugBank.d299.s6.p24	selective serotonin reuptake inhibitors ssris ssris e g fluoxetine drug paroxetine sertraline have been rarely reported to cause weakness hyperreflexia and incoordination when coadministered with drug 	DDI-effect
DDI-MedLine.d59.s4.p0	drug at microm preferentially blocked the secretory effect of drug and its synergism with camp whereas it had no effect on histamine or camp stimulated acid secretion within min 	DDI-effect
DDI-DrugBank.d263.s24.p2	metoclopramide bioavailability is mildly reduced approximately when drug and drug are coadministered 	DDI-mechanism
DDI-DrugBank.d340.s7.p0	drugs which require a dose reduction when coadminstered with drug drug rifabutin	DDI-advise
DDI-MedLine.d12.s0.p4	dexamethasone and drug similarly inhibit and stimulate egf or drug induced proliferation of prostatic epithelium 	DDI-effect
DDI-DrugBank.d94.s16.p2	additionally drug such as chloroquine and mefloquine may antagonize the activity of drug 	DDI-effect
DDI-DrugBank.d495.s10.p0	epidural drug may prolong the duration of pharmacologic effects of epidural local drug including both sensory and motor blockade 	DDI-effect
DDI-DrugBank.d450.s6.p19	antacids kaolin pectin sulfasalazine neomycin drug certain anticancer drugs and metoclopramide may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d4.s0.p4	synergism between xanthine bronchodilators e g drug ephedrine and other drug has been reported 	DDI-effect
DDI-DrugBank.d170.s5.p30	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics drug skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d517.s0.p1	drug a bacteriostatic antibiotic may antagonize the bactercidal effect of drug and concurrent use of these drugs should be avoided 	DDI-effect
DDI-DrugBank.d41.s3.p0	in a small n combination study of drug with drug a to fold elevation in liver enzymes was seen in of patients 	DDI-effect
DDI-DrugBank.d94.s4.p0	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following drug azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d30.s4.p0	drug an inhibitor of p c decreased active metabolite concentration and increased drug concentration 	DDI-mechanism
DDI-DrugBank.d358.s2.p0	population pharmacokinetic studies showed higher concentrations of drug among patients concurrently treated with drug an inhibitor of c p a 	DDI-mechanism
DDI-DrugBank.d98.s7.p2	digitalis drug dosage must be determined with care in patients undergoing treatment with drug as hypercalcemia in such patients may precipitate cardiac arrhythmias 	DDI-advise
DDI-DrugBank.d158.s21.p2	phenytoin drug may delay intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d47.s5.p1	drug salts may reduce the bioavailability of carbidopa and drug 	DDI-mechanism
DDI-DrugBank.d141.s12.p2	erythromycin in hypercholesterolemic patients steady state drug auc and cmax increased approximately and respectively after days with co administration of drug a known inhibitor of cytochrome p a 	DDI-mechanism
DDI-DrugBank.d44.s2.p2	drug should not be administered during drug treatment 	DDI-advise
DDI-DrugBank.d487.s5.p2	this could lead to decreased salicylate serum levels or increase the risk of drug toxicity when drug is withdrawn 	DDI-effect
DDI-DrugBank.d340.s6.p5	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole drug antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d559.s1.p23	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other drug causing increased cns depression 	DDI-effect
DDI-DrugBank.d332.s0.p0	administration of drug to patients who are receiving drug or monoamine oxidase inhibiting drugs may result in an additive pressor effect 	DDI-effect
DDI-DrugBank.d261.s0.p1	drug a bacteriostatic antibiotic may antagonize the bactericidal effect of drug and concurrent use of these drugs should be avoided 	DDI-effect
DDI-DrugBank.d413.s2.p10	mercaptopurine azathioprine drug inhibits the enzymatic oxidation of mercaptopurine and drug to thiouric acid 	DDI-mechanism
DDI-DrugBank.d446.s0.p12	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium add on corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and drug	DDI-int
DDI-DrugBank.d446.s0.p12	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids drug cyclosporine dantrolene nicotine somatropin tamoxifen and corticotropin	DDI-int
DDI-DrugBank.d446.s0.p12	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen adrenocorticotrophin and drug	DDI-int
DDI-DrugBank.d446.s0.p12	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and drug 	DDI-int
DDI-DrugBank.d566.s0.p7	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g drug thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d506.s0.p0	if drug or other hepatic enzyme inducers are taken concurrently with drug or norpace cr lower plasma levels of disopyramide may occur 	DDI-mechanism
DDI-DrugBank.d76.s17.p7	this interaction which has not been investigated using higher doses of fluvoxamine may be more pronounced if a mg daily dose is co administered particularly since fluvoxamine exhibits non linear pharmacokinetics over the dosage range mg if drug is co administered with drug tablets the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended 	DDI-advise
DDI-DrugBank.d485.s16.p3	atorvastatin drug increases the auc for drug and ethinyl estradiol 	DDI-mechanism
DDI-DrugBank.d324.s4.p2	imipramine coadministration of single doses of drug mg and drug mg produced additive effects on decreased alertness and impaired psychomotor performance for to hours after administration 	DDI-effect
DDI-DrugBank.d18.s1.p8	injection lorazepam injection like other injectable drug produces depression of the central nervous system when administered with drug phenothiazines barbiturates mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d504.s0.p0	there have been rare reports of significant respiratory depression stupor and or hypotension with the concomitant use of drug and drug 	DDI-effect
DDI-DrugBank.d26.s0.p20	patients receiving other narcotic analgesics general anesthetics drug tranquilizers sedative hypnotics tricyclic antidepressants or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d422.s10.p1	although the interactions observed in these studies do not appear to be of major clinical importance drug should be titrated with caution in patients being treated concurrently with digoxin drug succinylcholine or warfarin 	DDI-advise
DDI-DrugBank.d373.s0.p2	beta adrenergic blocking agents experience in over patients in a non comparative clinical trial has shown that concomitant administration of drug and drug is usually well tolerated but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure severe hypotension or exacerbation of angina 	DDI-effect
DDI-DrugBank.d438.s26.p5	morphine a literature article reported that when a mg controlled release drug capsule was administered hours prior to a mg drug capsule n mean gabapentin auc increased by compared to gabapentin administered without morphine 	DDI-mechanism
DDI-MedLine.d25.s10.p0	the concomitant administration of drug and other drug have resulted in previous reports of rhabdomyolysis 	DDI-effect
DDI-DrugBank.d188.s0.p5	concurrent administration of hexalen and antidepressants of the mao inhibitor class may cause severe orthostatic hypotension drug an inhibitor of microsomal drug metabolism increased drug s half life and toxicity in a rat model 	DDI-mechanism
DDI-DrugBank.d463.s8.p0	in vitro drug may displace less firmly bound drugs like drug 	DDI-mechanism
DDI-DrugBank.d463.s6.p0	however there has been one report of prolonged prothrombin time when drug was added to the regimen of a patient treated with drug 	DDI-effect
DDI-DrugBank.d53.s7.p10	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil drug intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d434.s30.p33	effects of other antiepileptic drugs on felbatol phenytoin phenytoin causes an approximate doubling of the clearance of felbatol felbamate at steady state and therefore the addition of drug causes an approximate decrease in the steady state trough concentrations of drug as compared to the same dose of felbatol given as monotherapy 	DDI-mechanism
DDI-DrugBank.d26.s0.p25	patients receiving other narcotic analgesics general anesthetics phenothiazines drug sedative hypnotics tricyclic antidepressants or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d48.s10.p0	if drug therapy is needed the antacid dose should be administered at least hours prior to or hours after the dose of drug 	DDI-advise
DDI-DrugBank.d359.s2.p0	a two way interaction between drug the drug and the coumarin anticoagulants has been suggested	DDI-int
DDI-DrugBank.d359.s2.p0	a two way between the drug drug and the coumarin anticoagulants has been suggested	DDI-int
DDI-DrugBank.d359.s2.p0	a two way interaction between the drug cause drug and the coumarin anticoagulants has been suggested	DDI-int
DDI-DrugBank.d359.s2.p0	a two way interaction between the drug drug and the coumarin anticoagulants has been suggested 	DDI-int
DDI-DrugBank.d75.s14.p8	the effects of medicinal products with similar properties such as inotropes milrinone drug amrinone olprinone and cilostazol may be exacerbated by drug 	DDI-effect
DDI-DrugBank.d492.s1.p0	drug may have additive effects with drug and other cns depressants e g hypnotics sedatives tranquilizers antianxiety agents 	DDI-effect
DDI-DrugBank.d150.s1.p2	drug may enhance the effects of alcohol barbiturates and other drug 	DDI-effect
DDI-DrugBank.d568.s12.p5	because lithium may enhance the serotonergic effects of escitalopram caution should be exercised when drug and drug are coadministered 	DDI-advise
DDI-DrugBank.d94.s4.p20	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene drug quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-MedLine.d45.s6.p0	dose response curves derived from the results of using the tablets as well as pure powders showed that drug was responsible for the inhibitory activity which was partially antagonized by drug 	DDI-effect
DDI-DrugBank.d338.s1.p4	the action of the drug may be potentiated by anticonvulsants antihistamines alcohol barbiturates drug narcotics phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d107.s3.p2	agents causing renin release the antihypertensive effect of drug and enalapril iv is augmented by antihypertensive agents that cause renin release e g drug 	DDI-effect
DDI-DrugBank.d54.s15.p4	tricyclic antidepressants use of drug with imipramine and other drug may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed 	DDI-effect
DDI-DrugBank.d382.s31.p4	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole itraconazole nefazodone troleandomycin drug ritonavir nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d387.s1.p1	drug may partially counteract the anticoagulation effects of heparin or drug 	DDI-effect
DDI-DrugBank.d441.s2.p4	adrenergic agents some individuals receiving drug may experience a reversible enhancement of the pressor response to indirect acting drug vasopressor or dopaminergic agents 	DDI-effect
DDI-DrugBank.d382.s41.p4	diltiazem in patients with mild to moderate hypertension administration of drug once daily as a tablet formulation comparable to mg of the capsule formulation with drug mg times daily for days resulted in a fold increase of aprepitant auc and a simultaneous fold increase of diltiazem auc 	DDI-mechanism
DDI-DrugBank.d450.s2.p15	quinidine drug amiodarone propafenone indomethacin itraconazole alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d484.s0.p34	dilantin may interact with the following ampicillin acetaminophen wort antibiotics such invirase medications and tetracycline anticonvulsants drug inhibitors tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv prednisolone classified as protease phenobarbital agenerase crixivan fortovase as kaletra norvir viracept morphine astramorph kadian drug phenylbutazone drugs prelone rifadin rifampin st johns tylenol temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p34	drug may interact with the medications tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital trileptal topamax felbatol gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian drug phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p34	dose may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals jaun gris peg nizoral itraconazole lipitor lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs sort as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphia astramorph kadian dose phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p34	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian drug phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d323.s0.p0	co administration of drug and drug or other agents interfering with neuromuscular transmission e g curare like compounds should only be performed with caution as the effect of the toxin may be potentiated 	DDI-advise
DDI-DrugBank.d158.s13.p2	ethosuximide drug may delay intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d514.s4.p0	drug sometimes proves to be fatal when used in combination with drug 	DDI-effect
DDI-DrugBank.d448.s2.p0	when drug are given to patients receiving drug hypertensive reactions including hypertensive crises may occur 	DDI-effect
DDI-DrugBank.d516.s24.p4	warfarin drug may enhance the effects of the oral anticoagulant drug or its derivatives 	DDI-effect
DDI-DrugBank.d341.s2.p0	in a study in which patients with active ra were treated for up to weeks with concurrent drug and drug therapy a rate of serious infections was observed which was higher than that observed with enbrel alone 	DDI-effect
DDI-DrugBank.d313.s3.p8	beta blockers clonidine drug salts and alcohol may either potentiate or weaken the blood glucose lowering effect of drug 	DDI-effect
DDI-DrugBank.d226.s7.p0	thus smaller doses of drug may be effective in the presence of drug 	DDI-effect
DDI-DrugBank.d450.s6.p14	antacids kaolin pectin drug neomycin cholestyramine certain anticancer drugs and metoclopramide may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d76.s7.p2	drug astemizole and cisapride are all metabolized by the cytochrome p iiia isozyme and it has been demonstrated that drug a potent inhibitor of iiia blocks the metabolism of these drugs resulting in increased plasma concentrations of parent drug 	DDI-mechanism
DDI-DrugBank.d384.s5.p0	some reports have shown that the concomitant administration of drug with drug causes hypercalcemia 	DDI-effect
DDI-DrugBank.d60.s12.p18	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines drug polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d171.s0.p9	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline and drug thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d236.s21.p3	methenamine therapy urinary excretion of drug is increased and efficacy is reduced by drug used in methenamine therapy 	DDI-mechanism
DDI-DrugBank.d400.s8.p0	during concomitant therapy of drug with drug the patient should be observed closely for signs of renal failure as well as to assure diuretic efficacy 	DDI-advise
DDI-DrugBank.d374.s1.p1	drug should not be used together with penicillamine drug cuprimine another arthritis medication 	DDI-advise
DDI-DrugBank.d422.s10.p3	although the interactions observed in these studies do not appear to be of major clinical importance drug should be titrated with caution in patients being treated concurrently with digoxin morphine succinylcholine or drug 	DDI-advise
DDI-DrugBank.d94.s4.p13	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole drug loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d76.s11.p2	consequently it is recommended that drug not be used in combination with either terbinafine astemizole or drug 	DDI-advise
DDI-DrugBank.d448.s3.p3	the antihypertensive effects of drug mecamylamine reserpine and veratrum alkaloids may be reduced by drug 	DDI-effect
DDI-DrugBank.d60.s9.p1	in long surgical procedures during drug or isoflurane anesthesia less frequent maintenance dosing lower maintenance doses or reduced infusion rates of drug may be necessary 	DDI-advise
DDI-DrugBank.d5.s17.p6	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine drug antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d347.s7.p8	drug and or aluminum containing antacids products containing ferrous sulfate iron multivitamin preparations containing zinc or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d565.s8.p0	administration of drug concomitantly with drug in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 	DDI-mechanism
DDI-DrugBank.d165.s8.p0	data suggest that coadministration of oral drug and drug can result in prolongation of the qt interval on the ecg 	DDI-effect
DDI-DrugBank.d131.s9.p4	data from in vitro studies of alprazolam suggest a possible drug interaction with drug for the following sertraline and drug	DDI-int
DDI-DrugBank.d131.s9.p4	data from in vitro studies of following suggest a drug drug interaction with drug for the alprazolam sertraline and possible	DDI-int
DDI-DrugBank.d131.s9.p4	data from in vitro studies of alprazolam suggest a possible dose interaction with dose for the following zoloft and dose	DDI-int
DDI-DrugBank.d131.s9.p4	data from in vitro studies of alprazolam suggest a possible drug interaction with drug for the following sertraline and drug 	DDI-int
DDI-DrugBank.d217.s5.p3	quinolones including drug may enhance the effects of oral drug including warfarin or its derivatives or similar agents 	DDI-effect
DDI-DrugBank.d226.s5.p1	in the presence of these drug larger doses of adenosine may be required or drug may not be effective 	DDI-advise
DDI-DrugBank.d484.s0.p28	may interact with following medications acetaminophen tylenol antibiotics as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase drug norvir viracept morphine astramorph ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p28	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals pediapred lipitor gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs stick with classified vitamin a as protease inhibitors agenerase crixivan fortovase invirase phenytoin drug norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st lipitor johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p28	drug tylenol following with anticonvulsants interact medications acetaminophen may antibiotics such as ampicillin and tetracycline the dilantin phenobarbital tegretol trileptal topamax felbatol antifungals as peg nizoral sporanox atorvastatin lipitor clofibrate astramorph s cyclosporine neoral temazepam hiv drugs classified gris protease inhibitors agenerase crixivan fortovase invirase drug norvir viracept morphine atromid kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort sandimmune theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p28	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase drug norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d536.s10.p2	however the peak plasma level of metformin was reduced by approximately when taking drug due to a slight delay in the absorption of drug 	DDI-mechanism
DDI-DrugBank.d389.s2.p3	drug may reduce the antihypertensive effects of reserpine veratrum alkaloids methyldopa and drug 	DDI-effect
DDI-DrugBank.d76.s12.p11	other potentially important drug interactions benzodiazepines benzodiazepines metabolized by hepatic oxidation e g drug midazolam triazolam elc should be used with caution because the clearance of these drugs is likely to be reduced by drug 	DDI-mechanism
DDI-DrugBank.d562.s6.p2	antacids or drug substantially interfere with the absorption of some drug resulting in low urine levels 	DDI-mechanism
DDI-DrugBank.d488.s2.p35	platelet inhibitors drugs such as acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole drug and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d270.s39.p2	a dose increase of lopinavir drug to mg twice daily with food isrecommended in combination with drug 	DDI-advise
DDI-DrugBank.d528.s2.p2	gentamicin drug may protect against the ototoxic effects of drug 	DDI-effect
DDI-DrugBank.d341.s4.p0	patients in a clinical study who were on established therapy with drug to which drug was added were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either enbrel ci or sulfasalazine alone 	DDI-effect
DDI-DrugBank.d484.s0.p8	drug may interact the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital topamax antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone rifadin rifampin st johns wort theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p8	do drugs may interact with the following medications acetaminophen tylenol antibiotics such as polycillin and tetracycline anticonvulsants dilantin phenobarbital do drugs trileptal topamax felbatol fungicide gris peg nizoral sporanox lipitor lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified ad as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p8	drug may interact with the following medications acetaminophen tylenol antibiotics as such ampicillin and tetracycline anticonvulsants dilantin phenobarbital drug trileptal topamax felbatol antifungals gris peg kadian sporanox theophylline lipitor clofibrate atromid s and neoral sandimmune hiv drugs nizoral as protease inhibitors agenerase crixivan fortovase invirase classified norvir viracept morphine astramorph kaletra ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam atorvastatin theo dur cyclosporine vitamin c	DDI-int
DDI-DrugBank.d484.s0.p8	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital drug trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d165.s6.p5	based on the chemical resemblance of itraconazole and ketoconazole coadministration of drug with drug is contraindicated 	DDI-advise
DDI-DrugBank.d114.s2.p17	concurrent administration of drugs possessing nephrotoxic e g aminoglycosides indomethacin myelotoxic e g cytotoxic chemotherapy cardiotoxic e g drug or hepatotoxic e g methotrexate asparaginase effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d305.s7.p0	administration of drug may potentiate drug induced neuromuscular block 	DDI-effect
DDI-DrugBank.d283.s4.p5	resins since bile acid sequestrants may bind other drugs given concurrently patients should take drug at least hour before or hours after a drug to avoid impeding its absorption 	DDI-mechanism
DDI-DrugBank.d140.s9.p5	erythromycin in healthy individuals plasma concentrations of atorvastatin increased approximately with coadministration of drug and drug a known inhibitor of cytochrome p a 	DDI-mechanism
DDI-DrugBank.d499.s10.p3	diuretic drug given concomitantly with drug produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone 	DDI-effect
DDI-DrugBank.d170.s3.p3	the concomitant use of other cyp a inhibitors such as diltiazem and drug with transdermal drug may also result in an increase in fentanyl plasma concentrations which could increase or prolong adverse drug effects and may cause serious respiratory depression 	DDI-mechanism
DDI-MedLine.d73.s3.p1	the drug induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of drug in rats responding in a schedule controlled paradigm 	DDI-effect
DDI-DrugBank.d550.s4.p7	probenecid as with other b lactam antibiotics co administration of drug with drug resulted in an increase in the plasma exposure of cefditoren with a increase in mean cmax a increase in mean auc and a increase in half life 	DDI-mechanism
DDI-DrugBank.d435.s2.p3	co medications that induce cyp a e g drug phenytoin carbamazepine phenobarbital or st john s wort may significantly decrease exposure to drug 	DDI-mechanism
DDI-DrugBank.d313.s3.p6	beta blockers drug lithium salts and alcohol may either potentiate or weaken the blood glucose lowering effect of drug 	DDI-effect
DDI-DrugBank.d249.s18.p2	protein binding in vitro drug interferes minimally or not at all with the protein binding of salicylic acid decrease in binding tolbutamide drug decrease in binding or warfarin 	DDI-mechanism
DDI-DrugBank.d247.s5.p2	administration of drug to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as drug which sensitize the myocardium may induce cardiac arrhythmia 	DDI-effect
DDI-DrugBank.d395.s5.p2	caffeine related adverse effects have occurred in patients consuming drug while on therapy with drug 	DDI-effect
DDI-DrugBank.d357.s3.p43	dopamine antagonists since apomorphine is a dopamine agonist it is possible that dopamine antagonists such as the neuroleptics phenothiazines butyrophenones drug or metoclopramide may diminish the effectiveness of drug 	DDI-effect
DDI-DrugBank.d250.s2.p17	curariform muscle relaxants eg tubocurarine and other drugs including ether succinylcholine drug decamethonium and sodium citrate potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d263.s17.p0	if intravenous drug is required to treat pneumocystis carinii pneumonia treatment with drug should be interrupted 	DDI-advise
DDI-DrugBank.d283.s13.p1	concomitant administration of drug equivalent to mg tricor with drug mg once daily for days has been shown to increase the mean cmax and auc values for pravastatin by range from decrease to increase and range from decrease to increase respectively and for hydroxy iso pravastatin by range from decrease to increase and range from decrease to increase respectively in healthy adults 	DDI-mechanism
DDI-DrugBank.d485.s38.p2	salicylic acid combination drug may increase the clearance of drug 	DDI-mechanism
DDI-MedLine.d87.s1.p1	drug is a novel peripherally restricted opioid antagonist that may selectively prevent drug induced gastrointestinal effects without reversing analgesia 	DDI-effect
DDI-MedLine.d116.s4.p0	withdrawal of drug decreased the drug requirement by 	DDI-mechanism
DDI-DrugBank.d217.s1.p2	there have been reports of theophylline related side effects in patients on concomitant therapy with drug and drug 	DDI-effect
DDI-DrugBank.d144.s1.p5	if treatment with inhibitors of cyp a activity such as drug intraconazole ritonavir indinavir saquinavir erythromycin etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-DrugBank.d446.s0.p3	drug may calcium with antidepressants aspirin barbiturates drug interact supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p3	drug may interact with antidepressants aspirin barbiturates drug calcium supplements adrenal cortical steroid corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p3	drug may interact antidepressants aspirin drug calcium corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p3	drug may interact with antidepressants aspirin barbiturates drug calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d17.s26.p0	therefore when drug and drug are used concomitantly the patient should be observed closely to determine if the desired effect of the diuretic is obtained 	DDI-advise
DDI-DrugBank.d325.s10.p1	therefore extreme caution should be exercised when administering drug to patients receiving cyclopropane or drug 	DDI-advise
DDI-DrugBank.d272.s3.p0	concomitant use of drug with other drug is not recommended 	DDI-advise
DDI-DrugBank.d196.s6.p7	stavudine and zidovudine drug can antagonize the in vitro antiviral activity of drug and zidovudine against hiv 	DDI-effect
DDI-DrugBank.d94.s16.p5	additionally anti malarial drugs such as chloroquine and drug may antagonize the activity of drug 	DDI-effect
DDI-DrugBank.d216.s7.p0	the auc of drug was increased fold by coadministration of drug a potent inhibitor of cyp a mg daily for days 	DDI-mechanism
DDI-DrugBank.d299.s6.p21	selective serotonin reuptake inhibitors ssris ssris e g drug fluvoxamine paroxetine sertraline have been rarely reported to cause weakness hyperreflexia and incoordination when coadministered with drug 	DDI-effect
DDI-MedLine.d63.s4.p5	intrathecal injection of naloxone at doses of to micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of beta endorphin and a high dose of drug micrograms completely blocked the tail flick inhibition induced by intraventricular drug micrograms 	DDI-effect
DDI-DrugBank.d5.s26.p0	the consumption of drug during treatment with drug should be minimized or avoided also see a href bupropz od htm ci contraindications 	DDI-advise
DDI-DrugBank.d170.s5.p24	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other drug sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d210.s31.p2	warfarin anticoagulant activity should be monitored particularly in the first few days after initiating or changing drug therapy in patients receiving drug or similar agents since these patients are at an increased risk of bleeding complications 	DDI-advise
DDI-DrugBank.d488.s2.p14	platelet inhibitors drugs such as drug dextran phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d53.s2.p0	although a dose adjustment of drug is not recommended when administered in combination with drug close monitoring for known side effects of azithromycin such as liver enzyme abnormalities and hearing impairment is warranted 	DDI-advise
DDI-DrugBank.d142.s0.p6	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics amantadine haloperidol phenothiazines monoamine oxidase mao inhibitors tricyclic antidepressants or some drug 	DDI-effect
DDI-DrugBank.d521.s1.p9	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate drug or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d175.s16.p0	inhibitors of endogenous prostaglandin synthesis it has been reported that drug may reduce the antihypertensive effect of drug especially in cases of low renin hypertension 	DDI-effect
DDI-DrugBank.d466.s17.p2	these studies indicate that ketoconazole or drug co administration enhances drug gastrointestinal absorption 	DDI-mechanism
DDI-DrugBank.d183.s2.p5	although there are no study data to evaluate the possibility nitric oxide donor compounds including sodium nitroprusside and drug may have an additive effect with drug on the risk of developing methemoglobinemia 	DDI-effect
DDI-DrugBank.d314.s2.p0	in addition there have been cases reported in which concomitant use of drug and drug was followed by cardiac enlargement and congestive heart failure 	DDI-effect
DDI-DrugBank.d386.s11.p0	the extent to which drug drug interactions may pose clinical problems the depend on the involved of inhibition and the pharmacokinetics of will ssri degree	DDI-int
DDI-DrugBank.d386.s11.p0	the extent to drug drug may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of ssri involved	DDI-int
DDI-DrugBank.d386.s11.p0	the extent to which drug drug interactions may pose clinical problems will depend calculate on the degree of inhibition prohibition and the pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d386.s11.p0	the extent to which drug drug interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ssri involved 	DDI-int
DDI-DrugBank.d334.s14.p0	agents increasing serum potassium drug attenuates potassium loss caused by drug 	DDI-effect
DDI-DrugBank.d565.s23.p0	when used concomitantly drug and drug should be titrated carefully 	DDI-advise
DDI-DrugBank.d158.s12.p3	chlorpromazine drug blocks dopamine and norepinephrine receptors thus inhibiting the central stimulant effects of drug and can be used to treat amphetamine poisoning 	DDI-effect
DDI-DrugBank.d427.s3.p0	drug have been shown to interfere with the metabolism of drug 	DDI-mechanism
DDI-MedLine.d36.s2.p0	we report the case of an adolescent with altered consciousness caused by drug overdose with a positive drug level to alert clinicians to the cross reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants 	DDI-effect
DDI-DrugBank.d220.s9.p4	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or beta adrenergic blocking agents calcium channel blockers antihistamines or drug tricyclic antidepressants and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d219.s7.p2	cyclosporine digoxin methotrexate drug like other nsaids through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine drug methotrexate and increased toxicity 	DDI-mechanism
DDI-DrugBank.d303.s2.p0	although not observed in this study adverse effects could potentially arise from co administration of drug and drug by inhibition of tubular secretion via organic cationic transporter systems 	DDI-mechanism
DDI-DrugBank.d276.s0.p2	antacids containing drug when administered concomitantly with drug reduce both the rate and extent of absorption 	DDI-mechanism
DDI-DrugBank.d437.s10.p0	coadministration of drug and drug as compared to a non matched historicalcontrol group resulted in a and decrease in serum amprenavir auc cmax andcmin respectively 	DDI-mechanism
DDI-DrugBank.d217.s11.p18	multivitamins or other products containing iron or zinc antacids or drug should not be administered concomitantly with or within hours of the administration of drug because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin 	DDI-advise
DDI-DrugBank.d386.s23.p1	if drug is to be combined with other psychotropic agents such as drug or sedative hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines e g chlordiazepoxide or diazepam are additive 	DDI-effect
DDI-DrugBank.d94.s8.p0	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following drug doxorubicin hcl felbamate rifampin phenobarbital phenytoin primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d231.s17.p0	patients receiving both drug and drug should be observed closely to determine if the desired diuretic and or antihypertensive effect of furosemide is achieved 	DDI-advise
DDI-DrugBank.d552.s1.p3	drug has been shown to have an additive cns depressant effect when given with either diazepam secobarbitone sodium alcohol or drug 	DDI-effect
DDI-DrugBank.d123.s5.p3	methotrexate renal tubular transport of drug may be inhibited by concomitant administration of drug potentially leading to increased plasma levels of methotrexate 	DDI-mechanism
DDI-DrugBank.d340.s16.p4	ritonavir coadministration of drug with drug resulted in a increase in nelfinavir plasma auc and very little change in ritonavir plasma a c 	DDI-mechanism
DDI-MedLine.d110.s6.p3	both ibogaine and drug block drug induced and nicotine induced dopamine release in the nucleus accumbens 	DDI-effect
DDI-DrugBank.d94.s8.p8	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate rifampin phenobarbital phenytoin primidone methsuximide and drug thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d559.s1.p12	butalbital drug and caffeine may enhance the effects of other narcotic analgesics alcohol general drug tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d324.s28.p2	drugs that inhibit both aldehyde oxidase and cyp a cimetidine drug inhibits both aldehyde oxidase in vitro and cyp a in vitro and in vivo the primary and secondary enzymes respectively responsible for drug metabolism 	DDI-mechanism
DDI-DrugBank.d97.s84.p5	dose reduction of rifabutin to half the standard dose and a dose increase of crixivan to mg three mg capsules every hours are recommended when drug and drug are coadministered 	DDI-advise
DDI-DrugBank.d374.s1.p2	drug should not be used together with penicillamine depen drug another arthritis medication 	DDI-advise
DDI-DrugBank.d283.s13.p3	concomitant administration of fenofibrate equivalent to mg drug with drug mg once daily for days has been shown to increase the mean cmax and auc values for pravastatin by range from decrease to increase and range from decrease to increase respectively and for hydroxy iso pravastatin by range from decrease to increase and range from decrease to increase respectively in healthy adults 	DDI-mechanism
DDI-DrugBank.d466.s1.p1	however co administration of drug with either ketoconazole or drug led to increased plasma concentrations of fexofenadine 	DDI-mechanism
DDI-DrugBank.d508.s1.p8	in addition to bleeding associated with heparin and drug drugs that alter platelet function such as acetylsalicylic acid dipyridamole and abciximab may increase the risk of bleeding if administered prior to during or after drug therapy 	DDI-effect
DDI-DrugBank.d269.s18.p8	insulin or oral hypoglycemics drug may enhance the blood sugar reducing effect of insulin and oral drug 	DDI-effect
DDI-DrugBank.d226.s4.p0	the effects of drug are antagonized by drug such as caffeine and theophylline 	DDI-effect
DDI-DrugBank.d231.s8.p0	drug may decrease arterial responsiveness to drug 	DDI-effect
DDI-DrugBank.d131.s10.p7	data from in vitro studies of drug benzodiazepines than drug suggest a possible drug interaction for the following ergotamine other amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p7	information from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the survey ergotamine drug amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p7	data from in vitro studies of benzodiazepines other than drug dose suggest a possible drug fundamental interaction interaction for the following ergotamine drug amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p7	data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following ergotamine drug amiodarone nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d437.s7.p0	drug steady state cmax a c and cmin were increased decreased and decreased respectively by concomitant drug 	DDI-mechanism
DDI-DrugBank.d224.s1.p2	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with cns depressants alcohol drug opiates sedatives anesthetics should be considered 	DDI-advise
DDI-DrugBank.d99.s10.p0	nevertheless caution is indicated in the coadministration of drug with any of the drug and also in switching from one class to the other 	DDI-advise
DDI-DrugBank.d132.s19.p0	drug should be used with caution in patients taking drug and renal function should be carefully monitored 	DDI-advise
DDI-MedLine.d5.s4.p0	in ewes given mg of drug kg for days intraperitoneally ip the anticholinesterase effect of mg of drug kg was significantly reduced and signs of toxicity were not present 	DDI-effect
DDI-DrugBank.d166.s1.p0	drug may potentiate the adverse effects of other drug administered concomitantly 	DDI-effect
DDI-DrugBank.d485.s17.p11	benzodiazepines combination drug may decrease the clearance of some benzodiazepines alprazolam chlordiazepoxide drug and increase the clearance of others lorazepam oxazepam temazepam 	DDI-mechanism
DDI-DrugBank.d531.s38.p2	increasing the indinavir dose to mg every hours does not compensate for the increased drug metabolism due to drug 	DDI-mechanism
DDI-DrugBank.d107.s3.p4	agents causing renin release the antihypertensive effect of enalapril and drug iv is augmented by antihypertensive agents that cause renin release e g drug 	DDI-effect
DDI-DrugBank.d247.s7.p1	drug also should be used cautiously with other drugs e g digitalis drug that sensitize the myocardium to the actions of sympathomimetic drugs 	DDI-advise
DDI-DrugBank.d411.s2.p8	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract aluminum hydoxide drug resin colestipol hydrochloride ferrous sulfate sodium polystyrene sulfonate soybean flour e g infant formula sucralfate 	DDI-mechanism
DDI-DrugBank.d46.s19.p4	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d450.s2.p40	quinidine verapamil amiodarone propafenone indomethacin itraconazole drug and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d94.s4.p2	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals drug clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d172.s16.p2	fluconazole concomitant administration of drug at mg qd resulted in a two fold increase in drug plasma concentration 	DDI-mechanism
DDI-DrugBank.d82.s2.p0	therefore drug and drug should not be used concomitantly 	DDI-advise
DDI-DrugBank.d94.s4.p11	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice drug itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d60.s12.p15	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain drug e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d254.s0.p4	other drug e g barbiturates tranquilizers opioids and general anesthetics have additive or potentiating effects with drug 	DDI-effect
DDI-DrugBank.d162.s11.p0	refer to the package insert for drug preparations before use of such preparations with drug 	DDI-advise
DDI-DrugBank.d78.s3.p13	caffeine theobromine grepafloxacin like other drug may inhibit the metabolism of caffeine and drug 	DDI-mechanism
DDI-DrugBank.d389.s0.p0	drug may enhance the effects of drug barbiturates alcohol and other cns depressants 	DDI-effect
DDI-DrugBank.d107.s0.p1	hypotension patients on diuretic therapy patients on drug and especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or drug 	DDI-effect
DDI-DrugBank.d438.s37.p5	antacid maalox drug reduced the bioavailability of drug n by about 	DDI-mechanism
DDI-DrugBank.d380.s7.p0	patients should be warned of the potential danger of the intravenous self administration of drug while under treatment with drug or subutex 	DDI-advise
DDI-DrugBank.d400.s1.p2	methotrexate drug have been reported to competitively inhibit drug accumulation in rabbit kidney slices 	DDI-mechanism
DDI-DrugBank.d29.s8.p0	coadministration of drug mg and drug a cyp c substrate resulted in a decrease in clearance of diazepam 	DDI-mechanism
DDI-DrugBank.d566.s0.p5	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as drug penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d430.s3.p1	products containing drug and other multivalent cations likely will interfere with absorption of drug 	DDI-mechanism
DDI-DrugBank.d82.s9.p0	when drug is given to patients receiving drug the plasma levels of indomethacin are likely to be increased 	DDI-mechanism
DDI-DrugBank.d331.s5.p0	this antagonistic effect of drug on drug natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide 	DDI-mechanism
DDI-DrugBank.d558.s7.p0	co administration of drug with drug resulted in increases in dofetilide peak plasma levels of although overall exposure to dofetilide was not significantly increased 	DDI-mechanism
DDI-DrugBank.d115.s10.p1	drug will increase plasmaconcentration of other cyp a metabolized drugs e g triazolo benzodiazepines drug certain hmg coa reductase inhibitors etc 	DDI-mechanism
DDI-DrugBank.d238.s6.p19	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g drug phenytoin and such an effect may be anticipated with drug as well 	DDI-mechanism
DDI-DrugBank.d217.s3.p2	elevated serum levels of cyclosporine have been reported with concomitant use of drug with drug 	DDI-mechanism
DDI-DrugBank.d512.s6.p0	co administration of drug a strong inhibitor of cyp a increased drug exposure following a single mg dose of sensipar by fold 	DDI-mechanism
DDI-DrugBank.d485.s19.p2	cyclosporine combination drug may inhibit the metabolism of drug leading to increased plasma concentrations 	DDI-mechanism
DDI-DrugBank.d309.s0.p2	additive cns depression may occur when drug are administered concomitantly with other cns depressants including barbiturates drug and alcohol 	DDI-effect
DDI-DrugBank.d12.s6.p0	fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another drug and drug but may be seen after several months 	DDI-effect
DDI-DrugBank.d291.s11.p1	drug or mao inhibitors with hepatotoxic potential must not be administered together with drug or bezalip retard 	DDI-advise
DDI-DrugBank.d3.s3.p0	in vitro studies indicate that at therapeutic concentrations of drug m g ml the binding of drug was reduced from approximately to representing a potential twofold increase in unbound ketorolac plasma levels 	DDI-mechanism
DDI-DrugBank.d440.s1.p8	products containing calcium and other multivalent cations such as aluminum drug iron are likely to interfere with absorption of drug 	DDI-mechanism
DDI-MedLine.d25.s12.p3	conclusions drug inhibit the metabolism of hmg coa reductase inhibitors that are metabolized by cyp a i e atorvastatin cerivastatin drug simvastatin 	DDI-mechanism
DDI-DrugBank.d458.s27.p0	after the coadministration of mg oral drug twice daily and one mg dose of drug to subjects the auc and cmax of loratadine averaged s d and s d respectively of those obtained after co treatment with placebo 	DDI-mechanism
DDI-DrugBank.d441.s2.p6	adrenergic agents some individuals receiving drug may experience a reversible enhancement of the pressor response to indirect acting sympathomimetic agents vasopressor or drug 	DDI-effect
DDI-DrugBank.d340.s35.p9	ethinyl estradiol and norethindrone coadministration of drug with drug resulted in a decrease in ethinyl estradiol and an decrease in norethindrone plasma concentrations 	DDI-mechanism
DDI-DrugBank.d98.s0.p27	interactions for vitamin d analogues vitamin d vitamin d calcitriol and calcidiol cholestyramine drug has been reported to reduce intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d443.s0.p4	uricosuric agents drug may decrease the effects of drug sulfinpyrazone and phenylbutazone 	DDI-effect
DDI-DrugBank.d51.s2.p2	anticholinergic agents although drug is minimally absorbed into the systemic circulation there is some potential for an additive interaction with concomitantly used drug 	DDI-effect
DDI-DrugBank.d537.s0.p3	drug may interact with acetaminophen e g tylenol chloramphenicol e g drug local anaesthetic e g benzocaine and lidocaine para aminobenzoic acid paba containing readying e g sunblock and some multivitamins procainamide e g pronestyl sulfonamides sulpha medicines thiazide diuretics utilisation of these medicines during the test period will affect the test results and pancreatic append utilisation of pancreatic append may give false test results	DDI-int
DDI-DrugBank.d537.s0.p3	drug e interact aminobenzoic acetaminophen e g tylenol chloramphenicol e g drug local anesthetics may g benzocaine and lidocaine para with acid paba containing preparations e g sunscreens and some multivitamins procainamide pancreatic g pronestyl sulfonamides sulfa medicines thiazide the pancreatic of these medicines during may test period will affect the test results and e supplements use of use supplements diuretics give false test results	DDI-int
DDI-DrugBank.d537.s0.p3	drug may effect interact with acetaminophen e g tylenol chloramphenicol e g drug local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide menstruation e g pronestyl sulfonamides catamenia sulfa medicines thiazide diuretics use of these medicines during the test period will tocopherol affect the test results and pancreatic supplements use of pancreatic supplements catamenia topical anesthetic may give false test results	DDI-int
DDI-DrugBank.d537.s0.p3	drug may interact with acetaminophen e g tylenol chloramphenicol e g drug local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d75.s14.p14	the effects of medicinal products with similar properties such as inotropes milrinone enoximone amrinone olprinone and drug may be exacerbated by drug 	DDI-effect
DDI-DrugBank.d132.s23.p0	the concomitant use of drug tablets and other drug is not recommended due to the increased possibility of gastrointestinal toxicity with little or no increase in efficacy 	DDI-effect
DDI-DrugBank.d73.s4.p0	if the two drugs are coadministered the drug should be withdrawn several days before the gradual withdrawal of drug 	DDI-advise
DDI-MedLine.d63.s6.p1	intraventricular injection of drug at doses of to micrograms equally antagonized in a dose dependent manner the tail flick inhibition induced by intraventricular beta endorphin and drug 	DDI-effect
DDI-DrugBank.d291.s1.p1	for this reason the dose of the drug should be reduced by at the start of treatment with bezalip or drug retard and then titrated according to the blood clotting parameters	DDI-advise
DDI-DrugBank.d503.s5.p0	consider additive sedative effects and confusional states to emerge if drug is given with drug or barbituates 	DDI-effect
DDI-DrugBank.d484.s0.p30	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine whitethorn neoral sandimmune hiv drugs classified as rimactane protease inhibitors agenerase crixivan fortovase invirase elixophyllin kaletra norvir drug morphine vitamin a astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam phenytoin theophylline theo dur and vitamin itraconazole c	DDI-int
DDI-DrugBank.d484.s0.p30	drug may interact with the following medications acetaminophen tylenol such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid cyclosporine neoral sandimmune hiv drugs classified as protease agenerase crixivan fortovase invirase kaletra norvir drug morphine astramorph kadian ms contin phenylbutazone prednisolone prelone johns theophylline theo dur vitamin c	DDI-int
DDI-DrugBank.d484.s0.p30	drug may interact with the following medications acetaminophen tylenol antibiotics such as polycillin and tetracycline anticonvulsants diphenylhydantoin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase saquinavir kaletra norvir drug morphine astramorph kadian ms contin phenylbutazone pediapred pediapred rifadin rifadin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p30	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir drug morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d450.s6.p17	antacids kaolin pectin sulfasalazine drug cholestyramine certain anticancer drugs and metoclopramide may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d53.s7.p2	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine drug didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d202.s6.p2	there have been greater than fold increases in previously stable plasma levels of other antidepressants including drug when drug has been administered in combination with these agents 	DDI-mechanism
DDI-DrugBank.d522.s19.p4	triazolam drug has been reported to decrease the clearance of triazolam and thus may increase the pharmacologic effect of drug 	DDI-effect
DDI-DrugBank.d139.s8.p2	warfarin drug can antagonize the effect of drug 	DDI-effect
DDI-DrugBank.d140.s5.p0	however ldl c reduction was greater when drug and drug were coadministered than when either drug was given alone 	DDI-effect
DDI-DrugBank.d484.s0.p2	drug may interact with the following hiv acetaminophen tylenol drug such morphine ampicillin and tetracycline anticonvulsants dilantin phenobarbital theo cyclosporine topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s trileptal neoral sandimmune medications drugs classified wort protease inhibitors ms crixivan fortovase invirase kaletra norvir viracept as astramorph kadian agenerase contin phenylbutazone prednisolone prelone rifadin rifampin st johns as temazepam theophylline tegretol dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p2	drug english hawthorn interact with the following medications acetaminophen datril drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin atorvastatin clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifadin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p2	drug may interact with the following medications acetaminophen tylenol drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified protease inhibitors agenerase crixivan fortovase kaletra norvir viracept morphine astramorph kadian ms phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p2	drug may interact with the following medications acetaminophen tylenol drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d423.s0.p6	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine drug venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d210.s0.p2	ace inhibitors reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-MedLine.d34.s7.p0	additional drug significantly inhibited the absorption of drug in both dietary cobalt treatments 	DDI-mechanism
DDI-DrugBank.d165.s4.p4	another oral azole antifungal drug inhibits the metabolism of drug resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong qt intervals 	DDI-mechanism
DDI-DrugBank.d5.s22.p2	drugs that lower seizure threshold concurrent administration of drug and agents e g antipsychotics other antidepressants drug systemic steroids etc that lower seizure threshold should be undertaken only with extreme caution 	DDI-advise
DDI-DrugBank.d41.s0.p8	cholestyramine and charcoal administration of drug or activated charcoal in patients n and volunteers n resulted in a rapid and significant decrease in plasma m the active metabolite of drug concentration 	DDI-mechanism
DDI-DrugBank.d97.s37.p0	drug and drug formulations containing buffer should be administered at least one hour apart on an empty stomach 	DDI-advise
DDI-DrugBank.d373.s14.p0	if drug therapy is initiated in a patient currently receiving drug cautious titration is advised 	DDI-advise
DDI-DrugBank.d131.s10.p2	data from in vitro studies of drug other than alprazolam suggest a potential drug interaction for the fall out ergotamine drug amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p2	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine drug amiodarone nicardipine and	DDI-int
DDI-DrugBank.d131.s10.p2	data from in vitro studies of drug other than alprazolam suggest potential a possible drug interaction for the following ergotamine drug amiodarone nicardipine vitamin a and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p2	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine drug amiodarone nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d495.s2.p9	amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats epidural injection drug may potentiate the cns depressive effect of drug barbiturates or other sedating drugs 	DDI-effect
DDI-DrugBank.d60.s12.p21	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin drug colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d18.s1.p9	injection lorazepam injection like other injectable drug produces depression of the central nervous system when administered with ethyl alcohol drug barbiturates mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d86.s0.p6	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg drug an antiparkinsonian drug eg drug and or a tricyclic antidepressant eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d272.s2.p3	compounds in these categories result in a decreased efficacy of drug phenothiazines haloperidol metoclopramide drug 	DDI-effect
DDI-DrugBank.d198.s7.p0	drug mg once daily produced a fold increase in drug auc and a fold increase in cmax when co administered with vardenafil mg in healthy volunteers 	DDI-mechanism
DDI-DrugBank.d484.s0.p6	drug may interact with the following tylenol such as and tetracycline anticonvulsants drug phenobarbital tegretol topamax felbatol antifungals gris nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin	DDI-int
DDI-DrugBank.d484.s0.p6	dose may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dose phenobarbitone tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra ritonavir viracept morphine astramorph kadian ms contin butazolidin prelone prelone rifadin rimactane st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p6	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline atorvastatin anticonvulsants drug nail phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan saquinavir human immunodeficiency virus fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin atorvastatin rifampin st johns wort temazepam theophylline theo dur and reciprocal ohm vitamin c	DDI-int
DDI-DrugBank.d484.s0.p6	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants drug phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-MedLine.d25.s12.p2	conclusions drug inhibit the metabolism of hmg coa reductase inhibitors that are metabolized by cyp a i e atorvastatin drug lovastatin simvastatin 	DDI-mechanism
DDI-DrugBank.d462.s3.p0	in one controlled clinical study the ureidopenicillins including drug were reported to prolong the action of drug 	DDI-effect
DDI-DrugBank.d324.s1.p4	cns active drugs ethanol drug mg potentiated the cns impairing effects of drug g kg on balance testing and reaction time for hour after ethanol administration and on the digit symbol substitution test dsst symbol copying test and the variability component of the divided attention test for hours after ethanol administration 	DDI-effect
DDI-DrugBank.d219.s7.p4	cyclosporine digoxin methotrexate lodine like other drug through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of drug digoxin methotrexate and increased toxicity 	DDI-mechanism
DDI-DrugBank.d500.s2.p1	absorption of drug is impaired by antacids containing drug calcium or magnesium and iron containing preparations 	DDI-mechanism
DDI-MedLine.d130.s2.p0	drug is a neutralizing agent for drug that protects against renal damage 	DDI-effect
DDI-DrugBank.d514.s2.p2	toxicology studies of drug related deaths reveal frequent involvement of other central nervous system depressants including alcohol drug such as diazepam valium and to a rising degree methadone 	DDI-effect
DDI-DrugBank.d395.s16.p2	or with multivitamins containing drug may substantially interfere with drug absorption and result in insufficient plasma and tissue drug concentrations 	DDI-mechanism
DDI-DrugBank.d267.s5.p9	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate drug salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d150.s2.p0	drug may block the antihypertensive action of drug and similarly acting compounds 	DDI-effect
DDI-DrugBank.d73.s6.p0	concomitant use of prostaglandin synthase inhibiting drugs eg drug may decrease the hypotensive effects of drug 	DDI-effect
DDI-MedLine.d21.s2.p0	treatment with drug can directly interfere with blood glucose levels or may interact with drug	DDI-int
DDI-MedLine.d21.s2.p0	treatment with drug can directly interfere with blood glucose layer or may interact with drug	DDI-int
DDI-MedLine.d21.s2.p0	treatment with drug can directly tin can interfere with blood glucose levels or may interact with drug	DDI-int
DDI-MedLine.d21.s2.p0	treatment with drug can directly interfere with blood glucose levels or may interact with drug 	DDI-int
DDI-DrugBank.d97.s59.p0	caution is warranted and therapeutic concentration monitoring is recommended for drug when coadministered with drug 	DDI-advise
DDI-DrugBank.d499.s8.p0	therefore concurrent use of drug and drug is not recommended 	DDI-advise
DDI-DrugBank.d484.s0.p20	drug may interact with the inhibitors medications acetaminophen tylenol vitamin such ampicillin as and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor johns atromid s drug neoral sandimmune hiv theo classified as protease following agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st temazepam wort clofibrate theophylline drugs dur and antibiotics c	DDI-int
DDI-DrugBank.d484.s0.p20	drug may interact with the following medications acetaminophen tylenol antibiotics such as tylenol morphia ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox nelfinavir lipitor atorvastatin lipitor clofibrate atromid s drug neoral sandimmune hiv drugs classified as protease saquinavir tylenol inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p20	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral atorvastatin lipitor clofibrate atromid s drug neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra viracept morphine astramorph kadian contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p20	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s drug neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-MedLine.d130.s0.p0	high dose drug with drug protection 	DDI-effect
DDI-DrugBank.d469.s0.p0	drugs which may enhance the neuromuscular blocking action of drug include drug 	DDI-effect
DDI-DrugBank.d514.s2.p1	toxicology studies of drug related deaths reveal frequent involvement of other central nervous system depressants including drug benzodiazepines such as diazepam valium and to a rising degree methadone 	DDI-effect
DDI-DrugBank.d512.s7.p2	dose adjustment of drug may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp a inhibitor e g ketoconazole erythromycin drug 	DDI-advise
DDI-DrugBank.d320.s0.p0	drug should be used with caution in patients receiving other local drug or agents structurally related to amide type local anesthetics since the toxic effects of these drugs could be additive 	DDI-advise
DDI-DrugBank.d438.s38.p0	this decrease in bioavailability was about when drug was administered hours after drug 	DDI-mechanism
DDI-DrugBank.d158.s24.p2	veratrum alkaloids drug inhibit the hypotensive effect of drug 	DDI-effect
DDI-DrugBank.d114.s2.p14	concurrent administration of drugs possessing nephrotoxic e g aminoglycosides indomethacin myelotoxic e g drug chemotherapy cardiotoxic e g doxorubicin or hepatotoxic e g methotrexate asparaginase effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d62.s0.p3	drug can interact with alcohol or other cns depressants may potentiate the cns depressant effects of either these medications drug or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of	DDI-int
DDI-DrugBank.d62.s0.p3	drug can oxidase with alcohol or other and depressants may potentiate cns cns depressant monoamine of either these medications or antihistamines drug or other medications with anticholinergic activity anticholinergic effects may be potentiated when cns medications are used concurrently with antihistamines the effects of mao inhibitors concurrent use with antihistamines may prolong and intensify the anticholinergic and these depressant effects interact antihistamines	DDI-int
DDI-DrugBank.d62.s0.p3	drug can interact with alcohol or other cns depressants may potentiate the cns depressant effects mao tsetung of either these medications or antihistamines central nervous system drug or other medications with anticholinergic activity anticholinergic effects may be whitethorn potentiated when these medications natural process are used concurrently with antihistamines and sustain monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the whitethorn anticholinergic and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p3	drug can interact with alcohol or other cns depressants may potentiate the cns depressant effects of either these medications or antihistamines drug or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of antihistamines 	DDI-int
DDI-DrugBank.d507.s1.p0	the administration of drug concomitantly with known microsomal enzyme inducer drug or phenytoin to two patients with renal impairment reportedly resulted in significant reductions in elimination half life and plasma concentration 	DDI-mechanism
DDI-MedLine.d8.s6.p8	when combined with ofloxacin krm exhibited strong synergistic activity while only additive effects were observed with the combination of drug or rifabutin and drug 	DDI-effect
DDI-MedLine.d12.s6.p0	however drug stimulated but did not significantly inhibit proliferation in the presence of drug 	DDI-effect
DDI-DrugBank.d86.s0.p8	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg drug an antiparkinsonian drug eg trihexyphenidyl and or a tricyclic antidepressant eg drug commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d334.s7.p1	reports suggest that drug may diminish the antihypertensive effect of ace inhibitors including drug 	DDI-effect
DDI-DrugBank.d11.s4.p1	in em individuals treated with drug or fluoxetine the auc of drug is approximately to fold and css max is about to fold greater than atomoxetine alone 	DDI-mechanism
DDI-DrugBank.d87.s13.p4	limited data in patients receiving known enzyme inducers phenytoin drug carbamazepine indicate only a increase in the rate of drug elimination 	DDI-mechanism
DDI-DrugBank.d165.s17.p0	rhabdomyolysis has been observed in patients receiving drug administered alone at recommended dosages or concomitantly with drug including cyclosporine 	DDI-effect
DDI-DrugBank.d40.s10.p16	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone drug succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d545.s0.p1	drug carbenicillin indanyl sodium blood levels may be increased and prolonged by concurrent administration of drug 	DDI-mechanism
DDI-DrugBank.d186.s3.p2	as with other drug it should be noted that haldol may be capable of potentiating cns depressants such as drug opiates and alcohol 	DDI-effect
DDI-DrugBank.d108.s0.p1	drug should be administered with caution to patients receiving antabuse drug wyeth ayerst laboratories 	DDI-advise
DDI-DrugBank.d54.s14.p0	therefore patients without a functioning drug gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug or estrogen containing oral contraceptives are given 	DDI-advise
DDI-DrugBank.d537.s0.p7	drug may interact with acetaminophen e para aminobenzoic acid g tylenol chloramphenicol e g chloromycetin local whitethorn anesthetics e g benzocaine and lidocaine drug paba containing preparations e involve g sunscreens and some multivitamins procainamide e g mental testing pronestyl sulfonamides sulfa medicines tocopherol thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic tylenol supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p7	drug may e with acetaminophen e g tylenol chloramphenicol e g lidocaine results of e g benzocaine and chloromycetin drug paba containing preparations e g sunscreens false some multivitamins procainamide interact g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during period test the will affect the test results and pancreatic supplements use anesthetics pancreatic supplements may give and test local	DDI-int
DDI-DrugBank.d537.s0.p7	drug may interact with acetaminophen e g tylenol chloramphenicol e g local anesthetics e g and lidocaine drug paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines diuretics use these medicines during the test period will affect the test results and supplements use of pancreatic supplements may give test results	DDI-int
DDI-DrugBank.d537.s0.p7	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine drug paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d430.s0.p0	intravenous drug was shown to double the bioavailability of oral drug 	DDI-mechanism
DDI-DrugBank.d5.s17.p3	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine drug paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d511.s4.p4	because of foscarnets tendency to cause renal impairment the use of drug should be avoided in combination with potentially nephrotoxic drugs such as drug amphotericin b and intravenous pentamidine unless the potential benefits outweigh the risks to the patient 	DDI-advise
DDI-DrugBank.d499.s24.p2	lithium drug have been reported to increase steadystate plasma drug levels 	DDI-mechanism
DDI-DrugBank.d114.s5.p4	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug and antineoplastic agents specifically dacarbazine cis platinum tamoxifen and drug 	DDI-effect
DDI-DrugBank.d559.s1.p14	butalbital drug and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as drug sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d499.s6.p0	however in a study of normal subjects concurrent administration of drug decreased drug protein binding and increased ketoprofen plasma clearance from l kg h without aspirin to l kg h with aspirin 	DDI-mechanism
DDI-DrugBank.d257.s6.p29	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg pentazocine nalbuphine drug dezocine and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d140.s7.p3	digoxin when multiple doses of drug and drug were coadministered steady state plasma digoxin concentrations increased by approximately 	DDI-mechanism
DDI-DrugBank.d142.s0.p1	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics drug haloperidol phenothiazines monoamine oxidase mao inhibitors tricyclic antidepressants or some antihistamines 	DDI-effect
DDI-DrugBank.d104.s0.p3	drug may increase slightly the effect of antihypertensive drugs e g guanethidine methyldopa drug 	DDI-effect
DDI-DrugBank.d245.s0.p0	the hypoglycemic action of drug may be potentiated by certain drugs including drug and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d73.s5.p5	if replacing clonidine by beta blocker therapy the introduction of drug should be delayed for several days after drug administration has stopped 	DDI-advise
DDI-DrugBank.d484.s0.p31	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungal jaun gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as proteolytic enzyme inhibitors agenerase crixivan fortovase saquinavir kaletra norvir viracept drug astramorph kadian ms contin phenylbutazone prednisolone prelone rimactane rifampin st johns wort temazepam theophylline theo dur and vitamin deoxycytidine monophosphate	DDI-int
DDI-DrugBank.d484.s0.p31	drug may interact with the following medications tylenol antibiotics as ampicillin and tetracycline anticonvulsants dilantin phenobarbital trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra viracept drug astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p31	drug may interact with the following medications sandimmune tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin rifampin tegretol acetaminophen topamax felbatol antifungals gris peg nizoral sporanox atorvastatin viracept clofibrate atromid s lipitor contin trileptal hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir cyclosporine drug astramorph kadian ms neoral phenylbutazone prednisolone prelone rifadin phenobarbital st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p31	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept drug astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d82.s23.p0	in some patients the administration of drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d389.s0.p2	drug may enhance the effects of tricyclic antidepressants barbiturates drug and other cns depressants 	DDI-effect
DDI-DrugBank.d431.s12.p2	therefore it is theoretically possible that drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability e g ketoconazole ampicillin esters drug salts digoxin 	DDI-mechanism
DDI-DrugBank.d328.s46.p5	these increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral drug for women taking drug 	DDI-advise
DDI-DrugBank.d263.s25.p2	doxorubicin drug caused a decrease in drug phosphorylation inhibition of total phosphate formation in u molt cells 	DDI-effect
DDI-DrugBank.d331.s7.p4	indomethacin drug blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the drug induced increase in plasma renin activity 	DDI-effect
DDI-DrugBank.d210.s25.p3	rifampin co administration of drug with drug mg daily a potent inducer of hepatic metabolism produced an approximate decrease in rofecoxib plasma concentrations 	DDI-mechanism
DDI-DrugBank.d148.s4.p0	however the concomitant use of drug and drug mg initial oral dose followed by mg day orally for days results in prolongation of the prothrombin time pt and international normalized ratio inr 	DDI-effect
DDI-DrugBank.d107.s0.p0	hypotension patients on diuretic therapy patients on drug and especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug or enalaprilat 	DDI-effect
DDI-DrugBank.d79.s1.p0	oral drug may be less effective while you are taking drug 	DDI-effect
DDI-MedLine.d111.s14.p14	coingestion of acetaminophen with theophylline phenobarbital with acetaminophen and drug with drug at high to toxic concentrations decreases the binding of the target drug 	DDI-effect
DDI-DrugBank.d236.s3.p2	adrenergic blockers drug are inhibited by drug 	DDI-effect
DDI-DrugBank.d434.s19.p0	the drug steady state cmin decreased to micrograms ml when drug mg day divided into three doses was coadministered 	DDI-mechanism
DDI-DrugBank.d373.s11.p5	cimetidine a study in healthy volunteers has shown a significant increase in peak nifedipine plasma levels and area under the curve after a week course of drug at mg per day and drug at mg per day 	DDI-mechanism
DDI-DrugBank.d257.s6.p35	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg pentazocine nalbuphine butorphanol dezocine and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a drug such as drug 	DDI-advise
DDI-DrugBank.d260.s3.p0	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous drug e g tobramycin gentamicin and amikacin amphotericin b foscarnet intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d296.s1.p0	drug prolong and intensify the anticholinergic drying effects of drug 	DDI-effect
DDI-DrugBank.d17.s31.p0	drug may increase the responsiveness to drug 	DDI-effect
DDI-DrugBank.d328.s24.p2	drug caused a statistically significant increase in plasma exposures of r warfarin and s warfarin and respectively and in the pharmacodynamic effects prothrombin time measured as inr of drug 	DDI-effect
DDI-DrugBank.d357.s3.p28	dopamine antagonists since apomorphine is a dopamine agonist it is possible that drug such as the neuroleptics phenothiazines butyrophenones thioxanthenes or drug may diminish the effectiveness of apokyn 	DDI-effect
DDI-DrugBank.d470.s1.p0	caution is advised when drug is coadministered with other medications that can prolong the qt interval e g certain drug or thioridazine or lead to electrolyte abnormalities such as diuretics or amphotericin b 	DDI-advise
DDI-DrugBank.d512.s3.p4	amitriptyline concurrent administration of mg or mg drug with mg drug increased amitriptyline exposure and nortriptyline active metabolite exposure by approximately in cyp d extensive metabolizers 	DDI-mechanism
DDI-DrugBank.d107.s3.p3	agents causing renin release the antihypertensive effect of enalapril and drug iv is augmented by drug that cause renin release e g diuretics 	DDI-effect
DDI-DrugBank.d249.s9.p0	in patients taking drug and drug concomitantly lithium toxicity may develop 	DDI-effect
DDI-DrugBank.d194.s1.p0	high dose drug resulting in concentrations above ng ml administered with oral drug has led to an increase in etoposide exposure with a decrease in total body clearance of etoposide compared to etoposide alone 	DDI-mechanism
DDI-DrugBank.d289.s27.p2	drug is also expected to reduce plasma concentrations of other statins that have significant metabolism by cyp a such as lovastatin and drug 	DDI-mechanism
DDI-DrugBank.d327.s0.p0	there have been isolated reports of patients experiencing increases in their prothrombin times when drug was added to drug therapy 	DDI-effect
DDI-DrugBank.d13.s0.p65	drug interactions flupenthixol may interact with some drugs like monoamine oxidase inhibitors maoi maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants drug increases the effect of drug 	DDI-effect
DDI-DrugBank.d480.s30.p0	therefore co administration of drug with other drugs that are metabolized by this isozyme including drug phenothiazines carbamazepine and type c antiarrhythmics e g propafenone flecainide and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d350.s7.p0	in two clinical studies drug one mg kg dose or two mg kg doses increased the auc of drug by approximately 	DDI-mechanism
DDI-DrugBank.d158.s3.p7	antidepressants tricyclic drug may enhance the activity of drug or sympathomimetic agents 	DDI-effect
DDI-MedLine.d34.s7.p1	additional drug significantly inhibited the absorption of cobalt in both dietary drug treatments 	DDI-mechanism
DDI-MedLine.d79.s5.p0	drug may be taken with a light meal h following the administration of mg of drug 	DDI-advise
DDI-DrugBank.d303.s3.p2	accordingly careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking drug and drug 	DDI-advise
DDI-DrugBank.d249.s13.p1	a direct causal relationship has not been established but physicians should consider the possibility that drug may alter a diabetic patient s response to insulin or oral drug 	DDI-effect
DDI-DrugBank.d410.s6.p0	vasospastic reactions have been reported with therapeutic doses of drug containing drugs when co administered with these drug 	DDI-effect
DDI-MedLine.d116.s6.p0	the effect of drug on the drug requirement of our patient appeared to be maximal to days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal 	DDI-effect
DDI-DrugBank.d224.s1.p0	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with drug alcohol barbiturates opiates sedatives anesthetics should be considered 	DDI-advise
DDI-DrugBank.d548.s9.p3	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as drug amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d148.s6.p0	co administration concomitant use of drug with drug thrombolytics and other anticoagulants may increase the risk of bleeding 	DDI-effect
DDI-DrugBank.d470.s1.p3	caution is advised when drug is coadministered with other medications that can prolong the qt interval e g certain antiarrhythmics or thioridazine or lead to electrolyte abnormalities such as diuretics or drug 	DDI-advise
DDI-DrugBank.d54.s21.p3	vasopressors drug increases the adrenergic effect of catecholamines such as drug and norepinephrine 	DDI-effect
DDI-DrugBank.d265.s8.p0	drug and related drugs may decrease arterial responsiveness to drug 	DDI-effect
DDI-DrugBank.d331.s9.p2	antihypertensives drug may potentiate the effect of various drug necessitating a reduction in the dosage of these drugs 	DDI-effect
DDI-DrugBank.d113.s1.p0	therefore when drug is given to a patient receiving drug the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time 	DDI-advise
DDI-MedLine.d86.s6.p2	apparent oral clearance and volume of distribution of sirolimus decreased with and respectively when drug was given with drug 	DDI-mechanism
DDI-DrugBank.d351.s0.p5	probenecid as with other drug renal excretion of loracarbef is inhibited by drug and resulted in an approximate increase in the auc for loracarbef 	DDI-mechanism
DDI-DrugBank.d48.s1.p6	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir drug nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d416.s2.p0	drug depresses tubular secretion of certain weak acids such as drug 	DDI-mechanism
DDI-DrugBank.d458.s9.p0	therefore concomitant administration of drug tablets with drug is contraindicated 	DDI-advise
DDI-DrugBank.d331.s3.p4	lithium drug should generally not be given with drug such as bumetanide because they reduce its renal clearance and add a high risk of lithium toxicity 	DDI-advise
DDI-DrugBank.d529.s16.p1	other drug that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with drug 	DDI-effect
DDI-DrugBank.d484.s0.p5	saquinavir drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline drug dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral medication sodium thiopental sporanox atorvastatin lipitor clofibrate atromid principen s prelone cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan vitamin a fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p5	drug may interact with medications temazepam the acetaminophen tylenol antibiotics such lipitor ampicillin and tetracycline drug dilantin phenobarbital tegretol trileptal topamax felbatol antifungals kadian peg nizoral sporanox atorvastatin as clofibrate atromid s cyclosporine neoral sandimmune hiv drugs and as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph gris ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort dur theophylline theo following classified vitamin c	DDI-int
DDI-DrugBank.d484.s0.p5	drug english hawthorn interact with the following medications acetaminophen tylenol antibiotics such as sk ampicillin and tetracycline drug dilantin phenobarbitone tegretol trileptal topamax felbatol fungicide gris peg nizoral sporanox atorvastatin lipitor atromid s atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone pediapred rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p5	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline drug dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d175.s0.p4	hypotension patients on diuretic therapy patients on drug and especially those in whom diuretic therapy was recently instituted as well as those on severe dietary salt restriction or dialysis may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of drug 	DDI-effect
DDI-DrugBank.d89.s3.p23	based on adult data lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination e g cimetidine and ketoconazole and higher drug doses may be needed following coadministration of drugs that increase caffeine elimination e g drug and phenytoin 	DDI-advise
DDI-DrugBank.d331.s3.p5	lithium drug should generally not be given with diuretics such as drug because they reduce its renal clearance and add a high risk of lithium toxicity 	DDI-advise
DDI-DrugBank.d226.s5.p0	in the presence of these drug larger doses of drug may be required or adenosine may not be effective 	DDI-advise
DDI-MedLine.d130.s8.p0	this study demonstrates that concurrent administration of drug permits at least a twofold increase in dose and total exposure to drug 	DDI-mechanism
DDI-DrugBank.d198.s9.p2	since higher doses of ketoconazole mg daily may result in higher increases in cmax and auc a single mg dose of drug should not be exceeded in a hour period when used in combination with drug mg daily 	DDI-advise
DDI-DrugBank.d170.s5.p23	central nervous system depressants the concomitant use of duragesic drug transdermal system with other drug including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d226.s6.p0	drug effects are potentiated by drug 	DDI-effect
DDI-DrugBank.d171.s0.p2	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin drug nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d132.s1.p0	this may occur because drug competitively displaces drug from protein binding sites 	DDI-mechanism
DDI-DrugBank.d423.s2.p0	at least days should elapse between discontinuation of a drug and initiation of treatment with drug 	DDI-advise
DDI-DrugBank.d566.s0.p10	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and drug and digitalis 	DDI-mechanism
DDI-DrugBank.d231.s14.p0	there are case reports of patients who developed increased bun serum creatinine and serum potassium levels and weight gain when drug was used in conjunction with drug 	DDI-effect
DDI-DrugBank.d245.s0.p2	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates drug chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d328.s19.p0	even so drug plasma concentrations in the presence of high doses of drug were almost fold lower than those seen in cyp d poor metabolizers suggesting that dose adjustment is not necessary 	DDI-mechanism
DDI-DrugBank.d224.s0.p0	drug should not be used in patients receiving drug 	DDI-advise
DDI-DrugBank.d12.s9.p0	therefore the combined use of drug with drug should generally be avoided 	DDI-advise
DDI-DrugBank.d139.s6.p2	orlistat drug may decrease the absorption of drug 	DDI-mechanism
DDI-DrugBank.d412.s0.p0	in one survey of patients taking drug in combination with drug experienced tremor as compared to reported to occur with labetalol hcl alone 	DDI-effect
DDI-DrugBank.d170.s7.p9	mao inhibitors duragesic is not recommended for use in patients who have received maoi within days because severe and unpredictable potentiation by drug has been reported with drug 	DDI-advise
DDI-DrugBank.d54.s8.p4	cholestyramine drug binds both drug and t in the intestine thus impairing absorption of these thyroid hormones 	DDI-mechanism
DDI-DrugBank.d500.s4.p5	barbiturates carbamazepine and drug decrease the half life of drug 	DDI-mechanism
DDI-DrugBank.d39.s1.p4	colchicine drug and heavy alcohol intake for longer than weeks may produce malabsorption of drug 	DDI-mechanism
DDI-DrugBank.d60.s13.p1	resistance to the neuromuscular blocking action of drug has been demonstrated in patients chronically administered phenytoin or drug 	DDI-effect
DDI-DrugBank.d40.s19.p0	drugs whose efficacy is impaired by drug include drug corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d5.s17.p7	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline drug e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d146.s2.p0	drug may increase sensitivity to the drug 	DDI-effect
DDI-DrugBank.d249.s4.p0	ingestion of drug may increase serum concentrations of drug and methotrexate and increase cyclosporine s nephrotoxicity 	DDI-mechanism
DDI-DrugBank.d458.s23.p0	it is suggested to monitor both drug and drug 	DDI-advise
DDI-DrugBank.d516.s6.p0	separating the doses of drug and drug minimizes this decrease in bioavailability 	DDI-mechanism
DDI-DrugBank.d456.s0.p0	co treatment with the potent cyp a inhibitor drug increases drug auc by 	DDI-mechanism
DDI-DrugBank.d346.s3.p0	lethargy and somnolence have been reported following doses of drug and drug 	DDI-effect
DDI-DrugBank.d260.s3.p1	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g drug gentamicin and amikacin amphotericin b foscarnet intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d401.s0.p12	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other drug tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d249.s2.p7	because prostaglandins play an important role in hemostasis and nsaids affect platelet function as well concurrent therapy with all nsaids including drug and drug requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required 	DDI-advise
DDI-DrugBank.d533.s4.p3	ketoconazole co administration of mg twice daily drug with drug resulted in an approximate increase in plasma levels of aliskiren 	DDI-mechanism
DDI-DrugBank.d314.s0.p2	aminoglutethimide drug may diminish adrenal suppression by drug 	DDI-effect
DDI-DrugBank.d369.s3.p0	the response to drug may be blunted by drug and dopamine antagonists which cause a rise in prolactin 	DDI-effect
DDI-DrugBank.d339.s2.p2	warfarin and drug increased prothrombin time with or without clinical bleeding has been reported when drug is administered concomitantly 	DDI-effect
DDI-DrugBank.d435.s2.p9	co medications that induce cyp a e g rifampicin phenytoin carbamazepine drug or st john s wort may significantly decrease exposure to drug 	DDI-mechanism
DDI-DrugBank.d47.s2.p4	drug e g phenothiazines butyrophenones risperidone and isoniazid may reduce the therapeutic effects of drug 	DDI-effect
DDI-DrugBank.d401.s0.p6	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain drug such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d40.s10.p7	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram drug ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d196.s0.p0	treatment with drug once weekly for weeks in healthy subjects was associated with an inhibition of p a and a increase in drug auc 	DDI-mechanism
DDI-DrugBank.d48.s15.p69	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl drug quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d3.s8.p4	furosemide drug iv im reduced the diuretic response to drug in normovolemic healthy subjects by approximately mean sodium and urinary output decreased 	DDI-effect
DDI-DrugBank.d401.s0.p16	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and drug 	DDI-effect
DDI-DrugBank.d132.s21.p0	in some patients the combined use of drug and drug has been associated with fatal gastrointestinal hemorrhage 	DDI-effect
DDI-DrugBank.d178.s7.p0	a interaction between drug and a fluoroquinolone antibiotic has been reported resulting in a potentiation of the hypoglycemic action of glyburide	DDI-int
DDI-DrugBank.d178.s7.p0	a possible interaction between drug and drug a fluoroquinolone antibiotic has been reported resulting in a potentiation tween of the vitamin a hypoglycemic action of glyburide	DDI-int
DDI-DrugBank.d178.s7.p0	a possible interaction between resulting and drug a fluoroquinolone antibiotic has been reported drug potentiation a in of the hypoglycemic action of glyburide	DDI-int
DDI-DrugBank.d178.s7.p0	a possible interaction between drug and drug a fluoroquinolone antibiotic has been reported resulting in a potentiation of the hypoglycemic action of glyburide 	DDI-int
DDI-MedLine.d126.s6.p1	pretreatment of rats with drug mg kg ip or vitamin e mg kg per day ig for days and a dose of mg kg on the th day provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues induced by single high dose of oral drug administration within h 	DDI-effect
DDI-DrugBank.d40.s12.p0	drugs that may decrease plasma drug concentrations include drug chronic alcohol abuse reserpine	DDI-mechanism
DDI-DrugBank.d94.s18.p1	because of its primary cns effect caution should be used when drug is taken with other centrally acting drugs and drug 	DDI-advise
DDI-DrugBank.d382.s38.p3	rifampin when a single mg dose of drug was administered on day of a day regimen of mg day of drug a strong cyp a inducer the auc of aprepitant decreased approximately fold and the mean terminal half life decreased approximately fold 	DDI-mechanism
DDI-DrugBank.d144.s1.p10	if treatment with inhibitors of cyp a activity such as ketoconazole drug ritonavir indinavir saquinavir erythromycin etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-DrugBank.d368.s14.p0	drug may elevate drug levels 	DDI-mechanism
DDI-DrugBank.d313.s3.p9	beta blockers clonidine lithium salts and drug may either potentiate or weaken the blood glucose lowering effect of drug 	DDI-effect
DDI-DrugBank.d413.s12.p3	thiazide diuretics the reports that the concomitant use of drug and drug may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause and effect relationship and a mechanism of causation 	DDI-effect
DDI-DrugBank.d5.s17.p1	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g drug imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d318.s7.p2	flucytosine while a synergistic relationship with drug has been reported concomitant use may increase the toxicity of drug by possibly increasing its cellular uptake and or impairing its renal excretion 	DDI-effect
DDI-DrugBank.d267.s5.p5	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins drug clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d479.s2.p0	marked symptomatic orthostatic hypotension has been reported when drug and drug were used in combination 	DDI-effect
DDI-DrugBank.d341.s3.p0	two percent of patients treated concurrently with drug and drug developed neutropenia anc x l 	DDI-effect
DDI-DrugBank.d269.s4.p2	clonidine concomitant administration of drug with drug may potentiate blood pressure and heart rate lowering effects 	DDI-effect
DDI-DrugBank.d151.s0.p1	drug in large amounts may counteract the antiepileptic effect of phenobarbital drug and primidone and increase the frequency of seizures in susceptible pediatric patients 	DDI-effect
DDI-DrugBank.d40.s19.p6	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens drug oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d466.s18.p3	this observed increase in the bioavailability of fexofenadine may be due to transport related effects such as p glycoprotein in vivo animal studies also suggest that in addition to enhancing absorption drug decreases drug gastrointestinal secretion while erythromycin may also decrease biliary excretion 	DDI-mechanism
DDI-DrugBank.d434.s14.p0	increasing the drug dose to mg day in six of these subjects increased the steady state drug cmin to micrograms ml 	DDI-mechanism
DDI-DrugBank.d334.s20.p2	it is recommended that serum lithium levels be monitored frequently if drug is administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d224.s2.p0	drug have been reported to blunt the hypotensive effect of systemic drug 	DDI-effect
DDI-DrugBank.d202.s3.p0	in well controlled patients undergoing concurrent therapy with drug a decrease in the steady state serum concentrations of drug may occur when cime tidine therapy is discontinued 	DDI-mechanism
DDI-DrugBank.d99.s21.p0	drug is reported to reduce hepatic metabolism of certain drug thereby delaying elimination and increasing steady state concentrations of these drugs 	DDI-mechanism
DDI-MedLine.d110.s6.p1	both drug and mc block drug induced and nicotine induced dopamine release in the nucleus accumbens 	DDI-effect
DDI-DrugBank.d283.s5.p4	cyclosporine because drug can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine and because renal excretion is the primary elimination route of fibrate drugs including drug there is a risk that an interaction will lead to deterioration 	DDI-effect
DDI-DrugBank.d48.s13.p4	the use of antacids should be considered in place of drug or proton pump inhibitors in patients receiving drug therapy 	DDI-advise
DDI-DrugBank.d105.s0.p8	anticoagulants including coumarin derivatives indandione derivatives and drug such as nonsteroidal anti inflammatory drugs nsaids and aspirin may increase the risk of bleeding when administered concomitantly with drug 	DDI-effect
DDI-DrugBank.d226.s1.p2	digoxin and drug use may be rarely associated with ventricular fibrillation when combined with drug 	DDI-effect
DDI-DrugBank.d249.s4.p2	ingestion of drug may increase serum concentrations of digoxin and methotrexate and increase drug s nephrotoxicity 	DDI-effect
DDI-DrugBank.d355.s2.p0	concurrent administration of drug and drug may result in elevated serum levels of oxyphenbutazone 	DDI-mechanism
DDI-DrugBank.d314.s18.p3	hepatic enzyme inducers inhibitors and substrates drugs which induce cytochrome p a cyp a enzyme activity e g drug phenytoin carbamazepine rifampin may enhance the metabolism of drug and require that the dosage of the corticosteroid be increased 	DDI-mechanism
DDI-DrugBank.d537.s0.p5	drug crataegus oxycantha interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g drug and xylocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamide sulfa medicament thiazide diuretic use of these medicament during the test period will affect the test results and pancreatic append use of pancreatic append crataegus oxycantha give false test results	DDI-int
DDI-DrugBank.d537.s0.p5	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g drug and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g sulfonamides sulfa thiazide diuretics of these medicines during the test period affect the test results and pancreatic supplements use of pancreatic supplements false test results	DDI-int
DDI-DrugBank.d537.s0.p5	drug may interact with acetaminophen and g tylenol chloramphenicol e g chloromycetin local anesthetics e g drug and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens diuretics some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide e use of test medicines during test these period will affect the test results and pancreatic supplements use of pancreatic supplements may give false the results	DDI-int
DDI-DrugBank.d537.s0.p5	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g drug and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d484.s0.p21	drug may interact privy antibiotic drug restoril with the following medications nelfinavir acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine drug sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph jaun gris kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo toilet dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p21	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants phenobarbital tegretol trileptal topamax felbatol antifungals gris nizoral atorvastatin lipitor clofibrate atromid s cyclosporine drug sandimmune hiv drugs classified as protease inhibitors fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p21	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline prednisolone dilantin atromid tegretol trileptal fortovase felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate phenobarbital s cyclosporine drug sandimmune c drugs classified hiv protease inhibitors agenerase norvir topamax invirase kaletra crixivan viracept morphine astramorph kadian ms contin phenylbutazone anticonvulsants prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin as	DDI-int
DDI-DrugBank.d484.s0.p21	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine drug sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d423.s0.p19	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine drug venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d247.s7.p0	drug also should be used cautiously with other drugs e g drug glycosides that sensitize the myocardium to the actions of sympathomimetic drugs 	DDI-advise
DDI-DrugBank.d480.s22.p4	however other published reports describe modest elevations less than two fold of clozapine and metabolite concentrations when drug was taken with drug fluoxetine and sertraline 	DDI-mechanism
DDI-MedLine.d25.s9.p0	discussion drug is a potent inhibitor of cyp a the major enzyme responsible for drug metabolism 	DDI-mechanism
DDI-DrugBank.d229.s3.p0	the addition of mg kg day of drug approximately times the maximum recommended daily inhalation dose in adults on a mg m basis to mg kg day of drug approximately times the maximum recommended daily inhalation dose in adults on a mg m basis appears to have increased the incidence of both resorptions and malformations 	DDI-effect
DDI-DrugBank.d489.s6.p0	hypotension av conduction disturbances and left ventricular failure have been reported in some patients receiving drug when an oral drug was added to the treatment regimen 	DDI-effect
DDI-DrugBank.d409.s1.p1	since bacteriostatic drugs such as the drug of antibiotics may interfere with the bactericidal action of drug it is not advisable to administer these drugs concomitantly 	DDI-effect
DDI-MedLine.d23.s1.p16	in a comparison of digitalis tolerance in dogs anesthetized with ketamine drug or pentobarbital the dosage of drug needed to cause ventricular tachycardia was significantly higher as was the ld of ouabain with ketamine or innovar than with pentobarbital 	DDI-effect
DDI-DrugBank.d66.s6.p0	in another report nine patients with breast cancer were reported to have decreased symptoms of drug related toxicity when given supplemental drug at a dose of gram kilogram day 	DDI-effect
DDI-DrugBank.d122.s0.p2	nephrotoxicity has been reported following concomitant administration of drug with aminoglycoside antibiotics or potent diuretics such as drug 	DDI-effect
DDI-DrugBank.d53.s7.p3	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine drug efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d562.s7.p3	also concomitant administration of drug with products containing iron multivitamins containing zinc or drug didanosine chewable buffered tablets or the pediatric powder for oral solution may result in low urine levels 	DDI-mechanism
DDI-DrugBank.d325.s4.p2	cardiac effects of drug are antagonized by beta adrenergic blocking agents such as propranolol and drug 	DDI-effect
DDI-DrugBank.d219.s11.p1	nevertheless clinical studies as well as postmarketing observations have shown that drug can reduce the natriuretic effect of furosemide and drug in some patients 	DDI-effect
DDI-DrugBank.d124.s26.p135	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and drug may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d382.s31.p6	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir drug should be approached with caution 	DDI-advise
DDI-DrugBank.d388.s2.p0	exaggerated hypertensive responses have been reported from the combined use of drug and drug including those contained in proprietary cold remedies and vasoconstrictive nasal drops 	DDI-effect
DDI-DrugBank.d245.s0.p1	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound drug sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d359.s6.p0	caution is therefore advised when administering drug to patients receiving drug 	DDI-advise
DDI-DrugBank.d170.s7.p4	mao inhibitors drug is not recommended for use in patients who have received drug within days because severe and unpredictable potentiation by mao inhibitors has been reported with opioid analgesics	DDI-advise
DDI-DrugBank.d509.s2.p0	adrenergic receptor antagonism drug has the potential to enhance the effect of certain drug 	DDI-effect
DDI-DrugBank.d443.s9.p2	antacids enteric coated drug should not be given concurrently with drug since an increase in the ph of the stomach may effect the enteric coating of the tablets 	DDI-advise
DDI-DrugBank.d283.s5.p3	cyclosporine because drug can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine and because renal excretion is the primary elimination route of drug including tricor there is a risk that an interaction will lead to deterioration 	DDI-effect
DDI-MedLine.d42.s9.p0	however patients with moderate to severe cardiovascular disease or those taking drug therapy are at increased risk for potentially serious cardiovascular adverse effects with drug therapy 	DDI-effect
DDI-DrugBank.d236.s22.p2	norepinephrine drug enhance the adrenergic effect of drug 	DDI-effect
DDI-DrugBank.d562.s0.p0	elevated plasma levels of drug have been reported with concomitant use of some drug 	DDI-mechanism
DDI-MedLine.d8.s6.p0	when combined with drug drug exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin or rifabutin and ofloxacin 	DDI-effect
DDI-DrugBank.d410.s2.p1	drug and d h e drug injection usp should not be taken within hours of each other 	DDI-advise
DDI-DrugBank.d450.s2.p37	quinidine verapamil amiodarone propafenone indomethacin drug alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d559.s1.p6	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as drug sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d509.s0.p4	drug drug interactions given the primary cns effects of aripiprazole caution should be used when drug is taken in combination with other centrally acting drugs and drug 	DDI-advise
DDI-DrugBank.d334.s2.p0	if it is necessary to continue the drug initiate therapy with drug at a dose of mg daily and provide close medical supervision after the initial dose until blood pressure has stabilized 	DDI-advise
DDI-DrugBank.d522.s24.p7	other drugs drug interactions have been reported with concomitant administration of drug and other dilantin medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine drug dose astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p7	other drugs drug interactions have been account with concomitant administration of drug and other medications include cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine drug astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p7	other drugs drug interactions have been reported with concomitant administration of drug and other phenytoin including cyclosporine hexobarbital carbamazepine alfentanil disopyramide astemizole bromocriptine drug medications and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p7	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine drug astemizole and lovastatin 	DDI-int
DDI-DrugBank.d8.s0.p3	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug is administered in combination with other cns depressants such as barbiturates tranquilizers drug or inhalation general anesthetics 	DDI-effect
DDI-DrugBank.d87.s14.p0	in healthy subjects receiving drug gm daily for one week plasma drug levels increased by about and half life increased by about 	DDI-mechanism
DDI-DrugBank.d359.s1.p1	considerable caution should be exercised if drug is administered concurrently with phenurone drug since paranoid symptoms have been reported during therapy with this combination 	DDI-advise
DDI-DrugBank.d412.s7.p0	during controlled hypotensive anesthesia using drug in association with drug high concentrations or above of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure 	DDI-effect
DDI-DrugBank.d245.s7.p0	since animal studies suggest that the action of drug may be prolonged by therapy with drug barbiturates should be employed with caution 	DDI-effect
DDI-DrugBank.d506.s7.p0	patients taking drug and drug concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the qrs complex and or prolongation of the q t interval 	DDI-mechanism
DDI-DrugBank.d249.s5.p9	patients who begin taking diclofenac or who increase their diclofenac dose or any other drug while taking drug methotrexate or cyclosporine may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d99.s26.p0	transient delirium has been reported in patients who were treated with one gram of drug and mg of drug 	DDI-effect
DDI-DrugBank.d568.s17.p0	if concomitant treatment with drug and an drug e g fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d492.s0.p0	drug prolong and intensify the anticholinergic effects of drug 	DDI-effect
DDI-DrugBank.d382.s31.p5	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin drug nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d309.s0.p0	additive cns depression may occur when drug are administered concomitantly with other drug including barbiturates tranquilizers and alcohol 	DDI-effect
DDI-DrugBank.d124.s30.p3	coadministration with compounds that are potent inducers of cyp a eg drug phenytoin dexamethasone carbamazepine may result in decreased plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d249.s14.p5	diuretics diclofenac and other drug can inhibit the activity of drug 	DDI-effect
DDI-DrugBank.d55.s2.p0	drug should be used with caution if at all when potent inhalational drug such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines 	DDI-advise
DDI-DrugBank.d401.s0.p15	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the drug salts and antihistamines 	DDI-effect
DDI-DrugBank.d172.s6.p1	identify clinical studies with drug have identified potentially significant interactions with fluconazole and drug	DDI-int
DDI-DrugBank.d172.s6.p1	clinical significant with drug have identified potentially studies interactions with fluconazole and drug	DDI-int
DDI-DrugBank.d172.s6.p1	clinical studies with drug have identified potentially interactions with fluconazole and drug	DDI-int
DDI-DrugBank.d172.s6.p1	clinical studies with drug have identified potentially significant interactions with fluconazole and drug 	DDI-int
DDI-DrugBank.d344.s0.p0	concomitant use of drug supplements and drug may increase calcium absorption	DDI-mechanism
DDI-DrugBank.d60.s12.p28	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and drug 	DDI-effect
DDI-DrugBank.d456.s1.p11	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin drug and voriconazole 	DDI-advise
DDI-DrugBank.d123.s8.p1	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as drug or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d395.s4.p2	trough plasma enoxacin levels were also higher when drug and drug were administered concomitantly 	DDI-mechanism
DDI-DrugBank.d186.s3.p8	as with other antipsychotic agents it should be noted that drug may be capable of potentiating cns depressants such as anesthetics opiates and drug 	DDI-effect
DDI-DrugBank.d338.s8.p5	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a nefazodone fluvoxamine cimetidine diltiazem isoniazide and some drug 	DDI-mechanism
DDI-DrugBank.d170.s5.p32	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and drug may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d488.s6.p11	drugs decreasing heparin effect digitalis drug nicotine or antihistamines may partially counteract the anticoagulant action of drug 	DDI-effect
DDI-DrugBank.d53.s7.p4	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine drug fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d325.s4.p1	cardiac effects of drug are antagonized by beta adrenergic blocking agents such as drug and metoprolol 	DDI-effect
DDI-DrugBank.d530.s2.p4	selegiline drug and the selective mao inhibitor drug may have synergistic antidepressant activity if used concomitantly 	DDI-effect
DDI-DrugBank.d266.s1.p1	it is recommended that if drug is started in patients already receiving coumarin anticoagulants prothrombin times should be closely monitored and adjustment of the drug dose may be necessary 	DDI-advise
DDI-DrugBank.d397.s1.p5	in case of theophylline toxicity and or elevated serum theophylline levels the dose of drug should be reduced while the patient is receiving concomitant drug therapy 	DDI-advise
DDI-DrugBank.d464.s0.p5	drug in combination with other narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics or other drug including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d325.s8.p1	drug or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug such as dopamine 	DDI-effect
DDI-DrugBank.d488.s2.p25	platelet inhibitors drugs such as acetylsalicylic acid dextran drug ibuprofen indomethacin dipyridamole hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d485.s4.p0	drug interferes with the contraceptive effect of microdosed drug containing minipill preparations 	DDI-effect
DDI-MedLine.d61.s9.p0	these alterations in drug pharmacokinetics produced by drug explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically 	DDI-mechanism
DDI-DrugBank.d382.s14.p4	the iv methylprednisolone dose should be reduced by approximately and the oral drug dose should be reduced by approximately when coadministered with drug to achieve exposures of methylprednisolone similar to those obtained when it is given without aprepitant 	DDI-advise
DDI-DrugBank.d364.s9.p0	caution should be used when drug and drug are administered concomitantly 	DDI-advise
DDI-DrugBank.d267.s6.p2	as with some other drug the time of onset of neuromuscular block induced by nuromax is lengthened and the duration of block is shortened in patients receiving phenytoin or drug 	DDI-effect
DDI-DrugBank.d115.s10.p2	drug will increase plasmaconcentration of other cyp a metabolized drugs e g triazolo benzodiazepines dihydropyridine calcium channel blockers certain drug etc 	DDI-mechanism
DDI-DrugBank.d446.s0.p8	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine drug nicotine somatropin tamoxifen and coumadin	DDI-int
DDI-DrugBank.d446.s0.p8	drug may interact with antidepressants aspirin barbiturates bromocriptine supplements corticosteroids cyclosporine drug nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p8	drug warfarin interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine drug nicotine somatropin tamoxifen and may	DDI-int
DDI-DrugBank.d446.s0.p8	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine drug nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d565.s34.p2	the elimination half life of midazolam and drug also increased fold during coadministration with drug 	DDI-mechanism
DDI-DrugBank.d124.s26.p44	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone drug quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d460.s1.p0	drug is a potential inhibitor of the cyp c isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of drug 	DDI-mechanism
DDI-DrugBank.d347.s7.p41	magnesium and or aluminum containing antacids products containing ferrous sulfate iron multivitamin preparations containing drug or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d186.s3.p6	as with other antipsychotic agents it should be noted that drug may be capable of potentiating cns depressants such as drug opiates and alcohol 	DDI-effect
DDI-DrugBank.d357.s0.p28	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the ht antagonist class including for example ondansetron granisetron dolasetron drug and alosetron is contraindicated 	DDI-advise
DDI-DrugBank.d399.s0.p0	preliminary data which suggest that drug may inhibit the anti inflammatory activity of drug have not been confirmed 	DDI-effect
DDI-DrugBank.d558.s22.p2	in addition drugs that are actively secreted via this route e g drug metformin and amiloride should be co administered with care as they might increase drug levels 	DDI-advise
DDI-DrugBank.d484.s0.p23	drug may interact with morphine following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal classified felbatol antifungals gris peg nizoral viracept atorvastatin c clofibrate atromid s cyclosporine neoral sandimmune hiv drugs topamax as drug agenerase crixivan st invirase kaletra norvir vitamin the astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin fortovase johns wort temazepam theophylline theo dur and sporanox lipitor	DDI-int
DDI-DrugBank.d484.s0.p23	drug may interact antibiotic drug with sm the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline vitamin a anticonvulsants vitamin a dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as drug agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone atorvastatin prelone rifadin rifampin st johns wort temazepam theophylline theo drug dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p23	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and achromycin anticonvulsants diphenylhydantoin purple heart tegretol trileptal topamax felbatol antifungals jaun gris nail nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as drug agenerase crixivan fortovase invirase kaletra ritonavir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p23	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as drug agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d40.s10.p11	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists drug isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d450.s2.p33	quinidine verapamil amiodarone propafenone drug itraconazole alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d231.s4.p0	drug has a tendency to antagonize the skeletal muscle relaxing effect of drug and may potentiate the action of succinylcholine 	DDI-effect
DDI-DrugBank.d60.s12.p9	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and drug magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d368.s13.p0	drug and drug used concurrently increases the risk of renal calculus formation 	DDI-effect
DDI-DrugBank.d238.s6.p0	plasma levels of several closely related drug have been reported to be increased by the concomitant administration of drug or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with cmi as well 	DDI-mechanism
DDI-MedLine.d102.s6.p0	endothelium intact aortic rings from high drug rats were supersensitive to drug when compared to vehicle progesterone and progesterone high estradiol treated rats pd values and respectively 	DDI-effect
DDI-DrugBank.d241.s1.p2	when other antiplatelet agents or drug are used concomitantly there is the potential for drug to increase the risk of bleeding 	DDI-effect
DDI-DrugBank.d256.s0.p0	drug has been shown to have neuromuscular blocking properties that may enhance the action of other drug 	DDI-effect
DDI-DrugBank.d458.s6.p0	coadministration of drug with drug tablets is therefore contraindicated 	DDI-advise
DDI-DrugBank.d249.s5.p2	patients who begin taking drug or who increase their diclofenac dose or any other nsaid while taking drug methotrexate or cyclosporine may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d537.s0.p1	drug may interact with acetaminophen e g drug chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics of these during the test period will affect test results and pancreatic supplements use of pancreatic supplements may give results	DDI-int
DDI-DrugBank.d537.s0.p1	drug may interact with acetaminophen e g drug check chloramphenicol e g chloromycetin local anesthetics e g benzocaine and diuretic lidocaine para aminobenzoic acid paba containing preparations e g sunscreens untrue effect and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic untrue supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p1	drug may interact with acetaminophen e gb drug chloramphenicol e gb chloromycetin local anesthetics e gb benzocaine and lidocaine para aminobenzoic acid paba containing preparations e gb sunscreens and some multivitamins procainamide e gb pronestyl sulfonamides sulfa medicines thiazide diuretics manipulation of these medicines during the test menstruum will pretend the test results and pancreatic appurtenance manipulation of pancreatic appurtenance may present false test results	DDI-int
DDI-DrugBank.d537.s0.p1	drug may interact with acetaminophen e g drug chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d55.s2.p1	drug should be used with caution if at all when potent inhalational anesthetics such as drug are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines 	DDI-advise
DDI-MedLine.d49.s6.p0	combinations of drug and drug were indifferent for strains and synergistic for strains 	DDI-effect
DDI-DrugBank.d328.s4.p3	aspirin concomitant administration of drug with drug may result in an increased risk of gi ulceration and complications compared to valdecoxib alone 	DDI-effect
DDI-DrugBank.d142.s0.p0	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other drug amantadine haloperidol phenothiazines monoamine oxidase mao inhibitors tricyclic antidepressants or some antihistamines 	DDI-effect
DDI-DrugBank.d509.s20.p0	when drug is added to drug therapy aripiprazole dose should be doubled 	DDI-advise
DDI-DrugBank.d434.s17.p3	carbamazepine drug causes a decrease in the steady state drug plasma concentrations and an increase in the steady state carbamazepine epoxide plasma concentration 	DDI-mechanism
DDI-DrugBank.d405.s1.p2	other depressasnts such as drug barbiturates and maois may enhance cns depression when administered with drug 	DDI-effect
DDI-DrugBank.d340.s14.p4	indinavir coadministration of drug with drug resulted in an increase in nelfinavir plasma auc and a increase in indinavir plasma a c 	DDI-mechanism
DDI-DrugBank.d260.s3.p3	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and drug amphotericin b foscarnet intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d400.s5.p0	this interaction should be given consideration in patients taking drug concomitantly with drug 	DDI-advise
DDI-DrugBank.d552.s1.p0	drug has been shown to have an additive cns depressant effect when given with either drug secobarbitone sodium alcohol or codeine 	DDI-effect
DDI-DrugBank.d400.s0.p5	aspirin as with other nsaids concomitant administration of drug and drug is not generally recommended because of the potential of increased adverse effects 	DDI-advise
DDI-DrugBank.d314.s19.p5	drugs which inhibit cyp a e g ketoconazole macrolide antibiotics such as drug have the potential to result in increased plasma concentrations of drug 	DDI-mechanism
DDI-DrugBank.d227.s0.p1	drug potentiates the muscle relaxant effect of all muscle relaxants most notably drug and mac minimum alveolar concentration is reduced by concomitant administration of n o 	DDI-effect
DDI-DrugBank.d401.s0.p13	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics drug certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d10.s2.p0	drug administration to three cancer patients over a dose range of mg to mg led to a dose dependent inhibition of drug elimination the effect of alternate day administration of mg of betaseron on drug metabolism in ms patients is unknown 	DDI-mechanism
DDI-DrugBank.d85.s9.p3	naproxen and other drug can reduce the antihypertensive effect of drug and other beta blockers 	DDI-effect
DDI-DrugBank.d11.s3.p1	dosage adjustment of drug may be necessary when coadministered with cyp d inhibitors e g paroxetine drug and quinidine 	DDI-advise
DDI-DrugBank.d499.s20.p0	therefore the combination of drug and drug is not recommended 	DDI-advise
DDI-DrugBank.d19.s9.p5	in rats simultaneous ingestion of disulfiram and nitrite in the diet for weeks has been reported to cause tumors and it has been suggested that drug may react with drug in the rat stomach to form a nitrosamine which is tumorigenic 	DDI-effect
DDI-DrugBank.d179.s38.p7	methotrexate e g mexate use of drug with drug may increase the chance of side effects affecting the liver and or the side effects of methotrexate	DDI-effect
DDI-DrugBank.d353.s11.p2	tetracyclines since both drug and drug can cause increased intracranial pressure their combined use is contraindicated 	DDI-effect
DDI-DrugBank.d329.s3.p0	because of the small effect on half life the coadministration with drug to extend the half life of drug is not recommended 	DDI-advise
DDI-DrugBank.d478.s1.p6	because there is a theoretical basis that these effects may be additive use of ergotamine containing or drug like dihydroergotamine or methysergide and drug within hours is contraindicated 	DDI-advise
DDI-DrugBank.d115.s9.p0	particular caution is recommended when administering drug with cyp a substrates that have a narrow therapeutic window e g drug or pimozide 	DDI-advise
DDI-DrugBank.d53.s7.p6	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole drug midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d484.s0.p24	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and dose tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg morphine nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors drug crixivan fortovase invirase acetaminophen kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st acetaminophen johns wort temazepam theophylline theo jaun gris morphia dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p24	drug may interact with the following medications classified tegretol antibiotics such protease ampicillin and tetracycline anticonvulsants dilantin phenobarbital tylenol trileptal topamax felbatol antifungals gris peg nizoral sporanox prelone lipitor clofibrate atromid s cyclosporine neoral norvir hiv drugs rifadin as as inhibitors drug crixivan fortovase invirase kaletra sandimmune viracept morphine astramorph kadian ms contin phenylbutazone prednisolone atorvastatin acetaminophen rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p24	dose may interact with the stick to medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors dose indinavir fortovase invirase kaletra norvir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rimactane st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p24	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors drug crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d77.s2.p8	avoid the use of preparations such as decongestants and local drug which contain any sympathomimetic amine e g epinephrine norepinephrine since it has been reported that drug can potentiate the effects of catecholamines 	DDI-advise
DDI-DrugBank.d296.s0.p4	drug has additive effects with alcohol and other cns depressants hypnotics sedatives drug etc 	DDI-effect
DDI-DrugBank.d568.s39.p8	concomitant administration with racemic citalopram citalopram since drug is the active isomer of racemic citalopram drug the two agents should not be coadministered 	DDI-advise
DDI-DrugBank.d267.s5.p7	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin drug and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d207.s7.p4	drugs that cause significant sustained elevation in gastric ph histamine h receptor antagonists such as drug or cimetidine may reduce plasma concentrations of drug and therefore potentially may reduce efficacy 	DDI-mechanism
DDI-DrugBank.d398.s0.p2	the use of drug may result in additive cns depressant effects when coadministered with alcohol antihistamines drug or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d241.s0.p0	additional reductions in blood pressure may occur when drug is administered with drug antihypertensive agents or other vasodilators 	DDI-effect
DDI-DrugBank.d340.s6.p11	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam drug gi motility agents cisapride	DDI-advise
DDI-DrugBank.d314.s18.p7	hepatic enzyme inducers inhibitors and substrates drugs which induce cytochrome p a cyp a enzyme activity e g barbiturates drug carbamazepine rifampin may enhance the metabolism of drug and require that the dosage of the corticosteroid be increased 	DDI-mechanism
DDI-DrugBank.d5.s22.p3	drugs that lower seizure threshold concurrent administration of drug and agents e g antipsychotics other antidepressants theophylline systemic drug etc that lower seizure threshold should be undertaken only with extreme caution 	DDI-advise
DDI-DrugBank.d228.s1.p0	similarly drug decreased the rate of elimination of drug by approximately by the same mechanism 	DDI-mechanism
DDI-DrugBank.d165.s15.p0	coadministration of drug and drug tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs 	DDI-mechanism
DDI-DrugBank.d165.s3.p0	coadministration of drug with drug has led to elevated plasma concentrations of terfenadine resulting in rare instances of life threatening cardiac dysrhythmias and one death 	DDI-mechanism
DDI-MedLine.d3.s7.p1	drug significantly increased the area under the curve at steady state auc ss of rifabutin by fold and the auc ss of drug by fold 	DDI-mechanism
DDI-DrugBank.d450.s12.p2	although beta adrenergic blockers or drug and drug may be useful in combination to control atrial fibrillation their additive effects on av node conduction can result in advanced or complete heart block 	DDI-effect
DDI-DrugBank.d171.s0.p8	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine drug and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d123.s8.p2	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or drug antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d131.s6.p0	coadministration of drug decreased the maximum plasma concentration of drug by decreased clearance by and increased half life by 	DDI-mechanism
DDI-DrugBank.d488.s1.p0	therefore when drug is given with drug or warfarin sodium a period of at least hours after the last intravenous dose or hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained 	DDI-advise
DDI-DrugBank.d350.s12.p13	in addition results from regression analyses of patient pharmacokinetic data suggest that co administration of other inducers of drug clearance efavirenz nevirapine drug dexamethasone or carbamazepine with drug may result in clinically meaningful reductions in caspofungin concentrations 	DDI-mechanism
DDI-DrugBank.d267.s5.p2	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides drug bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d4.s0.p2	synergism between drug e g theophylline ephedrine and other drug has been reported 	DDI-effect
DDI-DrugBank.d368.s10.p0	drug reduces urinary excretion of drug and may enhance its effect 	DDI-mechanism
DDI-DrugBank.d257.s6.p20	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg drug nalbuphine butorphanol dezocine and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d238.s6.p17	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine drug and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with drug as well 	DDI-mechanism
DDI-DrugBank.d13.s0.p0	drug interactions drug may interact with some drugs like drug antidepressant drug antidepressant maoi dose maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-int
DDI-DrugBank.d13.s0.p0	drug interactions drug may interact with some drugs like drug maoi maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressant drug antidepressant drug flupenthixol increment the effect of tricyclic antidepressant drug antidepressant drug	DDI-int
DDI-DrugBank.d13.s0.p0	drug interactions drug may interact with some drugs drug maoi maoi could theoretically pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-int
DDI-DrugBank.d13.s0.p0	drug interactions drug may interact with some drugs like drug maoi maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-int
DDI-DrugBank.d107.s9.p0	this interaction should be given consideration in patients taking drug concomitantly with drug 	DDI-advise
DDI-DrugBank.d537.s0.p2	g give interact e acetaminophen with g tylenol drug e drug chloromycetin local anesthetics e supplements benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines test the during affect will period the test results and pancreatic supplements use of pancreatic g may may false test results	DDI-int
DDI-DrugBank.d537.s0.p2	drug may interact with acetaminophen mental testing e sulpha g tylenol drug e g chloromycetin local anesthetics e g benzocaine and santa maria de belem lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics mental testing use of whitethorn these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p2	dose may interact with tylenol e g tylenol dose e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid para aminobenzoic acid containing homework e g sun blocker and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretic use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p2	drug may interact with acetaminophen e g tylenol drug e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d86.s0.p3	the concurrent use of two or more drugs with anticholinergic activity such as an drug eg chlorpromazine an antiparkinsonian drug eg trihexyphenidyl and or a drug eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d516.s5.p7	magnesium and aluminum containing drug administered concomitantly with drug significantly decreased the bioavailability of lomefloxacin 	DDI-mechanism
DDI-DrugBank.d334.s19.p2	lithium toxicity was usually reversible upon discontinuation of drug and the drug 	DDI-effect
DDI-DrugBank.d163.s0.p4	vitamin a because of the relationship of drug to drug patients should be advised against taking vitamin supplements containing vitamin a to avoid additive toxic effects	DDI-effect
DDI-DrugBank.d382.s23.p3	the potential effects of increased plasma concentrations of drug or other benzodiazepines metabolized via cyp a alprazolam triazolam should be considered when coadministering these agents with drug 	DDI-advise
DDI-DrugBank.d60.s6.p8	isoflurane or drug administered with nitrous oxide oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of nimbex and decrease the required infusion rate of drug 	DDI-effect
DDI-MedLine.d61.s1.p0	drug is known to raise serum drug levels 	DDI-mechanism
DDI-DrugBank.d114.s10.p19	although glucocorticoids have been shown to reduce proleukin induced side effects including fever renal insufficiency hyperbilirubinemia confusion and dyspnea concomitant administration of these agents with proleukin may reduce the antitumor effectiveness of proleukin and thus should be avoided drug and other antihypertensives may potentiate the hypotension seen with drug 	DDI-effect
DDI-DrugBank.d405.s1.p5	other depressasnts such as alcohol barbiturates and drug may enhance cns depression when administered with drug 	DDI-effect
DDI-DrugBank.d48.s1.p7	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir drug nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d94.s8.p5	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate rifampin phenobarbital drug primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d142.s1.p0	drug may interfere with the absorption of drug 	DDI-mechanism
DDI-DrugBank.d263.s3.p2	lamivudine in vitro studies in peripheral blood mononuclear cells u and molt cells revealed that drug significantly inhibited drug phosphorylation in a dose dependent manner 	DDI-effect
DDI-DrugBank.d498.s1.p0	these drug should be used in the myasthenic patient only where definitely indicated and then careful adjustment should be made of adjunctive drug dosage 	DDI-advise
DDI-DrugBank.d288.s0.p9	in a phase i trial using escalating doses of taxol mg m and cisplatin or mg m given as sequential infusions myelosuppression was more profound when drug was given after drug than with the alternate sequence ie taxol before cisplatin 	DDI-effect
DDI-DrugBank.d485.s16.p4	atorvastatin drug increases the auc for norethindrone and drug 	DDI-mechanism
DDI-DrugBank.d238.s6.p10	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of drug or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with drug as well 	DDI-mechanism
DDI-DrugBank.d76.s4.p1	therefore it is recommended that drug tablets not be used in combination with maois or within days of discontinuing treatment with a drug 	DDI-advise
DDI-DrugBank.d544.s3.p1	total body clearance of drug was reduced by an average and when azathioprine and drug respectively were added to a regimen consisting of cyclosporine usp modified and corticosteroids 	DDI-mechanism
DDI-DrugBank.d522.s20.p3	digoxin concomitant administration of drug and drug has been reported to result in elevated digoxin serum levels 	DDI-mechanism
DDI-DrugBank.d314.s4.p2	anticholinesterases concomitant use of drug and drug may produce severe weakness in patients with myasthenia gravis 	DDI-effect
DDI-DrugBank.d5.s17.p13	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and drug e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d412.s10.p0	if drug is used with drug in patients with angina pectoris additional antihypertensive effects may occur 	DDI-effect
DDI-DrugBank.d350.s12.p4	in addition results from regression analyses of patient pharmacokinetic data suggest that co administration of other inducers of drug clearance drug nevirapine phenytoin dexamethasone or carbamazepine with drug may result in clinically meaningful reductions in caspofungin concentrations 	DDI-mechanism
DDI-DrugBank.d226.s4.p2	the effects of drug are antagonized by methylxanthines such as caffeine and drug 	DDI-effect
DDI-DrugBank.d328.s29.p0	plasma exposure auc to drug was increased when coadministered with drug and when coadministered with ketoconazole 	DDI-mechanism
DDI-DrugBank.d60.s12.p13	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics drug and quinidine 	DDI-effect
DDI-DrugBank.d538.s1.p3	diphenoxylate hcl and drug may interact with drug in studies with male scum bag diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of magnesium kilogram day	DDI-int
DDI-DrugBank.d538.s1.p3	diphenoxylate kilogram hcl and follow drug may interact with drug in studies with male rats diphenoxylate hydrochloride was found to fink inhibit the hepatic microsomal enzyme system at a dose of mg kg day	DDI-int
DDI-DrugBank.d538.s1.p3	diphenoxylate hcl and drug may interact with drug in studies with male rats diphenoxylate was found to inhibit the hepatic microsomal enzyme at dose of mg kg day	DDI-int
DDI-DrugBank.d538.s1.p3	diphenoxylate hcl and drug may interact with drug in studies with male rats diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of mg kg day 	DDI-int
DDI-DrugBank.d5.s17.p8	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g drug risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d48.s15.p12	therefore cyp a substrates known to have a narrow therapeutic index such as drug astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-MedLine.d49.s0.p0	interaction of drug and drug vitro	DDI-int
DDI-MedLine.d49.s0.p0	interaction of dose and dose in vitro	DDI-int
DDI-MedLine.d49.s0.p0	interaction of drug and in drug vitro	DDI-int
DDI-MedLine.d49.s0.p0	interaction of drug and drug in vitro 	DDI-int
DDI-DrugBank.d60.s6.p7	isoflurane or drug administered with nitrous oxide oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of drug and decrease the required infusion rate of nimbex 	DDI-effect
DDI-DrugBank.d198.s6.p0	it is recommended not to exceed a single mg dose of drug in a hour period when used in combination with drug 	DDI-advise
DDI-DrugBank.d39.s1.p2	drug para aminosalicylic acid and heavy alcohol intake for longer than weeks may produce malabsorption of drug 	DDI-mechanism
DDI-DrugBank.d53.s7.p9	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin drug theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-MedLine.d29.s2.p2	the higher serum concentrations of penicillins and drug reached after administration of drug are due not only to slower renal elimination but also to an altered distribution in the body 	DDI-mechanism
DDI-DrugBank.d97.s87.p0	drug dose should not exceed a maximum of mg in a hour period in patients receiving concomitant drug therapy 	DDI-advise
DDI-DrugBank.d78.s3.p10	caffeine theobromine drug like other quinolones may inhibit the metabolism of drug and theobromine 	DDI-mechanism
DDI-MedLine.d111.s14.p0	coingestion of drug with drug phenobarbital with acetaminophen and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug 	DDI-effect
DDI-DrugBank.d423.s0.p12	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine drug sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d76.s30.p3	warfarin when drug mg tid was administered concomitantly with drug for two weeks warfarin plasma concentrations increased by and prothrombin times were prolonged 	DDI-mechanism
DDI-DrugBank.d62.s0.p0	drug can interact with drug or other cns sedative drug may potentiate the cns sedative drug effects of either these medicine or antihistamines anticholinergics or other medicine with anticholinergic natural process anticholinergic effects may be potentiated when these medicine are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent function with antihistamines may prolong and compound the anticholinergic and cns sedative drug effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p0	drug can interact with drug or other cns depressants may potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or other medications with anticholinergic effects may be potentiated when these medications are used concurrently antihistamines and monoamine oxidase mao inhibitors concurrent with antihistamines prolong and intensify the anticholinergic and cns depressant effects of	DDI-int
DDI-DrugBank.d62.s0.p0	drug can interact with drug or other cns depressants may potentiate mao tsetung the cns depressant effects depressant of either these medications or antihistamines anticholinergics or other medications with anticholinergic medication activity anticholinergic effects may be potentiated when these medications personal effects medication are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent antihistamine use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p0	drug can interact with drug or other cns depressants may potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of antihistamines 	DDI-int
DDI-DrugBank.d237.s2.p12	antibiotics in vitro and or in vivo data show that clarithromycin erythromycin and drug markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d392.s0.p1	patients who are applying drug gel should not concurrently use products that contain deet n drug a common component of insect repellent products 	DDI-advise
DDI-DrugBank.d163.s2.p9	tetracyclines concomitant treatment with accutane and tetracyclines should be avoided because drug use has been associated with a number of cases of pseudotumor cerebri benign intracranial hypertension some of which involved concomitant use of drug 	DDI-effect
DDI-DrugBank.d18.s1.p5	injection drug injection like other injectable benzodiazepines produces depression of the central nervous system when administered with ethyl alcohol phenothiazines barbiturates mao inhibitors and other drug when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d382.s31.p1	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole drug nefazodone troleandomycin clarithromycin ritonavir nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d338.s1.p0	the action of the drug may be potentiated by drug antihistamines alcohol barbiturates monoamine oxidase inhibitors narcotics phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d374.s0.p0	drug should be avoided by patients with a history of serious reaction to any drug including solganal and myochrysine 	DDI-advise
DDI-DrugBank.d238.s3.p1	close supervision and careful adjustment of dosage are required when drug is administered with anticholinergic or drug 	DDI-advise
DDI-DrugBank.d0.s6.p0	patients taking drug concomitantly with drug more commonly reported both weight gain and weight loss compared with patients taking either medication alone 	DDI-effect
DDI-DrugBank.d559.s1.p17	butalbital acetaminophen and drug may enhance the effects of other drug s alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d471.s0.p0	drug interferes with the absorption of drug including vitamin d preparations 	DDI-mechanism
DDI-DrugBank.d217.s11.p16	multivitamins or other products containing iron or zinc drug or sucralfate should not be administered concomitantly with or within hours of the administration of drug because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin 	DDI-advise
DDI-DrugBank.d53.s7.p13	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim drug or zidovudine 	DDI-mechanism
DDI-DrugBank.d423.s0.p13	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine drug venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d60.s12.p10	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate drug salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d291.s9.p2	when drug or bezalip retard is used concurrently with anion exchange resins e g drug an interval of at least hours should be maintained between the two medicines since the absorption of bezalip or bezalip retard is impaired	DDI-advise
DDI-DrugBank.d219.s7.p3	cyclosporine digoxin methotrexate drug like other nsaids through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine digoxin drug and increased toxicity 	DDI-mechanism
DDI-DrugBank.d17.s12.p0	concurrent use with drug may enhance the possibility of drug toxicity associated with hypokalemia 	DDI-effect
DDI-DrugBank.d537.s0.p0	drug whitethorn interact with drug es gee tylenol chloramphenicol es gee chloromycetin local anesthetics es gee ethyl aminobenzoate and lidocaine para aminobenzoic acid paba containing training es gee sunscreens and some multivitamins procainamide es gee pronestyl sulfonamides sulfa medicines thiazide diuretics consumption of these medicines during the test period will affect the test results and pancreatic supplements consumption of pancreatic supplements whitethorn give false test results	DDI-int
DDI-DrugBank.d537.s0.p0	drug may interact with drug e g tylenol chloramphenicol e chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p0	drug may e interact with drug e g tylenol topical anesthetic chloramphenicol e g multivitamin chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide use of goods and services diuretics use of mental testing these tocopherol medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p0	drug may interact with drug e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d522.s24.p0	other drugs drug interactions have been reported bromocriptine concomitant hexobarbital of drug and other medications including drug administration carbamazepine alfentanil disopyramide phenytoin with valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p0	other drugs drug interactions have been reported cause with concomitant administration of drug and other medications including drug hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine dose valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p0	other drugs drug interactions have been reported with concomitant governing of drug and other medications including drug hexobarbital carbamazepine alfentanil disopyramide diphenylhydantoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p0	other drugs drug interactions have been reported with concomitant administration of drug and other medications including drug hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d54.s17.p2	digitalis drug may potentiate the toxic effects of drug 	DDI-effect
DDI-DrugBank.d568.s12.p0	because drug may enhance the serotonergic effects of drug caution should be exercised when lexapro and lithium are coadministered 	DDI-effect
DDI-DrugBank.d219.s22.p2	warfarin the effects of drug and drug on gi bleeding are synergistic such that users of both drugs together have a risk of serious gi bleeding higher than that of users of either drug alone 	DDI-effect
DDI-DrugBank.d236.s4.p0	alkalinizing agents gastrointestinal alkalinizing agents drug etc increase absorption of drug 	DDI-mechanism
DDI-DrugBank.d562.s7.p4	also concomitant administration of drug with products containing iron multivitamins containing zinc or videx drug chewable buffered tablets or the pediatric powder for oral solution may result in low urine levels 	DDI-mechanism
DDI-DrugBank.d131.s10.p9	data from in vitro studies of benzodiazepines other drug suggest a possible drug interaction for the following cyclosporine amiodarone and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p9	dose data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following ergotamine information cyclosporine amiodarone drug and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p9	data from in vitro studies of benzodiazepine other than drug advise a possible drug interaction for the following ergotamine cyclosporine amiodarone drug and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p9	data from in vitro studies of benzodiazepines other than drug suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone drug and nifedipine 	DDI-int
DDI-MedLine.d126.s0.p0	drug induced oxidative stress in rat brain and liver is prevented by drug or allopurinol 	DDI-effect
DDI-DrugBank.d132.s8.p0	drug decreased the hyperuricemic effect of drug 	DDI-effect
DDI-DrugBank.d469.s7.p9	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the aminoglycosides and polymyxins lithium magnesium salts procainamide and drug 	DDI-effect
DDI-DrugBank.d382.s9.p18	corticosteroids dexamethasone aprepitant when given as a regimen of mg with dexamethasone coadministered orally as mg on day and drug when given as mg day with drug coadministered orally as mg on days through increased the auc of dexamethasone a cyp a substrate by fold on days and 	DDI-mechanism
DDI-DrugBank.d85.s9.p2	drug and other nsaids can reduce the antihypertensive effect of propranolol and other drug 	DDI-effect
DDI-MedLine.d20.s4.p0	the successive application of drug or mg kg egg weight e w and drug mg kg e w in a min interval significantly increased the activation of spontaneous motility of day old chick embryos in comparison with the effect of glutamate alone 	DDI-effect
DDI-DrugBank.d485.s40.p2	theophylline drug may inhibit the metabolism of drug leading to increased plasma concentrations 	DDI-mechanism
DDI-DrugBank.d245.s0.p6	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins drug and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d220.s9.p3	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or beta adrenergic blocking agents calcium channel blockers drug or h blocking agents tricyclic antidepressants and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d284.s13.p0	drug not only block the therapeutic effects of drug but may produce severe bronchospasm in copd patients 	DDI-effect
DDI-DrugBank.d484.s0.p33	drug may theophylline with the following tetracycline acetaminophen tylenol antibiotics such as ampicillin and medications anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris vitamin nizoral sporanox atorvastatin lipitor clofibrate prednisolone s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase atromid kaletra norvir viracept morphine astramorph drug ms c phenylbutazone invirase prelone rifadin rifampin st johns wort temazepam interact theo dur and peg contin	DDI-int
DDI-DrugBank.d484.s0.p33	drug may interact with the following medications acetaminophen acetaminophen antibiotics such as ampicillin and tetracycline anticonvulsants diphenylhydantoin phenobarbital tegretol trileptal topamax felbatol antifungals gris nail down nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune human immunodeficiency virus drugs sort as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphia astramorph drug ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p33	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax dose felbatol sm phenytoin antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as restoril protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph drug ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo vitamin a dur and vitamin sm c	DDI-int
DDI-DrugBank.d484.s0.p33	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph drug ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d458.s18.p0	it is therefore advisable to monitor drug concentrations in patients receiving drug 	DDI-advise
DDI-DrugBank.d420.s4.p7	probenecid as with other b lactam antibiotics drug inhibits the renal excretion of drug resulting in an approximate doubling in a c a increase in peak cefdinir plasma levels and a prolongation in the apparent elimination half life 	DDI-mechanism
DDI-DrugBank.d195.s9.p0	drug containing therapies should not be used with drug as they may diminish its pharmacologic action 	DDI-advise
DDI-DrugBank.d382.s4.p1	drug has been shown to induce the metabolism of s warfarin and drug which are metabolized through cyp c 	DDI-mechanism
DDI-DrugBank.d76.s12.p8	other potentially important drug interactions benzodiazepines drug metabolized by hepatic oxidation e g alprazolam midazolam triazolam elc should be used with caution because the clearance of these drugs is likely to be reduced by drug 	DDI-mechanism
DDI-DrugBank.d121.s1.p0	concomitant administration of drug doubled the auc for drug 	DDI-mechanism
DDI-DrugBank.d426.s4.p0	if concomitant treatment with drug and an drug is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d106.s9.p0	the immediate release but not the coat core formulation of drug increased plasma drug concentrations by about 	DDI-mechanism
DDI-DrugBank.d331.s0.p0	drugs with ototoxic potential especially in the presence of impaired renal function the use of parenterally administered drug in patients to whom drug are also being given should be avoided except in life threatening conditions 	DDI-advise
DDI-DrugBank.d443.s2.p0	drug concomitant administration with drug may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels 	DDI-effect
DDI-DrugBank.d374.s0.p2	drug should be avoided by patients with a history of serious reaction to any gold medication including solganal and drug 	DDI-advise
DDI-DrugBank.d559.s1.p13	butalbital drug and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics drug such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d419.s5.p1	in common with other drug augmentin xr may reduce the efficacy of oral drug 	DDI-effect
DDI-DrugBank.d158.s6.p4	mao inhibitors drug as well as a metabolite of furazolidone slow drug metabolism 	DDI-mechanism
DDI-DrugBank.d107.s1.p1	the possibility of hypotensive effects with drug or enalaprilat can be minimized by either discontinuing the drug or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat 	DDI-effect
DDI-DrugBank.d429.s0.p8	antacids and kaolin drug and kaolin can reduce absorption of drug 	DDI-mechanism
DDI-DrugBank.d249.s11.p1	there are rare reports however from marketing experiences of changes in effects of drug or oral hypoglycemic agents in the presence of drug that necessitated changes in the doses of such agents 	DDI-effect
DDI-DrugBank.d2.s0.p0	drug may augment the activity of other drug 	DDI-effect
DDI-DrugBank.d526.s17.p5	barbiturates phenytoin or drug increased metabolic clearance of drug because of the induction of hepatic enzymes 	DDI-mechanism
DDI-DrugBank.d299.s4.p2	other ht b d agonists concomitant use of other drug within hours of treatment with drug is contraindicated 	DDI-advise
DDI-DrugBank.d231.s6.p0	drug may add to or potentiate the therapeutic effect of other drug 	DDI-effect
DDI-DrugBank.d97.s47.p0	drug concentrations may be decreased in the presence of drug 	DDI-mechanism
DDI-DrugBank.d82.s13.p0	drug has been reported to decrease the tubular secretion of drug and to potentiate its toxicity 	DDI-mechanism
DDI-DrugBank.d482.s9.p0	wait weeks after stopping drug before starting a drug 	DDI-advise
DDI-DrugBank.d130.s0.p0	drug has been shown to have neuromuscular blocking properties that may enhance the action of other drug 	DDI-effect
DDI-DrugBank.d86.s0.p11	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg chlorpromazine an drug eg trihexyphenidyl and or a tricyclic antidepressant eg drug commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d435.s2.p8	co medications that induce cyp a e g rifampicin phenytoin drug phenobarbital or st john s wort may significantly decrease exposure to drug 	DDI-mechanism
DDI-DrugBank.d165.s28.p0	tinnitus and decreased hearing have been reported in patients concomitantly receiving drug and drug 	DDI-effect
DDI-DrugBank.d328.s12.p5	anticonvulsants phenytoin steady state plasma exposure auc of drug mg bid for days was decreased by when co administered with multiple doses mg qd for days of drug a cyp a inducer 	DDI-mechanism
DDI-DrugBank.d77.s2.p4	avoid the use of preparations such as drug and local anesthetics which contain any sympathomimetic amine e g epinephrine norepinephrine since it has been reported that drug can potentiate the effects of catecholamines 	DDI-advise
DDI-DrugBank.d425.s1.p44	medications interfere with folate utilization including anticonvulsant medications such as phenytoin primidone metformin sometimes prescribed to blood sugar type diabetes sulfasalazine used to control inflammation associated with crohns disease and ulcerative colitis triamterene a diuretic methotrexate there has been concern about the between drug and	DDI-int
DDI-DrugBank.d425.s1.p44	medications can interfere with folate utilization let in anticonvulsant medications such as phenytoin and primidone metformin sometimes prescribed to ensure blood sugar in character diabetes sulfasalazine used to ensure fervour associated with crohns disease and ulcerative colitis triamterene a diuretic drug methotrexate there has been concern about the interaction between drug and drug	DDI-int
DDI-DrugBank.d425.s1.p44	medications sometimes interfere with folate utilization including anticonvulsant diuretic such as phenytoin and primidone metformin can prescribed to control blood sugar in type diabetes sulfasalazine used to interaction inflammation associated with has disease and ulcerative methotrexate triamterene a medications colitis there crohns been concern about the control between drug and drug	DDI-int
DDI-DrugBank.d425.s1.p44	medications can interfere with folate utilization including anticonvulsant medications such as phenytoin and primidone metformin sometimes prescribed to control blood sugar in type diabetes sulfasalazine used to control inflammation associated with crohns disease and ulcerative colitis triamterene a diuretic methotrexate there has been concern about the interaction between drug and drug 	DDI-int
DDI-DrugBank.d178.s0.p5	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid drug monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d345.s11.p8	the absorption of tetracycline drug penicillin g hydrochlorothiazide and gemfibrozil was significantly decreased when given simultaneously with drug 	DDI-mechanism
DDI-DrugBank.d470.s1.p1	caution is advised when drug is coadministered with other medications that can prolong the qt interval e g certain antiarrhythmics or drug or lead to electrolyte abnormalities such as diuretics or amphotericin b 	DDI-advise
DDI-DrugBank.d509.s0.p3	drug drug interactions given the primary cns effects of aripiprazole caution should be used when drug is taken in combination with other drug and alcohol 	DDI-advise
DDI-DrugBank.d568.s32.p5	however there are limited in vivo data suggesting a modest cyp d inhibitory effect for escitalopram i e coadministration of drug mg day for days with the tricyclic antidepressant drug single dose of mg a substrate for cyp d resulted in a increase in cmax and a increase in auc of desipramine 	DDI-mechanism
DDI-DrugBank.d298.s0.p1	drug may interfere with the anti glaucoma action of carbachol or drug 	DDI-effect
DDI-DrugBank.d314.s19.p2	drugs which inhibit cyp a e g drug macrolide antibiotics such as erythromycin have the potential to result in increased plasma concentrations of drug 	DDI-mechanism
DDI-DrugBank.d240.s0.p0	drug may interact with drug or other cns depressants causing increased sedative effects 	DDI-effect
DDI-DrugBank.d154.s2.p9	because nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because drug increases the rate of excretion of drug the concomitant use of nalfon and salicylates is not recommended 	DDI-mechanism
DDI-MedLine.d12.s7.p12	these results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and drug may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of drug and egf 	DDI-effect
DDI-DrugBank.d198.s32.p2	in a similar study with tamsulosin in healthy volunteers of subjects dosed with drug mg and drug mg separated by hours experienced a standing systolic blood pressure below mm hg 	DDI-effect
DDI-DrugBank.d40.s19.p11	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral contraceptives rifampin quinidine theophylline drug 	DDI-effect
DDI-DrugBank.d495.s6.p0	drug may exacerbate the hypertensive response seen with drug withdrawl 	DDI-effect
DDI-DrugBank.d389.s2.p2	drug may reduce the antihypertensive effects of reserpine veratrum alkaloids drug and mecamylamine 	DDI-effect
DDI-DrugBank.d82.s15.p0	drug should be used with caution in patients taking drug and renal function should be carefully monitored 	DDI-advise
DDI-DrugBank.d548.s1.p0	inhibitors of cyp a concomitant use of drug with drug an inhibitor of cyp a results in approximately a fold increase in auc and about a fold increase in cmax of duloxetine 	DDI-mechanism
DDI-DrugBank.d384.s15.p5	magnesium magnesium containing preparations eg drug may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-advise
DDI-DrugBank.d73.s3.p0	drug may exacerbate the rebound hypertension which can follow the withdrawal of drug 	DDI-effect
DDI-DrugBank.d485.s14.p4	ascorbic acid doses of drug vitamin c g day have been reported to increase plasma concentration of drug by possibly by inhibiting conjugation 	DDI-mechanism
DDI-DrugBank.d76.s4.p0	therefore it is recommended that drug tablets not be used in combination with drug or within days of discontinuing treatment with a maoi 	DDI-advise
DDI-DrugBank.d114.s5.p0	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug and drug specifically dacarbazine cis platinum tamoxifen and interferon alfa 	DDI-effect
DDI-MedLine.d34.s0.p0	interactions of drug and drug in absorption and retention 	DDI-mechanism
DDI-DrugBank.d48.s1.p3	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin drug ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d270.s53.p0	drug and drug should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug 	DDI-advise
DDI-DrugBank.d9.s0.p1	drug should not be administered concomitantly with amikacin drug gentamicin netilmicin or tobramycin 	DDI-advise
DDI-DrugBank.d518.s0.p1	prolonged recovery time may occur if drug and or narcotics are used concurrently with drug 	DDI-effect
DDI-DrugBank.d401.s0.p9	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain drug such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d132.s16.p2	methotrexate caution should be used if drug is administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d364.s5.p0	concomitant administration of drug and moderate cyp a inhibitors including drug and cimetidine has not been evaluated but should be avoided unless clinically necessary because of similar potential drug interactions 	DDI-advise
DDI-DrugBank.d99.s9.p0	the extent to which drug drug interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ssri involved 	DDI-effect
DDI-DrugBank.d40.s10.p19	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides drug trazodone	DDI-mechanism
DDI-DrugBank.d60.s12.p0	other drugs which may enhance the neuromuscular blocking action of drug such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d237.s11.p2	the gastrointestinal absorption of cimetidine and drug is accelerated when they are coadministered with drug 	DDI-mechanism
DDI-DrugBank.d468.s2.p2	cimetidine drug increases drug plasma levels 	DDI-mechanism
DDI-DrugBank.d40.s14.p1	drugs that may either increase or decrease plasma drug concentrations include phenobarbital vaiproic acid and drug 	DDI-mechanism
DDI-DrugBank.d124.s26.p107	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus drug ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d291.s9.p5	when bezalip or drug is used concurrently with drug e g cholestryramine an interval of at least hours should be maintained between the two medicines since the absorption of bezalip or bezalip retard is impaired	DDI-advise
DDI-DrugBank.d450.s6.p10	antacids drug pectin sulfasalazine neomycin cholestyramine certain anticancer drugs and metoclopramide may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d224.s1.p3	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with cns depressants alcohol barbiturates drug sedatives anesthetics should be considered 	DDI-advise
DDI-DrugBank.d397.s13.p5	there have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride resulting in qt prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation and torsades de pointes most like due to inhibition of hepatic metabolism of drug by drug 	DDI-mechanism
DDI-DrugBank.d43.s5.p2	drugs whose absorption can be affected by the level of acidity in the stomach drugs such as ketoconazole and drug should be administered at least hours prior to dosing with drug 	DDI-advise
DDI-DrugBank.d397.s6.p2	drug has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these drug 	DDI-effect
DDI-DrugBank.d529.s4.p3	aspirin concurrent administration of drug and drug resulted in lower serum flurbiprofen concentrations 	DDI-mechanism
DDI-DrugBank.d237.s11.p1	the gastrointestinal absorption of drug and ranitidine is accelerated when they are coadministered with drug 	DDI-mechanism
DDI-DrugBank.d549.s1.p0	however drug has the potential to increase the hypotensive effect of drug and antihypertensive agents 	DDI-effect
DDI-DrugBank.d26.s0.p32	patients receiving other narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics drug or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d511.s4.p6	because of foscarnets tendency to cause renal impairment the use of drug should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides amphotericin b and intravenous drug unless the potential benefits outweigh the risks to the patient 	DDI-advise
DDI-DrugBank.d324.s12.p3	promethazine coadministration of a single dose of drug and drug and mg respectively resulted in a decrease in maximal plasma concentrations of zaleplon but no change in the area under the plasma concentration time curve 	DDI-mechanism
DDI-DrugBank.d338.s1.p6	the action of the drug may be potentiated by anticonvulsants antihistamines alcohol barbiturates monoamine oxidase inhibitors narcotics drug psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d318.s2.p2	drug and corticotropin acth may potentiate drug induced hypokalemia which may predispose the patient to cardiac dysfunction 	DDI-effect
DDI-DrugBank.d250.s2.p14	curariform muscle relaxants eg tubocurarine and other drugs including ether drug gallamine decamethonium and sodium citrate potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d95.s2.p2	organic nitrates drug supplements theoretically may potentiate the effects of organic drug if taken concomitantly 	DDI-effect
DDI-DrugBank.d429.s6.p2	cyclosporin after introduction of drug oral form a sudden increase in serum drug level has been reported 	DDI-mechanism
DDI-DrugBank.d202.s9.p1	close supervision and careful adjustment of the dosage are required when drug is used with other anticholinergic drugs or drug 	DDI-advise
DDI-DrugBank.d210.s20.p0	at higher than recommended doses drug mg administered once daily for days increased plasma concentrations by as measured by auc hr in patients receiving drug to mg week for rheumatoid arthritis 	DDI-mechanism
DDI-DrugBank.d171.s0.p7	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants drug theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d485.s41.p12	tricyclic antidepressants amitriptyline imipramine drug metabolism may be inhibited by drug increasing plasma levels of antidepressant 	DDI-mechanism
DDI-DrugBank.d180.s1.p5	the pressor effects of catecholamines such as dopamine or drug are enhanced by drug 	DDI-effect
DDI-DrugBank.d326.s1.p7	pyrantel e g antiminth taking drug and drug together may decrease the effects of piperazine 	DDI-effect
DDI-DrugBank.d559.s1.p19	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics alcohol general drug tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d314.s11.p2	cyclosporine increased activity of both drug and drug may occur when the two are used concurrently 	DDI-effect
DDI-DrugBank.d71.s6.p0	therefore use of drug in combination with drug is not recommended	DDI-advise
DDI-DrugBank.d267.s6.p3	as with some other nondepolarizing neuromuscular blocking agents the time of onset of neuromuscular block induced by drug is lengthened and the duration of block is shortened in patients receiving drug or carbamazepine 	DDI-effect
DDI-DrugBank.d172.s14.p0	however concomitant administration of drug with drug may result in an increased rate of gi ulceration or other complications compared to use of celebrex alone 	DDI-effect
DDI-DrugBank.d94.s4.p8	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem drug fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d85.s9.p4	naproxen and other drug can reduce the antihypertensive effect of propranolol and other drug 	DDI-effect
DDI-DrugBank.d110.s0.p10	the administration of local anesthetic solutions containing epinephrine or drug to patients receiving monoamine oxidase inhibitors drug or phenothiazines may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d249.s1.p4	anticoagulants while studies have not shown drug to interact with anticoagulants of the warfarin type caution should be exercised nonetheless since interactions have been seen with other drug 	DDI-advise
DDI-DrugBank.d307.s1.p0	in addition several drug s that are cytochrome p inducers can decrease plasma concentrations of drug and mhd 	DDI-mechanism
DDI-DrugBank.d180.s1.p2	the pressor effects of drug such as dopamine or norepinephrine are enhanced by drug 	DDI-effect
DDI-DrugBank.d223.s22.p2	cimetidine drug has been reported to produce clinically significant fluctuations in steady state serum concentrations of various drug 	DDI-mechanism
DDI-DrugBank.d108.s0.p0	drug should be administered with caution to patients receiving drug disulfiram wyeth ayerst laboratories 	DDI-advise
DDI-DrugBank.d252.s1.p0	close observation of the patient is recommended when a drug is administered to patients receiving catecholamine depleting drugs such as drug because of possible additive effects and the production of hypotension and or marked bradycardia which may produce vertigo syncope or postural hypotension 	DDI-advise
DDI-DrugBank.d484.s0.p27	drug may interact with the following medications acetaminophen tylenol antibiotics as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv classified protease inhibitors agenerase crixivan fortovase drug kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur vitamin c	DDI-int
DDI-DrugBank.d484.s0.p27	drug may viracept with the medications following acetaminophen tylenol antibiotics such as phenylbutazone and tetracycline prednisolone dilantin phenobarbital tegretol kadian topamax felbatol antifungals gris peg rifadin sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase drug kaletra norvir interact morphine astramorph trileptal ms contin ampicillin anticonvulsants prelone nizoral rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p27	drug may interact with the following medications acetaminophen elixophyllin tylenol antibiotics proteolytic enzyme such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral phenytoin sporanox atorvastatin lipitor morphia clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase drug kaletra norvir viracept morphine astramorph kadian drug ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin acetaminophen c	DDI-int
DDI-DrugBank.d484.s0.p27	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase drug kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d241.s5.p1	however patients on drug may show elevations of digoxin concentrations after initiation of therapy with drug which may be clinically significant in patients prone to digoxin toxicity 	DDI-mechanism
DDI-DrugBank.d328.s35.p2	because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near mg dl dose adjustment for drug mg qd and mg bid with drug coadministration up to mg qd is not indicated 	DDI-advise
DDI-DrugBank.d60.s12.p17	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides drug bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-MedLine.d39.s3.p0	the serum estrogen concentrations of drug drug treated rats decreased by while those of the endotoxin treated rats increased to fold 	DDI-mechanism
DDI-DrugBank.d437.s14.p0	appropriate laboratory testing should be considered prior to initiating combination therapy with drug and drug and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy 	DDI-advise
DDI-DrugBank.d165.s27.p0	blood glucose concentrations should be carefully monitored when drug and oral drug are coadministered 	DDI-advise
DDI-DrugBank.d198.s30.p0	with simultaneous dosing of drug mg and drug mg of subjects experienced a standing systolic blood pressure of less than mm hg 	DDI-effect
DDI-DrugBank.d178.s0.p3	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides drug probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d186.s3.p1	as with other drug it should be noted that haldol may be capable of potentiating drug such as anesthetics opiates and alcohol 	DDI-effect
DDI-DrugBank.d47.s2.p8	dopamine d receptor antagonists e g drug butyrophenones risperidone and isoniazid may reduce the therapeutic effects of drug 	DDI-effect
DDI-DrugBank.d76.s7.p5	terfenadine astemizole and drug are all metabolized by the cytochrome p iiia isozyme and it has been demonstrated that drug a potent inhibitor of iiia blocks the metabolism of these drugs resulting in increased plasma concentrations of parent drug 	DDI-mechanism
DDI-DrugBank.d568.s17.p4	if concomitant treatment with drug and an ssri e g fluoxetine fluvoxamine paroxetine drug citalopram escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d505.s4.p2	cholinesterase inhibitors drug may counteract the anticholinesterase effect of drug thereby potentially aggravating myasthenia gravis 	DDI-effect
DDI-DrugBank.d398.s0.p1	the use of drug may result in additive cns depressant effects when coadministered with alcohol drug psychotropics or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d401.s0.p5	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics drug certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d476.s3.p5	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine verapamil and benzothiazepine drug classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d267.s6.p4	as with some other nondepolarizing neuromuscular blocking agents the time of onset of neuromuscular block induced by drug is lengthened and the duration of block is shortened in patients receiving phenytoin or drug 	DDI-effect
DDI-DrugBank.d106.s7.p0	the blood pressure effect of drug tended to be greater in patients on drug than in patients on no other antihypertensive therapy 	DDI-effect
DDI-DrugBank.d358.s1.p2	pharmacokinetic studies have demonstrated that omeprazole and drug significantly increased the systemic exposure of drug and or its major metabolites 	DDI-mechanism
DDI-DrugBank.d132.s18.p3	cyclosporine administration of drug concomitantly with drug has been associated with an increase in cyclosporine induced toxicity possibly due to decreased synthesis of renal prostacyclin 	DDI-mechanism
DDI-DrugBank.d207.s7.p5	drugs that cause significant sustained elevation in gastric ph histamine h receptor antagonists such as ranitidine or drug may reduce plasma concentrations of drug and therefore potentially may reduce efficacy 	DDI-mechanism
DDI-MedLine.d85.s9.p0	drug has a complex effect on oral drug pharmacokinetics 	DDI-mechanism
DDI-DrugBank.d252.s0.p2	although betagan used alone has little or no effect on pupil size mydriasis resulting from concomitant therapy with drug and drug may occur 	DDI-effect
DDI-DrugBank.d91.s3.p0	drug may interact with the drug preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye 	DDI-mechanism
DDI-DrugBank.d440.s2.p0	drug should be taken at least minutes before any oral medications containing multivalent cations including drug supplements or vitamins 	DDI-advise
DDI-MedLine.d5.s3.p0	the treatment of ewes with an intravenous iv injection of drug insufficient to produce significant inhibition of erythrocyte acetylcholinesterase ache activity appeared to produce additive effects with those produced by subsequent treatment with mg of drug kg day 	DDI-effect
DDI-DrugBank.d352.s3.p1	conversely drug may interfere drug antihypertensive drugs i e with a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p1	conversely drug may interfere with antihypertensive drugs i e drug a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p1	conversely drug may interfere with antihypertensive drugs i vitamin e drug a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p1	conversely drug may interfere with antihypertensive drugs i e drug a methyldopa 	DDI-int
DDI-DrugBank.d256.s2.p0	antagonism has been demonstrated between drug and drug in vitro 	DDI-effect
DDI-DrugBank.d94.s4.p5	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin drug delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d416.s0.p2	renal clearance measurements of drug cannot be made with any significant accuracy in patients receiving sulfonamides procaine or drug 	DDI-effect
DDI-DrugBank.d132.s17.p0	drug have been reported to decrease the tubular secretion of drug and to potentiate its toxicity 	DDI-mechanism
DDI-DrugBank.d562.s8.p2	drug including cinoxacin may enhance the effects of oral anticoagulants such as drug or its derivatives 	DDI-effect
DDI-DrugBank.d297.s3.p0	concurrent administration of a drug with drug has been associated with an increased risk of serious infections and no significant additional efficacy over use of the tnf antagonists alone 	DDI-effect
DDI-DrugBank.d246.s5.p0	when the drug was administered minutes after the drug nasal spray the auc of butorphanol increased and cmax decreased 	DDI-mechanism
DDI-MedLine.d12.s7.p13	these results suggest that both dexamethasone and retinyl acetate and possibly other glucocorticoids and drug may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and drug 	DDI-effect
DDI-DrugBank.d350.s11.p0	patients on drug should receive mg of drug daily 	DDI-advise
DDI-DrugBank.d350.s12.p9	in addition results from regression analyses of patient pharmacokinetic data suggest that co administration of other inducers of drug clearance efavirenz drug phenytoin dexamethasone or carbamazepine with drug may result in clinically meaningful reductions in caspofungin concentrations 	DDI-mechanism
DDI-DrugBank.d333.s5.p5	cytochrome p inducers such as phenytoin drug and phenobarbital induce drug metabolism causing an approximately decrease in plasma clonazepam levels 	DDI-mechanism
DDI-MedLine.d3.s12.p0	drug plus drug was poorly tolerated and of subjects discontinued therapy 	DDI-effect
DDI-MedLine.d110.s6.p2	both drug and mc block morphine induced and drug induced dopamine release in the nucleus accumbens 	DDI-effect
DDI-DrugBank.d114.s2.p19	concurrent administration of drugs possessing nephrotoxic e g aminoglycosides indomethacin myelotoxic e g cytotoxic chemotherapy cardiotoxic e g doxorubicin or hepatotoxic e g drug asparaginase effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d395.s21.p0	drug interferes with the metabolism of drug resulting in a to dose related decrease in theophylline clearance and a subsequent to increase in serum theophylline levels 	DDI-mechanism
DDI-DrugBank.d333.s3.p14	in a study in which the mg clonazepam orally disintegrating tablet was administered with and without propantheline an anticholinergic agent with multiple effects on the gi tract to healthy volunteers the auc of clonazepam was lower and the cmax of drug was lower when the orally disintegrating tablet was given with drug compared to when it was given alone 	DDI-mechanism
DDI-MedLine.d12.s7.p7	these results suggest that both dexamethasone and drug and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of drug and egf 	DDI-effect
DDI-DrugBank.d422.s9.p0	the onset of neuromuscular blockade by drug was unaffected by drug but the duration of neuromuscular blockade was prolonged from minutes to minutes 	DDI-effect
DDI-DrugBank.d17.s25.p0	in some patients the drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d542.s1.p2	aspirin concomitant drug may decrease the metabolic clearance of drug 	DDI-mechanism
DDI-DrugBank.d279.s3.p0	lymphocytopenia has been reported in patients receiving drug and it is possible that the administration of drug as antiemetic prophylaxis may have enhanced the likelihood of this effect 	DDI-effect
DDI-DrugBank.d180.s0.p0	drug toxicity may be aggravated by the initial release of norepinephrine caused by drug injection 	DDI-effect
DDI-DrugBank.d438.s15.p3	naproxen coadministration n of drug capsules mg with drug mg appears to increase the amount of gabapentin absorbed by to 	DDI-mechanism
DDI-DrugBank.d78.s11.p5	drugs metabolized by cytochrome p enzymes the drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that drug inhibits drug metabolism which is mediated by cyp a 	DDI-mechanism
DDI-DrugBank.d53.s7.p14	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or drug 	DDI-mechanism
DDI-DrugBank.d306.s0.p3	the effectiveness of drug only pills is reduced by hepatic enzyme inducing drugs such as the anticonvulsants phenytoin carbamazepine and drug and the antituberculosis drug rifampin 	DDI-effect
DDI-DrugBank.d382.s19.p7	oral contraceptives drug when given once daily for days as a mg capsule with an oral contraceptive containing mcg of drug and mg of norethindrone decreased the auc of ethinyl estradiol by and decreased the auc of norethindrone by 	DDI-mechanism
DDI-DrugBank.d478.s3.p0	because their vasospastic effects may be additive coadministration of drug and other drug within hours of each other is not recommended 	DDI-advise
DDI-DrugBank.d340.s6.p10	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines drug triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d238.s6.p4	plasma levels of several closely related drug have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates drug and such an effect may be anticipated with cmi as well 	DDI-mechanism
DDI-DrugBank.d276.s2.p4	uricosuric drugs such as drug and sulfinpyrazone can inhibit renal tubular secretion of drug 	DDI-mechanism
DDI-DrugBank.d350.s14.p2	when drug is co administered with inducers of drug clearance such as efavirenz nevirapine drug dexamethasone or carbamazepine use of a daily dose of mg of cancidas should be considered	DDI-advise
DDI-DrugBank.d40.s19.p9	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral contraceptives rifampin drug theophylline vitamin d 	DDI-effect
DDI-DrugBank.d176.s1.p0	the possibility of hypotensive effects can be minimized by either discontinuing the drug or increasing salt intake prior to initiation of treatment with drug 	DDI-effect
DDI-DrugBank.d40.s10.p12	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane drug methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d210.s32.p0	in single and multiple dose studies in healthy subjects receiving both drug and drug prothrombin time measured as inr was increased by approximately to 	DDI-effect
DDI-DrugBank.d499.s22.p5	methotrexate ketoprofen like other drug may cause changes in the elimination of drug leading to elevated serum levels of the drug and increased toxicity 	DDI-mechanism
DDI-DrugBank.d222.s1.p0	the following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of drug and drug 	DDI-advise
DDI-DrugBank.d132.s25.p5	aspirin in normal volunteers a small decrease in diflunisal levels was observed when multiple doses of drug and drug were administered concomitantly 	DDI-mechanism
DDI-DrugBank.d397.s6.p0	drug has been reported to decrease the clearance of drug and midazolam and thus may increase the pharmacologic effect of these benzodiazepines 	DDI-mechanism
DDI-DrugBank.d518.s0.p2	prolonged recovery time may occur if barbiturates and or drug are used concurrently with drug 	DDI-effect
DDI-DrugBank.d289.s16.p0	caution should be exercised if drug and drug are used together 	DDI-advise
DDI-DrugBank.d64.s90.p26	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg aspirin and other non steroidal anti inflammatory drugs dipyridamole hydrochloroquine drug dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d568.s17.p6	if concomitant treatment with drug and an ssri e g fluoxetine fluvoxamine paroxetine sertraline citalopram drug is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d446.s0.p1	drug may interact with antidepressants drug barbiturates bromocriptine calcium appurtenance corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p1	drug may interact with antidepressants drug barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and adrenocorticotrophin warfarin	DDI-int
DDI-DrugBank.d446.s0.p1	drug may interact with antidepressants drug barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene and somatropin tamoxifen nicotine warfarin	DDI-int
DDI-DrugBank.d446.s0.p1	drug may interact with antidepressants drug barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d114.s10.p0	although drug have been shown to reduce drug induced side effects including fever renal insufficiency hyperbilirubinemia confusion and dyspnea concomitant administration of these agents with proleukin may reduce the antitumor effectiveness of proleukin and thus should be avoided beta blockers and other antihypertensives may potentiate the hypotension seen with proleukin 	DDI-effect
DDI-DrugBank.d236.s1.p5	urinary acidifying agents ammonium chloride drug etc increase the concentration of the ionized species of the drug molecule thereby increasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d338.s4.p1	while no in vivo drug drug interaction studies were conducted between drug and inducers of cyp a compounds that are potent cyp a inducers such as carbamazepine drug rifampin and barbiturates would be expected to decrease estazolam concentrations 	DDI-mechanism
DDI-DrugBank.d110.s0.p11	the administration of local anesthetic solutions containing epinephrine or drug to patients receiving monoamine oxidase inhibitors tricyclic antidepressants or drug may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d529.s10.p0	drug did not affect the pharmacokinetic profile of either drug and the mechanism unknown lying the with interference drug s hypotensive effect is under	DDI-int
DDI-DrugBank.d529.s10.p0	drug did not affect the pharmacokinetic profile of either drug and the mechanism under lying the interference with unknown quantity drug s dose hypotensive effect is unknown	DDI-int
DDI-DrugBank.d529.s10.p0	dose did not affect the pharmacokinetic profile of either dose and the mechanism under rest the interference with dose s hypotensive effect is unknown	DDI-int
DDI-DrugBank.d529.s10.p0	drug did not affect the pharmacokinetic profile of either drug and the mechanism under lying the interference with drug s hypotensive effect is unknown 	DDI-int
DDI-DrugBank.d98.s2.p13	phenytoin phenobarbital the coadministration of phenytoin or drug will not affect plasma concentrations of vitamin d but may reduce endogenous plasma levels of drug ergocalcitriol by accelerating metabolism 	DDI-mechanism
DDI-DrugBank.d29.s12.p0	therefore drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability eg drug iron salts and digoxin 	DDI-mechanism
DDI-DrugBank.d217.s5.p1	drug including norfloxacin may enhance the effects of oral drug including warfarin or its derivatives or similar agents 	DDI-effect
DDI-DrugBank.d314.s18.p10	hepatic enzyme inducers inhibitors and substrates drugs which induce cytochrome p a cyp a enzyme activity e g barbiturates phenytoin drug rifampin may enhance the metabolism of drug and require that the dosage of the corticosteroid be increased 	DDI-mechanism
DDI-DrugBank.d252.s5.p0	drug and drug may have additive hypotensite effects due to the inhibition of each other s metabolism 	DDI-mechanism
DDI-DrugBank.d41.s0.p9	cholestyramine and charcoal administration of cholestyramine or drug in patients n and volunteers n resulted in a rapid and significant decrease in plasma m the active metabolite of drug concentration 	DDI-mechanism
DDI-MedLine.d25.s12.p1	conclusions drug inhibit the metabolism of hmg coa reductase inhibitors that are metabolized by cyp a i e drug cerivastatin lovastatin simvastatin 	DDI-mechanism
DDI-DrugBank.d237.s2.p7	antibiotics in vitro and or in vivo data show that drug erythromycin and troleandomycin markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d480.s8.p12	although it has not been established that there is an interaction between clozapine and benzodiazepines or other psychotropics caution is advised when drug is initiated in patients taking a drug or any other psychotropic drug 	DDI-advise
DDI-DrugBank.d347.s6.p2	the absorption of oral drug is significantly reduced by the concomitant administration of an antacid containing aluminum and drug 	DDI-mechanism
DDI-DrugBank.d493.s2.p4	anakinra concurrent administration of drug an interleukin antagonist and another drug has been associated with an increased risk of serious infections an increased risk of neutropenia and no additional benefit compared to these medicinal products alone 	DDI-effect
DDI-DrugBank.d186.s0.p0	an encephalopathic syndrome characterized by weakness lethargy fever tremulousness and confusion extrapyramidal symptoms leukocytosis elevated serum enzymes bun and fbs followed by irreversible brain damage has occurred in a few patients treated with drug plus drug 	DDI-effect
DDI-DrugBank.d480.s30.p1	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants drug carbamazepine and type c antiarrhythmics e g propafenone flecainide and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d60.s12.p12	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local drug procainamide and quinidine 	DDI-effect
DDI-DrugBank.d415.s1.p9	however because bleeding has been reported when ibuprofen and other nonsteroidal anti inflammatory agents have been administered to patients on coumarin type anticoagulants the physician should be cautious when administering drug to patients on drug 	DDI-advise
DDI-DrugBank.d5.s17.p10	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone drug beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d334.s7.p0	reports suggest that drug may diminish the antihypertensive effect of drug including lisinopril 	DDI-effect
DDI-DrugBank.d289.s27.p1	drug is also expected to reduce plasma concentrations of other statins that have significant metabolism by cyp a such as drug and atorvastatin 	DDI-mechanism
DDI-DrugBank.d471.s0.p1	drug interferes with the absorption of fat soluble vitamins including drug 	DDI-mechanism
DDI-DrugBank.d41.s15.p2	because of the potential for arava levels to continue to increase with multiple dosing caution should be used if patients are to be receiving both drug and drug 	DDI-advise
DDI-DrugBank.d353.s6.p0	microdosed minipill drug preparations are not recommended for use with drug 	DDI-advise
DDI-DrugBank.d75.s14.p11	the effects of medicinal products with similar properties such as inotropes milrinone enoximone drug olprinone and cilostazol may be exacerbated by drug 	DDI-effect
DDI-DrugBank.d85.s0.p0	the use of drug in patients who are receiving drug may potentiate renal disease states 	DDI-effect
DDI-DrugBank.d83.s1.p0	concomitant use of drug usually depresses drug activity and may necessitate raising the dosage 	DDI-effect
DDI-DrugBank.d353.s9.p0	consequently the combination of drug with drug is also contraindicated 	DDI-advise
DDI-DrugBank.d446.s0.p2	drug may interact with antidepressants aspirin drug bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p2	drug may interact with antidepressants aspirin drug bromocriptine calcium cyclosporine corticosteroids corticotropin supplements dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p2	adrenal cortical steroid drug may interact with antidepressants aspirin drug bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p2	drug may interact with antidepressants aspirin drug bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d299.s11.p11	although the interaction between almotriptan and other potent cyp a inhibitors e g itraconazole drug and erythromycin has not been studied increased exposures to almotriptan may be expected when drug is used concomitantly with these medications 	DDI-advise
DDI-DrugBank.d568.s17.p3	if concomitant treatment with drug and an ssri e g fluoxetine fluvoxamine drug sertraline citalopram escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d484.s0.p16	do drugs may interact with the following medications acetaminophen phenaphen antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox do drugs lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rimactane rimactane st whoremaster wort temazepam elixophyllin theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p16	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin drug vitamin trileptal topamax felbatol antifungals gris peg prelone sporanox rifampin tegretol theo atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone nizoral rifadin phenobarbital st johns wort temazepam theophylline clofibrate dur and lipitor c	DDI-int
DDI-DrugBank.d484.s0.p16	drug may interact with following medications acetaminophen tylenol antibiotics such as ampicillin and anticonvulsants dilantin phenobarbital tegretol antifungals gris peg nizoral sporanox drug lipitor clofibrate atromid s neoral sandimmune hiv drugs classified as protease inhibitors crixivan fortovase invirase kaletra norvir viracept morphine kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st wort temazepam theophylline theo dur and c	DDI-int
DDI-DrugBank.d484.s0.p16	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox drug lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d550.s1.p0	although the clinical significance is not known it is not recommended that drug be taken concomitantly with drug 	DDI-advise
DDI-DrugBank.d99.s19.p0	hyperpyrexia has been reported when drug is administered with drug agents or with neuroleptic drugs particularly during hot weather 	DDI-effect
DDI-DrugBank.d40.s19.p3	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin drug doxycycline estrogens furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d378.s1.p0	nephrotoxicity has been reported following concomitant administration of other drug with potent drug such as furosemide 	DDI-effect
DDI-DrugBank.d552.s0.p4	drug should be administered with caution to patients who are taking other psychoactive drugs or cns depressants including alcohol barbiturates and drug or to those with a history of psychiatric disorder including manic depressive illness and schizophrenia 	DDI-advise
DDI-DrugBank.d458.s25.p2	inh drug is also reported to affect drug concentrations adversely 	DDI-mechanism
DDI-DrugBank.d562.s7.p0	also concomitant administration of drug with products containing drug multivitamins containing zinc or videx didanosine chewable buffered tablets or the pediatric powder for oral solution may result in low urine levels 	DDI-mechanism
DDI-DrugBank.d413.s4.p19	in patients receiving mercaptopurine purinethol or azathioprine imuran the concomitant administration of mg of drug per day will require a reduction in dose to approximately one third to one fourth of the usual dose of mercaptopurine or drug 	DDI-advise
DDI-DrugBank.d398.s2.p2	the use of drug may result in additive cns depressant effects when coadministered with alcohol antihistamines drug or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d347.s7.p16	magnesium and or drug containing antacids products containing ferrous sulfate iron multivitamin preparations containing zinc or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d236.s15.p2	antihypertensives drug may antagonize the hypotensive effects of drug 	DDI-effect
DDI-DrugBank.d11.s3.p2	dosage adjustment of drug may be necessary when coadministered with cyp d inhibitors e g paroxetine fluoxetine and drug 	DDI-advise
DDI-DrugBank.d172.s11.p4	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of furosemide and drug in some patients 	DDI-effect
DDI-DrugBank.d82.s35.p0	drug can reduce the antihypertensive effects of drug and losartan 	DDI-effect
DDI-DrugBank.d207.s4.p1	substances that are potent inhibitors of cyp a activity eg drug and itraconazole decrease drug metabolism and increase gefitinib plasma concentrations 	DDI-mechanism
DDI-MedLine.d87.s8.p0	we conclude that drug prevents drug induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia 	DDI-effect
DDI-DrugBank.d441.s1.p0	therefore drug has the potential for interaction with drug and serotonergic agents	DDI-int
DDI-DrugBank.d441.s1.p0	so drug has the potential for interaction with drug and serotonergic agents	DDI-int
DDI-DrugBank.d441.s1.p0	therefore drug has the serotonergic for interaction with drug and potential agents	DDI-int
DDI-DrugBank.d441.s1.p0	therefore drug has the potential for interaction with drug and serotonergic agents 	DDI-int
DDI-DrugBank.d238.s6.p14	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g drug fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with drug as well 	DDI-mechanism
DDI-DrugBank.d306.s0.p5	the effectiveness of drug only pills is reduced by hepatic enzyme inducing drugs such as the anticonvulsants phenytoin carbamazepine and barbiturates and the antituberculosis drug drug 	DDI-effect
DDI-DrugBank.d82.s21.p0	drug given concomitantly with drug has been reported to increase the serum concentration and prolong the half life of digoxin 	DDI-mechanism
DDI-DrugBank.d23.s0.p0	drug may augment the activity of other drug 	DDI-effect
DDI-DrugBank.d561.s1.p2	the possibility of hypotensive effects with lotensin can be minimized by either discontinuing the drug or increasing the salt intake prior to initiation of treatment with drug 	DDI-advise
DDI-DrugBank.d60.s12.p20	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins drug clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d236.s5.p2	urinary alkalinizing agents acetazolamide some drug increase the concentration of the non ionized species of the drug molecule thereby decreasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d404.s15.p4	magnesium drug containing preparations eg antacids may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-effect
DDI-DrugBank.d531.s52.p0	because the potential interaction of drug with oral drug has not been fully characterized a reliable method of barrier contraception should be used in addition to oral contraceptives 	DDI-advise
DDI-DrugBank.d404.s0.p27	interactions for vitamin d analogues vitamin d vitamin d calcitriol and calcidiol cholestyramine drug has been reported to reduce intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d480.s18.p5	although concomitant use of clozapine and carbamazepine is not recommended it should be noted that discontinuation of concomitant drug administration may result in an increase in drug plasma levels 	DDI-mechanism
DDI-DrugBank.d97.s63.p0	drug may not be effective due to decreased drug concentrations in patients taking these agents concomitantly 	DDI-effect
DDI-DrugBank.d148.s6.p1	co administration concomitant use of drug with antiplatelet agents drug and other anticoagulants may increase the risk of bleeding 	DDI-effect
DDI-DrugBank.d226.s3.p0	the use of drug in patients receiving drug may be rarely associated with ventricular fibrillation 	DDI-effect
DDI-DrugBank.d545.s0.p2	geocillin drug blood levels may be increased and prolonged by concurrent administration of drug 	DDI-mechanism
DDI-DrugBank.d122.s3.p0	drug has been shown to be antagonistic to drug including ceftazidime based on in vitro studies and time kill curves with enteric gram negative bacilli 	DDI-effect
DDI-MedLine.d12.s0.p3	dexamethasone and drug similarly inhibit and stimulate drug or insulin induced proliferation of prostatic epithelium 	DDI-effect
DDI-DrugBank.d476.s3.p1	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain drug particularly of the phenylalkylamine verapamil and benzothiazepine diltiazem classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d469.s7.p7	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the aminoglycosides and polymyxins lithium drug salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d95.s1.p2	ibuprofen drug may increase the absorption of drug if taken concomitantly 	DDI-mechanism
DDI-DrugBank.d60.s12.p22	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin drug and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d397.s15.p0	patients receiving concomitant drug and drug should be carefully monitored 	DDI-advise
DDI-DrugBank.d12.s5.p0	the hypoglycemic effect of drug has been reported to increase when drug is given concurrently 	DDI-effect
DDI-DrugBank.d211.s2.p8	bacteriostatic antibiotics drug erythromycins sulfonamides or tetracyclines may interfere with the bactericidal effect of drug 	DDI-effect
DDI-DrugBank.d98.s11.p2	corticosteroids a relationship of functional antagonism exists between drug which promote calcium absorption and drug which inhibit calcium absorption 	DDI-mechanism
DDI-DrugBank.d548.s9.p6	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline amitriptyline and imipramine drug and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d325.s5.p0	the peripheral vasoconstriction caused by high doses of drug is antagonized by drug 	DDI-effect
DDI-DrugBank.d40.s12.p2	drugs that may decrease plasma drug concentrations include carbamazepine chronic alcohol abuse drug 	DDI-mechanism
DDI-DrugBank.d480.s30.p3	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines carbamazepine and drug e g propafenone flecainide and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-MedLine.d1.s5.p0	drug is contraindicated in patients using drug or who may need to use short acting nitrates because the combination may cause a sharp fall of the blood pressure 	DDI-advise
DDI-DrugBank.d94.s4.p17	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide drug protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d115.s0.p13	drugs that may alter imatinib plasma concentrations drugs that may increase imatinib plasma concentrations caution is recommended when administering drug with inhibitors of the cyp a family e g ketoconazole itraconazole drug clarithromycin 	DDI-advise
DDI-DrugBank.d260.s3.p7	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and amikacin amphotericin b foscarnet intravenous pentamidine drug and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d76.s5.p0	after stopping drug tablets at least weeks should be allowed before starting a drug 	DDI-advise
DDI-MedLine.d68.s0.p12	the effect of cimetidine on the renal excretion of verografin and iodamide in dogs the intravenous injection of drug in a dose of mg kg enhanced drug and iodamide excretion in chronic canine experiments 	DDI-mechanism
DDI-DrugBank.d177.s3.p0	for example when drug are administered concomitantly with drug prothrombin time should be carefully monitored and if necessary the dosage of vitamin k antagonists should be reduced 	DDI-advise
DDI-DrugBank.d40.s10.p2	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol drug cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-MedLine.d110.s7.p0	only drug enhances drug induced increases in accumbal dopamine 	DDI-effect
DDI-DrugBank.d143.s13.p2	monitoring for amiodarone toxicity and serial measurement of drug serum concentration during concomitant drug therapy should be considered 	DDI-advise
DDI-DrugBank.d325.s12.p2	the concomitant use of vasopressors vasoconstricting agents such as drug and some drug may result in severe hypertension 	DDI-effect
DDI-DrugBank.d107.s16.p5	lithium lithium toxicity has been reported in patients receiving drug concomitantly with drugs which cause elimination of sodium including drug 	DDI-effect
DDI-DrugBank.d523.s1.p0	interactions attributed to the combined use of drug injection and epidural drug include hypotension and dyspnea 	DDI-effect
DDI-DrugBank.d13.s0.p1	drug interactions drug may interact with some drugs like monoamine oxidase inhibitors drug maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol stimulate additive systema nervosum centrale depression tricyclic antidepressants flupenthixol increase the effect of tricyclic antidepressants	DDI-int
DDI-DrugBank.d13.s0.p1	drug drug interactions drug may interact with some drugs like monoamine oxidase inhibitors drug maoi could theoretically affect involve flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants flupenthixol increases the effect close to of tricyclic antidepressants	DDI-int
DDI-DrugBank.d13.s0.p1	drug interactions drug may interact depression some drugs like monoamine oxidase inhibitors drug maoi could pharmacodynamics affect flupenthixol theoretically arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns with tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-int
DDI-DrugBank.d13.s0.p1	drug interactions drug may interact with some drugs like monoamine oxidase inhibitors drug maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-int
DDI-MedLine.d29.s2.p1	the higher serum concentrations of drug and cephaloridine reached after administration of drug are due not only to slower renal elimination but also to an altered distribution in the body 	DDI-mechanism
DDI-DrugBank.d431.s12.p1	therefore it is theoretically possible that drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability e g ketoconazole drug esters iron salts digoxin 	DDI-mechanism
DDI-DrugBank.d60.s12.p3	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides drug bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d94.s8.p7	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate rifampin phenobarbital phenytoin primidone drug and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d480.s17.p5	cimetidine caffeine and drug may increase plasma levels of drug potentially resulting in adverse effects 	DDI-mechanism
DDI-DrugBank.d18.s1.p1	injection drug injection like other injectable benzodiazepines produces depression of the central nervous system when administered with drug phenothiazines barbiturates mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d495.s2.p0	drug in combination with drug enhances the manifestation of corneal lesions in rats epidural injection clonidine may potentiate the cns depressive effect of alcohol barbiturates or other sedating drugs 	DDI-effect
DDI-DrugBank.d247.s2.p1	drug should not be administered concomitantly with other sympathomimetic drugs such as drug because of possible additive effects and increased toxicity 	DDI-advise
DDI-DrugBank.d350.s5.p0	drug reduced the blood auc of drug by approximately peak blood concentration cmax by and hour blood concentration c hr by in healthy subjects when tacrolimus doses of mg kg hours apart was administered on the th day of cancidas mg daily as compared to results from a control period in which tacrolimus was administered alone 	DDI-mechanism
DDI-DrugBank.d140.s17.p2	caution should be exercised if an drug is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole spironolactone and drug 	DDI-advise
DDI-DrugBank.d338.s4.p2	while no in vivo drug drug interaction studies were conducted between drug and inducers of cyp a compounds that are potent cyp a inducers such as carbamazepine phenytoin drug and barbiturates would be expected to decrease estazolam concentrations 	DDI-mechanism
DDI-DrugBank.d284.s4.p2	the ecg changes and or hypokalemia that may result from the administration of drug such as loop or thiazide diuretics can be acutely worsened by drug especially when the recommended dose of the beta agonist is exceeded 	DDI-effect
DDI-DrugBank.d569.s1.p1	in clinical trials in patients undergoing ptca pci co administration of drug with heparin drug thrombolytics or glycoprotein iib iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications 	DDI-effect
DDI-MedLine.d47.s4.p0	drug may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either drug or minocycline 	DDI-effect
DDI-DrugBank.d151.s0.p2	drug in large amounts may counteract the antiepileptic effect of phenobarbital phenytoin and drug and increase the frequency of seizures in susceptible pediatric patients 	DDI-effect
DDI-DrugBank.d443.s7.p2	phenytoin serum drug levels may be increased by drug 	DDI-effect
DDI-DrugBank.d217.s5.p2	drug including norfloxacin may enhance the effects of oral anticoagulants including drug or its derivatives or similar agents 	DDI-effect
DDI-DrugBank.d562.s5.p2	although this interaction has not been reported with cinoxacin caution should be exercised when drug is given concomitantly with drug containing products 	DDI-advise
DDI-MedLine.d84.s5.p0	synergism was observed when drug was combined with drug against bacillus subtilis and klebsiella oxytoca 	DDI-effect
DDI-DrugBank.d153.s0.p5	the administration of local anesthetic solutions containing drug or norepinephrine to patients receiving drug or tricyclic antidepressants may produce severe prolonged hypertension 	DDI-effect
DDI-DrugBank.d98.s2.p11	phenytoin phenobarbital the coadministration of drug or phenobarbital will not affect plasma concentrations of vitamin d but may reduce endogenous plasma levels of drug ergocalcitriol by accelerating metabolism 	DDI-mechanism
DDI-DrugBank.d357.s0.p24	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the drug including for example ondansetron granisetron dolasetron palonosetron and alosetron is contraindicated 	DDI-advise
DDI-DrugBank.d400.s4.p2	ace inhibitors reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-DrugBank.d340.s33.p0	drug and drug should not be coadministered 	DDI-advise
DDI-DrugBank.d338.s8.p3	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a nefazodone fluvoxamine cimetidine drug isoniazide and some macrolide antibiotics 	DDI-mechanism
DDI-DrugBank.d186.s3.p7	as with other antipsychotic agents it should be noted that drug may be capable of potentiating cns depressants such as anesthetics drug and alcohol 	DDI-effect
DDI-DrugBank.d289.s18.p0	therefore the concomitant administration of drug and drug is contraindicated and alternative hypoglycemic agents should be considered 	DDI-advise
DDI-DrugBank.d314.s31.p0	drug may also potentiate the replication of some organisms contained in drug 	DDI-effect
DDI-DrugBank.d245.s0.p4	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol drug coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d5.s17.p9	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol drug thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d249.s5.p11	patients who begin taking diclofenac or who increase their diclofenac dose or any other drug while taking digoxin methotrexate or drug may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d559.s1.p22	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide drug or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d266.s1.p0	it is recommended that if drug is started in patients already receiving drug prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary 	DDI-advise
DDI-DrugBank.d530.s3.p0	drug drug may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them 	DDI-effect
DDI-DrugBank.d139.s4.p3	colestipol concomitant intake of drug and drug may reduce the absorption of vitamin k 	DDI-mechanism
DDI-DrugBank.d77.s2.p13	avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine e g drug norepinephrine since it has been reported that drug can potentiate the effects of catecholamines 	DDI-advise
DDI-DrugBank.d114.s11.p2	delayed adverse reactions to iodinated contrast media a review of the literature revealed that range of patients treated with various drug containing regimens who were subsequently administered drug experienced acute atypical adverse reactions 	DDI-effect
DDI-DrugBank.d401.s0.p7	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the drug salts and antihistamines 	DDI-effect
DDI-DrugBank.d458.s19.p1	when taken orally drug like ketoconazole may enhance the anticoagulant effect of drug like drugs 	DDI-effect
DDI-DrugBank.d158.s2.p2	adrenergic blockers drug are inhibited by drug 	DDI-effect
DDI-DrugBank.d299.s11.p8	although the interaction between almotriptan and other potent cyp a inhibitors e g drug ritonavir and erythromycin has not been studied increased exposures to almotriptan may be expected when drug is used concomitantly with these medications 	DDI-advise
DDI-DrugBank.d47.s2.p13	dopamine d receptor antagonists e g phenothiazines butyrophenones drug and isoniazid may reduce the therapeutic effects of drug 	DDI-effect
DDI-DrugBank.d110.s0.p9	the administration of local anesthetic solutions containing epinephrine or drug to patients receiving drug tricyclic antidepressants or phenothiazines may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d484.s0.p43	drug interact with the following medications acetaminophen such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine sandimmune hiv drugs classified as protease inhibitors crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin prelone rifadin rifampin st johns wort temazepam theophylline theo dur and	DDI-int
DDI-DrugBank.d484.s0.p43	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax ritonavir atromid s felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid inhibitor s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra elixophyllin norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin prelone rifampin st johns wort temazepam toilet theophylline theo dur and drug	DDI-int
DDI-DrugBank.d484.s0.p43	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase saquinavir kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone pediapred prelone rifadin rimactane st privy wort restoril theophylline theo dur and drug	DDI-int
DDI-DrugBank.d484.s0.p43	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and drug 	DDI-int
DDI-DrugBank.d4.s0.p5	synergism between xanthine bronchodilators e g theophylline drug and other drug has been reported 	DDI-effect
DDI-DrugBank.d114.s10.p20	although glucocorticoids have been shown to reduce proleukin induced side effects including fever renal insufficiency hyperbilirubinemia confusion and dyspnea concomitant administration of these agents with proleukin may reduce the antitumor effectiveness of proleukin and thus should be avoided beta blockers and other drug may potentiate the hypotension seen with drug 	DDI-effect
DDI-DrugBank.d48.s15.p87	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or drug ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d463.s3.p0	in a study in normal volunteers concomitant administration of drug and drug resulted in increased serum haloperidol concentrations 	DDI-mechanism
DDI-DrugBank.d85.s9.p1	drug and other nsaids can reduce the antihypertensive effect of drug and other beta blockers 	DDI-effect
DDI-DrugBank.d458.s8.p0	data suggest that coadministration of oral drug and drug can result in prolongation of the qt interval on the ecg 	DDI-effect
DDI-DrugBank.d269.s14.p0	inducers and inhibitors of hepatic metabolism drug reduced plasma concentrations of drug by about 	DDI-mechanism
DDI-DrugBank.d17.s18.p0	for adult onset diabetics dosage adjustment of drug may be necessary during and after drug therapy 	DDI-advise
DDI-DrugBank.d132.s6.p0	drug decreased the hyperuricemic effect of drug 	DDI-effect
DDI-DrugBank.d410.s1.p4	sumatriptan drug has been reported to cause coronary artery vasospasm and its effect could be additive with d h e drug injection usp 	DDI-effect
DDI-DrugBank.d320.s3.p3	although no clinical studies have been conducted it is likely that the metabolism of drug may be affected by the known cyp a inducers such as phenytoin phenobarbital rifampin cyp a inhibitors azole antimycotics e g drug 	DDI-mechanism
DDI-DrugBank.d397.s5.p1	concurrent use of drug and ergotamine or drug has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia 	DDI-effect
DDI-DrugBank.d431.s12.p3	therefore it is theoretically possible that drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability e g ketoconazole ampicillin esters iron salts drug 	DDI-mechanism
DDI-DrugBank.d60.s13.p0	resistance to the neuromuscular blocking action of drug has been demonstrated in patients chronically administered drug or carbamazepine 	DDI-effect
DDI-DrugBank.d484.s0.p19	drug interact with the following medications acetaminophen antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin clofibrate drug cyclosporine neoral sandimmune hiv drugs classified as inhibitors crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur vitamin c	DDI-int
DDI-DrugBank.d484.s0.p19	drug may interact with the following medications acetaminophen itraconazole tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol human immunodeficiency virus antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate drug cyclosporine nelfinavir neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra medication norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone saquinavir rifadin rifampin st johns wort temazepam nelfinavir theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p19	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and achromycin anticonvulsant drug phenytoin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin atorvastatin clofibrate drug cyclosporine neoral sandimmune hiv drugs classified as protease inhibitor agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p19	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate drug cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-MedLine.d12.s7.p10	these results suggest that both dexamethasone and retinyl acetate and possibly other drug and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of drug and egf 	DDI-effect
DDI-DrugBank.d198.s28.p2	alpha blockers when drug or mg was given to healthy volunteers either simultaneously or hours after a mg dose of drug significant hypotension developed in a substantial number of subjects 	DDI-effect
DDI-DrugBank.d217.s11.p9	multivitamins or other products containing drug or zinc antacids or sucralfate should not be administered concomitantly with or within hours of the administration of drug because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin 	DDI-advise
DDI-DrugBank.d529.s17.p0	patients receiving drug and drug or other diuretics should be observed closely to determine if the desired effect is obtained 	DDI-advise
DDI-MedLine.d116.s2.p0	drug has been reported to increase the drug requirements in human subjects ingesting these agents simultaneously 	DDI-mechanism
DDI-DrugBank.d60.s12.p1	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain drug e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d368.s3.p2	by decreasing the gastrointestinal absorption of primidone drug may decrease serum concentrations of drug and its metabolites with a consequent possible decrease in anticonvulsant effect 	DDI-mechanism
DDI-DrugBank.d480.s15.p2	drug nicotine and rifampin may decrease drug plasma levels resulting in a decrease in effectiveness of a previously effective clozapine dose 	DDI-mechanism
DDI-DrugBank.d247.s5.p0	administration of drug to patients receiving drug or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium may induce cardiac arrhythmia 	DDI-effect
DDI-DrugBank.d29.s14.p0	concomitant administration of drug with drug is contraindicated 	DDI-advise
DDI-MedLine.d12.s0.p2	drug and retinyl acetate similarly inhibit and stimulate egf or drug induced proliferation of prostatic epithelium 	DDI-effect
DDI-DrugBank.d5.s17.p0	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain drug e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d55.s0.p0	drug injection and drug should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias 	DDI-advise
DDI-MedLine.d39.s2.p0	injection of drug min before a nonlethal dose of drug changed the serum sex steroid hormone response of male rats to endotoxin 	DDI-effect
DDI-DrugBank.d484.s0.p3	drug may interact with the following medications acetaminophen tylenol antibiotics such as drug and tetracycline anticonvulsants dilantin phenobarbital tegretol atromid s trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin achromycin lipitor clofibrate atromid s cyclosporine neoral sandimmune atromid s hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir morphia viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin reciprocal ohm atromid s rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p3	drug antifungals interact with the following medications neoral tylenol antibiotics such as protease and cyclosporine anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol may gris peg nizoral rifampin atorvastatin lipitor clofibrate atromid s tetracycline acetaminophen sandimmune ms drugs classified as drug inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian hiv contin phenylbutazone prednisolone prelone rifadin sporanox st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p3	drug may interact with the following medications acetaminophen tylenol antibiotics such as drug and tetracycline anticonvulsants dilantin tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p3	drug may interact with the following medications acetaminophen tylenol antibiotics such as drug and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d438.s30.p0	thus drug appeared to alter the renal excretion of both drug and creatinine an endogenous marker of renal function 	DDI-mechanism
DDI-DrugBank.d48.s9.p0	simultaneous administration of drug with drug should be avoided 	DDI-advise
DDI-DrugBank.d267.s5.p3	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines drug polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d5.s14.p0	in a study of male subjects ages to years who were extensive metabolizers of the cyp d isoenzyme daily doses of drug given as mg twice daily followed by a single dose of mg drug increased the cmax auc and t of desipramine by an average of approximately and fold respectively 	DDI-mechanism
DDI-MedLine.d90.s0.p0	of drug and drug in anaesthetised horses	DDI-int
DDI-MedLine.d90.s0.p0	interaction of drug and drug dose in anaesthetised horses	DDI-int
DDI-MedLine.d90.s0.p0	interaction of drug and drug in anaesthetise horses	DDI-int
DDI-MedLine.d90.s0.p0	interaction of drug and drug in anaesthetised horses 	DDI-int
DDI-DrugBank.d434.s31.p5	carbamazepine drug causes an approximate increase in the clearance of drug at steady state and therefore the addition of carbamazepine results in an approximate decrease in the steady state trough concentrations of felbatol as compared to the same dose of felbatol given as monotherapy 	DDI-mechanism
DDI-DrugBank.d240.s0.p1	drug may interact with alcohol or other drug causing increased sedative effects 	DDI-effect
DDI-DrugBank.d537.s0.p4	drug may interact and acetaminophen e g tylenol some e g chloromycetin local drug e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g pronestyl and chloramphenicol multivitamins procainamide e g medicines sulfonamides sulfa sunscreens the diuretics use of these medicines during give test period will affect the test results with pancreatic supplements use of pancreatic supplements may thiazide false test results	DDI-int
DDI-DrugBank.d537.s0.p4	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local e g and para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e pronestyl sulfonamides sulfa medicines thiazide diuretics use of these during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give test results	DDI-int
DDI-DrugBank.d537.s0.p4	dose may interact with acetaminophen e g tylenol chloromycetin e g chloromycetin local dose e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamin pill procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretic drug employment of these medicines during the trial run period will affect the trial run results and pancreatic supplements employment of pancreatic supplements may give false trial run results	DDI-int
DDI-DrugBank.d537.s0.p4	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local drug e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d356.s6.p1	since drug and potassium sparing diuretics including drug may each be associated with increased serum potassium levels the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently 	DDI-effect
DDI-DrugBank.d423.s0.p20	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine sertraline drug there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d325.s1.p0	patients who have been treated with drug within two to three weeks prior to the administration of drug should receive initial doses of dopamine hcl no greater than one tenth of the usual dose 	DDI-advise
DDI-DrugBank.d211.s2.p13	bacteriostatic antibiotics chloramphenicol erythromycins drug or tetracyclines may interfere with the bactericidal effect of drug 	DDI-effect
DDI-DrugBank.d153.s0.p6	the administration of local anesthetic solutions containing drug or norepinephrine to patients receiving monoamine oxidase inhibitors or drug may produce severe prolonged hypertension 	DDI-effect
DDI-DrugBank.d357.s3.p44	dopamine antagonists since apomorphine is a dopamine agonist it is possible that dopamine antagonists such as the neuroleptics phenothiazines butyrophenones thioxanthenes or drug may diminish the effectiveness of drug 	DDI-effect
DDI-DrugBank.d186.s3.p5	as with other antipsychotic agents it should be noted that drug may be capable of potentiating drug such as anesthetics opiates and alcohol 	DDI-effect
DDI-DrugBank.d144.s1.p17	if treatment with inhibitors of cyp a activity such as ketoconazole intraconazole ritonavir drug saquinavir erythromycin etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-MedLine.d85.s14.p0	we propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral drug cytotoxicity by drug 	DDI-mechanism
DDI-DrugBank.d307.s36.p0	therefore when using doses of drug greater than mg day during adjunctive therapy a decrease in the dose of drug may be required 	DDI-advise
DDI-DrugBank.d538.s1.p1	drug and atropine sulfate may interact with drug in studies with male rats diphenoxylate hydrochloride was found to inhibit the liverwort microsomal enzyme organisation at a dose of mg kg mean solar day	DDI-int
DDI-DrugBank.d538.s1.p1	drug and atropine dose sulfate may interact with drug in studies with male rats diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose kilogram suppress of mg kg day	DDI-int
DDI-DrugBank.d538.s1.p1	drug and interact of may atropine with drug in studies with male rats diphenoxylate hydrochloride was found to inhibit the hepatic day enzyme system at a dose sulfate mg kg microsomal	DDI-int
DDI-DrugBank.d538.s1.p1	drug and atropine sulfate may interact with drug in studies with male rats diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of mg kg day 	DDI-int
DDI-DrugBank.d423.s0.p10	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with serotoninergic agents e g drug fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d356.s4.p0	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d186.s3.p3	as with other drug it should be noted that haldol may be capable of potentiating cns depressants such as anesthetics drug and alcohol 	DDI-effect
DDI-DrugBank.d485.s17.p14	benzodiazepines combination drug may decrease the clearance of some benzodiazepines alprazolam chlordiazepoxide diazepam and increase the clearance of others lorazepam oxazepam drug 	DDI-mechanism
DDI-DrugBank.d283.s15.p1	concomitant administration of drug equivalent to mg tricor with drug mg once daily for days resulted in approximately decrease range from decrease to increase in atorvastatin auc values in healthy males 	DDI-mechanism
DDI-DrugBank.d337.s3.p5	experience with co administration of hmg coa reductase inhibitors and fentanyl in patients is limited therefore consideration should be given to temporarily suspending use of drug in patients receiving drug 	DDI-advise
DDI-DrugBank.d236.s28.p2	veratrum alkaloids drug inhibit the hypotensive effect of drug 	DDI-effect
DDI-DrugBank.d158.s14.p2	haloperidol drug blocks dopamine receptors thus inhibiting the central stimulant effects of drug 	DDI-effect
DDI-DrugBank.d146.s3.p0	response to drug may be enhanced by drug 	DDI-effect
DDI-DrugBank.d44.s1.p0	drug should not be used with other drug 	DDI-advise
DDI-DrugBank.d211.s2.p14	bacteriostatic antibiotics chloramphenicol erythromycins sulfonamides or drug may interfere with the bactericidal effect of drug 	DDI-effect
DDI-DrugBank.d299.s1.p8	because there is a theoretical basis that these effects may be additive use of ergotamine containing or ergot type medications like drug or methysergide and drug within hours of each other should be avoided 	DDI-advise
DDI-DrugBank.d131.s9.p3	data from vitro studies of alprazolam suggest a drug interaction with drug the following drug and paroxetine	DDI-int
DDI-DrugBank.d131.s9.p3	data point from in vitro studies of alprazolam suggest a potential drug interaction with drug for the following drug and paroxetine	DDI-int
DDI-DrugBank.d131.s9.p3	data suggest in vitro studies of alprazolam and a possible drug interaction with drug for the following drug from paroxetine	DDI-int
DDI-DrugBank.d131.s9.p3	data from in vitro studies of alprazolam suggest a possible drug interaction with drug for the following drug and paroxetine 	DDI-int
DDI-DrugBank.d398.s1.p1	serious toxicity may result if drug is coadministered with monoamine oxidase inhibitors drug 	DDI-effect
DDI-DrugBank.d236.s20.p2	meperidine drug potentiate the analgesic effect of drug 	DDI-effect
DDI-DrugBank.d562.s14.p2	elevated cyclosporine serum levels have been reported with the concomitant use of drug and drug 	DDI-mechanism
DDI-DrugBank.d272.s0.p2	the risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated but drug may potentiate the side effects of drug 	DDI-effect
DDI-DrugBank.d202.s6.p1	there have been greater than fold increases in previously stable plasma levels of other drug including nortriptyline when drug has been administered in combination with these agents 	DDI-mechanism
DDI-DrugBank.d254.s0.p14	other cns depressant drugs e g barbiturates tranquilizers opioids and general drug have additive or potentiating effects with drug 	DDI-effect
DDI-DrugBank.d46.s19.p5	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d9.s0.p2	drug should not be administered concomitantly with amikacin ciprofloxacin drug netilmicin or tobramycin 	DDI-advise
DDI-DrugBank.d202.s9.p0	close supervision and careful adjustment of the dosage are required when drug is used with other drug or sympathomimetic drugs 	DDI-advise
DDI-DrugBank.d334.s3.p0	when a drug is added to the therapy of a patient receiving drug an additional antihypertensive effect is usually observed 	DDI-effect
DDI-DrugBank.d440.s2.p1	drug should be taken at least minutes before any oral medications containing multivalent cations including antacids supplements or drug 	DDI-advise
DDI-DrugBank.d413.s9.p5	uricosuric agents since the excretion of oxipurinol is similar to that of urate drug which increase the excretion of urate are also likely to increase the excretion of drug and thus lower the degree of inhibition of xanthine oxidase 	DDI-mechanism
DDI-DrugBank.d40.s10.p18	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides drug tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d347.s7.p44	magnesium and or aluminum containing antacids products containing ferrous sulfate iron multivitamin preparations containing zinc or other metal cations or videx drug chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d318.s2.p5	corticosteroids and corticotropin drug may potentiate drug induced hypokalemia which may predispose the patient to cardiac dysfunction 	DDI-effect
DDI-DrugBank.d32.s7.p0	however mg of drug q h for days increased the drug c max by and ceftibuten auc by 	DDI-mechanism
DDI-DrugBank.d97.s72.p8	use lowest possible dose of atorvastatin with careful monitoring or consider drug that are not primarily metabolized by cyp a such as pravastatin fluvastatin or rosuvastatin in combination with drug 	DDI-advise
DDI-DrugBank.d64.s4.p0	drug may cause an increased prothrombin response by displacing the drug from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction thus leading to inter patient variation in ultimate prothrombin effect 	DDI-mechanism
DDI-DrugBank.d269.s12.p0	both drug and drug slow av conduction 	DDI-effect
DDI-DrugBank.d219.s1.p0	this interaction should be given consideration in patients taking drug concomitantly with drug 	DDI-advise
DDI-DrugBank.d25.s0.p0	drug may accentuate the electrolyte loss associated with drug therapy 	DDI-effect
DDI-DrugBank.d420.s4.p5	probenecid as with other drug probenecid inhibits the renal excretion of drug resulting in an approximate doubling in a c a increase in peak cefdinir plasma levels and a prolongation in the apparent elimination half life 	DDI-mechanism
DDI-DrugBank.d97.s72.p4	use lowest possible dose of drug with careful monitoring or consider hmg coa reductase inhibitors that are not primarily metabolized by cyp a such as pravastatin fluvastatin or rosuvastatin in combination with drug 	DDI-advise
DDI-DrugBank.d41.s14.p3	rifampin following concomitant administration of a single dose of drug to subjects receiving multiple doses of drug m peak levels were increased over those seen when arava was given alone 	DDI-mechanism
DDI-DrugBank.d284.s4.p7	the ecg changes and or hypokalemia that may result from the administration of non potassium sparing diuretics such as loop or drug can be acutely worsened by drug especially when the recommended dose of the beta agonist is exceeded 	DDI-effect
DDI-DrugBank.d340.s6.p2	drugs that should not be coadministered with drug antiarrhythmics amiodarone drug antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-MedLine.d106.s0.p0	clinical implications of do drugs interactions with five do drugs	DDI-int
DDI-MedLine.d106.s0.p0	clinical implications of drug fundamental interaction interactions with five drug	DDI-int
DDI-MedLine.d106.s0.p0	five implications of drug interactions with clinical drug	DDI-int
DDI-MedLine.d106.s0.p0	clinical implications of drug interactions with five drug 	DDI-int
DDI-DrugBank.d110.s0.p3	the administration of local drug containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors drug or phenothiazines may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-MedLine.d114.s4.p0	pretreatment of megakaryocytes with extracellular drug microm also inhibited drug induced responses 	DDI-effect
DDI-DrugBank.d562.s6.p1	drug or sucralfate substantially interfere with the absorption of some drug resulting in low urine levels 	DDI-mechanism
DDI-DrugBank.d170.s5.p27	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics drug e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d529.s16.p0	other drug that inhibit prostaglandin synthesis have been shown to interfere with drug in some studies and with potassium sparing diuretics 	DDI-effect
DDI-DrugBank.d94.s4.p12	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid drug ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d272.s2.p1	compounds in these categories result in a decreased efficacy of drug phenothiazines drug metoclopramide pimozide 	DDI-effect
DDI-DrugBank.d347.s4.p5	however because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients the prothrombin time or other suitable coagulation test should be closely monitored if a drug is administered concomitantly with drug or its derivatives 	DDI-advise
DDI-DrugBank.d469.s7.p1	drugs which may enhance the neuromuscular blocking action of drug include enflurane drug halothane certain antibiotics especially the aminoglycosides and polymyxins lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d131.s10.p3	data point from in vitro studies of drug other than xanax suggest a possible drug interaction for the following ergotamine cyclosporine drug nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p3	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following nicardipine cyclosporine drug nifedipine and ergotamine	DDI-int
DDI-DrugBank.d131.s10.p3	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine drug nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p3	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine cyclosporine drug nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d307.s37.p0	the increase of drug level however is small when given with drug 	DDI-mechanism
DDI-DrugBank.d183.s2.p2	although there are no study data to evaluate the possibility drug including sodium nitroprusside and nitroglycerin may have an additive effect with drug on the risk of developing methemoglobinemia 	DDI-effect
DDI-MedLine.d55.s0.p0	increased hepatotoxicity of drug by concomitant administration of drug in the rat 	DDI-effect
DDI-MedLine.d128.s13.p1	drug and morphine and mg kg s c inhibited the drug mg kg p o induced diarrhea in cecectomized rats 	DDI-effect
DDI-DrugBank.d40.s19.p4	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin drug estrogens furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d328.s8.p2	ace inhibitors reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-DrugBank.d404.s7.p2	digitalis drug dosage must be determined with care in patients undergoing treatment with drug as hypercalcemia in such patients may precipitate cardiac arrhythmias 	DDI-advise
DDI-DrugBank.d548.s9.p5	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline amitriptyline and drug phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d562.s8.p1	drug including cinoxacin may enhance the effects of oral drug such as warfarin or its derivatives 	DDI-effect
DDI-DrugBank.d210.s16.p3	lithium drug have produced an elevation of plasma drug levels and a reduction in renal lithium clearance 	DDI-mechanism
DDI-DrugBank.d509.s9.p3	ketoconazole coadministration of drug mg day for days with a mg single dose of drug increased the auc of aripiprazole and its active metabolite by and respectively 	DDI-mechanism
DDI-DrugBank.d487.s2.p1	drugs such as drug and ketoconazole may inhibit the metabolism of drug and thus decrease their clearance 	DDI-mechanism
DDI-DrugBank.d247.s1.p0	all drug should be used cautiously in patients taking drug 	DDI-advise
DDI-DrugBank.d423.s0.p18	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with serotoninergic agents e g fluoxetine fluvoxamine drug sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-MedLine.d25.s12.p4	conclusions drug inhibit the metabolism of hmg coa reductase inhibitors that are metabolized by cyp a i e atorvastatin cerivastatin lovastatin drug 	DDI-mechanism
DDI-DrugBank.d172.s19.p7	lithium in a study conducted in healthy subjects mean steady state lithium plasma levels increased approximately in subjects receiving drug mg bid with drug mg bid as compared to subjects receiving lithium alone 	DDI-mechanism
DDI-DrugBank.d328.s10.p3	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of drug and thiazides in some patients 	DDI-effect
DDI-DrugBank.d400.s6.p3	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of drug and thiazides in some patients 	DDI-effect
DDI-DrugBank.d269.s3.p0	catecholamine depleting agents patients taking both drug and a drug that can deplete catecholamines e g drug and monoamine oxidase inhibitors should be observed closely for signs of hypotension and or severe bradycardia 	DDI-effect
DDI-DrugBank.d352.s3.p0	conversely drug may interpose with drug i e guanethidine a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p0	conversely drug may interfere with drug i e alpha methyl dopa guanethidine a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p0	conversely drug may with drug i e guanethidine a methyldopa	DDI-int
DDI-DrugBank.d352.s3.p0	conversely drug may interfere with drug i e guanethidine a methyldopa 	DDI-int
DDI-DrugBank.d404.s5.p0	some reports have shown that the concomitant administration of drug with drug causes hypercalcemia 	DDI-effect
DDI-DrugBank.d140.s10.p6	oral contraceptives coadministration of drug and an oral contraceptive increased auc values for norethindrone and drug by approximately and 	DDI-mechanism
DDI-DrugBank.d144.s1.p20	if treatment with inhibitors of cyp a activity such as ketoconazole intraconazole ritonavir indinavir saquinavir drug etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-DrugBank.d40.s19.p8	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral contraceptives drug quinidine theophylline vitamin d 	DDI-effect
DDI-MedLine.d2.s1.p1	studies in rats have shown that drug administration attenuates certain types of adrenocortical steroid dependent hypertension including drug hypertension 	DDI-effect
DDI-DrugBank.d132.s2.p0	accordingly when drug is administered with oral drug the prothrombin time should be closely monitored during and for several days after concomitant drug administration 	DDI-advise
DDI-DrugBank.d86.s0.p12	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg chlorpromazine an antiparkinsonian drug eg drug and or a drug eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d331.s6.p0	thus drug should not be administered concurrently with drug 	DDI-advise
DDI-DrugBank.d94.s4.p23	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin drug verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d165.s23.p0	therefore prothrombin time should be carefully monitored in patients receiving drug and drug like drugs simultaneously 	DDI-advise
DDI-DrugBank.d207.s4.p2	substances that are potent inhibitors of cyp a activity eg drug and itraconazole decrease gefitinib metabolism and increase drug plasma concentrations 	DDI-mechanism
DDI-DrugBank.d60.s12.p6	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins drug clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d178.s0.p1	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound drug sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d456.s2.p0	pre treatment with the cyp a inducer drug decreased drug auc by about 	DDI-mechanism
DDI-DrugBank.d64.s90.p24	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg aspirin and other non steroidal anti inflammatory drugs dipyridamole drug clofibrate dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d224.s1.p4	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with cns depressants alcohol barbiturates opiates drug anesthetics should be considered 	DDI-advise
DDI-DrugBank.d123.s8.p12	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum drug sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d298.s0.p0	drug may interfere with the anti glaucoma action of drug or pilocarpine 	DDI-effect
DDI-DrugBank.d170.s5.p16	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives drug tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d86.s0.p7	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg drug an antiparkinsonian drug eg trihexyphenidyl and or a drug eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d384.s8.p2	ketoconazole drug may inhibit both synthetic and catabolic enzymes of drug 	DDI-mechanism
DDI-DrugBank.d236.s7.p7	antidepressants tricyclic drug may enhance the activity of drug or sympathomimetic agents 	DDI-effect
DDI-DrugBank.d466.s1.p0	however co administration of drug with either drug or erythromycin led to increased plasma concentrations of fexofenadine 	DDI-mechanism
DDI-DrugBank.d3.s19.p8	psychoactive drugs hallucinations have been reported when drug was used in patients taking psychoactive drugs fluoxetine thiothixene drug 	DDI-effect
DDI-DrugBank.d325.s11.p0	it has been reported that results of studies in animals indicate that drug induced ventricular arrhythmias during anesthesia can be reversed by drug 	DDI-effect
DDI-DrugBank.d274.s0.p0	animal studies indicate that drug may be ineffective if the patient has recently received a drug 	DDI-effect
DDI-DrugBank.d562.s8.p3	quinolones including drug may enhance the effects of oral drug such as warfarin or its derivatives 	DDI-effect
DDI-DrugBank.d511.s4.p5	because of foscarnets tendency to cause renal impairment the use of drug should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides drug and intravenous pentamidine unless the potential benefits outweigh the risks to the patient 	DDI-advise
DDI-DrugBank.d94.s13.p7	agents with increased levels in the presence of carbamazepine drug increases the plasma levels of the following agents clomipramine hcl phenytoin and drug thus if a patient has been titrated to a stable dosage on one of the agents in this category and then begins a course of the treatment with equetrotm it is reasonable to expect that a dose decrease for the concomitant agent may be necessary 	DDI-mechanism
DDI-DrugBank.d480.s17.p2	drug caffeine and erythromycin may increase plasma levels of drug potentially resulting in adverse effects 	DDI-mechanism
DDI-MedLine.d110.s6.p4	both ibogaine and drug block morphine induced and drug induced dopamine release in the nucleus accumbens 	DDI-effect
DDI-DrugBank.d43.s11.p0	in a single subject given one dose of drug hours after a dose of drug placebo tablets a greater than reduction in the auc of ciprofloxacin was observed 	DDI-mechanism
DDI-DrugBank.d368.s4.p0	caution is advised when beginning discontinuing or changing the dose of drug in patients receiving drug 	DDI-advise
DDI-DrugBank.d48.s15.p45	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine drug cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d288.s11.p1	hypersensitivity reactions patients with a history of severe hypersensitivity reactions to products containing cremophor el eg drug for injection concentrate and teniposide for injection concentrate should not be treated with drug 	DDI-advise
DDI-DrugBank.d440.s1.p3	products containing drug and other multivalent cations such as aluminum magnesium iron are likely to interfere with absorption of drug 	DDI-mechanism
DDI-DrugBank.d232.s0.p1	after multiple dosing drug avonex mcg im once weekly reduced drug clearance by approximately 	DDI-mechanism
DDI-DrugBank.d198.s29.p0	with simultaneous dosing of drug mg and drug mg of subjects experienced a standing systolic blood pressure of less than mm hg 	DDI-effect
DDI-DrugBank.d415.s6.p0	this may indicate that drug could enhance the toxicity of drug 	DDI-effect
DDI-DrugBank.d175.s18.p9	lithium increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant drug and drug therapy 	DDI-effect
DDI-DrugBank.d40.s19.p1	drugs whose efficacy is impaired by drug include anticoagulants drug coumarin digitoxin doxycycline estrogens furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d405.s1.p4	other depressasnts such as alcohol drug and maois may enhance cns depression when administered with drug 	DDI-effect
DDI-DrugBank.d430.s3.p2	products containing calcium and other drug likely will interfere with absorption of drug 	DDI-mechanism
DDI-DrugBank.d123.s8.p15	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing drug iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-MedLine.d17.s9.p0	there is thus an enhancement effect of drug upon the reaction of placental vessels to drug in vitro 	DDI-effect
DDI-DrugBank.d103.s3.p9	monoamine oxidase inhibitors and tricyclic antidepressants drug should be administered with extreme caution in patients being treated with drug or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents 	DDI-advise
DDI-DrugBank.d245.s0.p7	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and drug 	DDI-effect
DDI-DrugBank.d482.s10.p0	wait weeks after stopping an drug before starting drug 	DDI-advise
DDI-DrugBank.d500.s0.p0	because drug have been shown to depress plasma prothrombin activity patients who are on drug therapy may require downward adjustment of their anticoagulant dosage 	DDI-advise
DDI-DrugBank.d314.s30.p4	vaccines patients on drug therapy may exhibit a diminished response to toxoids and live or drug due to inhibition of antibody response 	DDI-effect
DDI-DrugBank.d176.s0.p2	diuretics patients on drug especially those with intravascular volume depletion may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug 	DDI-effect
DDI-MedLine.d111.s14.p9	coingestion of acetaminophen with theophylline drug with drug and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug 	DDI-effect
DDI-DrugBank.d107.s4.p2	non steroidal anti inflammatory agents in some patients with compromised renal function who are being treated with drug the co administration of drug may result in a further deterioration of renal function 	DDI-effect
DDI-DrugBank.d236.s17.p2	ethosuximide drug may delay intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d187.s7.p15	carbamazepine isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels drug levels should be determined prior to concurrent administration with drug signs and symptoms of carbamazepine toxicity should be monitored closely and appropriate dosage adjustment of the anticonvulsant should be made 	DDI-advise
DDI-MedLine.d116.s0.p0	drug and drug a interaction drug	DDI-int
DDI-MedLine.d116.s0.p0	drug and drug a drug	DDI-int
DDI-MedLine.d116.s0.p0	drug vitamin a and drug a drug interaction	DDI-int
DDI-MedLine.d116.s0.p0	drug and drug a drug interaction 	DDI-int
DDI-DrugBank.d124.s26.p15	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg drug dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d237.s2.p10	antibiotics in vitro and or in vivo data show that clarithromycin drug and troleandomycin markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d469.s7.p0	drugs which may enhance the neuromuscular blocking action of drug include drug isoflurane halothane certain antibiotics especially the aminoglycosides and polymyxins lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d565.s27.p0	if these agents are to be administered concurrently drug concentrations should be monitored especially when drug therapy is initiated adjusted or discontinued 	DDI-advise
DDI-DrugBank.d569.s1.p0	in clinical trials in patients undergoing ptca pci co administration of drug with drug warfarin thrombolytics or glycoprotein iib iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications 	DDI-effect
DDI-DrugBank.d279.s8.p0	the incidence of akathisia in clinical trials of the weekly dosage schedule was greater patients when drug was administered on the same day as drug than when these drugs were given on separate days patients 	DDI-effect
DDI-DrugBank.d296.s0.p1	drug has additive effects with alcohol and other drug hypnotics sedatives tranquilizers etc 	DDI-effect
DDI-DrugBank.d31.s1.p1	when other potent parental drug such as diazoxide are used in combination with drug patients should be continuously observed for several hours for any excessive fall in blood pressure 	DDI-effect
DDI-DrugBank.d423.s0.p5	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine drug sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-MedLine.d128.s15.p0	drug mg kg s c completely antagonized the inhibitory effect of drug and partly antagonized the effect of morphine 	DDI-effect
DDI-DrugBank.d500.s5.p0	the concurrent use of drug and drug methoxyflurane has been reported to result in fatal renal toxicity 	DDI-effect
DDI-DrugBank.d314.s30.p3	vaccines patients on drug therapy may exhibit a diminished response to toxoids and drug due to inhibition of antibody response 	DDI-effect
DDI-DrugBank.d514.s2.p5	toxicology studies of drug related deaths reveal frequent involvement of other central nervous system depressants including alcohol benzodiazepines such as diazepam valium and to a rising degree drug 	DDI-effect
DDI-DrugBank.d480.s30.p6	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines carbamazepine and type c antiarrhythmics e g propafenone flecainide and drug or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d347.s7.p38	magnesium and or aluminum containing antacids products containing ferrous sulfate iron drug containing zinc or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d123.s8.p16	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium drug or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d64.s90.p27	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg aspirin and other non steroidal anti inflammatory drugs dipyridamole hydrochloroquine clofibrate drug may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d132.s11.p3	acetaminophen in normal volunteers concomitant administration of drug and drug resulted in an approximate increase in plasma levels of acetaminophen 	DDI-mechanism
DDI-DrugBank.d85.s12.p5	naproxen drug and other nsaids have been reported to reduce the tubular secretion of drug in an animal model possibly increasing the toxicity of methotrexate 	DDI-mechanism
DDI-DrugBank.d357.s4.p0	patients with major psychotic disorders treated with drug should be treated with drug only if the potential benefits outweigh the risks 	DDI-advise
DDI-DrugBank.d466.s20.p0	drug should not be taken closely in time with drug and magnesium containing antacids 	DDI-advise
DDI-DrugBank.d260.s3.p6	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and amikacin amphotericin b foscarnet intravenous drug vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d325.s8.p2	drug or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines such as drug 	DDI-effect
DDI-DrugBank.d382.s23.p9	the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via cyp a alprazolam drug should be considered when coadministering these agents with drug 	DDI-advise
DDI-DrugBank.d299.s11.p13	although the interaction between almotriptan and other potent cyp a inhibitors e g itraconazole ritonavir and drug has not been studied increased exposures to almotriptan may be expected when drug is used concomitantly with these medications 	DDI-advise
DDI-DrugBank.d388.s4.p0	blunting of the antihypertensive effect of drug by drug has been reported 	DDI-effect
DDI-DrugBank.d54.s21.p4	vasopressors drug increases the adrenergic effect of catecholamines such as epinephrine and drug 	DDI-effect
DDI-DrugBank.d91.s2.p0	when you are using drug it is especially important that your health care professional know if you are using the following eye product containing drug 	DDI-advise
DDI-DrugBank.d299.s1.p6	because there is a theoretical basis that these effects may be additive use of ergotamine containing or drug like dihydroergotamine or methysergide and drug within hours of each other should be avoided 	DDI-advise
DDI-DrugBank.d89.s3.p1	based on adult data lower doses of drug may be needed following coadministration of drugs which are reported to decrease caffeine elimination e g drug and ketoconazole and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination e g phenobarbital and phenytoin 	DDI-advise
DDI-DrugBank.d467.s4.p0	concomitant administration of drug capsules and drug resulted in substantial increases in plasma concentrations of bexarotene probably at least partially related to cytochrome p a inhibition by gemfibrozil 	DDI-mechanism
DDI-DrugBank.d395.s20.p2	theophylline drug is a potent inhibitor of the cytochrome p isozymes responsible for the metabolism of drug 	DDI-mechanism
DDI-MedLine.d12.s2.p5	although neither dexamethasone nor drug affected the proliferation of prostatic epithelium in rpmi containing transferrin alone they modify the mitogenic effect of drug and insulin 	DDI-effect
DDI-DrugBank.d165.s18.p1	when drug was coadministered with phenytoin drug or h antagonists reduced plasma concentrations of itraconazole were reported 	DDI-mechanism
DDI-DrugBank.d138.s3.p0	drug have been reported to blunt the hypotensive effect of systemic drug it is not known whether the concurrent use of these agents with alphagan p in humans can lead to resulting interference with the iop lowering effect 	DDI-effect
DDI-DrugBank.d4.s2.p0	concurrent administration of drug and drug which competes for tubular secretion has been shown to increase the plasma half life of dyphylline 	DDI-mechanism
DDI-DrugBank.d171.s0.p5	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide drug certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d485.s14.p5	ascorbic acid doses of ascorbic acid drug g day have been reported to increase plasma concentration of drug by possibly by inhibiting conjugation 	DDI-mechanism
DDI-DrugBank.d154.s2.p14	because nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of nalfon the concomitant use of drug and drug is not recommended 	DDI-advise
DDI-DrugBank.d328.s48.p0	plasma exposure of drug mg bid was increased by following administration of drug mg bid for days while plasma exposure of valdecoxib mg bid was not substantially increased following administration of diazepam mg bid for days 	DDI-mechanism
DDI-DrugBank.d568.s17.p5	if concomitant treatment with drug and an ssri e g fluoxetine fluvoxamine paroxetine sertraline drug escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d170.s5.p28	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g drug general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d94.s4.p25	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil drug 	DDI-mechanism
DDI-DrugBank.d562.s13.p0	physicians are provided this information to increase awareness of the potential for serious interactions when drug and certain drug are administered concomitantly 	DDI-advise
DDI-DrugBank.d20.s11.p0	the administration of other drug with drug has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function 	DDI-effect
DDI-DrugBank.d413.s18.p4	cytotoxic agents enhanced bone marrow suppression by drug and other cytotoxic agents has been reported among patients with neoplastic disease except leukemia in the presence of drug 	DDI-effect
DDI-DrugBank.d340.s6.p4	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines drug terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d162.s5.p2	single doses of either drug or colestipol resins bind the drug and reduce its absorption from the gastrointestinal tract by up to and percent respectively 	DDI-mechanism
DDI-DrugBank.d236.s0.p10	acidifying agents drug guanethidine reserpine glutamic acid hcl ascorbic acid fruit juices etc lower absorption of drug 	DDI-mechanism
DDI-DrugBank.d158.s3.p8	antidepressants tricyclic drug may enhance the activity of tricyclic antidepressants or drug 	DDI-effect
DDI-DrugBank.d395.s9.p4	non steroidal anti inflammatory agents seizures have been reported in patients taking drug concomitantly with the nonsteroidal anti inflammatory drug drug 	DDI-effect
DDI-DrugBank.d198.s12.p0	drug mg b i d co administered with drug mg resulted in a fold increase in vardenafil auc and a fold increase in vardenafil cmax 	DDI-mechanism
DDI-DrugBank.d453.s0.p1	drug a cytostatic agent has been reported to inactivate the antifungal activity of drug by competitive inhibition 	DDI-effect
DDI-DrugBank.d154.s4.p0	when drug is added to or withdrawn from treatment dosage adjustment of drug may be required 	DDI-advise
DDI-DrugBank.d212.s13.p2	effect of aeds in pediatric patients there was about a increase of apparent total body clearance of drug when it was co administered with enzyme inducing drug 	DDI-mechanism
DDI-DrugBank.d511.s1.p0	concomitant treatment of four patients in the united kingdom with drug and intravenous drug may have caused hypocalcemia 	DDI-effect
DDI-DrugBank.d86.s0.p13	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg chlorpromazine an antiparkinsonian drug eg drug and or a tricyclic antidepressant eg drug commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d333.s3.p0	in a study in which the mg drug orally disintegrating tablet was administered with and without drug an anticholinergic agent with multiple effects on the gi tract to healthy volunteers the auc of clonazepam was lower and the cmax of clonazepam was lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone 	DDI-mechanism
DDI-DrugBank.d480.s22.p5	however other published reports describe modest elevations less than two fold of clozapine and metabolite concentrations when drug was taken with paroxetine drug and sertraline 	DDI-mechanism
DDI-DrugBank.d124.s26.p125	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide drug fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d77.s5.p0	the plasma concentration of drug may increase when the drug is given concomitantly with hepatic enzyme inhibitors e g drug fluoxetine and decrease by concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and adjustment of the dosage of imipramine may therefore be necessary 	DDI-mechanism
DDI-DrugBank.d131.s10.p1	data from in vitro studies dose of drug other than alprazolam suggest a possible drug procardia interaction for the following drug cyclosporine amiodarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p1	amiodarone from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following drug cyclosporine data nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p1	data from in vitro studies of drug other than alprazolam advise a possible drug interaction for the following drug cyclosporine cordarone nicardipine and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p1	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following drug cyclosporine amiodarone nicardipine and nifedipine 	DDI-int
DDI-DrugBank.d5.s21.p0	administration of drug tablets to patients receiving either drug or amantadine concurrently should be undertaken with caution using small initial doses and small gradual dose increases 	DDI-advise
DDI-DrugBank.d18.s1.p10	injection lorazepam injection like other injectable drug produces depression of the central nervous system when administered with ethyl alcohol phenothiazines drug mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d394.s0.p1	the hypotensive effect of drug is augmented by that of most other hypotensive drugs including drug negative inotropic agents and inhaled anesthetics 	DDI-effect
DDI-DrugBank.d320.s3.p0	although no clinical studies have been conducted it is likely that the metabolism of drug may be affected by the known cyp a inducers such as drug phenobarbital rifampin cyp a inhibitors azole antimycotics e g ketoconazole 	DDI-mechanism
DDI-DrugBank.d338.s6.p0	consequently drug should be avoided in patients receiving drug and itraconazole which are very potent inhibitors of cyp a 	DDI-advise
DDI-DrugBank.d223.s28.p2	tolazamide a case of severe hypoglycemia has been reported in a type ii diabetic patient maintained on drug gm day days after the addition of drug mg day 	DDI-effect
DDI-DrugBank.d94.s4.p22	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin drug valproate verapamil zileuton 	DDI-mechanism
DDI-MedLine.d12.s4.p1	higher concentrations of drug m or retinyl acetate x m enhance the mitogenic activity of drug 	DDI-effect
DDI-DrugBank.d410.s2.p0	drug and drug dihydroergotamine mesylate injection usp should not be taken within hours of each other 	DDI-advise
DDI-DrugBank.d62.s0.p1	drug can interact with alcohol or other anticholinergic drug drug may potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or natural process other medications with anticholinergic activity anticholinergic effects may be potentiated depressant when these medications are used concurrently early with downer antihistamines and monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the depressant anticholinergic and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p1	drug of interact with alcohol or other the may potentiate the cns depressant effects of other these medications or antihistamines anticholinergics or either medications with anticholinergic activity anticholinergic and may be potentiated when these medications are used concurrently concurrent antihistamines and monoamine oxidase mao inhibitors with use with effects may prolong and intensify drug anticholinergic effects cns depressant antihistamines can antihistamines	DDI-int
DDI-DrugBank.d62.s0.p1	drug can interact with alcohol or other drug crataegus oxycantha potentiate the cns sedative effects of either these medications or antihistamine anticholinergic or other medications with anticholinergic activity anticholinergic effects crataegus oxycantha be potentiated when these medications are utilise concurrently with antihistamine and monoamine oxidase mao inhibitors coinciding use with antihistamine crataegus oxycantha prolong and intensify the anticholinergic and cns sedative effects of antihistamine	DDI-int
DDI-DrugBank.d62.s0.p1	drug can interact with alcohol or other drug may potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and monoamine oxidase mao inhibitors concurrent use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of antihistamines 	DDI-int
DDI-DrugBank.d269.s3.p1	catecholamine depleting agents patients taking both drug and a drug that can deplete catecholamines e g reserpine and drug should be observed closely for signs of hypotension and or severe bradycardia 	DDI-effect
DDI-DrugBank.d456.s1.p0	caution should be used when administering or taking drug with drug and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d458.s12.p1	coadministration of drug tablets with midazolam or drug has resulted in elevated plasma concentrations of the latter two drugs 	DDI-mechanism
DDI-DrugBank.d123.s8.p17	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or drug may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d306.s0.p1	the effectiveness of drug only pills is reduced by hepatic enzyme inducing drugs such as the anticonvulsants drug carbamazepine and barbiturates and the antituberculosis drug rifampin 	DDI-effect
DDI-DrugBank.d140.s17.p1	caution should be exercised if an drug is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole drug and cimetidine 	DDI-advise
DDI-DrugBank.d480.s17.p4	cimetidine drug and erythromycin may increase plasma levels of drug potentially resulting in adverse effects 	DDI-mechanism
DDI-DrugBank.d387.s2.p0	drug may enhance the effects of drug 	DDI-effect
DDI-DrugBank.d516.s4.p0	drug administered hours before drug resulted in a slower absorption mean c max decreased by and mean t max increased by hour and a lesser extent of absorption mean auc decreased by approximately 	DDI-mechanism
DDI-DrugBank.d345.s10.p0	studies in humans show that the absorption of drug as reflected in urinary excretion is markedly decreased even when administered one hour before drug 	DDI-mechanism
DDI-DrugBank.d443.s0.p5	uricosuric agents drug may decrease the effects of probenecid drug and phenylbutazone 	DDI-effect
DDI-DrugBank.d480.s15.p7	phenytoin nicotine and drug may decrease drug plasma levels resulting in a decrease in effectiveness of a previously effective clozapine dose 	DDI-mechanism
DDI-DrugBank.d397.s3.p0	there have been reports of increased anticoagulant effects when drug and oral drug were used concomitantly 	DDI-effect
DDI-DrugBank.d208.s0.p0	drug may interact with drug blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs norepinephrine nsaids like aleve or ibuprofen and high pressure medications	DDI-int
DDI-DrugBank.d208.s0.p0	drug may nonsteroidal anti inflammatory drug interact with drug blood thinners decongestant drugs care allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p0	drug may interact drug with blood thinners decongestant drugs allergy cold and and medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen sinus high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p0	drug may interact with drug blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d35.s0.p2	interaction may occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs and herbs such as garlic genus allium sativum and drug ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p2	interactions may not occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs bayer and herbs such as garlic allium sativum and drug ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p2	may occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and drug ginkgo biloba	DDI-int
DDI-DrugBank.d35.s0.p2	interactions may occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and drug ginkgo biloba 	DDI-int
DDI-DrugBank.d441.s2.p5	adrenergic agents some individuals receiving drug may experience a reversible enhancement of the pressor response to indirect acting sympathomimetic agents drug or dopaminergic agents 	DDI-effect
DDI-DrugBank.d135.s8.p2	carbamazepine in healthy subjects receiving the cyp a inducer drug at mg twice daily for days and mg twice daily for days systemic exposure auc to drug was decreased approximately 	DDI-mechanism
DDI-DrugBank.d54.s2.p0	patients stabilized on oral drug who are found to require drug replacement therapy should be watched very closely when thyroid is started 	DDI-advise
DDI-DrugBank.d272.s2.p0	compounds in these categories result in a decreased efficacy of drug drug haloperidol metoclopramide pimozide 	DDI-effect
DDI-DrugBank.d217.s11.p13	multivitamins or other products containing iron or drug antacids or sucralfate should not be administered concomitantly with or within hours of the administration of drug because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin 	DDI-advise
DDI-DrugBank.d153.s0.p7	the administration of local anesthetic solutions containing epinephrine or drug to patients receiving drug or tricyclic antidepressants may produce severe prolonged hypertension 	DDI-effect
DDI-DrugBank.d516.s11.p0	other drug have demonstrated moderate to marked interference with the metabolism of drug resulting in a reduced clearance a prolongation of plasma half life and an increase in symptoms that accompany high levels of caffeine 	DDI-mechanism
DDI-DrugBank.d434.s11.p9	specific effects of felbatol on other antiepileptic drugs phenytoin drug causes an increase in steady state drug plasma concentrations 	DDI-mechanism
DDI-DrugBank.d291.s1.p0	for this reason the dose of the drug should be reduced by at the start of treatment with drug or bezalip retard and then titrated according to the blood clotting parameters	DDI-advise
DDI-DrugBank.d145.s0.p0	plasma levels of drug may become subtherapeutic during drug therapy 	DDI-mechanism
DDI-DrugBank.d9.s0.p0	drug should not be administered concomitantly with drug ciprofloxacin gentamicin netilmicin or tobramycin 	DDI-advise
DDI-MedLine.d30.s11.p1	drug reduced or eliminated the increases in fi responding produced by intermediate doses of either nanm or drug in pigeons but did not antagonize the decreases in fi or fr responding produced by high doses of pcp or either stereoisomer of nanm 	DDI-effect
DDI-DrugBank.d247.s8.p0	drug may decrease vascular response to pressor drugs such as drug 	DDI-effect
DDI-DrugBank.d450.s9.p0	drug administration to a digitalized hypothyroid patient may increase the dose requirement of drug 	DDI-advise
DDI-MedLine.d87.s4.p0	drug prolonged gastrointestinal transit time from to minutes p this was prevented by drug p 	DDI-effect
DDI-DrugBank.d350.s12.p18	in addition results from regression analyses of patient pharmacokinetic data suggest that co administration of other inducers of drug clearance efavirenz nevirapine phenytoin dexamethasone or drug with drug may result in clinically meaningful reductions in caspofungin concentrations 	DDI-mechanism
DDI-DrugBank.d238.s6.p3	plasma levels of several closely related drug have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g drug phenytoin and such an effect may be anticipated with cmi as well 	DDI-mechanism
DDI-DrugBank.d98.s8.p2	ketoconazole drug may inhibit both synthetic and catabolic enzymes of drug 	DDI-mechanism
DDI-DrugBank.d410.s5.p24	macrolide antibiotics e g erythromycin and troleandomycin agents of the ergot alkaloid class of which drug dihydroergotamine mesylate injection usp is a member have been shown to interact with antibiotics of the drug resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction 	DDI-mechanism
DDI-DrugBank.d178.s9.p0	a potential interaction between oral drug and oral drug leading to severe hypoglycemia has been reported 	DDI-effect
DDI-DrugBank.d64.s90.p12	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg drug and other non steroidal anti inflammatory drugs dipyridamole hydrochloroquine clofibrate dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d236.s1.p4	urinary acidifying agents drug sodium acid phosphate etc increase the concentration of the ionized species of the drug molecule thereby increasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d226.s1.p1	drug and verapamil use may be rarely associated with ventricular fibrillation when combined with drug 	DDI-effect
DDI-DrugBank.d411.s13.p2	ketamine marked hypertension and tachycardia have been reported in association with concomitant administration of drug and drug 	DDI-effect
DDI-DrugBank.d353.s5.p0	however it has been established that drug interferes with the contraceptive effect of microdosed drug minipill preparations 	DDI-effect
DDI-DrugBank.d423.s0.p14	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine sertraline drug there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d87.s15.p0	when drug is added to drug therapy plasma flecainide levels may increase two fold or more in some patients if flecainide dosage is not reduced 	DDI-mechanism
DDI-DrugBank.d382.s11.p0	the daily dose of drug administered in clinical studies with drug reflects an approximate reduction of the dose of dexamethasone 	DDI-mechanism
DDI-DrugBank.d357.s0.p29	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the ht antagonist class including for example ondansetron granisetron dolasetron palonosetron and drug is contraindicated 	DDI-advise
DDI-DrugBank.d219.s7.p6	cyclosporine digoxin methotrexate lodine like other drug through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine digoxin drug and increased toxicity 	DDI-mechanism
DDI-DrugBank.d441.s1.p1	therefore drug has the potential for interaction with adrenergic and drug	DDI-int
DDI-DrugBank.d441.s1.p1	therefore drug has the potential for consequently interaction with adrenergic and drug	DDI-int
DDI-DrugBank.d441.s1.p1	thus drug has the potential for interaction with adrenergic and drug	DDI-int
DDI-DrugBank.d441.s1.p1	therefore drug has the potential for interaction with adrenergic and drug 	DDI-int
DDI-DrugBank.d314.s25.p0	drug should be used cautiously in conjunction with drug in hypoprothrombinemia 	DDI-advise
DDI-DrugBank.d77.s2.p14	avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine e g epinephrine drug since it has been reported that drug can potentiate the effects of catecholamines 	DDI-advise
DDI-DrugBank.d46.s20.p0	therefore when drug and drug are used concomitantly the patient should be observed closely to determine if the desired effect of the diuretic is obtained	DDI-advise
DDI-DrugBank.d386.s23.p30	if desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug and drug e g chlordiazepoxide or diazepam are additive 	DDI-effect
DDI-DrugBank.d378.s0.p0	renal function should be monitored carefully if high doses of drug are to be administered with drug because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics 	DDI-advise
DDI-DrugBank.d132.s20.p3	nonsteroidal anti inflammatory drugs the administration of drug to normal volunteers receiving drug decreased the renal clearance and significantly increased the plasma levels of indomethacin 	DDI-mechanism
DDI-DrugBank.d48.s15.p75	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide drug sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d85.s12.p7	naproxen naproxen sodium and other drug have been reported to reduce the tubular secretion of drug in an animal model possibly increasing the toxicity of methotrexate 	DDI-mechanism
DDI-DrugBank.d48.s15.p80	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine drug tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d114.s5.p1	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug and antineoplastic agents specifically drug cis platinum tamoxifen and interferon alfa 	DDI-effect
DDI-DrugBank.d40.s12.p1	drugs that may decrease plasma drug concentrations include carbamazepine chronic drug abuse reserpine	DDI-mechanism
DDI-DrugBank.d381.s2.p0	because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drug and drug it is suggested that the prothrombin time be monitored carefully and the dose of warfarin sodium or other coumarin like drugs should be adjusted accordingly in patients taking both drugs 	DDI-advise
DDI-DrugBank.d270.s11.p0	when drug is co administered with drug anticoagulation levels should be monitored frequently 	DDI-advise
DDI-DrugBank.d5.s17.p11	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine drug e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d74.s1.p0	drug may augment the hypotension caused by the ganglionic blocking effect of drug 	DDI-effect
DDI-DrugBank.d446.s0.p0	drug may interact with drug aspirin barbiturates bromocriptine calcium barbiturate supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p0	drug may interact with drug aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and coumadin	DDI-int
DDI-DrugBank.d446.s0.p0	drug may interact with drug aspirin barbiturates nicotine calcium supplements corticosteroids corticotropin cyclosporine dantrolene bromocriptine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p0	drug may interact with drug aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d75.s12.p0	drug demonstrates some limited inhibitory activity towards cyp a which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e g drug 	DDI-mechanism
DDI-DrugBank.d382.s22.p4	midazolam drug increased the auc of drug a sensitive cyp a substrate by fold on day and fold on day when a single oral dose of midazolam mg was coadministered on day and day of a regimen of aprepitant mg on day and mg day on days through 	DDI-mechanism
DDI-DrugBank.d484.s0.p7	drug may interact with following medications acetaminophen tylenol antibiotics as ampicillin and tetracycline anticonvulsants dilantin drug tegretol trileptal topamax felbatol antifungals gris peg nizoral atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase kaletra norvir viracept morphine kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin johns wort temazepam theophylline theo and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p7	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin theophylline wort anticonvulsants trileptal drug tegretol ms topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral as hiv drugs classified sandimmune protease inhibitors norvir crixivan fortovase invirase kaletra agenerase viracept morphine astramorph kadian dilantin contin phenylbutazone prednisolone prelone rifadin rifampin st johns tetracycline temazepam and theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p7	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin drug tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid morphia s cyclosporine neoral sandimmune hiv drugs acetaminophen classified as protease inhibitors agenerase indinavir crixivan fortovase invirase kaletra norvir viracept butazolidin morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline indinavir theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p7	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin drug tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d480.s30.p2	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines drug and type c antiarrhythmics e g propafenone flecainide and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d78.s14.p0	in addition other drug have been reported to decrease the cyp a mediated metabolism of drug 	DDI-mechanism
DDI-DrugBank.d443.s3.p8	pyrazolone derivatives phenylbutazone drug and possibly dipyrone concomitant administration with drug may increase the risk of gastrointestinal ulceration 	DDI-effect
DDI-DrugBank.d26.s0.p35	patients receiving other narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants or other cns depressants including drug concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d373.s2.p9	digitalis immediate release capsules since there have been isolated reports of give up patients with elevated digoxin levels and there is a possible interaction between drug and prompt drug it is recommended that digoxin levels patient role be monitored when initiating at that place adjusting and discontinuing nifedipine to avoid possible over or under digitalization	DDI-int
DDI-DrugBank.d373.s2.p9	digitalis drug release capsules since there have been isolated reports and patients with elevated digoxin levels of there is a possible initiating and immediate and drug it is recommended that digoxin levels be monitored when interaction adjusting between discontinuing nifedipine to avoid possible over or under digitalization	DDI-int
DDI-DrugBank.d373.s2.p9	digitalis immediate release capsules since have been isolated reports of patients with elevated digoxin levels and there is a possible interaction between drug and drug it is recommended that digoxin levels be monitored when initiating adjusting discontinuing nifedipine to avoid possible over or under digitalization	DDI-int
DDI-DrugBank.d373.s2.p9	digitalis immediate release capsules since there have been isolated reports of patients with elevated digoxin levels and there is a possible interaction between drug and drug it is recommended that digoxin levels be monitored when initiating adjusting and discontinuing nifedipine to avoid possible over or under digitalization 	DDI-int
DDI-DrugBank.d94.s4.p10	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine drug grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d198.s27.p0	in these patients whose hypertension was controlled with drug drug mg produced mean additional supine systolic diastolic blood pressure reductions of mm hg compared to placebo 	DDI-effect
DDI-DrugBank.d346.s5.p0	in an emergency situation when opioid analgesia must be administered to a patient receiving drug the amount of drug required may be greater than usual and the resulting respiratory depression may be deeper and more prolonged 	DDI-effect
DDI-MedLine.d16.s6.p0	it is concluded that drug is not a short acting drug and that concomitant use with drug would be expected to prolong further the duration of its action on the central nervous system 	DDI-effect
DDI-DrugBank.d36.s0.p0	caution is advised in patients receiving concomitant high dose drug and drug as anorexia tachypnea lethargy and coma have been rarely reported due to a possible drug interaction 	DDI-advise
DDI-DrugBank.d531.s63.p0	monitoring of liver enzymes is recommended when drug is used in combination with drug 	DDI-advise
DDI-DrugBank.d462.s7.p2	methotrexate drug may reduce the excretion of drug 	DDI-mechanism
DDI-DrugBank.d277.s7.p2	valproate drug causes a slight decrease about in steady state drug concentrations 	DDI-mechanism
DDI-DrugBank.d420.s11.p0	the reddish color is due to the formation of a nonabsorbable complex between drug or its breakdown products and drug in the gastrointestinal tract 	DDI-mechanism
DDI-DrugBank.d140.s17.p0	caution should be exercised if an drug is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as drug spironolactone and cimetidine 	DDI-advise
DDI-DrugBank.d416.s0.p1	renal clearance measurements of drug cannot be made with any significant accuracy in patients receiving sulfonamides drug or thiazolesulfone 	DDI-effect
DDI-MedLine.d106.s6.p2	barbiturates and drug should not be administered to patients receiving drug 	DDI-advise
DDI-MedLine.d82.s8.p0	drug administration to rachitic chicks was effective in significantly elevating duodenal drug absorption acting primarily to enhance serosal transport 	DDI-mechanism
DDI-DrugBank.d465.s0.p0	the vasodilating effects of drug may be additive with those of other drug 	DDI-effect
DDI-DrugBank.d456.s5.p0	if the drug dose is adjusted upward the dose will need to be reduced upon discontinuation of drug or other inducers 	DDI-advise
DDI-DrugBank.d395.s23.p5	warfarin drug including enoxacin decrease the clearance of drug the less active isomer of racemic warfarin 	DDI-mechanism
DDI-DrugBank.d394.s0.p2	the hypotensive effect of drug is augmented by that of most other hypotensive drugs including ganglionic blocking agents negative inotropic agents and inhaled drug 	DDI-effect
DDI-DrugBank.d170.s5.p31	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines drug and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d549.s1.p1	however drug has the potential to increase the hypotensive effect of vasodilators and drug 	DDI-effect
DDI-DrugBank.d434.s30.p22	effects of other antiepileptic drugs on felbatol phenytoin drug causes an approximate doubling of the clearance of felbatol drug at steady state and therefore the addition of phenytoin causes an approximate decrease in the steady state trough concentrations of felbatol as compared to the same dose of felbatol given as monotherapy 	DDI-mechanism
DDI-DrugBank.d485.s43.p5	ethanol nutrition herb interactions food cns effects of caffeine may be enhanced if drug are used concurrently with drug 	DDI-effect
DDI-DrugBank.d521.s1.p7	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate drug magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d291.s11.p4	perhexiline hydrogen maleate or drug with hepatotoxic potential must not be administered together with bezalip or drug 	DDI-advise
DDI-MedLine.d49.s8.p0	combinations of drug and drug were indifferent for and synergistic for of the resistant strains 	DDI-effect
DDI-DrugBank.d414.s6.p2	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-DrugBank.d89.s3.p2	based on adult data lower doses of drug may be needed following coadministration of drugs which are reported to decrease caffeine elimination e g cimetidine and drug and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination e g phenobarbital and phenytoin 	DDI-advise
DDI-DrugBank.d503.s7.p1	exert particular caution in combining drug with other anticholinergic drugs drug and antiparkinsonian agents particularly the elderly may develop delirium high fever severe obstipation even ileus and glaucoma 	DDI-advise
DDI-DrugBank.d153.s4.p1	drug and butyrophenones may reduce or reverse the pressor effect of drug 	DDI-effect
DDI-DrugBank.d170.s5.p20	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics drug skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d124.s30.p9	coadministration with compounds that are potent inducers of cyp a eg phenobarbital phenytoin dexamethasone drug may result in decreased plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d76.s12.p13	other potentially important drug interactions benzodiazepines benzodiazepines metabolized by hepatic oxidation e g alprazolam drug triazolam elc should be used with caution because the clearance of these drugs is likely to be reduced by drug 	DDI-mechanism
DDI-DrugBank.d338.s1.p2	the action of the drug may be potentiated by anticonvulsants antihistamines drug barbiturates monoamine oxidase inhibitors narcotics phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-MedLine.d111.s12.p0	drug diminished binding of drug by a net change of percentage increase in fdf at micromol l 	DDI-mechanism
DDI-DrugBank.d40.s10.p9	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide drug h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d567.s14.p0	however another drug has been found to produce a less than two second increase in prothrombin time in healthy volunteers receiving low doses of drug 	DDI-effect
DDI-DrugBank.d304.s0.p1	may interact with the following drug colestipol use with drug may prevent the diuretic from working properly 	DDI-effect
DDI-DrugBank.d198.s33.p0	two of subjects dosed simultaneously with drug mg and drug mg experienced a standing systolic blood pressure below mm hg 	DDI-effect
DDI-DrugBank.d401.s0.p10	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as drug the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d257.s6.p14	interactions with mixed agonist antagonist opioid analgesics drug eg pentazocine nalbuphine butorphanol dezocine and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d448.s3.p6	the antihypertensive effects of methyldopa drug reserpine and veratrum alkaloids may be reduced by drug 	DDI-effect
DDI-DrugBank.d83.s2.p0	the concomitant administration of drug has been reported to reduce the efficacy of oral drug and to increase the incidence of breakthrough bleeding 	DDI-effect
DDI-DrugBank.d291.s3.p1	the action of drug and insulin may be enhanced by drug or bezalip retard 	DDI-effect
DDI-MedLine.d3.s7.p0	drug significantly increased the area under the curve at steady state auc ss of drug by fold and the auc ss of o desacetylrifabutin by fold 	DDI-mechanism
DDI-DrugBank.d76.s21.p0	evidence supporting the conclusion that it is inadvisable to co administer drug and drug is derived from a study in which healthy volunteers taking mg day of fluvoxamine were administered a single oral dose of mg of diazepam 	DDI-advise
DDI-DrugBank.d112.s0.p0	concurrent use with drug or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of drug 	DDI-mechanism
DDI-DrugBank.d397.s12.p0	in addition deaths have been reported rarely with concomitant administration of drug and drug 	DDI-effect
DDI-MedLine.d119.s16.p0	although this effect was noted even when drug was given hours prior to drug this regimen did not result in diminished efficacy 	DDI-effect
DDI-DrugBank.d54.s8.p5	cholestyramine drug binds both t and drug in the intestine thus impairing absorption of these thyroid hormones 	DDI-mechanism
DDI-DrugBank.d485.s26.p2	morphine combination drug may increase the clearance of drug 	DDI-mechanism
DDI-DrugBank.d503.s0.p0	drug may increase the plasma level of concomitantly given drug 	DDI-mechanism
DDI-DrugBank.d176.s9.p12	antacids in a clinical pharmacology study coadministration of an drug aluminum hydroxide magnesium hydroxide and simethicone with drug reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone suggesting that antacids may impair absorption of fosinopril 	DDI-mechanism
DDI-DrugBank.d357.s0.p27	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the ht antagonist class including for example ondansetron granisetron drug palonosetron and alosetron is contraindicated 	DDI-advise
DDI-DrugBank.d131.s10.p5	data from in vitro studies suggest drug other than alprazolam of a possible following interaction for the drug ergotamine cyclosporine amiodarone nicardipine and drug	DDI-int
DDI-DrugBank.d131.s10.p5	data from in vitro studies of do drugs other than alprazolam suggest a possible do drugs interaction for the following ergotamine cyclosporine cordarone nicardipine and do drugs	DDI-int
DDI-DrugBank.d131.s10.p5	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone nicardipine and drug	DDI-int
DDI-DrugBank.d131.s10.p5	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone nicardipine and drug 	DDI-int
DDI-DrugBank.d397.s5.p0	concurrent use of drug and drug or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia 	DDI-effect
DDI-DrugBank.d330.s2.p3	oral drug inhibits the gastrointestinal absorption of penicillin v oral vitamin b methotrexate and drug 	DDI-mechanism
DDI-DrugBank.d154.s10.p0	patients treated with drug may be resistant to the effects of drug 	DDI-effect
DDI-DrugBank.d81.s14.p4	fentanyl anesthesia severe hypotension has been reported during drug anesthesia with concomitant use of a beta blocker and a drug 	DDI-effect
DDI-DrugBank.d220.s9.p1	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or drug calcium channel blockers antihistamines or h blocking agents tricyclic antidepressants and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d60.s12.p2	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g drug tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d249.s8.p3	lithium drug decreases drug renal clearance and increases lithium plasma levels 	DDI-mechanism
DDI-DrugBank.d219.s11.p0	nevertheless clinical studies as well as postmarketing observations have shown that drug can reduce the natriuretic effect of drug and thiazides in some patients 	DDI-effect
DDI-MedLine.d12.s2.p6	although neither dexamethasone nor drug affected the proliferation of prostatic epithelium in rpmi containing transferrin alone they modify the mitogenic effect of egf and drug 	DDI-effect
DDI-DrugBank.d382.s36.p4	ketoconazole when a single mg dose of drug was administered on day of a day regimen of mg day of drug a strong cyp a inhibitor the auc of aprepitant increased approximately fold and the mean terminal half life of aprepitant increased approximately fold 	DDI-mechanism
DDI-DrugBank.d324.s8.p2	thioridazine coadministration of single doses of drug mg and drug mg produced additive effects on decreased alertness and impaired psychomotor performance for to hours after administration 	DDI-effect
DDI-DrugBank.d382.s21.p0	although a day regimen of drug given concomitantly with oral drug has not been studied alternative or back up methods of contraception should be used 	DDI-advise
DDI-DrugBank.d566.s0.p4	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or drug basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d411.s2.p10	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract aluminum hydoxide cholestyramine resin colestipol hydrochloride drug sodium polystyrene sulfonate soybean flour e g infant formula sucralfate 	DDI-mechanism
DDI-DrugBank.d514.s2.p4	toxicology studies of drug related deaths reveal frequent involvement of other central nervous system depressants including alcohol benzodiazepines such as diazepam drug and to a rising degree methadone 	DDI-effect
DDI-DrugBank.d384.s2.p11	phenytoin phenobarbital the coadministration of drug or phenobarbital will not affect plasma concentrations of vitamin d but may reduce endogenous plasma levels of drug ergocalcitriol by accelerating metabolism 	DDI-mechanism
DDI-DrugBank.d82.s23.p2	in some patients the administration of drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-MedLine.d47.s4.p1	drug may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either azithromycin or drug 	DDI-effect
DDI-DrugBank.d82.s22.p0	therefore when drug and drug are used concomitantly serum digoxin levels should be closely monitored 	DDI-advise
DDI-DrugBank.d380.s7.p1	patients should be warned of the potential danger of the intravenous self administration of drug while under treatment with suboxone or drug 	DDI-advise
DDI-DrugBank.d423.s4.p1	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of drug ssris and agents for migraine therapy such as drug sumatriptan succinate and dihydroergotamine 	DDI-effect
DDI-MedLine.d113.s5.p0	the results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume drug and drug on a regular basis 	DDI-mechanism
DDI-DrugBank.d254.s2.p0	following the administration of drug the dose of other drug should be reduced 	DDI-advise
DDI-DrugBank.d340.s32.p3	rifampin coadministration of drug and drug resulted in an decrease in nelfinavir plasma a c 	DDI-mechanism
DDI-DrugBank.d388.s0.p2	catecholamine depleting drugs such as drug may have an additive effect when given with drug 	DDI-effect
DDI-DrugBank.d170.s5.p17	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics drug e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d224.s6.p0	an additive hypotensive effect has been reported with the combination of systemic drug and drug therapy 	DDI-effect
DDI-DrugBank.d328.s10.p4	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of furosemide and drug in some patients 	DDI-effect
DDI-DrugBank.d334.s0.p0	hypotension patients on diuretic therapy patients on drug and especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug 	DDI-effect
DDI-DrugBank.d330.s2.p1	oral drug inhibits the gastrointestinal absorption of penicillin v oral drug methotrexate and fluorouracil 	DDI-mechanism
DDI-DrugBank.d94.s4.p3	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine drug dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d249.s14.p4	diuretics drug and other nsaids can inhibit the activity of drug 	DDI-effect
DDI-DrugBank.d88.s4.p0	patients taking drug concomitantly with drug should be monitored regularly for alterations in their coagulation parameters pt or inr 	DDI-advise
DDI-DrugBank.d512.s7.p1	dose adjustment of drug may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp a inhibitor e g ketoconazole drug itraconazole 	DDI-advise
DDI-DrugBank.d400.s9.p4	lithium drug have produced an elevation of plasma lithium levels and a reduction in renal drug clearance 	DDI-mechanism
DDI-DrugBank.d537.s0.p10	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins drug e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will the test results and pancreatic supplements use of pancreatic supplements may false test results	DDI-int
DDI-DrugBank.d537.s0.p10	drug crataegus laevigata interact with datril east g tylenol chloramphenicol east g chloromycetin local anesthetic east g benzocaine and lidocaine para aminobenzoic acid paba containing readying east g sunscreens and some multivitamins drug east g pronestyl sulfonamides sulpha medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements crataegus laevigata give false test results	DDI-int
DDI-DrugBank.d537.s0.p10	e may interact para acetaminophen e g tylenol g e g chloromycetin local anesthetics may g benzocaine and lidocaine with aminobenzoic acid paba containing preparations drug g sunscreens and some multivitamins drug e e pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements chloramphenicol give false test results	DDI-int
DDI-DrugBank.d537.s0.p10	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins drug e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d469.s7.p6	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the aminoglycosides and polymyxins drug magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d382.s20.p0	therefore the efficacy of oral drug during administration of drug may be reduced 	DDI-effect
DDI-DrugBank.d237.s7.p12	antifungals in vitro and or in vivo data indicate that fluconazole itraconazole and oral drug markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d43.s2.p5	allopurinol the auc of didanosine was increased about fold when drug at mg day was coadministered with a single mg dose of drug to two patients with renal impairment clcr and ml min 	DDI-mechanism
DDI-DrugBank.d568.s17.p2	if concomitant treatment with drug and an ssri e g fluoxetine drug paroxetine sertraline citalopram escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d172.s6.p0	clinical studies with drug have place potentially significant interactions with drug and lithium	DDI-int
DDI-DrugBank.d172.s6.p0	clinical studies with drug have identified potentially significant interactions with drug and lithium	DDI-int
DDI-DrugBank.d172.s6.p0	clinical studies with drug have drug potentially significant interactions with identified and lithium	DDI-int
DDI-DrugBank.d172.s6.p0	clinical studies with drug have identified potentially significant interactions with drug and lithium 	DDI-int
DDI-MedLine.d30.s9.p1	the doses of drug required to antagonize the effects of nanm were more than times higher than those required to antagonize the effects of drug 	DDI-effect
DDI-DrugBank.d77.s5.p3	the plasma concentration of drug may increase when the drug is given concomitantly with hepatic enzyme inhibitors e g cimetidine fluoxetine and decrease by concomitant administration of hepatic enzyme inducers e g barbiturates drug and adjustment of the dosage of imipramine may therefore be necessary 	DDI-mechanism
DDI-DrugBank.d340.s7.p1	drugs which require a dose reduction when coadminstered with drug antimycobacterial agents drug 	DDI-advise
DDI-DrugBank.d533.s9.p3	furosemide when drug was co administered with drug the auc and cmax of furosemide were reduced by about and respectively 	DDI-mechanism
DDI-DrugBank.d500.s2.p2	absorption of drug is impaired by antacids containing aluminum drug or magnesium and iron containing preparations 	DDI-mechanism
DDI-MedLine.d102.s5.p0	aortic rings with intact endothelium from the high dose mg kg day drug group were supersensitive to drug compared to the vehicle or low dose microg kg day estradiol groups pd values and respectively 	DDI-effect
DDI-DrugBank.d509.s28.p0	as with most psychoactive medications patients should be advised to avoid drug while taking drug 	DDI-advise
DDI-DrugBank.d495.s3.p0	drug may potentiate the hypotensive effects of drug 	DDI-effect
DDI-DrugBank.d124.s26.p90	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine drug tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d72.s4.p4	because busulfan is eliminated from the body via conjugation with glutathione use of drug prior to hours or concurrent with drug may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues 	DDI-mechanism
DDI-DrugBank.d11.s4.p3	in em individuals treated with paroxetine or drug the auc of drug is approximately to fold and css max is about to fold greater than atomoxetine alone 	DDI-mechanism
DDI-DrugBank.d207.s7.p2	drugs that cause significant sustained elevation in gastric ph drug such as ranitidine or cimetidine may reduce plasma concentrations of drug and therefore potentially may reduce efficacy 	DDI-mechanism
DDI-DrugBank.d123.s8.p13	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids drug videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d165.s17.p1	rhabdomyolysis has been observed in patients receiving drug administered alone at recommended dosages or concomitantly with immunosuppressive drugs including drug 	DDI-effect
DDI-DrugBank.d42.s1.p4	blood levels of hydrodolasetron increased when drug was coadministered with cimetidine nonselective inhibitor of cytochrome p for days and decreased with coadministration of drug potent inducer of cytochrome p for days 	DDI-mechanism
DDI-DrugBank.d60.s12.p25	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts drug local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d443.s0.p6	uricosuric agents drug may decrease the effects of probenecid sulfinpyrazone and drug 	DDI-effect
DDI-MedLine.d1.s5.p1	drug is contraindicated in patients using long acting nitrates or who may need to use drug because the combination may cause a sharp fall of the blood pressure 	DDI-advise
DDI-DrugBank.d529.s3.p0	the physician should be cautious when administering drug to patients taking drug 	DDI-advise
DDI-DrugBank.d252.s2.p0	patients receiving drug along with either oral or intravenous drug should be monitored for possible atrioventricular conduction disturbances left ventricular failure and hypotension 	DDI-advise
DDI-DrugBank.d462.s1.p2	vecuronium when used in the perioperative period drug has been implicated in the prolongation of the neuromuscular blockade of drug 	DDI-effect
DDI-DrugBank.d276.s2.p2	drug such as probenecid and sulfinpyrazone can inhibit renal tubular secretion of drug 	DDI-mechanism
DDI-DrugBank.d395.s23.p7	warfarin quinolones including drug decrease the clearance of drug the less active isomer of racemic warfarin 	DDI-mechanism
DDI-DrugBank.d113.s0.p0	drug drug enhances the effect of warfarin 	DDI-effect
DDI-DrugBank.d438.s24.p0	drug increases drug auc values by 	DDI-mechanism
DDI-MedLine.d106.s8.p2	chloral hydrate not drug interact pharmacologically with orally administered drug but the effect is and clinically significant	DDI-int
DDI-MedLine.d106.s8.p2	chloral hydrate and drug interact pharmacologically with orally administered drug but the effect is not clinically significant	DDI-int
DDI-MedLine.d106.s8.p2	chloral hydrate and do drugs interact pharmacologically with orally administered do drugs but the effect is not clinically significant	DDI-int
DDI-MedLine.d106.s8.p2	chloral hydrate and drug interact pharmacologically with orally administered drug but the effect is not clinically significant 	DDI-int
DDI-DrugBank.d330.s2.p2	oral drug inhibits the gastrointestinal absorption of penicillin v oral vitamin b drug and fluorouracil 	DDI-mechanism
DDI-DrugBank.d559.s1.p8	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other drug causing increased cns depression 	DDI-effect
DDI-DrugBank.d5.s8.p0	while not systematically studied certain drugs may induce the metabolism of drug e g drug phenobarbital phenytoin 	DDI-mechanism
DDI-DrugBank.d450.s2.p28	quinidine verapamil amiodarone drug indomethacin itraconazole alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d334.s5.p2	non steroidal anti inflammatory agents in some patients with compromised renal function who are being treated with drug the co administration of drug may result in a further deterioration of renal function 	DDI-effect
DDI-DrugBank.d140.s10.p4	oral contraceptives coadministration of drug and an oral drug increased auc values for norethindrone and ethinyl estradiol by approximately and 	DDI-mechanism
DDI-DrugBank.d345.s14.p0	particular caution should be observed with drug since there are conflicting results for the effect of drug on the availability of digoxin and digitoxin 	DDI-effect
DDI-DrugBank.d114.s2.p10	concurrent administration of drugs possessing nephrotoxic e g aminoglycosides drug myelotoxic e g cytotoxic chemotherapy cardiotoxic e g doxorubicin or hepatotoxic e g methotrexate asparaginase effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d175.s6.p1	therefore drug or other nitrates as used for management of angina or other drugs having vasodilator activity should if possible be discontinued before starting drug 	DDI-advise
DDI-MedLine.d53.s5.p0	combined treatment with drug and drug enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation 	DDI-effect
DDI-DrugBank.d350.s14.p1	when drug is co administered with inducers of drug clearance such as efavirenz drug phenytoin dexamethasone or carbamazepine use of a daily dose of mg of cancidas should be considered	DDI-advise
DDI-DrugBank.d110.s0.p4	the administration of local drug containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors tricyclic antidepressants or drug may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d404.s11.p2	corticosteroids a relationship of functional antagonism exists between drug analogues which promote calcium absorption and drug which inhibit calcium absorption 	DDI-effect
DDI-DrugBank.d0.s2.p0	co administration of drug with drug produced a increase in auc and a increase in the cmax of acamprosate 	DDI-mechanism
DDI-DrugBank.d478.s1.p3	because there is a theoretical basis that these effects may be additive use of drug containing or ergot type medications like dihydroergotamine or methysergide and drug within hours is contraindicated 	DDI-advise
DDI-MedLine.d12.s7.p11	these results suggest that both dexamethasone and retinyl acetate and possibly other drug and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and drug 	DDI-effect
DDI-MedLine.d61.s4.p0	during drug administration systemic clearance of drug was reduced from ml min mean standard deviation to ml min p less than 	DDI-mechanism
DDI-DrugBank.d165.s26.p0	severe hypoglycemia has been reported in patients concomitantly receiving drug and oral drug 	DDI-effect
DDI-DrugBank.d66.s7.p3	paclitaxel in one report drug at a dose of grams three times daily given hours after receiving drug appeared to prevent the development of myalgia and arthralgia adverse reactions of paclitaxel 	DDI-effect
DDI-DrugBank.d220.s5.p2	concomitant administration of drug and other related compounds eg quinine quinidine and drug may produce electrocardiographic abnormalities and increase the risk of convulsions 	DDI-effect
DDI-DrugBank.d5.s20.p8	levodopa and amantadine limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug concurrently with either levodopa or drug 	DDI-effect
DDI-DrugBank.d137.s10.p2	anti arrhythmics and drug could exaggerate the prolongation of the qt interval observed with drug 	DDI-effect
DDI-DrugBank.d382.s32.p0	because moderate cyp a inhibitors e g drug result in fold increase in plasma concentrations of drug concomitant administration should also be approached with caution 	DDI-advise
DDI-DrugBank.d346.s2.p0	the safety and efficacy of concomitant use of drug and drug is unknown and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks 	DDI-effect
DDI-DrugBank.d382.s13.p0	drug when given as a regimen of mg on day and mg day on days and increased the auc of drug a cyp a substrate by fold on day and by fold on day when methylprednisolone was coadministered intravenously as mg on day and orally as mg on days and 	DDI-mechanism
DDI-DrugBank.d64.s90.p6	drugs that reduce the number of blood platelets by causing bone marrow depression such as drug or drugs which inhibit platelet function eg aspirin and other non steroidal anti inflammatory drugs dipyridamole hydrochloroquine clofibrate dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d507.s1.p1	the administration of drug concomitantly with known microsomal enzyme inducer phenobarbital or drug to two patients with renal impairment reportedly resulted in significant reductions in elimination half life and plasma concentration 	DDI-mechanism
DDI-DrugBank.d423.s0.p17	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with serotoninergic agents e g fluoxetine drug paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d3.s19.p6	psychoactive drugs hallucinations have been reported when drug was used in patients taking psychoactive drugs drug thiothixene alprazolam 	DDI-effect
DDI-DrugBank.d345.s5.p0	repeated doses of drug given prior to a single dose of drug in human trials have been reported to decrease propranolol absorption 	DDI-mechanism
DDI-DrugBank.d171.s4.p1	however a crossover study in healthy subjects receiving either drug mg q i d or mg h s concomitantly with a mg b i d dosage of theophylline drug key pharmaceuticals inc demonstrated less alteration in steady state theophylline peak serum levels with the mg h s regimen particularly in subjects aged years and older 	DDI-mechanism
DDI-DrugBank.d158.s6.p5	mao inhibitors maoi antidepressants as well as a metabolite of drug slow drug metabolism 	DDI-mechanism
DDI-DrugBank.d400.s3.p0	caution should be used when drug are administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d381.s0.p1	drug levamisole hydrochloride has been reported to produce antabuse like side effects when given concomitantly with drug 	DDI-effect
DDI-MedLine.d99.s9.p0	results during treatment with drug there was a statistically significant decrease in the median of the total clearance of drug from ml h to ml h among the volunteers who received mg d 	DDI-mechanism
DDI-DrugBank.d485.s18.p2	clofibric acid combination drug may increase the clearance of drug 	DDI-mechanism
DDI-DrugBank.d458.s12.p0	coadministration of drug tablets with drug or triazolam has resulted in elevated plasma concentrations of the latter two drugs 	DDI-mechanism
DDI-DrugBank.d476.s2.p2	in patients receiving concurrent therapy with clonidine if therapy is to be discontinued it is suggested that drug be discontinued for several days before the withdrawal of drug 	DDI-advise
DDI-DrugBank.d211.s5.p0	drug may decrease renal tubular secretion of drug resulting in increased blood levels and or ampicillin toxicity 	DDI-mechanism
DDI-DrugBank.d412.s11.p0	care should be taken if drug is used concomitantly with drug s of the verapamil type 	DDI-advise
DDI-DrugBank.d558.s3.p0	drug at doses of mg bid otc dose resulted in a increase in drug plasma levels mcg single dose 	DDI-mechanism
DDI-DrugBank.d94.s8.p3	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate drug phenobarbital phenytoin primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d299.s6.p26	selective serotonin reuptake inhibitors ssris ssris e g fluoxetine fluvoxamine drug sertraline have been rarely reported to cause weakness hyperreflexia and incoordination when coadministered with drug 	DDI-effect
DDI-DrugBank.d469.s7.p2	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane drug certain antibiotics especially the aminoglycosides and polymyxins lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d562.s3.p0	drug have also been shown to interfere with the metabolism of drug 	DDI-mechanism
DDI-DrugBank.d512.s7.p0	dose adjustment of drug may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp a inhibitor e g drug erythromycin itraconazole 	DDI-advise
DDI-DrugBank.d13.s0.p56	drug interactions flupenthixol may interact with some drugs like monoamine oxidase inhibitors maoi maoi could theoretically affect flupenthixol pharmacodynamics arecoline eproxindine ethanol drug and drug cause additive cns depression tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-effect
DDI-DrugBank.d568.s35.p4	metoprolol administration of mg day drug for days in healthy volunteers resulted in a increase in cmax and increase in auc of the beta adrenergic blocker drug given in a single dose of mg 	DDI-mechanism
DDI-DrugBank.d559.s1.p15	butalbital drug and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide drug or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d64.s90.p21	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg aspirin and other non steroidal anti inflammatory drugs drug hydrochloroquine clofibrate dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
DDI-DrugBank.d500.s3.p0	absorption of drug is impaired by drug 	DDI-mechanism
DDI-DrugBank.d492.s1.p5	drug may have additive effects with alcohol and other cns depressants e g hypnotics sedatives tranquilizers drug 	DDI-effect
DDI-DrugBank.d485.s34.p0	drug has been shown to increase plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d133.s0.p0	co administration of drug and drug or other agents interfering with neuromuscular transmission e g curare like compounds should only be performed with caution as the effect of the toxin may be potentiated 	DDI-advise
DDI-DrugBank.d94.s8.p4	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate rifampin drug phenytoin primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d536.s10.p0	however the peak plasma level of drug was reduced by approximately when taking drug due to a slight delay in the absorption of metformin 	DDI-mechanism
DDI-DrugBank.d123.s8.p7	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium drug or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d414.s4.p0	a number of drugs including drug have been shown to displace drug from plasma protein 	DDI-mechanism
DDI-DrugBank.d220.s5.p0	concomitant administration of drug and other related compounds eg drug quinidine and chloroquine may produce electrocardiographic abnormalities and increase the risk of convulsions 	DDI-effect
DDI-DrugBank.d247.s5.p1	administration of drug to patients receiving cyclopropane or drug such as halothane which sensitize the myocardium may induce cardiac arrhythmia 	DDI-effect
DDI-DrugBank.d40.s10.p8	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens drug fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-MedLine.d67.s7.p2	drug used at doses of mg kg and mg kg decreased the antinociceptive effect of morphine metamizol only in the tail flick test and drug 	DDI-effect
DDI-DrugBank.d60.s12.p8	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin drug and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d485.s17.p9	benzodiazepines combination drug may decrease the clearance of some benzodiazepines drug chlordiazepoxide diazepam and increase the clearance of others lorazepam oxazepam temazepam 	DDI-mechanism
DDI-DrugBank.d12.s7.p0	for these reasons it is felt that in most subjects who have had an unsatisfactory lipid response to either drug alone the possible benefits of combined therapy with drug and a drug do not outweigh the risks of severe myopathy rhabdomyolysis and acute renal failure 	DDI-effect
DDI-DrugBank.d85.s6.p0	concomitant administration of drug and drug is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin resulting in lower plasma concentrations and peak plasma levels 	DDI-advise
DDI-DrugBank.d459.s1.p1	caution should be taken when drug is used concomitantly with medications that are predominantly metabolized by cyp d and which have a narrow therapeutic window such as flecainide drug and tricyclic antidepressants see clinical pharmacology 	DDI-advise
DDI-DrugBank.d559.s1.p20	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics alcohol general anesthetics drug such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d299.s1.p3	because there is a theoretical basis that these effects may be additive use of drug containing or ergot type medications like dihydroergotamine or methysergide and drug within hours of each other should be avoided 	DDI-advise
DDI-DrugBank.d291.s9.p1	when drug or bezalip retard is used concurrently with drug e g cholestryramine an interval of at least hours should be maintained between the two medicines since the absorption of bezalip or bezalip retard is impaired	DDI-advise
DDI-DrugBank.d345.s11.p11	the absorption of tetracycline furosemide drug hydrochlorothiazide and gemfibrozil was significantly decreased when given simultaneously with drug 	DDI-mechanism
DDI-DrugBank.d228.s2.p3	reciprocal interactions may occur with concomitant use of drug and drugs that increase or inhibit the cytochrome p system e g phenytoin carbamazepine cimetidine drug though this has not been studied	DDI-mechanism
DDI-DrugBank.d110.s0.p8	the administration of local anesthetic solutions containing drug or norepinephrine to patients receiving monoamine oxidase inhibitors tricyclic antidepressants or drug may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d318.s5.p2	digitalis glycosides drug induced hypokalemia may potentiate drug toxicity 	DDI-effect
DDI-DrugBank.d508.s1.p11	in addition to bleeding assort with lipo hepin and vitamin k adversary drugs that alter platelet function such as drug dipyridamole and abciximab may increase the risk of bleeding if administered prior to during or after drug therapy	DDI-int
DDI-DrugBank.d508.s1.p11	such addition to bleeding associated with heparin and vitamin k antagonists dipyridamole that alter platelet function in as drug drugs and abciximab may increase the to of bleeding if administered prior risk during or after drug therapy	DDI-int
DDI-DrugBank.d508.s1.p11	anterior in addition to bleeding associated with heparin and vitamin k step up antagonists drugs that alter platelet function such as drug dipyridamole and abciximab run may increase the risk of bleeding if administered prior to during or after drug therapy	DDI-int
DDI-DrugBank.d508.s1.p11	in addition to bleeding associated with heparin and vitamin k antagonists drugs that alter platelet function such as drug dipyridamole and abciximab may increase the risk of bleeding if administered prior to during or after drug therapy 	DDI-int
DDI-DrugBank.d448.s0.p0	drug prolong and intensify the effects of drug 	DDI-effect
DDI-DrugBank.d458.s22.p0	concomitant administration of drug tablets with drug may alter the metabolism of one or both of the drugs 	DDI-mechanism
DDI-DrugBank.d82.s33.p0	blunting of the antihypertensive effect of drug by drug including indocin has been reported 	DDI-effect
DDI-DrugBank.d98.s5.p0	some reports have shown that the concomitant administration of drug with drug causes hypercalcemia 	DDI-effect
DDI-DrugBank.d476.s3.p0	drug should be used with care when drug or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine verapamil and benzothiazepine diltiazem classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d171.s0.p3	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol drug chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d176.s9.p44	antacids in a clinical pharmacology study coadministration of an antacid aluminum hydroxide magnesium hydroxide and simethicone with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone suggesting that drug may impair absorption of drug 	DDI-mechanism
DDI-DrugBank.d559.s1.p18	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics drug general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-MedLine.d128.s13.p2	loperamide and drug and mg kg s c inhibited the drug mg kg p o induced diarrhea in cecectomized rats 	DDI-effect
DDI-DrugBank.d124.s26.p129	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine drug alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d500.s4.p4	barbiturates drug and phenytoin decrease the half life of drug 	DDI-mechanism
DDI-DrugBank.d43.s12.p2	plasma concentrations of drug are decreased when administered with antacids containing magnesium drug or aluminum 	DDI-mechanism
DDI-MedLine.d12.s0.p1	drug and retinyl acetate similarly inhibit and stimulate drug or insulin induced proliferation of prostatic epithelium 	DDI-effect
DDI-DrugBank.d543.s6.p0	drug may antagonize the effects of the drugs that alter gastrointestinal motility such as drug 	DDI-mechanism
DDI-MedLine.d114.s3.p0	administering drug together with drug microm inhibited insp induced responses both ca and current responses in a dose dependent fashion 	DDI-effect
DDI-DrugBank.d382.s23.p6	the potential effects of increased plasma concentrations of midazolam or other drug metabolized via cyp a alprazolam triazolam should be considered when coadministering these agents with drug 	DDI-advise
DDI-MedLine.d30.s8.p2	in monkeys the effects of drug but not nanm or pcp were antagonized by drug 	DDI-effect
DDI-DrugBank.d51.s3.p0	caution is therefore advised in the coadministration of drug inhalation aerosol with other drug containing drugs 	DDI-advise
DDI-DrugBank.d124.s26.p69	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine drug quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d423.s0.p9	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with drug e g fluoxetine fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d249.s5.p10	patients who begin taking diclofenac or who increase their diclofenac dose or any other drug while taking digoxin drug or cyclosporine may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d48.s15.p35	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole drug cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d537.s0.p13	drug may interact sulpha with acetaminophen e g tylenol chloramphenicol supplementation e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e tocopherol g sunscreens and some multivitamins procainamide e spring g pronestyl sulfonamides sulfa medicines drug use of these anaesthetic medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may para aminobenzoic acid give false test results	DDI-int
DDI-DrugBank.d537.s0.p13	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines drug use of these medicines during the test period affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p13	drug of interact procainamide g e use tylenol chloramphenicol e acetaminophen chloromycetin local results e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins with e g pronestyl sulfonamides sulfa medicines drug g of these medicines during the test period will affect the test anesthetics and pancreatic supplements results may pancreatic supplements may give false test use	DDI-int
DDI-DrugBank.d537.s0.p13	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines drug use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d77.s5.p2	the plasma concentration of drug may increase when the drug is given concomitantly with hepatic enzyme inhibitors e g cimetidine fluoxetine and decrease by concomitant administration of hepatic enzyme inducers e g drug phenytoin and adjustment of the dosage of imipramine may therefore be necessary 	DDI-mechanism
DDI-DrugBank.d249.s4.p1	ingestion of drug may increase serum concentrations of digoxin and drug and increase cyclosporine s nephrotoxicity 	DDI-mechanism
DDI-DrugBank.d88.s6.p0	deaths from severe enterocolitis diarrhea and dehydration have been reported in elderly patients receiving weekly drug and drug 	DDI-effect
DDI-DrugBank.d219.s0.p2	ace inhibitors reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-DrugBank.d43.s4.p12	antacids concomitant administration of antacids containing magnesium or drug with drug chewable dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the antacid components 	DDI-effect
DDI-DrugBank.d560.s1.p0	if you are also using a drug inhaler take drug first and then wait about minutes before using the steroid inhaler 	DDI-advise
DDI-DrugBank.d131.s10.p4	data from in vitro studies of drug other than xanax suggest a potential drug interaction for the following ergotamine cyclosporine amiodarone drug and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p4	data from in vitro studies potential of drug other than alprazolam suggest a possible drug interaction for stick with the following ergotamine cyclosporine amiodarone drug and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p4	drug from in vitro studies of cyclosporine other than alprazolam suggest a possible drug interaction for the following ergotamine data amiodarone drug and nifedipine	DDI-int
DDI-DrugBank.d131.s10.p4	data from in vitro studies of drug other than alprazolam suggest a possible drug interaction for the following ergotamine cyclosporine amiodarone drug and nifedipine 	DDI-int
DDI-DrugBank.d399.s1.p0	if leprosy associated inflammatory reactions develop in patients being treated with drug and drug it is still advisable to continue treatment with both drugs 	DDI-advise
DDI-DrugBank.d392.s0.p0	patients who are applying drug gel should not concurrently use products that contain drug n n diethyl m toluamide a common component of insect repellent products 	DDI-advise
DDI-DrugBank.d325.s8.p4	cyclopropane or drug increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines such as drug 	DDI-effect
DDI-DrugBank.d238.s17.p0	drug has also been shown to inhibit p a an isoform also involved in drug metabolism 	DDI-mechanism
DDI-DrugBank.d480.s15.p5	phenytoin drug and rifampin may decrease drug plasma levels resulting in a decrease in effectiveness of a previously effective clozapine dose 	DDI-mechanism
DDI-DrugBank.d328.s33.p0	coadministration of drug mg bid day and mg qd days with drug mg glyburide bid resulted in increase in glyburide auc and a increase in glyburide cmax leading to a decrease in glucose auc 	DDI-mechanism
DDI-DrugBank.d347.s4.p0	however because some drug have been reported to enhance the anticoagulant effects of drug or its derivatives in patients the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives 	DDI-effect
DDI-DrugBank.d282.s0.p1	drug should not be administered concurrently with d antagonists such as phenothiazines drug thioxanthines or metoclopramide 	DDI-advise
DDI-DrugBank.d333.s5.p2	cytochrome p inducers such as drug carbamazepine and phenobarbital induce drug metabolism causing an approximately decrease in plasma clonazepam levels 	DDI-mechanism
DDI-DrugBank.d86.s0.p5	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg drug an drug eg trihexyphenidyl and or a tricyclic antidepressant eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d389.s2.p1	drug may reduce the antihypertensive effects of reserpine drug methyldopa and mecamylamine 	DDI-effect
DDI-DrugBank.d559.s1.p3	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics drug general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d492.s1.p4	drug may have additive effects with alcohol and other cns depressants e g hypnotics sedatives drug antianxiety agents 	DDI-effect
DDI-DrugBank.d246.s12.p0	it is not known if the effects of drug are altered by concomitant medications that affect hepatic metabolism of drugs drug etc but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed 	DDI-advise
DDI-DrugBank.d347.s7.p29	magnesium and or aluminum containing antacids products containing drug iron multivitamin preparations containing zinc or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d22.s0.p1	drug may decrease the amount of digoxin drug lanoxicaps that gets absorbed into your body 	DDI-mechanism
DDI-DrugBank.d53.s5.p0	concurrent use of drug and drug in clinical practice has been associated with increased anticoagulant effects 	DDI-effect
DDI-MedLine.d69.s5.p0	drug alone was found to have no effect on cas but can completely block drug induced phosphorylation of this protein in mda mb cells 	DDI-effect
DDI-DrugBank.d40.s19.p7	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline estrogens furosemide oral drug rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d443.s3.p9	pyrazolone derivatives phenylbutazone oxyphenbutazone and possibly drug concomitant administration with drug may increase the risk of gastrointestinal ulceration 	DDI-effect
DDI-DrugBank.d5.s17.p12	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g drug and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d53.s4.p0	however prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with drug and drug concomitantly 	DDI-advise
DDI-DrugBank.d196.s6.p8	stavudine and zidovudine drug can antagonize the in vitro antiviral activity of stavudine and drug against hiv 	DDI-effect
DDI-DrugBank.d269.s1.p14	poor metabolizers of debrisoquin interactions of carvedilol with strong inhibitors of cyp d such as drug fluoxetine paroxetine and propafenone have not been studied but these drugs would be expected to increase blood levels of the r enantiomer of drug 	DDI-effect
DDI-DrugBank.d123.s7.p0	therefore patients under drug therapy should be carefully monitored when concomitant drug therapy is indicated 	DDI-advise
DDI-DrugBank.d120.s2.p4	apomorphine prior ingestion of drug may decrease the emetic response to drug in the treatment of poisoning 	DDI-effect
DDI-DrugBank.d162.s10.p0	drug reduce the renal clearance of drug and add a high risk of lithium toxicity 	DDI-mechanism
DDI-DrugBank.d62.s0.p5	drug can interact with alcohol or other cns depressant crataegus oxycantha potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or other medications with anticholinergic activity anticholinergic effects crataegus oxycantha be potentiated when these medications are used concurrently with antihistamines and drug coincidental expend with antihistamines crataegus oxycantha prolong and deepen the anticholinergic and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p5	drug can interact with alcohol operating room or other cns depressants may potentiate the cns depressant effects of either medication these follow medications or antihistamines anticholinergics or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and drug concurrent use with antihistamines operating room may prolong and personal effects intensify the anticholinergic and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p5	drug can interact with alcohol or other cns depressants may potentiate the cns depressant of either these medications or antihistamines anticholinergics or medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used with and drug concurrent use with antihistamines may prolong and intensify the and cns depressant effects of antihistamines	DDI-int
DDI-DrugBank.d62.s0.p5	drug can interact with alcohol or other cns depressants may potentiate the cns depressant effects of either these medications or antihistamines anticholinergics or other medications with anticholinergic activity anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines and drug concurrent use with antihistamines may prolong and intensify the anticholinergic and cns depressant effects of antihistamines 	DDI-int
DDI-DrugBank.d210.s1.p1	in patients with mild to moderate hypertension administration of mg daily of drug with the ace inhibitor drug to mg for weeks was associated with an average increase in mean arterial pressure of about mm hg compared to ace inhibitor alone 	DDI-effect
DDI-DrugBank.d282.s0.p3	drug should not be administered concurrently with d antagonists such as phenothiazines butyrophenones thioxanthines or drug 	DDI-advise
DDI-DrugBank.d495.s2.p10	amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats epidural injection drug may potentiate the cns depressive effect of alcohol drug or other sedating drugs 	DDI-effect
DDI-DrugBank.d382.s31.p2	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole itraconazole drug troleandomycin clarithromycin ritonavir nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d347.s8.p0	drug should not be taken within hours of drug 	DDI-advise
DDI-DrugBank.d529.s14.p5	diuretics studies in normal volunteers have shown that flurbiprofen like other drug can interfere with the effects of drug 	DDI-effect
DDI-DrugBank.d456.s1.p3	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin drug itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d123.s15.p4	probenecid drug interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of drug in serum 	DDI-mechanism
DDI-DrugBank.d249.s0.p4	aspirin concomitant administration of drug and drug is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin resulting in lower plasma concentrations peak plasma levels and auc values 	DDI-advise
DDI-DrugBank.d480.s22.p6	however other published reports describe modest elevations less than two fold of clozapine and metabolite concentrations when drug was taken with paroxetine fluoxetine and drug 	DDI-mechanism
DDI-DrugBank.d522.s24.p8	other drugs dose interactions have been reported with concomitant administration of dose and other medications admit cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate dose and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p8	other drugs drug interactions been reported concomitant administration of drug and medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate drug and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p8	and drugs drug interactions have been reported with other administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate drug concomitant lovastatin	DDI-int
DDI-DrugBank.d522.s24.p8	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate drug and lovastatin 	DDI-int
DDI-DrugBank.d415.s2.p3	aspirin animal studies wshow that drug given with drug including ibuprofen yields a net decrease in anti inflammatory activity with lowered blood levels of the non aspirin drug 	DDI-effect
DDI-DrugBank.d413.s2.p9	mercaptopurine azathioprine drug inhibits the enzymatic oxidation of drug and azathioprine to thiouric acid 	DDI-mechanism
DDI-DrugBank.d178.s0.p7	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and drug 	DDI-effect
DDI-DrugBank.d338.s8.p1	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a nefazodone drug cimetidine diltiazem isoniazide and some macrolide antibiotics 	DDI-mechanism
DDI-DrugBank.d459.s0.p0	the daily dose of drug should not exceed mg when coadministered with potent cyp a inhibitors e g drug itraconazole ritonavir nelfinavir clarithromycin and nefazadone 	DDI-advise
DDI-DrugBank.d427.s5.p4	quinolones including drug may enhance the effects of the oral anticoagulant drug or its derivatives 	DDI-effect
DDI-DrugBank.d142.s0.p2	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics amantadine drug phenothiazines monoamine oxidase mao inhibitors tricyclic antidepressants or some antihistamines 	DDI-effect
DDI-MedLine.d20.s0.p0	interaction between drug and drug in the development of spontaneous motility in chick embryos 	DDI-effect
DDI-DrugBank.d170.s5.p18	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g drug general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d123.s8.p4	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum antacids drug videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d198.s8.p0	a mg drug dose should not be exceeded when used in combination with mg once daily drug 	DDI-advise
DDI-DrugBank.d419.s1.p0	it is not known whether this potentiation of drug rashes is due to drug or the hyperuricemia present in these patients 	DDI-effect
DDI-DrugBank.d543.s4.p0	drug may affect gastrointestinal absorption of various drugs such as slowly dissolving dosage forms of drug 	DDI-mechanism
DDI-DrugBank.d170.s3.p1	the concomitant use of other cyp a inhibitors such as drug and erythromycin with transdermal drug may also result in an increase in fentanyl plasma concentrations which could increase or prolong adverse drug effects and may cause serious respiratory depression 	DDI-mechanism
DDI-DrugBank.d568.s25.p4	ketoconazole combined administration of racemic drug mg and drug mg decreased the cmax and auc of ketoconazole by and respectively and did not significantly affect the pharmacokinetics of citalopram 	DDI-mechanism
DDI-DrugBank.d559.s1.p2	drug acetaminophen and caffeine may enhance the effects of other drug s alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d552.s1.p1	drug has been shown to have an additive cns depressant effect when given with either diazepam drug alcohol or codeine 	DDI-effect
DDI-DrugBank.d123.s8.p8	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or drug may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d46.s7.p20	cholestyramine and colestipol resins drug and colestipol resins have the potential of binding drug and reducing diuretic absorption from the gastrointestinal tract	DDI-mechanism
DDI-DrugBank.d258.s4.p0	plasma concentrations auc hrs of drug decreased with coadministration of drug relative to that observed with erythromycin alone 	DDI-mechanism
DDI-DrugBank.d236.s0.p19	acidifying agents gastrointestinal acidifying agents guanethidine reserpine drug ascorbic acid fruit juices etc lower absorption of drug 	DDI-mechanism
DDI-DrugBank.d114.s2.p20	concurrent administration of drugs possessing nephrotoxic e g aminoglycosides indomethacin myelotoxic e g cytotoxic chemotherapy cardiotoxic e g doxorubicin or hepatotoxic e g methotrexate drug effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d350.s12.p16	in addition results from regression analyses of patient pharmacokinetic data suggest that co administration of other inducers of drug clearance efavirenz nevirapine phenytoin drug or carbamazepine with drug may result in clinically meaningful reductions in caspofungin concentrations 	DDI-mechanism
DDI-MedLine.d86.s8.p0	conclusions single dose drug coadministration leads to higher drug exposure presumably by inhibition of the first pass metabolism of sirolimus 	DDI-mechanism
DDI-DrugBank.d241.s0.p2	additional reductions in blood pressure may occur when drug is administered with diuretics antihypertensive agents or other drug 	DDI-effect
DDI-DrugBank.d246.s14.p0	therefore a slower onset can be anticipated if drug is administered concomitantly with or immediately following a drug 	DDI-effect
DDI-DrugBank.d459.s2.p0	the concomitant use of drug with other drug may increase the frequency and or severity of dry mouth constipation blurred vision and other anticholinergic pharmacological effects 	DDI-effect
DDI-MedLine.d12.s7.p4	these results suggest that both drug and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and drug 	DDI-effect
DDI-DrugBank.d477.s3.p0	drug may enhance the effects of drug 	DDI-effect
DDI-DrugBank.d48.s1.p10	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir drug may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d277.s13.p14	valproate the addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics but drug significantly decreased drug binding in vitro from to which resulted in an increase of approximately in the free tiagabine concentration 	DDI-mechanism
DDI-DrugBank.d314.s3.p2	antibiotics drug have been reported to cause a significant decrease in drug clearance 	DDI-mechanism
DDI-DrugBank.d32.s7.p1	however mg of drug q h for days increased the ceftibuten c max by and drug auc by 	DDI-mechanism
DDI-DrugBank.d373.s3.p2	extended release tablets administration of nifedipine with drug increased drug levels in of normal volunteers 	DDI-mechanism
DDI-DrugBank.d531.s75.p0	potential for reduction in drug and or drug plasma levels 	DDI-mechanism
DDI-DrugBank.d94.s13.p6	agents with increased levels in the presence of carbamazepine drug increases the plasma levels of the following agents clomipramine hcl drug and primidone thus if a patient has been titrated to a stable dosage on one of the agents in this category and then begins a course of the treatment with equetrotm it is reasonable to expect that a dose decrease for the concomitant agent may be necessary 	DDI-mechanism
DDI-DrugBank.d566.s0.p9	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations drug and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d463.s0.p0	it is recommended that drug not be used concomitantly with drug because the effects of concomitant administration of buspirone hcl with most other psychotropic drugs have not been studied the concomitant use of buspirone hcl with other cns active drugs should be approached with caution 	DDI-advise
DDI-DrugBank.d495.s4.p0	drug may antagonize the hypotensive effects of drug 	DDI-effect
DDI-DrugBank.d470.s1.p2	caution is advised when drug is coadministered with other medications that can prolong the qt interval e g certain antiarrhythmics or thioridazine or lead to electrolyte abnormalities such as drug or amphotericin b 	DDI-advise
DDI-DrugBank.d328.s20.p3	lithium drug mg bid for days produced significant decreases in drug serum clearance and renal clearance with a higher serum exposure compared to lithium alone 	DDI-mechanism
DDI-DrugBank.d277.s11.p3	phenytoin population pharmacokinetic analyses indicate that drug clearance is greater in patients taking drug with or without other enzyme inducing aeds 	DDI-mechanism
DDI-DrugBank.d107.s1.p4	the possibility of hypotensive effects with enalapril or drug can be minimized by either discontinuing the drug or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat 	DDI-effect
DDI-DrugBank.d297.s4.p0	concurrent therapy with drug and drug is not recommended 	DDI-advise
DDI-DrugBank.d552.s0.p1	drug should be administered with caution to patients who are taking other psychoactive drugs or drug including alcohol barbiturates and narcotic analgesics or to those with a history of psychiatric disorder including manic depressive illness and schizophrenia 	DDI-advise
DDI-MedLine.d29.s8.p0	this might be explained by a blockade by drug of the elimination of drug by the liver 	DDI-mechanism
DDI-DrugBank.d88.s3.p6	coumarin anticoagulants altered coagulation parameters and or bleeding have been reported in patients taking drug concomitantly with coumarin derivative anticoagulants such as warfarin and drug 	DDI-effect
DDI-DrugBank.d208.s0.p1	drug may with alcohol drug s decongestant drugs allergy cold and sinus medicines diabetic drugs lithium like aleve ibuprofen and blood pressure	DDI-int
DDI-DrugBank.d208.s0.p1	do drugs may interact with intoxicant do drugs s decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p1	drug may interact with alcohol diabetic s decongestant drugs allergy cold and sinus and drug drugs lithium norepinephrine nsaids like aleve or ibuprofen medicines high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p1	drug may interact with alcohol drug s decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d299.s10.p0	coadministration of drug and the potent cyp a inhibitor drug mg q d for days resulted in an approximately increase in the area under the plasma concentration time curve and maximal plasma concentrations of almotriptan 	DDI-mechanism
DDI-DrugBank.d228.s2.p2	reciprocal interactions may occur with concomitant use of drug and drugs that increase or inhibit the cytochrome p system e g phenytoin carbamazepine drug ketoconazole though this has not been studied	DDI-mechanism
DDI-DrugBank.d506.s9.p5	until data on possible interactions between verapamil and disopyramide phosphate are obtained drug should not be administered within hours before or hours after drug administration 	DDI-advise
DDI-DrugBank.d528.s0.p7	acetaminophen and methotrexate drug may decrease hepatic toxicity in those with drug overdosage or in those taking methotrexate 	DDI-effect
DDI-DrugBank.d82.s14.p0	administration of drug concomitantly with drug has been associated with an increase in cyclosporine induced toxicity possibly due to decreased synthesis of renal prostacyclin 	DDI-effect
DDI-DrugBank.d508.s1.p13	in addition to bleeding associated with heparin and vitamin k antagonists drugs that alter platelet function such as acetylsalicylic acid drug and abciximab may increase the risk of bleeding if administered prior to during or after drug therapy 	DDI-effect
DDI-DrugBank.d381.s0.p2	ergamisol drug has been reported to produce antabuse like side effects when given concomitantly with drug 	DDI-effect
DDI-DrugBank.d446.s0.p10	drug dose may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine drug tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p10	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids adrenocorticotropic hormone cyclosporine dantrolene nicotine drug tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p10	drug may interact drug antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine with tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p10	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine drug tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d231.s5.p0	drug generally should not be given with drug because they reduce lithiums renal clearance and add a high risk of lithium toxicity 	DDI-advise
DDI-DrugBank.d434.s31.p12	carbamazepine carbamazepine causes an approximate increase in the clearance of felbatol at steady state and therefore the addition of drug results in an approximate decrease in the steady state trough concentrations of drug as compared to the same dose of felbatol given as monotherapy 	DDI-mechanism
DDI-DrugBank.d401.s0.p14	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain drug such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d516.s12.p2	cimetidine drug has been demonstrated to interfere with the elimination of other drug 	DDI-mechanism
DDI-DrugBank.d502.s1.p0	close observation of the patient is recommended when a drug is administered to patients receiving catecholamine depleting drugs such as drug because of possible additive effects and the production of hypotension and or marked bradycardia which may produce vertigo syncope or postural hypotension 	DDI-advise
DDI-DrugBank.d423.s0.p4	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine drug paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d443.s6.p0	drug decreases drug effectiveness by enzyme induction 	DDI-mechanism
DDI-MedLine.d23.s1.p21	in a comparison of digitalis tolerance in dogs anesthetized with ketamine innovar vet or drug the dosage of drug needed to cause ventricular tachycardia was significantly higher as was the ld of ouabain with ketamine or innovar than with pentobarbital 	DDI-effect
DDI-DrugBank.d48.s15.p62	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine drug pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d245.s9.p0	a potential interaction between oral drug and oral drug leading to severe hypoglycemia has been reported 	DDI-effect
DDI-DrugBank.d267.s5.p0	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain drug e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d522.s9.p0	thus the tween interaction observed between drug and drug is not expected for dirithromycin	DDI-int
DDI-DrugBank.d522.s9.p0	thus the interaction maintain between drug and drug is not expected for dirithromycin	DDI-int
DDI-DrugBank.d522.s9.p0	thus the interaction between drug and drug is not expected for dirithromycin	DDI-int
DDI-DrugBank.d522.s9.p0	thus the interaction observed between drug and drug is not expected for dirithromycin 	DDI-int
DDI-MedLine.d68.s0.p13	the effect of cimetidine on the renal excretion of verografin and iodamide in dogs the intravenous injection of drug in a dose of mg kg enhanced verografine and drug excretion in chronic canine experiments 	DDI-mechanism
DDI-DrugBank.d452.s0.p0	administration of drug to hypoparathyroid patients who are concurrently being treated with drug may cause hypercalcemia 	DDI-effect
DDI-DrugBank.d495.s7.p2	also due to the potential for additive effects such as bradycardia and av block caution is warranted in patients receiving drug with agents known to affect sinus node function or av nodal conduction e g digitalis calcium channel blockers and drug 	DDI-advise
DDI-DrugBank.d94.s8.p1	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin drug felbamate rifampin phenobarbital phenytoin primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d162.s10.p1	drug reduce the renal clearance of lithium and add a high risk of drug toxicity 	DDI-effect
DDI-DrugBank.d210.s33.p0	in post marketing experience bleeding events have been reported predominantly in the elderly in association with increases in prothrombin time in patients receiving drug concurrently with drug 	DDI-effect
DDI-DrugBank.d324.s20.p0	coadministration of single oral doses of drug with drug mg and mg respectively a strong selective cyp a inhibitor produced a increase in zaleplons maximal plasma concentrations and a increase in the area under the plasma concentration time curve 	DDI-mechanism
DDI-DrugBank.d446.s0.p11	drug may dose interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin drug and warfarin	DDI-int
DDI-DrugBank.d446.s0.p11	drug may interact and antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin drug with warfarin	DDI-int
DDI-DrugBank.d446.s0.p11	drug may interact with antidepressant drug aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin drug and warfarin	DDI-int
DDI-DrugBank.d446.s0.p11	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin drug and warfarin 	DDI-int
DDI-DrugBank.d267.s5.p12	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics drug and quinidine 	DDI-effect
DDI-DrugBank.d530.s1.p0	concomitant use of drug and drug may cause hypertension 	DDI-effect
DDI-DrugBank.d236.s0.p17	acidifying agents gastrointestinal acidifying agents guanethidine drug glutamic acid hcl ascorbic acid fruit juices etc lower absorption of drug 	DDI-mechanism
DDI-DrugBank.d236.s8.p0	drug with drug or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d amphetamine in the brain 	DDI-mechanism
DDI-DrugBank.d263.s23.p1	the clinical significance of this reduction is not known hence drug is not recommended to be ingested simultaneously with magnesium drug containing antacids 	DDI-advise
DDI-DrugBank.d345.s11.p4	the absorption of drug furosemide penicillin g hydrochlorothiazide and gemfibrozil was significantly decreased when given simultaneously with drug 	DDI-mechanism
DDI-DrugBank.d565.s34.p1	the elimination half life of drug and triazolam also increased fold during coadministration with drug 	DDI-mechanism
DDI-DrugBank.d26.s0.p29	patients receiving other narcotic analgesics general anesthetics phenothiazines tranquilizers drug tricyclic antidepressants or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d132.s27.p4	naproxen the concomitant administration of drug and drug in normal volunteers had no effect on the plasma levels of naproxen but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite 	DDI-mechanism
DDI-DrugBank.d110.s0.p7	the administration of local anesthetic solutions containing drug or norepinephrine to patients receiving monoamine oxidase inhibitors drug or phenothiazines may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d94.s4.p7	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine drug erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d484.s0.p37	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin atorvastatin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor medication clofibrate atromid s cyclosporine neoral sandimmune sm hiv drugs classified as protease inhibitors agenerase crixivan dose fortovase invirase kaletra norvir viracept stick with stick with morphine astramorph kadian ms contin phenylbutazone prednisolone drug rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p37	drug may interact with the following medications acetaminophen tylenol antibiotics such as sk ampicillin and tetracycline anticonvulsants dilantin luminal tegretol trileptal topamax felbatol antifungals gris oarlock nizoral sporanox atorvastatin atorvastatin clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classify as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone drug rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin blow	DDI-int
DDI-DrugBank.d484.s0.p37	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone drug rifadin st wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p37	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone drug rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d5.s17.p2	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline drug desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d283.s0.p2	oral anticoagulants caution should be exercised when drug are given in conjunction with drug 	DDI-advise
DDI-DrugBank.d202.s1.p0	serious anticholinergic symptoms severe dry mouth urinary retention blurred vision have been associated with elevations in the serum levels of drug when drug is added to the drug regimen 	DDI-effect
DDI-DrugBank.d333.s5.p7	cytochrome p inducers such as phenytoin carbamazepine and drug induce drug metabolism causing an approximately decrease in plasma clonazepam levels 	DDI-mechanism
DDI-DrugBank.d511.s0.p0	drug possible drug interaction of a and intravenous drug has been described	DDI-int
DDI-DrugBank.d511.s0.p0	a possible drug interaction of drug and intravenous drug has been	DDI-int
DDI-DrugBank.d511.s0.p0	a possible do drugs interaction of do drugs and intravenous do drugs has been described	DDI-int
DDI-DrugBank.d511.s0.p0	a possible drug interaction of drug and intravenous drug has been described 	DDI-int
DDI-DrugBank.d131.s1.p2	the steady state plasma concentrations of imipramine and drug have been reported to be increased an average of and respectively by the concomitant administration of drug tablets in doses up to mg day 	DDI-mechanism
DDI-DrugBank.d97.s90.p0	drug dose should not exceed a maximum of mg in a hour period in patients receiving concomitant drug therapy 	DDI-advise
DDI-DrugBank.d427.s5.p2	drug including nalidixic acid may enhance the effects of the oral anticoagulant drug or its derivatives 	DDI-effect
DDI-DrugBank.d48.s1.p4	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin drug atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d5.s17.p5	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine drug sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d208.s0.p6	drug may interact with alcohol blood atomic number thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like drug or ibuprofen and high blood stale pressure medications	DDI-int
DDI-DrugBank.d208.s0.p6	drug may interact with medicines blood thinners decongestant drugs allergy cold and sinus alcohol drugs diabetic lithium norepinephrine nsaids like drug or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p6	drug may interact with alcohol blood line thinners decongestant do drugs allergy cold and sinus medicines diabetic do drugs lithium norepinephrine nsaids like drug or ibuprofen and high blood line pressure medications	DDI-int
DDI-DrugBank.d208.s0.p6	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like drug or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d458.s24.p0	concomitant administration of drug with drug tablets reduces the blood levels of the latter 	DDI-mechanism
DDI-DrugBank.d208.s0.p5	drug may with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine drug like or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p5	dose may interact with alcohol blood thinners decongestant dose allergy cold and sinus medicines diabetic dose lithium norepinephrine dose like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p5	drug may interact with allergy blood thinners decongestant and alcohol cold and sinus medicines diabetic drugs lithium norepinephrine drug like aleve or ibuprofen drugs high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p5	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine drug like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d219.s7.p1	cyclosporine digoxin methotrexate drug like other nsaids through effects on renal prostaglandins may cause changes in the elimination of these drugs leading to elevated serum levels of drug digoxin methotrexate and increased toxicity 	DDI-mechanism
DDI-MedLine.d90.s9.p2	at recovery of fade hoof twitch was for atracurium alone and for drug plus drug 	DDI-effect
DDI-DrugBank.d314.s27.p2	phenytoin in post marketing experience there have been reports of both increases and decreases in drug levels with drug co administration leading to alterations in seizure control 	DDI-mechanism
DDI-DrugBank.d40.s10.p15	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines drug salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d373.s7.p2	since there have been isolated reports of patients with elevated digoxin levels it is recommended that drug levels be monitored when initiating adjusting and discontinuing drug to avoid possible over or under digitalization 	DDI-advise
DDI-DrugBank.d446.s0.p6	drug crataegus oxycantha interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids drug cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p6	drug may warfarin with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids drug cyclosporine dantrolene nicotine somatropin tamoxifen and interact	DDI-int
DDI-DrugBank.d446.s0.p6	drug may interact with aspirin barbiturates bromocriptine calcium supplements corticosteroids cyclosporine dantrolene nicotine somatropin tamoxifen warfarin	DDI-int
DDI-DrugBank.d446.s0.p6	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids drug cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d484.s0.p15	drug may interact with the butazolidin following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline restoril anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg pediapred butazolidin nizoral drug atromid s atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur saquinavir and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p15	viracept may interact with the following medications c tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol fortovase topamax felbatol antifungals dur peg nizoral drug atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan norvir invirase kaletra trileptal drug morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort acetaminophen theophylline theo gris and vitamin temazepam	DDI-int
DDI-DrugBank.d484.s0.p15	dose may interact with the keep an eye on medications acetaminophen tylenol antibiotic such as ampicillin and achromycin anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral dose atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prednisolone rifadin rifampin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p15	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral drug atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d217.s0.p0	elevated plasma levels of drug have been reported with concomitant drug use 	DDI-mechanism
DDI-DrugBank.d351.s0.p7	probenecid as with other b lactam antibiotics renal excretion of drug is inhibited by drug and resulted in an approximate increase in the auc for loracarbef 	DDI-mechanism
DDI-DrugBank.d231.s4.p1	drug has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of drug 	DDI-effect
DDI-DrugBank.d59.s0.p0	the effects of drug may be potentiated by drug which inhibits the metabolism of ergotamine 	DDI-mechanism
DDI-DrugBank.d561.s0.p2	diuretics patients on drug especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug 	DDI-effect
DDI-DrugBank.d559.s1.p10	butalbital drug and caffeine may enhance the effects of other drug s alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d114.s5.p3	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug and antineoplastic agents specifically dacarbazine cis platinum drug and interferon alfa 	DDI-effect
DDI-DrugBank.d75.s15.p0	there is a single case report which suggests that drug may interfere with drug absorption 	DDI-mechanism
DDI-DrugBank.d310.s0.p0	it is possible that the cardiovascular action of other drug could be enhanced by the addition of drug 	DDI-effect
DDI-DrugBank.d558.s22.p5	in addition drugs that are actively secreted via this route e g triamterene metformin and drug should be co administered with care as they might increase drug levels 	DDI-advise
DDI-DrugBank.d72.s0.p0	drug decreases drug clearance by up to and may produce aucs m min in some patients 	DDI-mechanism
DDI-DrugBank.d500.s2.p3	absorption of drug is impaired by antacids containing aluminum calcium or drug and iron containing preparations 	DDI-mechanism
DDI-DrugBank.d99.s22.p0	clinically significant effects have been reported with the drug when used concomitantly with drug 	DDI-effect
DDI-DrugBank.d18.s1.p35	injection lorazepam injection like other injectable benzodiazepines produces depression of the central nervous system when administered with ethyl alcohol phenothiazines barbiturates mao inhibitors and other antidepressants when drug is used concomitantly with injectable drug an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d296.s0.p3	drug has additive effects with alcohol and other cns depressants hypnotics drug tranquilizers etc 	DDI-effect
DDI-DrugBank.d210.s2.p0	this interaction should be given consideration in patients taking drug concomitantly with drug 	DDI-advise
DDI-DrugBank.d81.s7.p3	cimetidine in a study in healthy volunteers a one week course of drug at mg b i d with a single mg dose of drug on the sixth day showed an increase in isradipine mean peak plasma concentrations and significant increase in area under the curve 	DDI-mechanism
DDI-DrugBank.d172.s9.p2	ace inhibitors reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-DrugBank.d124.s30.p8	coadministration with compounds that are potent inducers of cyp a eg phenobarbital phenytoin drug carbamazepine may result in decreased plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d507.s4.p0	drug decrease the hypotensive effect of drug 	DDI-effect
DDI-DrugBank.d477.s5.p0	drug agents decrease blood levels and increase excretion of drug 	DDI-mechanism
DDI-DrugBank.d499.s6.p1	however in a study of normal subjects concurrent administration of drug decreased ketoprofen protein binding and increased drug plasma clearance from l kg h without aspirin to l kg h with aspirin 	DDI-mechanism
DDI-DrugBank.d450.s7.p0	drug may decrease serum drug concentration especially in patients with renal dysfunction by increasing the non renal clearance of digoxin 	DDI-mechanism
DDI-DrugBank.d82.s18.p0	as a consequence when drug and drug are given concomitantly the patient should be carefully observed for signs of lithium toxicity 	DDI-advise
DDI-DrugBank.d170.s5.p29	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general drug phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d110.s0.p6	the administration of local anesthetic solutions containing drug or norepinephrine to patients receiving drug tricyclic antidepressants or phenothiazines may produce severe prolonged hypotension or hypertension 	DDI-effect
DDI-DrugBank.d81.s8.p0	if drug therapy is initiated in a patient currently receiving drug careful monitoring for adverse reactions is advised and downward dose adjustment may be required 	DDI-advise
DDI-DrugBank.d74.s2.p0	caution should be exercised during the administration of drug to patients anaesthetised with drug as arrhythmias may be precipitated 	DDI-advise
DDI-DrugBank.d87.s13.p2	limited data in patients receiving known enzyme inducers drug phenobarbital carbamazepine indicate only a increase in the rate of drug elimination 	DDI-mechanism
DDI-DrugBank.d40.s10.p20	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide drug 	DDI-mechanism
DDI-DrugBank.d13.s0.p30	drug interactions flupenthixol may interact with some drugs like monoamine oxidase inhibitors maoi drug could theoretically affect drug pharmacodynamics arecoline eproxindine ethanol flupenthixol and ethanol cause additive cns depression tricyclic antidepressants flupenthixol increases the effect of tricyclic antidepressants	DDI-effect
DDI-DrugBank.d178.s0.p4	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol drug coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d26.s0.p34	patients receiving other narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants or other drug including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d124.s26.p80	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone drug warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d565.s26.p1	in renal and cardiac transplant recipients a reduction of drug dose ranging from to was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of drug 	DDI-mechanism
DDI-DrugBank.d398.s0.p0	the use of drug may result in additive cns depressant effects when coadministered with drug antihistamines psychotropics or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d441.s8.p0	if any signs or symptoms occur physicians should consider discontinuation of either one or both agents drug or concomitant drug 	DDI-advise
DDI-DrugBank.d220.s9.p6	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or beta adrenergic blocking agents calcium channel blockers antihistamines or h blocking agents tricyclic antidepressants and drug might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d48.s1.p1	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole drug erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d97.s52.p0	preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drug in combination with drug than those receiving crixivan mg q h 	DDI-effect
DDI-MedLine.d69.s3.p0	drug alone had no effect on tyrosine phosphorylation in t cells but dose dependently inhibits the effects of drug when both are added simultaneously 	DDI-effect
DDI-DrugBank.d410.s1.p3	sumatriptan drug has been reported to cause coronary artery vasospasm and its effect could be additive with drug dihydroergotamine mesylate injection usp 	DDI-effect
DDI-DrugBank.d250.s2.p5	drug eg tubocurarine and other drugs including ether succinylcholine gallamine decamethonium and sodium citrate potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d148.s6.p2	co administration concomitant use of drug with antiplatelet agents thrombolytics and other drug may increase the risk of bleeding 	DDI-effect
DDI-DrugBank.d47.s2.p11	dopamine d receptor antagonists e g phenothiazines drug risperidone and isoniazid may reduce the therapeutic effects of drug 	DDI-effect
DDI-DrugBank.d236.s25.p2	phenytoin drug may delay intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d238.s6.p20	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine fluoxetine and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates drug and such an effect may be anticipated with drug as well 	DDI-mechanism
DDI-DrugBank.d282.s0.p0	drug should not be administered concurrently with d antagonists such as drug butyrophenones thioxanthines or metoclopramide 	DDI-advise
DDI-DrugBank.d484.s0.p1	drug may interact with the following medications acetaminophen drug antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg ritonavir nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune morphia hiv drugs classified as protease inhibitors agenerase principen crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns restoril wort temazepam temazepam dose theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p1	drug may interact with the following medications acetaminophen drug antibiotics such as polycillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox lipitor lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitor agenerase crixivan fortovase invirase kaletra ritonavir viracept morphine astramorph kadian magnolia state contin phenylbutazone prelone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p1	drug may interact with the following medications acetaminophen drug such ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st wort temazepam theo dur and vitamin	DDI-int
DDI-DrugBank.d484.s0.p1	drug may interact with the following medications acetaminophen drug antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d559.s1.p5	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics drug such as chlordiazepoxide sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d458.s5.p0	pharmacokinetic data indicate that oral drug inhibits the metabolism of drug resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong qt intervals 	DDI-effect
DDI-DrugBank.d420.s0.p9	antacids aluminum or magnesium containing concomitant administration of mg drug capsules with ml drug suspension reduces the rate cmax and extent auc of absorption by approximately 	DDI-mechanism
DDI-DrugBank.d434.s30.p21	effects of other antiepileptic drugs on felbatol phenytoin drug causes an approximate doubling of the clearance of drug felbamate at steady state and therefore the addition of phenytoin causes an approximate decrease in the steady state trough concentrations of felbatol as compared to the same dose of felbatol given as monotherapy 	DDI-mechanism
DDI-DrugBank.d416.s0.p0	renal clearance measurements of drug cannot be made with any significant accuracy in patients receiving drug procaine or thiazolesulfone 	DDI-effect
DDI-DrugBank.d12.s3.p1	drug may displace acidic drugs such as phenytoin or drug from their binding sites 	DDI-mechanism
DDI-DrugBank.d484.s0.p41	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid rifadin s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase sodium thiopental crixivan fortovase invirase itraconazole kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam drug theo itraconazole dur phenytoin and dose vitamin c	DDI-int
DDI-DrugBank.d484.s0.p41	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor atromid cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam drug theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p41	drug may interact with the following medications acetaminophen datril antibiotics such as ampicillin and tetracycline anticonvulsants diphenylhydantoin luminal tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox lipitor lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase indinavir fortovase saquinavir kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam drug theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p41	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam drug theo dur and vitamin c 	DDI-int
DDI-DrugBank.d485.s32.p11	protease inhibitors amprenavir drug nelfinavir and ritonavir have been shown to decrease plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d549.s2.p0	since drug inhibits platelet function there is a potential for increased risk of bleeding particularly in patients maintained on drug 	DDI-effect
DDI-DrugBank.d60.s6.p11	isoflurane or enflurane administered with drug oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of nimbex and decrease the required infusion rate of drug 	DDI-effect
DDI-DrugBank.d103.s4.p19	corticosteroids methylxanthines and diuretics concomitant treatment with xanthine derivatives drug or diuretics may potentiate a possible hypokalemic effect of drug 	DDI-effect
DDI-DrugBank.d456.s1.p2	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir drug indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d454.s0.p2	drug may enhance the cns depressive effects of alcohol barbiturates and other drug 	DDI-effect
DDI-DrugBank.d487.s2.p2	drugs such as troleandomycin and drug may inhibit the metabolism of drug and thus decrease their clearance 	DDI-mechanism
DDI-DrugBank.d48.s1.p9	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir drug telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d469.s7.p4	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the drug and polymyxins lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d217.s10.p2	the concomitant use of nitrofurantoin is not recommended since drug may antagonize the antibacterial effect of drug in the urinary tract 	DDI-effect
DDI-DrugBank.d172.s24.p0	however caution should be used when administering drug with drug since these patients are at increased risk of bleeding complications 	DDI-advise
DDI-DrugBank.d183.s2.p4	although there are no study data to evaluate the possibility nitric oxide donor compounds including drug and nitroglycerin may have an additive effect with drug on the risk of developing methemoglobinemia 	DDI-effect
DDI-DrugBank.d94.s4.p14	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole drug nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d8.s0.p1	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug is administered in combination with other cns depressants such as drug tranquilizers opioids or inhalation general anesthetics 	DDI-effect
DDI-DrugBank.d456.s1.p12	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and drug 	DDI-advise
DDI-DrugBank.d3.s19.p7	psychoactive drugs hallucinations have been reported when drug was used in patients taking psychoactive drugs fluoxetine drug alprazolam 	DDI-effect
DDI-DrugBank.d359.s1.p0	considerable caution should be exercised if drug is administered concurrently with drug phenacemide since paranoid symptoms have been reported during therapy with this combination 	DDI-advise
DDI-DrugBank.d19.s2.p3	since the concomitant administration of these two drugs can lead to phenytoin intoxication prior to administering drug to a patient on drug therapy a baseline phenytoin serum level should be obtained 	DDI-effect
DDI-DrugBank.d131.s5.p7	drugs demonstrated to be cyp a inhibitors of possible clinical significance on the basis of clinical studies involving alprazolam caution is recommended during coadministration with alprazolam coadministration of drug with drug increased the maximum plasma concentration of alprazolam by decreased clearance by increased half life by and decreased measured psychomotor performance 	DDI-mechanism
DDI-DrugBank.d245.s0.p5	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid drug monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d495.s8.p0	there is one reported case of a patient with acute delirium associated with the simultaneous use of drug and oral drug 	DDI-effect
DDI-DrugBank.d537.s0.p9	drug acetaminophen may interact with acetaminophen e g anaesthetic tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine supplementation and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some drug procainamide e g acetaminophen pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period formulation will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p9	medicines may interact with acetaminophen e g tylenol affect e medicines chloromycetin local anesthetics e g diuretics and lidocaine para aminobenzoic acid paba containing preparations e g e and sunscreens drug procainamide some g pronestyl sulfonamides sulfa g thiazide benzocaine use of these drug during the test period will chloramphenicol the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p9	drug with acetaminophen e g tylenol chloramphenicol g local e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens drug procainamide e g pronestyl sulfonamides medicines diuretics use of these medicines during the test period will the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p9	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some drug procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d299.s8.p3	verapamil coadministration of drug and drug resulted in a increase in plasma concentrations of almotriptan 	DDI-mechanism
DDI-DrugBank.d19.s6.p0	it may be necessary to adjust the dosage of oral drug upon beginning or stopping drug since disulfiram may prolong prothrombin time 	DDI-advise
DDI-DrugBank.d456.s1.p1	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to drug clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d162.s9.p0	drug generally should not be given with drug 	DDI-advise
DDI-DrugBank.d495.s1.p0	drug may enhance the cns depressive effects of drug barbiturates or other sedatives 	DDI-effect
DDI-DrugBank.d389.s2.p0	drug may reduce the antihypertensive effects of drug veratrum alkaloids methyldopa and mecamylamine 	DDI-effect
DDI-DrugBank.d414.s7.p0	therefore when drug and drug are used concomitantly the patient should be observed closely to determine if the desired effect of the diuretic is obtained 	DDI-effect
DDI-DrugBank.d488.s1.p1	therefore when drug is given with dicumarol or drug a period of at least hours after the last intravenous dose or hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained 	DDI-advise
DDI-DrugBank.d267.s5.p8	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and drug magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d443.s1.p0	drug has a synergistic effect with drug in causing gastrointestinal bleeding 	DDI-effect
DDI-DrugBank.d165.s10.p0	therefore concomitant administration of drug with drug is contraindicated 	DDI-advise
DDI-DrugBank.d477.s1.p0	drug should not be used concomitantly with other drug 	DDI-advise
DDI-DrugBank.d236.s19.p2	lithium carbonate the stimulatory effects of drug may be inhibited by drug 	DDI-effect
DDI-DrugBank.d558.s5.p6	if a patient requires drug and anti ulcer therapy it is suggested that omeprazole ranitidine or antacids aluminum and magnesium hydroxides be used as alternatives to drug as these agents have no effect on the pharmacokinetic profile of tikosyn 	DDI-advise
DDI-DrugBank.d236.s7.p8	antidepressants tricyclic drug may enhance the activity of tricyclic or drug 	DDI-effect
DDI-DrugBank.d208.s0.p3	drug may interact with alcohol blood thinners decongestant allergy and sinus medicines diabetic drugs drug norepinephrine nsaids aleve or ibuprofen and medications	DDI-int
DDI-DrugBank.d208.s0.p3	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs drug norepinephrine nonsteroidal anti inflammatory care aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p3	drug and interact with alcohol blood thinners decongestant drugs allergy cold pressure sinus medicines diabetic drugs drug norepinephrine nsaids like aleve or ibuprofen and high blood may medications	DDI-int
DDI-DrugBank.d208.s0.p3	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs drug norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d509.s15.p4	quinidine coadministration of a mg single dose of drug with drug mg day for days a potent inhibitor of cyp d increased the auc of aripiprazole by but decreased the auc of its active metabolite dehydroaripiprazole by 	DDI-mechanism
DDI-DrugBank.d296.s0.p0	drug has additive effects with drug and other cns depressants hypnotics sedatives tranquilizers etc 	DDI-effect
DDI-DrugBank.d137.s4.p2	digoxin in controlled studies in healthy volunteers drug either had no effect one study or was associated with modest increases about two studies in steady state serum drug concentrations 	DDI-mechanism
DDI-DrugBank.d340.s6.p3	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine drug astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d536.s5.p0	drug has been shown to change the bioavailabillty drug when they are co administered which may require digoxin dose adjustment 	DDI-mechanism
DDI-MedLine.d16.s3.p0	however drug anesthetic requirement i e mac was depressed in a dose dependent fashion as much as hours and as much as hours after injection of drug mg kg im 	DDI-mechanism
DDI-DrugBank.d291.s3.p3	the action of sulphonylureas and drug may be enhanced by drug or bezalip retard 	DDI-effect
DDI-DrugBank.d162.s12.p4	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d374.s1.p0	drug should not be used together with drug depen cuprimine another arthritis medication 	DDI-advise
DDI-DrugBank.d9.s0.p4	drug should not be administered concomitantly with amikacin ciprofloxacin gentamicin netilmicin or drug 	DDI-advise
DDI-DrugBank.d107.s8.p0	however reports suggest that drug may diminish the antihypertensive effect of drug 	DDI-effect
DDI-MedLine.d131.s3.p0	it was shown that drug antagonized evidently the antinociceptive effect of drug and their analogue 	DDI-effect
DDI-DrugBank.d345.s14.p4	particular caution should be observed with digitalis preparations since there are conflicting results for the effect of drug on the availability of digoxin and drug 	DDI-mechanism
DDI-DrugBank.d484.s0.p32	drug may interact with the fortovase medications tegretol tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital acetaminophen trileptal topamax felbatol peg gris antifungals kaletra sporanox atorvastatin lipitor prelone atromid s cyclosporine neoral sandimmune hiv drugs drug as protease inhibitors agenerase crixivan following invirase nizoral norvir viracept morphine classified kadian ms contin phenylbutazone prednisolone clofibrate rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p32	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax antifungals peg atorvastatin lipitor clofibrate atromid neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir morphine drug kadian ms contin phenylbutazone prednisolone prelone rifampin st johns wort temazepam theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p32	drug may interact with the pursue medications acetaminophen tylenol antibiotic drug such as ampicillin and tetracycline antiepileptic dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs sort as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir nelfinavir morphine drug kadian ms contin phenylbutazone prelone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p32	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine drug kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-MedLine.d106.s6.p1	drug and glutethimide should not be administered to patients receiving drug 	DDI-advise
DDI-DrugBank.d393.s5.p0	there was a small decrease in the clearance of drug caused by a mg dose of drug 	DDI-mechanism
DDI-DrugBank.d345.s11.p13	the absorption of tetracycline furosemide penicillin g drug and gemfibrozil was significantly decreased when given simultaneously with drug 	DDI-mechanism
DDI-DrugBank.d289.s6.p12	hormonal contraceptives including oral injectable transdermal and implantable contraceptives an interaction study demonstrated that co administration of drug and the oral hormonal contraceptive drug produced average decreases of norethindrone and ethinyl estradiol levels of and respectively 	DDI-mechanism
DDI-DrugBank.d53.s7.p1	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin drug cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d340.s6.p8	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents drug benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d388.s0.p1	drug such as reserpine may have an additive effect when given with drug 	DDI-effect
DDI-DrugBank.d275.s2.p0	in a study in which patients with active ra were treated for up to weeks with concurrent drug and drug therapy a rate of serious infections was observed which was higher than that observed with etanercept alone 	DDI-effect
DDI-DrugBank.d400.s9.p3	lithium drug have produced an elevation of plasma drug levels and a reduction in renal lithium clearance 	DDI-mechanism
DDI-DrugBank.d86.s0.p4	the concurrent use of two or more drugs with anticholinergic activity such as an drug eg chlorpromazine an antiparkinsonian drug eg trihexyphenidyl and or a tricyclic antidepressant eg drug commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d158.s11.p2	antihypertensives drug may antagonize the hypotensive effects of drug 	DDI-effect
DDI-DrugBank.d267.s5.p13	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and drug 	DDI-effect
DDI-DrugBank.d410.s0.p4	vasoconstrictors drug dihydroergotamine mesylate injection usp should not be used with drug because the combination may cause synergistic elevation of blood pressure 	DDI-effect
DDI-DrugBank.d267.s6.p1	as with some other drug the time of onset of neuromuscular block induced by nuromax is lengthened and the duration of block is shortened in patients receiving drug or carbamazepine 	DDI-effect
DDI-DrugBank.d440.s1.p9	products containing calcium and other multivalent cations such as aluminum magnesium drug are likely to interfere with absorption of drug 	DDI-mechanism
DDI-DrugBank.d20.s6.p7	ace inhibitors and angiotensin ii receptor antagonists hypertension in clinical studies of patients with hypertension the addition of drug to mg to drug and angiotensin ii receptor antagonists increased mean serum potassium slightly about meq l 	DDI-effect
DDI-DrugBank.d552.s1.p2	drug has been shown to have an additive cns depressant effect when given with either diazepam secobarbitone sodium drug or codeine 	DDI-effect
DDI-MedLine.d81.s2.p0	core temperature was decreased in rats in a dose dependent manner when drug was administered to rats treated with drug hours before the ethanol challenge 	DDI-effect
DDI-DrugBank.d565.s12.p2	a study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels and auc after a week course of drug mg day and a single dose of drug mg 	DDI-mechanism
DDI-DrugBank.d329.s1.p0	based on total drug concentrations drug increased the auc by and reduced the plasma and renal clearances by and respectively 	DDI-mechanism
DDI-DrugBank.d364.s3.p0	drug increased mean drug plasma concentrations auc approximately fold and prolonged the half life by approximately fold 	DDI-mechanism
DDI-DrugBank.d72.s2.p0	drug increases the clearance of drug by or more possibly due to the induction of glutathione s transferase 	DDI-mechanism
DDI-MedLine.d116.s5.p0	this effect may be mediated by the ability of drug to induce microsomal enzymes and thus the catabolism of drug 	DDI-mechanism
DDI-DrugBank.d328.s24.p0	drug caused a statistically significant increase in plasma exposures of drug and s warfarin and respectively and in the pharmacodynamic effects prothrombin time measured as inr of warfarin 	DDI-mechanism
DDI-DrugBank.d64.s30.p0	drugs that reportedly may increase oral drug response ie increased prothrombin response in man include drug 	DDI-effect
DDI-DrugBank.d88.s5.p2	leucovorin the concentration of drug is increased and its toxicity may be enhanced by drug 	DDI-mechanism
DDI-DrugBank.d459.s1.p0	caution should be taken when drug is used concomitantly with medications that are predominantly metabolized by cyp d and which have a narrow therapeutic window such as drug thioridazine and tricyclic antidepressants see clinical pharmacology 	DDI-advise
DDI-DrugBank.d485.s41.p7	tricyclic antidepressants drug imipramine nortriptyline metabolism may be inhibited by drug increasing plasma levels of antidepressant 	DDI-mechanism
DDI-DrugBank.d98.s15.p4	magnesium drug containing preparations eg antacids may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-advise
DDI-DrugBank.d105.s0.p14	anticoagulants including coumarin derivatives indandione derivatives and platelet aggregation inhibitors such as nonsteroidal anti inflammatory drugs nsaids and drug may increase the risk of bleeding when administered concomitantly with drug 	DDI-effect
DDI-DrugBank.d85.s10.p0	drug given concurrently increases drug anion plasma levels and extends its plasma half life significantly 	DDI-mechanism
DDI-DrugBank.d95.s3.p2	sildenafil citrate theoretically drug supplements taken concomitantly with drug may potentiate the effects of the drug 	DDI-effect
DDI-DrugBank.d410.s5.p26	macrolide antibiotics e g erythromycin and troleandomycin agents of the ergot alkaloid class of which d h e drug injection usp is a member have been shown to interact with antibiotics of the drug resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction 	DDI-mechanism
DDI-DrugBank.d95.s0.p2	cyclosporine drug may counteract the antinaturetic effect of drug 	DDI-effect
DDI-DrugBank.d89.s3.p24	based on adult data lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination e g cimetidine and ketoconazole and higher drug doses may be needed following coadministration of drugs that increase caffeine elimination e g phenobarbital and drug 	DDI-advise
DDI-DrugBank.d384.s0.p27	interactions for vitamin d analogues vitamin d vitamin d calcitriol and calcidiol cholestyramine drug has been reported to reduce intestinal absorption of drug 	DDI-mechanism
DDI-DrugBank.d563.s0.p0	special consideration should be given to the administration of drug in patients receiving drug or other drugs that could cause or potentiate hypotension 	DDI-advise
DDI-DrugBank.d565.s25.p0	a pharmacokinetic interaction between drug and drug has been observed during studies take renal and cardiac transplant patients	DDI-int
DDI-DrugBank.d565.s25.p0	a pharmacokinetic interaction been drug and drug has between observed during studies involving renal and cardiac transplant patients	DDI-int
DDI-DrugBank.d565.s25.p0	a pharmacokinetic between drug and drug has been observed during studies involving renal and transplant patients	DDI-int
DDI-DrugBank.d565.s25.p0	a pharmacokinetic interaction between drug and drug has been observed during studies involving renal and cardiac transplant patients 	DDI-int
DDI-DrugBank.d398.s1.p0	serious toxicity may result if drug is coadministered with drug maois 	DDI-effect
DDI-DrugBank.d40.s10.p4	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine drug dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d469.s10.p0	drug should not be administered until a patient has recovered from drug induced neuromuscular block 	DDI-advise
DDI-DrugBank.d489.s5.p0	literature reports suggest that oral drug may be used in combination with drug when heart function is normal but should be avoided in patients with impaired cardiac function 	DDI-advise
DDI-DrugBank.d40.s10.p1	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake drug chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d514.s2.p0	toxicology studies of drug related deaths reveal frequent involvement of other drug including alcohol benzodiazepines such as diazepam valium and to a rising degree methadone 	DDI-effect
DDI-DrugBank.d103.s2.p0	concomitant administration of other drug may potentiate the undesirable effects of drug 	DDI-effect
DDI-DrugBank.d382.s4.p0	drug has been shown to induce the metabolism of drug and tolbutamide which are metabolized through cyp c 	DDI-mechanism
DDI-DrugBank.d213.s0.p9	iodine or iodine excess may decrease the effect of carbimazole and an drug deficiency can increase the effect of drug 	DDI-effect
DDI-DrugBank.d47.s5.p0	drug salts may reduce the bioavailability of drug and levodopa 	DDI-mechanism
DDI-DrugBank.d510.s1.p0	concomitant administration of drug injection and drug in a wax matrix may increase the severity of potassium chloride induced gastrointestinal lesions as a result of a slower gastrointestinal transit time 	DDI-mechanism
DDI-DrugBank.d234.s2.p0	particular caution is necessary when using drug in cases of mixed drug overdosage since the toxic effects such as convulsions and cardiac dysrhythmias of other drugs taken in overdose especially drug may emerge with the reversal of the benzodiazepine effect by flumazenil 	DDI-effect
DDI-DrugBank.d224.s1.p5	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with cns depressants alcohol barbiturates opiates sedatives drug should be considered 	DDI-advise
DDI-DrugBank.d43.s12.p1	plasma concentrations of drug are decreased when administered with antacids containing drug calcium or aluminum 	DDI-mechanism
DDI-DrugBank.d476.s3.p6	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine verapamil and benzothiazepine diltiazem classes or drug such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d188.s0.p0	concurrent administration of drug and drug may cause severe orthostatic hypotension cimetidine an inhibitor of microsomal drug metabolism increased altretamines half life and toxicity in a rat model 	DDI-effect
DDI-DrugBank.d450.s3.p12	erythromycin and clarithromycin and possibly other drug and tetracycline may increase drug absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine so that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d249.s2.p5	because prostaglandins play an important role in hemostasis and nsaids affect platelet function as well concurrent therapy with all drug including diclofenac and drug requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required 	DDI-advise
DDI-DrugBank.d450.s2.p42	quinidine verapamil amiodarone propafenone indomethacin itraconazole alprazolam and drug raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d448.s5.p0	increased ectopic pacemaker activity can occur when drug is used concomitantly with drug 	DDI-effect
DDI-DrugBank.d531.s42.p1	a dose increase of drug ritonavir to mg capsules or ml twice daily taken with food is recommended when used in combination with drug 	DDI-advise
DDI-DrugBank.d40.s10.p0	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute drug intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d522.s24.p3	other drugs drug interactions have been reported with concomitant administration of drug medications including cyclosporine carbamazepine disopyramide phenytoin bromocriptine valproate astemizole lovastatin	DDI-int
DDI-DrugBank.d522.s24.p3	other drugs medication drug interactions have been reported with concomitant administration of mevacor drug and other medications including cyclosporine hexobarbital carbamazepine drug disopyramide phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p3	other drugs other interactions phenytoin been reported with concomitant administration of drug and drug medications including cyclosporine hexobarbital carbamazepine drug disopyramide have bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p3	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine drug disopyramide phenytoin bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d124.s26.p120	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives drug carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d356.s4.p2	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-DrugBank.d568.s17.p1	if concomitant treatment with drug and an ssri e g drug fluvoxamine paroxetine sertraline citalopram escitalopram is clinically warranted appropriate observation of the patient is advised 	DDI-advise
DDI-DrugBank.d386.s23.p31	if desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug and benzodiazepines e g drug or diazepam are additive 	DDI-effect
DDI-DrugBank.d369.s3.p1	the response to drug may be blunted by phenothiazines and drug which cause a rise in prolactin 	DDI-effect
DDI-MedLine.d16.s5.p0	the half life of drug in plasma and brain was longer in the presence of drug than when ketamine was given alone 	DDI-mechanism
DDI-DrugBank.d458.s21.p1	because severe hypoglycemia has been reported in patients concomitantly receiving oral drug an imidazole and oral drug such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets an imidazole can not be ruled out 	DDI-effect
DDI-DrugBank.d484.s0.p14	drug may interact with the following medications acetaminophen antifungal tylenol nelfinavir antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg drug sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra reciprocal ohm norvir viracept morphine astramorph kadian ms contin phenylbutazone ritonavir prednisolone prelone rifadin rifampin viracept st johns wort temazepam theophylline theo dur ritonavir and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p14	drug may interact with the following sporanox acetaminophen tylenol antibiotics such as ampicillin and hiv anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg drug medications atorvastatin morphine clofibrate atromid johns cyclosporine sandimmune neoral tetracycline drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept lipitor astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st s wort temazepam theophylline theo dur and c vitamin	DDI-int
DDI-DrugBank.d484.s0.p14	drug english hawthorn interact with the stick with medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg drug sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prelone prelone rimactane rifampin st johns wort restoril slo bid theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p14	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg drug sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d250.s2.p19	curariform muscle relaxants eg tubocurarine and other drugs including ether succinylcholine gallamine drug and sodium citrate potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d22.s1.p0	in the case that you are taking drug while taking drug higher doses of digoxin may be needed 	DDI-advise
DDI-DrugBank.d400.s6.p4	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of furosemide and drug in some patients 	DDI-effect
DDI-DrugBank.d267.s5.p11	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local drug procainamide and quinidine 	DDI-effect
DDI-MedLine.d126.s7.p1	thus the results suggest that drug exposure of rats results in free radical mediated tissue damage as indicated by elevated cerebral and hepatic lipid peroxidation which was prevented by allopurinol and drug 	DDI-effect
DDI-DrugBank.d82.s6.p0	however when any additional drug including drug is added to the treatment of patients on drug therapy the patients should be observed for alterations of the prothrombin time 	DDI-advise
DDI-DrugBank.d66.s0.p2	human growth hormone concomitant use of drug and drug may enhance nutrient absorption in those with severe short bowel syndrome 	DDI-mechanism
DDI-MedLine.d124.s1.p1	previous studies have demonstrated a significant reduction in the oral bioavailability of drug and ciprofloxacin when administered concomitantly with an intravenous drug such as morphine 	DDI-mechanism
DDI-DrugBank.d154.s3.p0	chronic administration of drug a known enzyme inducer may be associated with a decrease in the plasma half life of drug 	DDI-mechanism
DDI-DrugBank.d165.s20.p0	although no studies have been conducted concomitant administration of drug and drug may alter the metabolism of phenytoin 	DDI-mechanism
DDI-DrugBank.d165.s15.p1	coadministration of drug and cyclosporine drug or digoxin has led to increased plasma concentrations of the latter three drugs 	DDI-mechanism
DDI-DrugBank.d514.s2.p3	toxicology studies of drug related deaths reveal frequent involvement of other central nervous system depressants including alcohol benzodiazepines such as drug valium and to a rising degree methadone 	DDI-effect
DDI-MedLine.d125.s6.p0	prior administration of drug mg kg body weight was shown to prevent the conversion of drug mg kg body weight to erythro fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in difluoro propanol intoxicated animals 	DDI-effect
DDI-DrugBank.d149.s0.p0	potential drug interactions of drug with drug or with other anticholinesterase agents	DDI-int
DDI-DrugBank.d149.s0.p0	possible drug anticholinesterase of drug with drug or with other interactions agents	DDI-int
DDI-DrugBank.d149.s0.p0	possible drug interactions of drug with drug or with other anticholinesterase agents	DDI-int
DDI-DrugBank.d149.s0.p0	possible drug interactions of drug with drug or with other anticholinesterase agents 	DDI-int
DDI-DrugBank.d60.s3.p3	infusion requirements of nimbex in patients administered drug prior to infusions of drug were comparable to or slightly greater than when succinylcholine was not administered 	DDI-effect
DDI-DrugBank.d40.s17.p0	although not a true drug interaction drug may precipitate seizures in susceptible patients and drug dosage may need to be adjusted	DDI-effect
DDI-DrugBank.d340.s6.p9	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin drug midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d423.s4.p4	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of selective serotonin reuptake inhibitors drug and agents for migraine therapy such as drug sumatriptan succinate and dihydroergotamine 	DDI-effect
DDI-DrugBank.d123.s16.p7	theophylline as with some other quinolones concurrent administration of drug with drug may lead to elevated serum concentrations of theophylline and prolongation of its elimination half life 	DDI-mechanism
DDI-DrugBank.d46.s7.p23	cholestyramine and colestipol resins cholestytamine and drug resins have the potential of binding drug and reducing diuretic absorption from the gastrointestinal tract	DDI-mechanism
DDI-DrugBank.d334.s18.p5	lithium lithium toxicity has been reported in patients receiving drug concomitantly with drugs which cause elimination of sodium including drug 	DDI-effect
DDI-DrugBank.d476.s3.p7	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine verapamil and benzothiazepine diltiazem classes or antiarrhythmic agents such as drug are used concurrently 	DDI-advise
DDI-DrugBank.d422.s10.p0	although the interactions observed in these studies do not appear to be of major clinical importance drug should be titrated with caution in patients being treated concurrently with drug morphine succinylcholine or warfarin 	DDI-advise
DDI-DrugBank.d284.s0.p0	if additional drug are to be administered by any route they should be used with caution because the pharmacologically predictable sympathetic effects of drug may be potentiated 	DDI-advise
DDI-DrugBank.d431.s7.p9	in a single dose crossover study examining lansoprazole mg and omeprazole mg each administered alone and concomitantly with sucralfate gram absorption of the drug was delayed and their bioavailability was reduced by and respectively when administered concomitantly with drug 	DDI-mechanism
DDI-DrugBank.d469.s7.p5	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain antibiotics especially the aminoglycosides and drug lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d18.s1.p12	injection lorazepam injection like other injectable drug produces depression of the central nervous system when administered with ethyl alcohol phenothiazines barbiturates mao inhibitors and other drug when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d273.s1.p0	however interactions may be expected and drug should not be used in combination with other drug 	DDI-advise
DDI-DrugBank.d537.s0.p12	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g whitethorn benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl tocopherol drug sulfa acetaminophen tocopherol medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic check supplements use tylenol of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p12	drug whitethorn interact with panadol atomic number g tylenol chloramphenicol atomic number g chloromycetin local anesthetics atomic number g benzocaine and lidocaine para aminobenzoic acid para aminobenzoic acid containing preparations atomic number g sunscreens and some multivitamins procainamide atomic number g pronestyl drug sulfa medicines thiazide diuretics use of these medicines during the try period will affect the try results and pancreatic supplements use of pancreatic supplements whitethorn give simulated try results	DDI-int
DDI-DrugBank.d537.s0.p12	drug may interact with e e g procainamide chloramphenicol acetaminophen g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid e containing preparations paba g sunscreens and some multivitamins tylenol e g pronestyl drug sulfa false thiazide diuretics use of these medicines during the affect period will test the test results test pancreatic supplements use of pancreatic supplements may give medicines and results	DDI-int
DDI-DrugBank.d537.s0.p12	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl drug sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-MedLine.d0.s4.p0	this study demonstrated that the potent cytochrome p enzyme inducer drug did indeed have a marked effect on the metabolism of drug resulting in a fold increase in clearance when administered concomitantly to patients with dsm iv diagnosed schizophrenia schizoaffective disorder or bipolar disorder 	DDI-mechanism
DDI-DrugBank.d237.s10.p4	h receptor antagonists drug coadministration leads to an increased peak plasma concentration and auc of drug there is no effect on cisapride absorption when it is coadministered with ranitidine 	DDI-mechanism
DDI-DrugBank.d423.s1.p2	because dexfenfluramine is a serotonin releaser and reuptake inhibitor drug should not be used concomitantly with a drug 	DDI-advise
DDI-DrugBank.d29.s12.p2	therefore drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability eg ketoconazole iron salts and drug 	DDI-mechanism
DDI-MedLine.d34.s8.p1	the lower rate of absorption in the groups receiving mg drug instead of mg of fe per kg diet resulted in a decreased renal excretion of drug 	DDI-mechanism
DDI-DrugBank.d172.s17.p0	this increase is due to the inhibition of drug metabolism via p c by drug see clinical pharmacology pharmacokinetics metabolism 	DDI-mechanism
DDI-DrugBank.d146.s0.p0	drug is inhibited by drug 	DDI-mechanism
DDI-DrugBank.d57.s1.p0	even when an drug and a drug type drug are administered separately by different routes a reduction in aminoglycoside serum half life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function 	DDI-mechanism
DDI-DrugBank.d307.s40.p4	hormonal contraceptives co administration of drug with an oral drug has been shown to influence the plasma concentrations of the two hormonal components ethinylestradiol ee and levonorgestrel lng 	DDI-mechanism
DDI-DrugBank.d60.s12.p14	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and drug 	DDI-effect
DDI-DrugBank.d340.s6.p0	drugs that should not be coadministered with drug drug amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d488.s6.p14	drugs decreasing heparin effect digitalis tetracyclines nicotine or drug may partially counteract the anticoagulant action of drug 	DDI-effect
DDI-DrugBank.d384.s7.p2	digitalis drug dosage must be determined with care in patients undergoing treatment with drug as hypercalcemia in such patients may precipitate cardiac arrhythmias 	DDI-advise
DDI-MedLine.d67.s7.p1	drug used at doses of mg kg and mg kg decreased the antinociceptive effect of morphine drug only in the tail flick test and indomethacin 	DDI-effect
DDI-DrugBank.d187.s7.p6	carbamazepine drug is known to slow the metabolism of drug and increase its serum levels carbamazepine levels should be determined prior to concurrent administration with isoniazid signs and symptoms of carbamazepine toxicity should be monitored closely and appropriate dosage adjustment of the anticonvulsant should be made 	DDI-mechanism
DDI-DrugBank.d46.s19.p6	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-DrugBank.d249.s8.p4	lithium drug decreases lithium renal clearance and increases drug plasma levels 	DDI-mechanism
DDI-DrugBank.d241.s1.p1	when other drug or anticoagulants are used concomitantly there is the potential for drug to increase the risk of bleeding 	DDI-effect
DDI-DrugBank.d503.s7.p0	exert particular caution in combining drug with other drug tricyclic antidepressants and antiparkinsonian agents particularly the elderly may develop delirium high fever severe obstipation even ileus and glaucoma 	DDI-advise
DDI-DrugBank.d488.s2.p34	platelet inhibitors drugs such as acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin drug hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d410.s5.p21	macrolide antibiotics e g erythromycin and troleandomycin agents of the drug of which d h e dihydroergotamine mesylate injection usp is a member have been shown to interact with antibiotics of the drug resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction 	DDI-mechanism
DDI-DrugBank.d85.s11.p0	caution should be used if drug is administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d464.s0.p6	drug in combination with other narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics or other cns depressants including drug has additive depressant effects 	DDI-effect
DDI-DrugBank.d115.s10.p0	drug will increase plasmaconcentration of other cyp a metabolized drugs e g triazolo drug dihydropyridine calcium channel blockers certain hmg coa reductase inhibitors etc 	DDI-mechanism
DDI-DrugBank.d165.s22.p0	it has been reported that drug enhances the anticoagulant effect of drug like drugs 	DDI-effect
DDI-DrugBank.d60.s12.p23	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and drug magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d44.s2.p4	acellular drug should not be administered during drug treatment 	DDI-advise
DDI-DrugBank.d382.s19.p8	oral contraceptives drug when given once daily for days as a mg capsule with an oral contraceptive containing mcg of ethinyl estradiol and mg of drug decreased the auc of ethinyl estradiol by and decreased the auc of norethindrone by 	DDI-mechanism
DDI-DrugBank.d338.s1.p3	the action of the drug may be potentiated by anticonvulsants antihistamines alcohol drug monoamine oxidase inhibitors narcotics phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d328.s24.p1	drug caused a statistically significant increase in plasma exposures of r warfarin and drug and respectively and in the pharmacodynamic effects prothrombin time measured as inr of warfarin 	DDI-mechanism
DDI-DrugBank.d303.s0.p4	metformin in healthy subjects given single mg doses of drug and drug plasma metformin mean cmax and auc increased by an average of and respectively and metformin mean renal clearance decreased by 	DDI-mechanism
DDI-DrugBank.d506.s0.p1	if drug or other hepatic enzyme inducers are taken concurrently with norpace or drug lower plasma levels of disopyramide may occur 	DDI-mechanism
DDI-DrugBank.d158.s10.p2	antihistamines drug may counteract the sedative effect of drug 	DDI-effect
DDI-DrugBank.d350.s14.p3	when drug is co administered with inducers of drug clearance such as efavirenz nevirapine phenytoin drug or carbamazepine use of a daily dose of mg of cancidas should be considered	DDI-advise
DDI-DrugBank.d257.s6.p32	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg pentazocine nalbuphine butorphanol drug and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d123.s8.p5	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum antacids sucralfate drug chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d154.s11.p0	in patients receiving drug and a drug concomitantly any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal 	DDI-advise
DDI-DrugBank.d484.s0.p42	drug may interact with the following medications acetaminophen antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid cyclosporine neoral sandimmune hiv drugs protease inhibitors agenerase fortovase invirase kaletra viracept morphine astramorph ms contin phenylbutazone prednisolone rifadin rifampin johns wort temazepam theophylline drug and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p42	drug may interact with the watch over medications panadol tylenol antibiotics such as ampicillin and achromycin anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin lipitor atromid s atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline drug and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p42	drug may interact with the following medications acetaminophen drug antibiotics such as rifadin and crixivan anticonvulsants felbatol phenobarbital tegretol trileptal topamax dilantin antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase tetracycline fortovase invirase kaletra norvir viracept c astramorph phenylbutazone ms contin kadian prednisolone prelone ampicillin rifampin st johns wort temazepam theophylline tylenol and vitamin morphine	DDI-int
DDI-DrugBank.d484.s0.p42	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline drug and vitamin c 	DDI-int
DDI-DrugBank.d77.s5.p1	the plasma concentration of drug may increase when the drug is given concomitantly with hepatic enzyme inhibitors e g cimetidine drug and decrease by concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and adjustment of the dosage of imipramine may therefore be necessary 	DDI-mechanism
DDI-DrugBank.d456.s1.p10	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin drug tao and voriconazole 	DDI-advise
DDI-DrugBank.d260.s3.p2	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin drug and amikacin amphotericin b foscarnet intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d269.s18.p7	insulin or oral hypoglycemics drug may enhance the blood sugar reducing effect of drug and oral hypoglycemics 	DDI-effect
DDI-DrugBank.d303.s4.p5	probenecid as with other b lactams the renal excretion of drug is inhibited by drug 	DDI-mechanism
DDI-DrugBank.d450.s3.p3	drug and clarithromycin and possibly other macrolide antibiotics and tetracycline may increase drug absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine so that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d236.s0.p20	acidifying agents gastrointestinal acidifying agents guanethidine reserpine glutamic acid hcl drug fruit juices etc lower absorption of drug 	DDI-mechanism
DDI-DrugBank.d207.s2.p0	international normalized ratio inr elevations and or bleeding events have been reported in some patients taking drug while on drug therapy 	DDI-effect
DDI-DrugBank.d105.s0.p4	drug including coumarin derivatives indandione derivatives and platelet aggregation inhibitors such as nonsteroidal anti inflammatory drugs nsaids and aspirin may increase the risk of bleeding when administered concomitantly with drug 	DDI-effect
DDI-DrugBank.d87.s6.p0	the effects of concomitant administration of drug and drug on the pr interval were less than additive 	DDI-effect
DDI-MedLine.d119.s15.p0	drug an anionic binding resin has a considerable effect in lowering the rate and extent of drug bioavailability 	DDI-mechanism
DDI-DrugBank.d249.s5.p3	patients who begin taking drug or who increase their diclofenac dose or any other nsaid while taking digoxin drug or cyclosporine may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d247.s2.p0	drug should not be administered concomitantly with other drug such as isoproterenol because of possible additive effects and increased toxicity 	DDI-advise
DDI-DrugBank.d162.s4.p9	cholestyramine and colestipol resins absorption of drug is impaired in the presence of drug 	DDI-mechanism
DDI-MedLine.d67.s6.p0	similarly drug decreased the antinociceptive effect of drug only in the tail flick test and indomethacin 	DDI-effect
DDI-DrugBank.d41.s16.p2	warfarin increased inr international normalized ratio when drug and drug were co administered has been rarely reported 	DDI-effect
DDI-DrugBank.d431.s8.p0	therefore drug should be taken at least minutes prior to drug 	DDI-advise
DDI-DrugBank.d71.s5.p0	drug and drug may inhibit the intracellular phosphorylation of one another 	DDI-effect
DDI-DrugBank.d434.s33.p2	phenobarbital it appears that drug may reduce plasma drug concentrations 	DDI-mechanism
DDI-DrugBank.d250.s2.p10	curariform muscle relaxants eg drug and other drugs including ether succinylcholine gallamine decamethonium and sodium citrate potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d528.s0.p8	acetaminophen and methotrexate drug may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking drug 	DDI-effect
DDI-DrugBank.d228.s2.p0	reciprocal interactions may occur with concomitant use of drug and drugs that increase or inhibit the cytochrome p system e g drug carbamazepine cimetidine ketoconazole though this has not been studied	DDI-mechanism
DDI-DrugBank.d225.s9.p0	a potential interaction between oral drug and oral drug leading to terrible hypoglycemia has been reported	DDI-int
DDI-DrugBank.d225.s9.p0	a potential interaction between oral drug and oral drug leading to severe hypoglycemia has been	DDI-int
DDI-DrugBank.d225.s9.p0	a potential interaction between oral drug and oral drug leading to has hypoglycemia severe been reported	DDI-int
DDI-DrugBank.d225.s9.p0	a potential interaction between oral drug and oral drug leading to severe hypoglycemia has been reported 	DDI-int
DDI-DrugBank.d548.s9.p2	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants drug such as nortriptyline amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d413.s21.p0	the risk of hypoglycemia secondary to this mechanism may be increased if drug and drug are given concomitantly in the presence of renal insufficiency 	DDI-effect
DDI-DrugBank.d422.s15.p2	additionally drug should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine epinephrine and drug because of the danger of blocking cardiac contractility when systemic vascular resistance is high 	DDI-advise
DDI-MedLine.d85.s7.p0	drug reduced the antitumour activity of oral drug by dose modifying factors dmf of 	DDI-effect
DDI-DrugBank.d81.s10.p0	if drug therapy is required drug concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine 	DDI-mechanism
DDI-DrugBank.d531.s42.p2	a dose increase of lopinavir drug to mg capsules or ml twice daily taken with food is recommended when used in combination with drug 	DDI-advise
DDI-DrugBank.d60.s12.p4	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines drug polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-MedLine.d125.s8.p0	we conclude that the prophylactic and antidotal properties of drug seen in animals treated with drug derive from its capacity to inhibit the nad dependent oxidation responsible for converting difluoro propanol to difluoroacetone in the committed step of the toxic pathway 	DDI-effect
DDI-DrugBank.d158.s17.p2	methenamine therapy urinary excretion of drug is increased and efficacy is reduced by acidifying agents used in drug therapy 	DDI-mechanism
DDI-DrugBank.d158.s0.p1	urinary acidifying agents these agents drug sodium acid phosphate etc increase the concentration of the ionized species of the drug molecule thereby increasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d401.s0.p11	drug interactions the central anticholinergic syndrome can occur when anticholinergic agents such as drug are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the drug and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d561.s12.p2	benazepril like other drug has had less than additive effects with drug presumably because both drugs lower blood pressure by inhibiting parts of the renin angiotensin system	DDI-effect
DDI-DrugBank.d94.s4.p4	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin drug danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d238.s6.p2	plasma levels of several closely related drug have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors e g cimetidine drug and decreased by the concomitant administration of hepatic enzyme inducers e g barbiturates phenytoin and such an effect may be anticipated with cmi as well 	DDI-mechanism
DDI-DrugBank.d249.s17.p2	phenobarbital toxicity has been reported to have occurred in a patient on chronic drug treatment following the initiation of drug therapy 	DDI-effect
DDI-DrugBank.d140.s4.p5	colestipol plasma concentrations of atorvastatin decreased approximately when drug and drug were coadministered 	DDI-mechanism
DDI-DrugBank.d99.s20.p0	paralytic ileus may occur in patients taking drug in combination with drug type drugs 	DDI-effect
DDI-DrugBank.d565.s1.p1	pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using drug or digitalis concomitantly with drug 	DDI-effect
DDI-DrugBank.d241.s3.p46	in clinical trials flolan was used with digoxin diuretics anticoagulants oral vasodilators and supplemental oxygen in a pharmacokinetic substudy in patients with congestive heart failure receiving drug or digoxin in whom therapy with drug was initiated apparent oral clearance values for furosemide n and digoxin n were decreased by and respectively on the second day of therapy and had returned to baseline values by day 	DDI-mechanism
DDI-DrugBank.d123.s10.p0	this time window is different than for other oral formulations of drug which are usually administered hours before or hours after drug 	DDI-advise
DDI-DrugBank.d31.s5.p0	drug increases drug s serum concentrations 	DDI-mechanism
DDI-DrugBank.d373.s2.p14	digitalis immediate release capsules since there have been isolated reports of patients with elevated digoxin levels and there is a possible interaction between digoxin and nifedipine it is recommended that drug levels be monitored when initiating adjusting and discontinuing drug to avoid possible over or under digitalization 	DDI-advise
DDI-DrugBank.d307.s35.p2	nc denotes a mean change of less than pediatrics mean increase in adults at high trileptal doses in vivo the plasma levels of drug increased by up to when drug was given at doses above mg day 	DDI-mechanism
DDI-MedLine.d90.s7.p2	recovery of hoof twitch from to took min for atracurium alone and min for drug plus drug p 	DDI-effect
DDI-DrugBank.d179.s1.p0	drug may interact with any of the following drug e g tylenol with long term high window pane use or	DDI-int
DDI-DrugBank.d179.s1.p0	drug may interact tocopherol with any of the following drug e g tylenol with long term high dose use or	DDI-int
DDI-DrugBank.d179.s1.p0	drug may interact with any of tylenol following drug e g the with long term high dose use or	DDI-int
DDI-DrugBank.d179.s1.p0	drug may interact with any of the following drug e g tylenol with long term high dose use or	DDI-int
DDI-DrugBank.d456.s1.p7	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir drug saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d395.s18.p0	the oral bioavailability of drug is reduced by with coadministration of drug 	DDI-mechanism
DDI-DrugBank.d275.s3.p0	two percent of patients treated concurrently with drug and drug developed neutropenia anc x l 	DDI-effect
DDI-DrugBank.d289.s12.p0	the concomitant administration of drug and drug is contraindicated 	DDI-advise
DDI-DrugBank.d238.s2.p0	drug should not be used with drug 	DDI-advise
DDI-DrugBank.d423.s0.p2	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with drug e g fluoxetine fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d477.s0.p0	hypertensive crises have resulted when drug have been used concomitantly within days following use of drug 	DDI-effect
DDI-MedLine.d7.s1.p0	this report describes two cases in which drug clearance accelerated markedly with concomitant drug administration 	DDI-mechanism
DDI-DrugBank.d480.s8.p13	although it has not been established that there is an interaction between clozapine and benzodiazepines or other psychotropics caution is advised when drug is initiated in patients taking a benzodiazepine or any other drug 	DDI-advise
DDI-DrugBank.d464.s0.p0	drug in combination with other drug general anesthetics phenothiazines tranquilizers sedative hypnotics or other cns depressants including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d175.s20.p0	if a drug is also used it may increase the risk of drug toxicity 	DDI-effect
DDI-DrugBank.d19.s9.p0	in rats simultaneous ingestion of drug and drug in the diet for weeks has been reported to cause tumors and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine which is tumorigenic 	DDI-effect
DDI-DrugBank.d291.s6.p0	in isolated cases a pronounced though reversible impairment of renal function accompanied by a corresponding increase in the serum creatinine level has been reported in organ transplant patients receiving drug therapy and concomitant drug 	DDI-effect
DDI-DrugBank.d468.s5.p5	nicardipine hcl usually does not alter the plasma levels of digoxin however serum drug levels should be evaluated after concomitant therapy with drug is initiated 	DDI-advise
DDI-DrugBank.d514.s1.p0	in combination with other drug drug may still kill even experienced users particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased 	DDI-effect
DDI-DrugBank.d246.s3.p2	however in another study in healthy volunteers the pharmacokinetics of butorphanol were significantly altered decrease in auc and decrease in cmax when a mg dose of drug was administered minute after a mg dose of drug nasal spray 	DDI-mechanism
DDI-DrugBank.d46.s16.p0	drug reduce the renal clearance of drug and add a high risk of lithium toxicity 	DDI-mechanism
DDI-DrugBank.d516.s24.p3	warfarin drug may enhance the effects of the oral drug warfarin or its derivatives 	DDI-effect
DDI-DrugBank.d566.s2.p12	cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation the discontinuance of drug resin could pose a hazard to health if a potentially toxic drug such as drug has been filtrated to a maintenance level while the patient was taking cholestyramine resin 	DDI-mechanism
DDI-MedLine.d105.s7.p1	drug had no significant impact on the cmax and auc of zidovudine although it significantly decreased the drug tmax by and increased the intracellular exposure to phosphorylated zidovudine by 	DDI-mechanism
DDI-DrugBank.d394.s0.p0	the hypotensive effect of drug is augmented by that of most other drug including ganglionic blocking agents negative inotropic agents and inhaled anesthetics 	DDI-effect
DDI-MedLine.d90.s8.p2	recovery from twitch to fade recovery took min for atracurium alone and min for drug plus drug 	DDI-effect
DDI-DrugBank.d121.s0.p0	nephrotoxicity has been reported following concomitant administration of drug and drug 	DDI-effect
DDI-DrugBank.d334.s1.p2	the possibility of hypotensive effects with prinivil can be minimized by either discontinuing the drug or increasing the salt intake prior to initiation of treatment with drug 	DDI-effect
DDI-DrugBank.d114.s8.p0	myocardial injury including myocardial infarction myocarditis ventricular hypokinesia and severe rhabdomyolysis appear to be increased in patients receiving drug and drug concurrently 	DDI-effect
DDI-DrugBank.d415.s1.p1	however because bleeding has been reported when drug and other nonsteroidal anti inflammatory agents have been administered to patients on drug the physician should be cautious when administering ibuprofen to patients on anticoagulants 	DDI-effect
DDI-DrugBank.d322.s1.p2	drug may decrease the effect of phenothiazines levodopa and drug 	DDI-effect
DDI-DrugBank.d401.s0.p1	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain drug such as meperidine the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d529.s14.p4	diuretics studies in normal volunteers have shown that drug like other nonsteroidal anti inflammatory drugs can interfere with the effects of drug 	DDI-effect
DDI-DrugBank.d499.s19.p3	probenecid drug increases both free and bound drug by reducing the plasma clearance of ketoprofen to about one third as well as decreasing its protein binding 	DDI-mechanism
DDI-DrugBank.d516.s15.p5	cyclosporine elevated serum levels of cyclosporine have been reported with concomitant use of drug with other members of the drug 	DDI-mechanism
DDI-DrugBank.d48.s1.p5	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir drug indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d340.s12.p0	because a similar interaction is likely drug should also not be administered concurrently with drug 	DDI-advise
DDI-DrugBank.d172.s11.p3	furosemide clinical studies as well as post marketing observations have shown that drug can reduce the natriuretic effect of drug and thiazides in some patients 	DDI-effect
DDI-DrugBank.d208.s0.p7	drug may interact medication with alcohol blood thinners decongestant drugs allergy cold and dose sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or drug and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p7	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine like aleve or drug and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p7	drug english hawthorn interact with alcohol blood thinners decongestant drugs allergy common cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or drug and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p7	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or drug and high blood pressure medications 	DDI-int
DDI-DrugBank.d509.s7.p0	agents that induce cyp a eg drug could cause an increase in drug clearance and lower blood levels 	DDI-mechanism
DDI-DrugBank.d467.s6.p0	concomitant administration of drug with drug capsules is not recommended 	DDI-advise
DDI-MedLine.d73.s3.p0	the drug induced neuronal damage produced a tolerance to the disruptive effects of drug and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm 	DDI-effect
DDI-DrugBank.d522.s24.p4	other drugs drug interactions have reported with administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil drug phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p4	other drugs drug interactions have fundamental interaction been reported with concomitant administration of drug and other medications early including cyclosporine hexobarbital carbamazepine alfentanil drug phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p4	other drugs drug fundamental interaction have been reported with attendant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil drug phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p4	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil drug phenytoin bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d220.s13.p0	when drug is taken concurrently with oral drug attenuation of immunization cannot be excluded 	DDI-effect
DDI-DrugBank.d347.s6.p1	the absorption of oral drug is significantly reduced by the concomitant administration of an antacid containing drug and magnesium 	DDI-mechanism
DDI-DrugBank.d544.s3.p0	total body clearance of drug was reduced by an average and when drug and mycophenolate mofetil respectively were added to a regimen consisting of cyclosporine usp modified and corticosteroids 	DDI-mechanism
DDI-DrugBank.d422.s6.p9	when intravenous morphine and brevibloc were concomitantly administered in normal subjects no effect on morphine blood levels was seen but drug steady state blood levels were increased by in the presence of drug 	DDI-mechanism
DDI-DrugBank.d469.s7.p3	drugs which may enhance the neuromuscular blocking action of drug include enflurane isoflurane halothane certain drug especially the aminoglycosides and polymyxins lithium magnesium salts procainamide and quinidine 	DDI-effect
DDI-DrugBank.d521.s1.p1	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another drug such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d236.s18.p2	haloperidol drug blocks dopamine and norepinephrine reuptake thus inhibiting the central stimulant effects of drug 	DDI-effect
DDI-DrugBank.d503.s5.p1	consider additive sedative effects and confusional states to emerge if drug is given with benzodiazepines or drug 	DDI-effect
DDI-DrugBank.d529.s17.p1	patients receiving drug and furosemide or other drug should be observed closely to determine if the desired effect is obtained 	DDI-advise
DDI-MedLine.d124.s1.p2	previous studies have demonstrated a significant reduction in the oral bioavailability of drug and ciprofloxacin when administered concomitantly with an intravenous opiate such as drug 	DDI-mechanism
DDI-DrugBank.d560.s1.p2	if you are also using a steroid inhaler take drug first and then wait about minutes before using the drug inhaler 	DDI-advise
DDI-DrugBank.d47.s2.p14	dopamine d receptor antagonists e g phenothiazines butyrophenones risperidone and drug may reduce the therapeutic effects of drug 	DDI-effect
DDI-DrugBank.d170.s5.p19	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general drug phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d202.s2.p0	in addition higher than expected steady state serum concentrations of drug have been observed when therapy is initiated in patients already taking drug 	DDI-mechanism
DDI-DrugBank.d82.s7.p0	in post marketing experience bleeding has been reported in patients on concomitant treatment with drug and drug 	DDI-effect
DDI-DrugBank.d160.s1.p0	it is recommended to avoid concurrent administration of drug with drug containing antacids for at least hours following ethambutol administration 	DDI-advise
DDI-DrugBank.d306.s0.p2	the effectiveness of drug only pills is reduced by hepatic enzyme inducing drugs such as the anticonvulsants phenytoin drug and barbiturates and the antituberculosis drug rifampin 	DDI-effect
DDI-DrugBank.d476.s3.p4	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine verapamil and drug diltiazem classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d249.s18.p1	protein binding in vitro drug interferes minimally or not at all with the protein binding of salicylic acid decrease in binding drug prednisolone decrease in binding or warfarin 	DDI-mechanism
DDI-DrugBank.d171.s0.p4	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine drug diazepam certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d338.s8.p4	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a nefazodone fluvoxamine cimetidine diltiazem drug and some macrolide antibiotics 	DDI-mechanism
DDI-DrugBank.d74.s0.p0	drug augments the action of drug s and the muscle relaxant effects of aminoglycosides 	DDI-effect
DDI-DrugBank.d124.s26.p134	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl drug and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d415.s1.p4	however because bleeding has been reported when ibuprofen and other drug have been administered to patients on drug the physician should be cautious when administering ibuprofen to patients on anticoagulants 	DDI-effect
DDI-DrugBank.d48.s15.p84	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus drug or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d410.s0.p5	vasoconstrictors d h e drug injection usp should not be used with drug because the combination may cause synergistic elevation of blood pressure 	DDI-effect
DDI-DrugBank.d393.s2.p0	in a multiple dose study of drug mg once daily for days and drug mg once daily for days a decrease in the clearance of cetirizine was observed 	DDI-mechanism
DDI-DrugBank.d21.s1.p0	these results would seem to dictate against the clinical use of drug with drug or during the period following elspar therapy when plasma asparagine levels are below normal 	DDI-advise
DDI-DrugBank.d537.s0.p6	drug may interact with acetaminophen e g tylenol chloramphenicol e g local anesthetics e benzocaine and drug para aminobenzoic acid paba preparations e g sunscreens and some multivitamins procainamide e g sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may false test results	DDI-int
DDI-DrugBank.d537.s0.p6	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetic agent e g ethyl aminobenzoate and drug para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulpha sulfa medicines thiazide diuretics use of these medicines during the test period will bear upon the test effect and pancreatic supplements use of pancreatic supplements may commit false test effect	DDI-int
DDI-DrugBank.d537.s0.p6	drug may multivitamin interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and drug para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides dose sulfa medicines thiazide diuretics use tocopherol of these medicines during untrue the test period will affect the test results and pancreatic diuretic supplements use of pancreatic supplements may give ethyl aminobenzoate false test results	DDI-int
DDI-DrugBank.d537.s0.p6	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and drug para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d142.s0.p3	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics amantadine haloperidol drug monoamine oxidase mao inhibitors tricyclic antidepressants or some antihistamines 	DDI-effect
DDI-DrugBank.d9.s0.p3	drug should not be administered concomitantly with amikacin ciprofloxacin gentamicin drug or tobramycin 	DDI-advise
DDI-DrugBank.d401.s0.p3	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as meperidine the drug and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d485.s27.p5	non nucleoside reverse transcriptase inhibitors nnrtis drug may decrease plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d283.s15.p3	concomitant administration of fenofibrate equivalent to mg drug with drug mg once daily for days resulted in approximately decrease range from decrease to increase in atorvastatin auc values in healthy males 	DDI-mechanism
DDI-DrugBank.d124.s30.p6	coadministration with compounds that are potent inducers of cyp a eg phenobarbital drug dexamethasone carbamazepine may result in decreased plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d269.s1.p20	poor metabolizers of debrisoquin interactions of carvedilol with strong inhibitors of cyp d such as quinidine fluoxetine paroxetine and drug have not been studied but these drugs would be expected to increase blood levels of the r enantiomer of drug 	DDI-effect
DDI-DrugBank.d237.s7.p7	antifungals in vitro and or in vivo data indicate that drug itraconazole and oral ketoconazole markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d75.s8.p0	drug alone had no effect on platelet aggregation but did slightly enhance the inhibition of platelet aggregation by drug 	DDI-effect
DDI-DrugBank.d521.s1.p11	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate drug 	DDI-advise
DDI-DrugBank.d414.s6.p1	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d272.s2.p2	compounds in these categories result in a decreased efficacy of drug phenothiazines haloperidol drug pimozide 	DDI-effect
DDI-DrugBank.d123.s8.p18	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of drug resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d423.s0.p7	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine fluvoxamine paroxetine sertraline drug there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-MedLine.d12.s7.p8	these results suggest that both dexamethasone and drug and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of insulin and drug 	DDI-effect
DDI-DrugBank.d459.s0.p1	the daily dose of drug should not exceed mg when coadministered with potent cyp a inhibitors e g ketoconazole drug ritonavir nelfinavir clarithromycin and nefazadone 	DDI-advise
DDI-DrugBank.d431.s12.p0	therefore it is theoretically possible that drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability e g drug ampicillin esters iron salts digoxin 	DDI-mechanism
DDI-DrugBank.d484.s0.p26	drug may interact with the following medications rimactane acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan drug invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns anticonvulsant phenytoin wort separate morphia temazepam theophylline restoril theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p26	drug english hawthorn interact with the following medications acetaminophen acetaminophen antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals jaun gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as peptidase inhibitors agenerase indinavir drug invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prednisolone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p26	interact with the following acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan drug invirase kaletra viracept morphine astramorph kadian ms phenylbutazone prednisolone prelone rifadin rifampin st wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p26	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan drug invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d132.s9.p2	antacids concomitant administration of drug may reduce plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d414.s2.p1	drug may increase the ototoxic potential of other drugs such as aminoglycoside and some drug 	DDI-effect
DDI-MedLine.d85.s0.p0	drug protects mouse tumour and normal tissues from the toxicity of oral drug 	DDI-effect
DDI-DrugBank.d163.s2.p4	tetracyclines concomitant treatment with drug and drug should be avoided because accutane use has been associated with a number of cases of pseudotumor cerebri benign intracranial hypertension some of which involved concomitant use of tetracyclines	DDI-advise
DDI-DrugBank.d548.s9.p8	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g drug flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d322.s1.p0	drug may decrease the effect of drug levodopa and ketoconazole 	DDI-effect
DDI-DrugBank.d104.s0.p2	drug may increase slightly the effect of antihypertensive drugs e g guanethidine drug reserpine 	DDI-effect
DDI-DrugBank.d86.s0.p2	the concurrent use of two or more drugs with anticholinergic activity such as an drug eg chlorpromazine an antiparkinsonian drug eg drug and or a tricyclic antidepressant eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d43.s10.p2	the auc of ciprofloxacin was decreased an average of fold in healthy subjects given drug and drug placebo tablets concurrently 	DDI-mechanism
DDI-DrugBank.d216.s3.p2	olanzapine coadministration of drug mg and drug mg produced a decrease in dsst scores 	DDI-effect
DDI-DrugBank.d77.s2.p11	avoid the use of preparations such as decongestants and local anesthetics which contain any drug e g epinephrine norepinephrine since it has been reported that drug can potentiate the effects of catecholamines 	DDI-advise
DDI-DrugBank.d565.s1.p2	pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using beta blockers or drug concomitantly with drug 	DDI-effect
DDI-DrugBank.d548.s8.p0	when drug was administered at a dose of mg bid in conjunction with a single mg dose of drug a cyp d substrate the auc of desipramine increased fold 	DDI-mechanism
DDI-DrugBank.d484.s0.p12	drug may interact with the following medications acetaminophen tylenol antibiotics such invirase ampicillin temazepam viracept anticonvulsants dilantin phenobarbital tegretol trileptal theo felbatol drug c peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune st drugs classified as protease inhibitors agenerase crixivan fortovase as kaletra norvir tetracycline morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin hiv johns wort and theophylline topamax dur and vitamin gris	DDI-int
DDI-DrugBank.d484.s0.p12	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax anticonvulsant felbatol drug gris peg nizoral sporanox atorvastatin lipitor clofibrate nelfinavir stick with phenytoin atromid s cyclosporine neoral sandimmune hiv drugs classified as separate protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo indinavir dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p12	drug may interact with the following medications acetaminophen tylenol antibiotic such as ampicillin and tetracycline anticonvulsants phenytoin sodium thiopental tegretol trileptal topamax felbatol drug gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drug classified as proteinase inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin speed of light	DDI-int
DDI-DrugBank.d484.s0.p12	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol drug gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d188.s2.p0	however it adversely affected response duration suggesting that drug should not be administered with drug and or cisplatin 	DDI-advise
DDI-DrugBank.d299.s1.p9	because there is a theoretical basis that these effects may be additive use of ergotamine containing or ergot type medications like dihydroergotamine or drug and drug within hours of each other should be avoided 	DDI-advise
DDI-DrugBank.d53.s7.p12	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam drug sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d43.s12.p3	plasma concentrations of drug are decreased when administered with antacids containing magnesium calcium or drug 	DDI-mechanism
DDI-DrugBank.d260.s3.p4	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and amikacin drug foscarnet intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d478.s1.p8	because there is a theoretical basis that these effects may be additive use of ergotamine containing or ergot type medications like drug or methysergide and drug within hours is contraindicated 	DDI-advise
DDI-DrugBank.d20.s9.p2	serum lithium levels should be monitored frequently if drug is administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d267.s5.p6	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin drug colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d22.s3.p0	therefore you may need to take a drug supplement while taking drug 	DDI-advise
DDI-DrugBank.d123.s8.p6	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing drug iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d288.s5.p5	reports in the literature suggest that plasma levels of doxorubicin and its active metabolite doxorubicinol may be increased when drug and drug are used in combination 	DDI-mechanism
DDI-DrugBank.d115.s0.p11	drugs that may alter imatinib plasma concentrations drugs that may increase imatinib plasma concentrations caution is recommended when administering drug with inhibitors of the cyp a family e g drug itraconazole erythromycin clarithromycin 	DDI-advise
DDI-DrugBank.d412.s6.p0	synergism has been shown between drug anesthesia and intravenously administered drug 	DDI-effect
DDI-DrugBank.d40.s10.p3	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide drug diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d450.s3.p8	erythromycin and drug and possibly other macrolide antibiotics and tetracycline may increase drug absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine so that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d386.s23.p0	if drug is to be combined with other drug such as tranquilizers or sedative hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines e g chlordiazepoxide or diazepam are additive 	DDI-effect
DDI-DrugBank.d78.s3.p11	caffeine theobromine drug like other quinolones may inhibit the metabolism of caffeine and drug 	DDI-mechanism
DDI-DrugBank.d484.s0.p38	drug may interact with the following atromid acetaminophen tylenol antibiotics such agenerase ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox dur lipitor clofibrate medications prednisolone cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors as crixivan fortovase invirase kaletra norvir wort morphine astramorph kadian ms contin viracept s prelone drug rifampin st johns phenylbutazone temazepam theophylline theo atorvastatin and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p38	drug may interact with the following medications acetaminophen tylenol antibiotics morphia such as ampicillin and tetracycline itraconazole anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid vitamin a s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin toilet phenylbutazone prednisolone prelone drug rifampin st johns wort temazepam dose theophylline theo dur and vitamin tylenol c	DDI-int
DDI-DrugBank.d484.s0.p38	drug may interact with the following medicine acetaminophen tylenol antibiotics such as polycillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor atromid s atromid s cyclosporine neoral sandimmune hiv dose classify as protease inhibitor agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone drug rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p38	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone drug rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d94.s4.p16	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone drug nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d220.s9.p2	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or beta adrenergic blocking agents drug antihistamines or h blocking agents tricyclic antidepressants and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d141.s5.p0	however in the second study administration of g drug hour before the evening meal and mg drug approximately hours after the same evening meal resulted in a decrease in the cerivastatin auc of less than and a decrease in cmax of about when compared to dosing cerivastatin sodium alone 	DDI-mechanism
DDI-DrugBank.d124.s26.p99	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin drug cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d99.s23.p1	increases in plasma levels of drug and in the frequency and severity of side effects particularly anticholinergic have been reported when drug was added to the drug regimen 	DDI-mechanism
DDI-DrugBank.d43.s14.p5	interactions with other antiretroviral drugs significant decreases in the auc of delavirdine and drug occurred following simultaneous administration of these agents with drug 	DDI-mechanism
DDI-DrugBank.d401.s0.p2	drug interactions the central drug syndrome can occur when anticholinergic agents such as akineton are administered concomitantly with drugs that have secondary anticholinergic actions e g certain narcotic analgesics such as drug the phenothiazines and other antipsychotics tricyclic antidepressants certain antiarrhythmics such as the quinidine salts and antihistamines 	DDI-effect
DDI-DrugBank.d122.s0.p0	nephrotoxicity has been reported following concomitant administration of drug with drug or potent diuretics such as furosemide 	DDI-effect
DDI-DrugBank.d356.s2.p0	drug generally should not be given with drug because they reduce its renal clearance and add a high risk of lithium toxicity 	DDI-advise
DDI-MedLine.d73.s2.p0	it was observed that drug induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by drug pretreatment 	DDI-effect
DDI-DrugBank.d171.s0.p0	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of drug phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d211.s2.p11	bacteriostatic antibiotics chloramphenicol drug sulfonamides or tetracyclines may interfere with the bactericidal effect of drug 	DDI-effect
DDI-DrugBank.d8.s0.p0	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug is administered in combination with other drug such as barbiturates tranquilizers opioids or inhalation general anesthetics 	DDI-effect
DDI-DrugBank.d338.s4.p0	while no in vivo drug drug interaction studies were conducted between drug and inducers of cyp a compounds that are potent cyp a inducers such as drug phenytoin rifampin and barbiturates would be expected to decrease estazolam concentrations 	DDI-mechanism
DDI-DrugBank.d559.s1.p16	butalbital drug and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide sedative hypnotics or other drug causing increased cns depression 	DDI-effect
DDI-DrugBank.d321.s0.p5	dexamethasone steady state trough concentrations of albendazole sulfoxide were about higher when mg drug was coadministered with each dose of drug mg kg day in eight neurocysticercosis patients 	DDI-mechanism
DDI-DrugBank.d114.s2.p5	concurrent administration of drugs possessing nephrotoxic e g drug indomethacin myelotoxic e g cytotoxic chemotherapy cardiotoxic e g doxorubicin or hepatotoxic e g methotrexate asparaginase effects with drug may increase toxicity in these organ systems 	DDI-effect
DDI-DrugBank.d476.s3.p2	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the drug verapamil and benzothiazepine diltiazem classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d311.s0.p0	taking a drug while you are taking or within weeks of taking drug may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction 	DDI-effect
DDI-DrugBank.d142.s0.p4	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics amantadine haloperidol phenothiazines drug tricyclic antidepressants or some antihistamines 	DDI-effect
DDI-DrugBank.d386.s24.p0	both the sedative and anticholinergic effects of the drug are also additive to those of drug 	DDI-effect
DDI-DrugBank.d522.s21.p2	anticoagulants there have been reports of increased anticoagulant effects when drug and oral drug were used concomitantly 	DDI-effect
DDI-DrugBank.d373.s9.p2	coumarin anticoagulants there have been rare reports of increased prothrombin time in patients taking drug to whom drug was administered 	DDI-effect
DDI-DrugBank.d495.s7.p0	also due to the potential for additive effects such as bradycardia and av block caution is warranted in patients receiving drug with agents known to affect sinus node function or av nodal conduction e g drug calcium channel blockers and beta blockers 	DDI-advise
DDI-DrugBank.d85.s6.p5	concomitant administration of naproxen and aspirin is not recommended because drug is displaced from its binding sites during the concomitant administration of drug resulting in lower plasma concentrations and peak plasma levels 	DDI-advise
DDI-DrugBank.d29.s6.p0	patients treated with drug and drug concomitantly may need to be monitored for increases in inr and prothrombin time 	DDI-effect
DDI-DrugBank.d423.s0.p15	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with drug e g fluoxetine fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d395.s0.p4	bismuth drug given concomitantly with drug or minutes following enoxacin administration decreased enoxacin bioavailability by approximately 	DDI-mechanism
DDI-DrugBank.d94.s18.p0	because of its primary cns effect caution should be used when drug is taken with other drug and alcohol 	DDI-advise
DDI-DrugBank.d87.s13.p5	limited data in patients receiving known enzyme inducers phenytoin phenobarbital drug indicate only a increase in the rate of drug elimination 	DDI-mechanism
DDI-DrugBank.d274.s2.p0	preliminary studies indicate that the concomitant use of drug and drug results in a higher cardiac output and usually a lower pulmonary wedge pressure than when either drug is used alone 	DDI-effect
DDI-DrugBank.d220.s9.p5	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg anti arrhythmic or beta adrenergic blocking agents calcium channel blockers antihistamines or h blocking agents drug and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d434.s1.p5	use in conjunction with other antiepileptic drugs the addition of drug to antiepileptic drugs drug affects the steady state plasma concentrations of aeds 	DDI-mechanism
DDI-DrugBank.d386.s23.p3	if drug is to be combined with other psychotropic agents such as tranquilizers or sedative drug careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines e g chlordiazepoxide or diazepam are additive 	DDI-effect
DDI-DrugBank.d131.s1.p1	the steady state plasma concentrations of drug and desipramine have been reported to be increased an average of and respectively by the concomitant administration of drug tablets in doses up to mg day 	DDI-mechanism
DDI-DrugBank.d387.s1.p0	drug may partially counteract the anticoagulation effects of drug or warfarin 	DDI-effect
DDI-DrugBank.d434.s28.p5	phenobarbital coadministration of drug with drug causes an increase in phenobarbital plasma concentrations in otherwise healthy male volunteers ingesting phenobarbital the steady state trough cmin phenobarbital concentration was micrograms ml 	DDI-mechanism
DDI-DrugBank.d526.s14.p2	rarely salicylate toxicity may occur in patients who discontinue drug after concurrent high dose drug therapy 	DDI-effect
DDI-MedLine.d133.s5.p0	drug also significantly decreased the incidence of lymphatic invasion of adenocarcinomas which was enhanced by drug 	DDI-effect
DDI-DrugBank.d437.s9.p3	methadone coadministration of drug and drug can decrease plasma levels of methadone 	DDI-effect
DDI-DrugBank.d186.s3.p4	as with other drug it should be noted that haldol may be capable of potentiating cns depressants such as anesthetics opiates and drug 	DDI-effect
DDI-DrugBank.d223.s10.p0	nevertheless caution is indicated in the co administration of drug with any of the drug and also in switching from one class to the other 	DDI-advise
DDI-DrugBank.d158.s15.p2	lithium carbonate the anorectic and stimulatory effects of drug may be inhibited by drug 	DDI-effect
DDI-MedLine.d30.s11.p0	drug reduced or eliminated the increases in fi responding produced by intermediate doses of either drug or pcp in pigeons but did not antagonize the decreases in fi or fr responding produced by high doses of pcp or either stereoisomer of nanm 	DDI-effect
DDI-DrugBank.d60.s12.p27	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics drug and quinidine 	DDI-effect
DDI-DrugBank.d389.s0.p1	drug may enhance the effects of tricyclic antidepressants drug alcohol and other cns depressants 	DDI-effect
DDI-DrugBank.d347.s7.p34	magnesium and or aluminum containing antacids products containing ferrous sulfate drug multivitamin preparations containing zinc or other metal cations or videx didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d566.s0.p3	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin drug acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d279.s10.p0	it would be expected that drug use during therapy with drug would worsen the incidence or severity of diarrhea but this has not been studied 	DDI-effect
DDI-DrugBank.d464.s0.p1	drug in combination with other narcotic analgesics general drug phenothiazines tranquilizers sedative hypnotics or other cns depressants including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d217.s11.p4	drug or other products containing iron or zinc antacids or sucralfate should not be administered concomitantly with or within hours of the administration of drug because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin 	DDI-advise
DDI-DrugBank.d179.s1.p1	drug interact with any of the following acetaminophen drug with long term high dose use or	DDI-int
DDI-DrugBank.d179.s1.p1	drug high interact with any of the following acetaminophen e g drug with long term may dose use or	DDI-int
DDI-DrugBank.d179.s1.p1	drug may interact with any of the following acetaminophen e g drug with long terminus high dose use or	DDI-int
DDI-DrugBank.d179.s1.p1	drug may interact with any of the following acetaminophen e g drug with long term high dose use or	DDI-int
DDI-DrugBank.d94.s8.p6	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl felbamate rifampin phenobarbital phenytoin drug methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d31.s2.p0	profound hypotensive episodes may occur when drug infection and drug are used concomitantly 	DDI-effect
DDI-DrugBank.d76.s11.p0	consequently it is recommended that drug not be used in combination with either drug astemizole or cisapride 	DDI-advise
DDI-DrugBank.d198.s13.p0	the interaction is a consequence of blocking hepatic metabolism of drug by drug a highly potent cyp a inhibitor which also inhibits cyp c 	DDI-mechanism
DDI-DrugBank.d485.s32.p14	protease inhibitors amprenavir lopinavir nelfinavir and drug have been shown to decrease plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d35.s0.p3	interactions may occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs and tween herbs such as garlic allium sativum and ginkgo genus allium drug	DDI-int
DDI-DrugBank.d35.s0.p3	interactions may occur between steroidal allium and aspirin and other non drug anti inflammatory drugs and herbs such as garlic supplements sativum and ginkgo drug	DDI-int
DDI-DrugBank.d35.s0.p3	interactions may occur between do drugs supplements and aspirin and other not steroidal anti inflammatory drugs and herbs such as garlic allium sativum and ginkgo do drugs	DDI-int
DDI-DrugBank.d35.s0.p3	interactions may occur between drug supplements and aspirin and other non steroidal anti inflammatory drugs and herbs such as garlic allium sativum and ginkgo drug 	DDI-int
DDI-DrugBank.d207.s4.p4	substances that are potent inhibitors of cyp a activity eg ketoconazole and drug decrease gefitinib metabolism and increase drug plasma concentrations 	DDI-mechanism
DDI-DrugBank.d562.s8.p4	quinolones including drug may enhance the effects of oral anticoagulants such as drug or its derivatives 	DDI-effect
DDI-DrugBank.d384.s15.p4	magnesium drug containing preparations eg antacids may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-advise
DDI-DrugBank.d299.s6.p27	selective serotonin reuptake inhibitors ssris ssris e g fluoxetine fluvoxamine paroxetine drug have been rarely reported to cause weakness hyperreflexia and incoordination when coadministered with drug 	DDI-effect
DDI-MedLine.d126.s6.p2	pretreatment of rats with allopurinol mg kg ip or drug mg kg per day ig for days and a dose of mg kg on the th day provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues induced by single high dose of oral drug administration within h 	DDI-effect
DDI-DrugBank.d548.s9.p1	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants drug tcas such as nortriptyline amitriptyline and imipramine phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-MedLine.d111.s9.p0	drug diminished the binding of drug to human serum by a net change of percentage increase in free drug fraction fdf at micromol l and by a net change of percentage increase in fdf at micromol l 	DDI-mechanism
DDI-DrugBank.d151.s2.p0	however high doses of drug may reduce the efficacy of intrathecally administered drug 	DDI-effect
DDI-DrugBank.d97.s35.p0	dose reduction of drug to mg every hours should be considered when taking drug mg three times a day 	DDI-advise
DDI-DrugBank.d314.s8.p2	antidiabetics because drug may increase blood glucose concentrations dosage adjustments of drug may be required 	DDI-effect
DDI-DrugBank.d142.s0.p5	additive adverse effects resulting from cholinergic blockade may occur when drug is administered concomitantly with other antimuscarinics amantadine haloperidol phenothiazines monoamine oxidase mao inhibitors drug or some antihistamines 	DDI-effect
DDI-DrugBank.d382.s31.p3	consequently concomitant administration of drug with strong cyp a inhibitors e g ketoconazole itraconazole nefazodone drug clarithromycin ritonavir nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d66.s2.p3	indomethacin concomitant use of drug and drug may ameliorate increased intestinal permeability caused by indomethacin 	DDI-effect
DDI-DrugBank.d326.s0.p2	phenothiazines taking drug and a drug together may increase the risk of convulsions seizures 	DDI-effect
DDI-DrugBank.d170.s5.p13	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other drug including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d458.s25.p1	drug isoniazid is also reported to affect drug concentrations adversely 	DDI-mechanism
DDI-DrugBank.d123.s14.p2	phenytoin altered serum levels of drug increased and decreased have been reported in patients receiving concomitant drug 	DDI-mechanism
DDI-DrugBank.d484.s0.p40	drug may interact with the following medications acetaminophen tylenol antibiotics such as drug and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals clofibrate peg nizoral sporanox atorvastatin lipitor sandimmune atromid s ampicillin inhibitors gris hiv drugs classified as protease neoral agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms phenylbutazone contin prednisolone prelone rifadin rifampin st johns wort cyclosporine theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p40	drug may interact with the following medications acetaminophen tylenol antibiotics such as sk ampicillin and achromycin anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals jaun gris peg nizoral sporanox atorvastatin atorvastatin clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir nelfinavir morphine astramorph kadian ms contin phenylbutazone prednisolone prednisolone rifadin rifampin st johns wort drug theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p40	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and butazolidin tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase phenytoin antibiotic drug kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone sodium thiopental prednisolone jaun gris prelone rifadin rifampin st johns wort drug theophylline theo dur and vitamin butazolidin c	DDI-int
DDI-DrugBank.d484.s0.p40	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort drug theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d42.s1.p3	blood levels of hydrodolasetron increased when drug was coadministered with drug nonselective inhibitor of cytochrome p for days and decreased with coadministration of rifampin potent inducer of cytochrome p for days 	DDI-mechanism
DDI-DrugBank.d46.s16.p1	drug reduce the renal clearance of lithium and add a high risk of drug toxicity 	DDI-mechanism
DDI-DrugBank.d336.s0.p0	although clinical studies have not established a cause and effect relationship physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral drug and drug 	DDI-effect
DDI-DrugBank.d314.s17.p5	estrogens including oral contraceptives drug may decrease the hepatic metabolism of certain drug thereby increasing their effect 	DDI-mechanism
DDI-DrugBank.d569.s1.p2	in clinical trials in patients undergoing ptca pci co administration of drug with heparin warfarin drug or glycoprotein iib iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications 	DDI-effect
DDI-MedLine.d46.s13.p0	coadministration of drug significantly decreased drug plasma concentrations 	DDI-mechanism
DDI-MedLine.d89.s2.p0	due to its nephrotoxicity drug may cause abnormal renal uptake to be seen on drug bone scintigraphy 	DDI-mechanism
DDI-DrugBank.d354.s1.p0	therefore caution should be used when administering drug concurrently with other highly plasma protein bound drugs with narrow therapeutic indices as competition for binding sites may occur e g drug 	DDI-mechanism
DDI-DrugBank.d187.s11.p0	therophylline a recent study has shown that concomitan administration of drug and drug may cause elevated plasma levels of theophylline and in some instances a slight decrease in the elimination of isoniazid 	DDI-mechanism
DDI-DrugBank.d428.s11.p0	drug treatment should be stopped during treatment with drug 	DDI-advise
DDI-DrugBank.d114.s5.p2	hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug and antineoplastic agents specifically dacarbazine drug tamoxifen and interferon alfa 	DDI-effect
DDI-DrugBank.d110.s3.p0	concurrent administration of drug for the treatment of hypotension related to obstetric blocks and drug may cause severe persistent hypertension or cerebrovascular accidents 	DDI-effect
DDI-DrugBank.d124.s26.p57	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers dapsone disopyramide drug amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d60.s9.p2	in long surgical procedures during enflurane or drug anesthesia less frequent maintenance dosing lower maintenance doses or reduced infusion rates of drug may be necessary 	DDI-advise
DDI-DrugBank.d207.s4.p3	substances that are potent inhibitors of cyp a activity eg ketoconazole and drug decrease drug metabolism and increase gefitinib plasma concentrations 	DDI-mechanism
DDI-DrugBank.d476.s0.p0	drug should not be combined with other drug 	DDI-advise
DDI-DrugBank.d516.s5.p2	drug and aluminum containing antacids administered concomitantly with drug significantly decreased the bioavailability of lomefloxacin 	DDI-mechanism
DDI-DrugBank.d478.s1.p9	because there is a theoretical basis that these effects may be additive use of ergotamine containing or ergot type medications like dihydroergotamine or drug and drug within hours is contraindicated 	DDI-advise
DDI-DrugBank.d415.s5.p4	methotrexate drug as well as other nonsteroidal anti inflammatory drugs probably reduces the tubular secretion of drug based on in vitro studies in rabbit kidney slices 	DDI-mechanism
DDI-DrugBank.d357.s3.p41	dopamine antagonists since apomorphine is a dopamine agonist it is possible that dopamine antagonists such as the neuroleptics phenothiazines drug thioxanthenes or metoclopramide may diminish the effectiveness of drug 	DDI-effect
DDI-DrugBank.d283.s6.p0	the benefits and risks of using drug with drug and other potentially nephrotoxic agents should be carefully considered and the lowest effective dose employed	DDI-advise
DDI-DrugBank.d299.s2.p2	monoamine oxidase inhibitors coadministration of drug resulted in a decrease in drug clearance and an increase in cmax of approximately 	DDI-mechanism
DDI-MedLine.d99.s0.p0	drug inhibits the cyp c catalyzed biotransformation of drug 	DDI-mechanism
DDI-DrugBank.d104.s0.p1	drug may increase slightly the effect of antihypertensive drugs e g drug methyldopa reserpine 	DDI-effect
DDI-DrugBank.d249.s18.p0	protein binding in vitro drug interferes minimally or not at all with the protein binding of drug decrease in binding tolbutamide prednisolone decrease in binding or warfarin 	DDI-mechanism
DDI-DrugBank.d22.s2.p0	drug may also decrease the absorption of drug which can lead to a deficiency 	DDI-mechanism
DDI-DrugBank.d368.s9.p0	drug decreases urinary excretion of drug and may enhance the magnitude and duration of their effect 	DDI-mechanism
DDI-DrugBank.d411.s2.p11	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract aluminum hydoxide cholestyramine resin colestipol hydrochloride ferrous sulfate drug soybean flour e g infant formula sucralfate 	DDI-mechanism
DDI-DrugBank.d94.s8.p2	agents that are cyp inducers that have been found or are expected to decrease plasma levels of drug are the following cisplatin doxorubicin hcl drug rifampin phenobarbital phenytoin primidone methsuximide and theophylline thus if a patient has been titrated to a stable dosage on equetrotm and then begins a course of treatment with one of these cyp a inducers it is reasonable to expect that a dose increase for equetrotm may be necessary 	DDI-mechanism
DDI-DrugBank.d565.s18.p0	administration of drug with drug in healthy male subjects increased plasma digoxin concentrations approximately 	DDI-mechanism
DDI-DrugBank.d162.s13.p0	therefore when drug and drug are used concomitantly the patient should be observed closely to determine if the desired effect of the diuretic is obtained 	DDI-advise
DDI-DrugBank.d459.s1.p2	caution should be taken when drug is used concomitantly with medications that are predominantly metabolized by cyp d and which have a narrow therapeutic window such as flecainide thioridazine and drug see clinical pharmacology 	DDI-advise
DDI-DrugBank.d484.s0.p22	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline dilantin phenobarbital tegretol felbatol gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral drug hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p22	dose may interact with the following medications tempra tylenol antibiotics such as principen and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox lipitor lipitor clofibrate atromid s cyclosporine neoral dose hiv dose classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin one hundred	DDI-int
DDI-DrugBank.d484.s0.p22	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline inhibitors dilantin phenobarbital tegretol trileptal topamax felbatol anticonvulsants gris peg phenylbutazone sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral prednisolone hiv viracept classified as protease antifungals agenerase crixivan fortovase invirase kaletra norvir johns morphine astramorph kadian ms contin nizoral drug prelone rifadin rifampin st drugs wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p22	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral drug hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d566.s0.p6	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline drug phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d84.s1.p12	although deferasirox has a lower affinity for aluminum than for iron drug should not be taken with drug containing antacid preparations 	DDI-advise
DDI-DrugBank.d233.s1.p0	patients receiving drug and drug concomitantly should have a dose reduction of azathioprine to approximately to the usual dose 	DDI-advise
DDI-DrugBank.d566.s0.p2	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone drug thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and digitalis 	DDI-mechanism
DDI-DrugBank.d165.s15.p2	coadministration of drug and cyclosporine tacrolimus or drug has led to increased plasma concentrations of the latter three drugs 	DDI-mechanism
DDI-DrugBank.d75.s14.p4	the effects of medicinal products with similar properties such as inotropes drug enoximone amrinone olprinone and cilostazol may be exacerbated by drug 	DDI-effect
DDI-DrugBank.d422.s13.p0	caution should be exercised when considering the use of drug and drug in patients with depressed myocardial function 	DDI-advise
DDI-DrugBank.d12.s3.p0	drug may displace acidic drugs such as drug or tolbutamide from their binding sites 	DDI-mechanism
DDI-DrugBank.d492.s1.p2	drug may have additive effects with alcohol and other cns depressants e g drug sedatives tranquilizers antianxiety agents 	DDI-effect
DDI-DrugBank.d46.s17.p0	refer to the package insert for drug preparations before use of such preparations with drug 	DDI-advise
DDI-DrugBank.d350.s9.p0	there were transient increases in liver alt and ast when drug and drug were co administered 	DDI-effect
DDI-DrugBank.d492.s1.p1	drug may have additive effects with alcohol and other drug e g hypnotics sedatives tranquilizers antianxiety agents 	DDI-effect
DDI-DrugBank.d226.s4.p1	the effects of drug are antagonized by methylxanthines such as drug and theophylline 	DDI-effect
DDI-DrugBank.d364.s4.p0	concomitant administration of drug and drug is contraindicated 	DDI-advise
DDI-DrugBank.d507.s0.p0	the potential for increased sedation when drug is given with other drug should be appreciated 	DDI-effect
DDI-DrugBank.d12.s0.p0	caution should be exercised when drug are given in conjunction with drug 	DDI-advise
DDI-DrugBank.d531.s29.p0	in uninfected volunteers developed rash while receiving drug and drug 	DDI-effect
DDI-DrugBank.d552.s0.p0	drug should be administered with caution to patients who are taking other drug or cns depressants including alcohol barbiturates and narcotic analgesics or to those with a history of psychiatric disorder including manic depressive illness and schizophrenia 	DDI-advise
DDI-MedLine.d67.s6.p1	similarly drug decreased the antinociceptive effect of metamizol only in the tail flick test and drug 	DDI-effect
DDI-DrugBank.d404.s15.p5	magnesium magnesium containing preparations eg drug may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-effect
DDI-DrugBank.d423.s0.p3	in patients receiving nonselective drug maois e g selegiline hydrochloride in combination with serotoninergic agents e g drug fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d39.s1.p5	colchicine para aminosalicylic acid and heavy drug intake for longer than weeks may produce malabsorption of drug 	DDI-mechanism
DDI-DrugBank.d43.s4.p10	antacids concomitant administration of antacids containing drug or aluminum with drug chewable dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the antacid components 	DDI-effect
DDI-DrugBank.d357.s3.p38	dopamine antagonists since apomorphine is a dopamine agonist it is possible that dopamine antagonists such as the neuroleptics drug butyrophenones thioxanthenes or metoclopramide may diminish the effectiveness of drug 	DDI-effect
DDI-DrugBank.d350.s10.p0	a drug drug interaction study with drug in healthy volunteers has shown a decrease in drug trough concentrations 	DDI-mechanism
DDI-DrugBank.d219.s4.p3	aspirin when drug is administered with drug its protein binding is reduced although the clearance of free etodolac is not altered 	DDI-mechanism
DDI-DrugBank.d178.s0.p2	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates drug chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d94.s13.p5	agents with increased levels in the presence of carbamazepine drug increases the plasma levels of the following agents drug phenytoin and primidone thus if a patient has been titrated to a stable dosage on one of the agents in this category and then begins a course of the treatment with equetrotm it is reasonable to expect that a dose decrease for the concomitant agent may be necessary 	DDI-mechanism
DDI-DrugBank.d287.s0.p0	drug should be administered with caution to patients taking drug because of the possibility of conduction disturbances 	DDI-advise
DDI-DrugBank.d82.s3.p0	in a study in normal volunteers it was found that chronic concurrent administration of g of drug per day decreases drug blood levels approximately 	DDI-mechanism
DDI-DrugBank.d115.s0.p12	drugs that may alter imatinib plasma concentrations drugs that may increase imatinib plasma concentrations caution is recommended when administering drug with inhibitors of the cyp a family e g ketoconazole drug erythromycin clarithromycin 	DDI-advise
DDI-DrugBank.d522.s24.p1	other drugs dose drug interactions presidency have been reported with concomitant administration of drug and other medications including cyclosporine drug carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p1	other drugs drug interactions have been reported with concomitant administration of drug and other medications cyclosporine drug carbamazepine alfentanil disopyramide phenytoin bromocriptine astemizole lovastatin	DDI-int
DDI-DrugBank.d522.s24.p1	other drugs drug interactions have been reported with incidental administration of drug and other medications include cyclosporine drug carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p1	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine drug carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d141.s4.p0	in the first study concomitant administration of mg drug and g drug resulted in decreases of more than for auc and for cmax when compared to dosing cerivastatin sodium alone 	DDI-mechanism
DDI-DrugBank.d463.s1.p1	there is one report suggesting that the concomitant use of drug desyrel and drug may have caused to fold elevations on sgpt alt in a few patients 	DDI-effect
DDI-DrugBank.d220.s16.p0	nevertheless the effects of drug on travelers receiving comedication particularly diabetics or patients using drug should be checked before departure 	DDI-advise
DDI-DrugBank.d365.s0.p2	medroxyprogesterone acetate drug was observed to enhance in tissue culture the effect of drug in reducing the number of human breast cancer cells that were in the s phase 	DDI-effect
DDI-DrugBank.d476.s1.p2	patients receiving catecholamine depleting drugs such as reserpine or drug should be closely monitored because the added beta adrenergic blocking action of drug may produce excessive reduction of sympathetic activity 	DDI-effect
DDI-DrugBank.d219.s19.p2	phenylbutazone drug causes increase by about in the free fraction of drug 	DDI-mechanism
DDI-DrugBank.d412.s4.p0	drug has been shown to increase the bioavailability of drug 	DDI-mechanism
DDI-DrugBank.d8.s0.p4	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug is administered in combination with other cns depressants such as barbiturates tranquilizers opioids or inhalation general drug 	DDI-effect
DDI-DrugBank.d459.s0.p3	the daily dose of drug should not exceed mg when coadministered with potent cyp a inhibitors e g ketoconazole itraconazole ritonavir drug clarithromycin and nefazadone 	DDI-advise
DDI-DrugBank.d456.s1.p5	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole drug nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d154.s8.p0	in patients receiving drug the addition of drug to therapy could prolong the prothrombin time 	DDI-effect
DDI-DrugBank.d40.s10.p5	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam drug disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d123.s8.p10	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as drug or aluminum antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d529.s11.p0	patients taking both drug and a drug should be monitored to ensure that a satisfactory hypotensive effect is achieved 	DDI-advise
DDI-MedLine.d7.s0.p0	enhanced drug clearance secondary to drug therapy 	DDI-mechanism
DDI-DrugBank.d484.s0.p11	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin saquinavir phenobarbital tegretol inhibitor trileptal topamax drug antifungals gris peg nizoral stick with sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase human immunodeficiency virus crixivan fortovase invirase kaletra norvir viracept morphine nelfinavir astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo antibiotic drug dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p11	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax drug antifungal agent gris stick nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune human immunodeficiency virus drugs classified as proteolytic enzyme inhibitors agenerase crixivan fortovase invirase kaletra ritonavir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p11	drug may interact with as following medications acetaminophen tylenol dilantin drugs dur ampicillin and tetracycline anticonvulsants as phenobarbital tegretol trileptal topamax drug antifungals lipitor peg nizoral sporanox atorvastatin gris clofibrate atromid s cyclosporine neoral sandimmune hiv such classified the protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo antibiotics and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p11	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax drug antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d533.s2.p0	co administration of drug reduced drug cmax up to after multiple dosing 	DDI-mechanism
DDI-DrugBank.d464.s0.p4	drug in combination with other narcotic analgesics general anesthetics phenothiazines tranquilizers drug or other cns depressants including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d48.s1.p2	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole drug clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-MedLine.d30.s9.p0	the doses of drug required to antagonize the effects of drug were more than times higher than those required to antagonize the effects of morphine 	DDI-effect
DDI-DrugBank.d116.s0.p0	careful observation is required when drug is administered concurrently with drug 	DDI-advise
DDI-MedLine.d59.s5.p0	drug inhibited the drug stimulated intracellular ca concentration ca i increase due to release from the ca store 	DDI-effect
DDI-DrugBank.d270.s58.p0	abased on reports of narcotic withdrawal syndrome in patients treated with drug and drug concurrently and evidence of decreased plasma concentrations of methadone 	DDI-effect
DDI-DrugBank.d368.s0.p0	drug modifies drug metabolism with increased serum levels of phenytoin 	DDI-mechanism
DDI-DrugBank.d332.s1.p2	in patients who have received muscle relaxants drug may temporarily mask the residual effects of drug 	DDI-effect
DDI-DrugBank.d522.s24.p2	other drugs cause drug interactions have been reported with concomitant administration of drug and other medications dose including cyclosporine hexobarbital drug alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p2	other drug drug interactions have been reported with concomitant administration of drug and other medicinal drug including cyclosporine hexobarbital drug alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p2	other and drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital drug alfentanil valproate phenytoin bromocriptine disopyramide astemizole drugs lovastatin	DDI-int
DDI-DrugBank.d522.s24.p2	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital drug alfentanil disopyramide phenytoin bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d257.s6.p34	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg pentazocine nalbuphine butorphanol dezocine and drug should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d66.s5.p2	methotrexate there is one report that drug may decrease the possible effectiveness of supplemental drug for chemotherapy induced mucositis 	DDI-effect
DDI-MedLine.d105.s7.p2	drug had no significant impact on the cmax and auc of zidovudine although it significantly decreased the zidovudine tmax by and increased the intracellular exposure to phosphorylated drug by 	DDI-mechanism
DDI-DrugBank.d476.s3.p3	drug should be used with care when myocardial depressants or inhibitors of av conduction such as certain calcium antagonists particularly of the phenylalkylamine drug and benzothiazepine diltiazem classes or antiarrhythmic agents such as disopyramide are used concurrently 	DDI-advise
DDI-DrugBank.d442.s1.p2	therefore close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when drug capsules are administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d196.s1.p2	theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both drug and drug 	DDI-advise
DDI-DrugBank.d325.s12.p1	the concomitant use of drug s vasoconstricting agents such as ergonovine and some drug may result in severe hypertension 	DDI-effect
DDI-DrugBank.d398.s2.p0	the use of drug may result in additive cns depressant effects when coadministered with drug antihistamines psychotropics or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d5.s25.p5	alcohol in post marketing experience there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking drug during treatment with drug 	DDI-effect
DDI-DrugBank.d521.s1.p6	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others drug arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d33.s0.p2	although the occurrence has not been reported with cefizox nephrotoxicity has been reported following concomitant administration of other drug and drug 	DDI-effect
DDI-DrugBank.d18.s1.p2	injection drug injection like other injectable benzodiazepines produces depression of the central nervous system when administered with ethyl alcohol drug barbiturates mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d26.s0.p14	patients receiving other narcotic analgesics general drug phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d132.s26.p2	sulindac the concomitant administration of drug and drug in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one third 	DDI-mechanism
DDI-DrugBank.d537.s0.p8	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid drug use of goods and services containing preparations e g formulation sunscreens and some multivitamins procainamide ethyl aminobenzoate e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements supplementation sulpha may give false test results	DDI-int
DDI-DrugBank.d537.s0.p8	pancreatic may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics results drug benzocaine and lidocaine para aminobenzoic acid and containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides of medicines thiazide diuretics use of these medicines during pancreatic test period will affect the test e g the supplements use sulfa drug supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p8	do drugs may interact with acetaminophen tocopherol g tylenol chloromycetin tocopherol g chloromycetin local anesthetics tocopherol g ethyl aminobenzoate and lidocaine para aminobenzoic acid do drugs containing preparations tocopherol g sunscreens and some multivitamins procainamide tocopherol g pronestyl sulfonamides sulfonamide medicines thiazide diuretics use of these medicines during the test menstruum will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p8	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid drug containing preparations e g sunscreens and some multivitamins procainamide e g pronestyl sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-DrugBank.d454.s0.p0	drug may enhance the cns depressive effects of drug barbiturates and other sedatives	DDI-effect
DDI-DrugBank.d254.s0.p8	other cns depressant drugs e g drug tranquilizers opioids and general anesthetics have additive or potentiating effects with drug 	DDI-effect
DDI-DrugBank.d238.s18.p0	the extent to which drug drug interactions may pose clinical problems will depend on the degree inhibition and pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d238.s18.p0	the extent to which drug drug interactions may pose clinical problems will depend on the calculate degree of inhibition and the pharmacokinetics of whitethorn the ssri involved	DDI-int
DDI-DrugBank.d238.s18.p0	the extent to which drug drug interactions may dumbfound clinical trouble will depend on the degree of inhibition and the pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d238.s18.p0	the extent to which drug drug interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ssri involved 	DDI-int
DDI-DrugBank.d236.s0.p14	acidifying agents gastrointestinal acidifying agents drug reserpine glutamic acid hcl ascorbic acid fruit juices etc lower absorption of drug 	DDI-mechanism
DDI-DrugBank.d558.s22.p4	in addition drugs that are actively secreted via this route e g triamterene drug and amiloride should be co administered with care as they might increase drug levels 	DDI-advise
DDI-DrugBank.d484.s0.p39	drug may interact with saquinavir ritonavir the following medications acetaminophen tylenol antibiotics sodium thiopental such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin ritonavir lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept dose morphine astramorph kadian ms contin phenylbutazone sm prednisolone prelone rifadin drug st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p39	drug may interact prelone the following antifungals and tylenol antibiotics such as sandimmune acetaminophen tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal crixivan felbatol medications gris peg nizoral sporanox atorvastatin temazepam clofibrate atromid s cyclosporine neoral ampicillin hiv drugs classified as protease inhibitors agenerase topamax fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone with rifadin drug st johns wort lipitor theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p39	drug may interact with following medications acetaminophen tylenol antibiotics as ampicillin and tetracycline anticonvulsants dilantin tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone drug st wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p39	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin drug st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d328.s49.p2	although the magnitude of changes in diazepam plasma exposure when coadministered with drug were not sufficient to warrant dosage adjustments patients may experience enhanced sedative side effects caused by increased exposure of drug under this circumstance 	DDI-effect
DDI-DrugBank.d257.s6.p25	interactions with mixed agonist antagonist opioid analgesics agonist antagonist analgesics eg pentazocine drug butorphanol dezocine and buprenorphine should not be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as drug 	DDI-advise
DDI-DrugBank.d485.s32.p8	protease inhibitors drug lopinavir nelfinavir and ritonavir have been shown to decrease plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d340.s6.p12	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents drug 	DDI-advise
DDI-DrugBank.d76.s7.p4	terfenadine drug and cisapride are all metabolized by the cytochrome p iiia isozyme and it has been demonstrated that drug a potent inhibitor of iiia blocks the metabolism of these drugs resulting in increased plasma concentrations of parent drug 	DDI-mechanism
DDI-DrugBank.d48.s15.p90	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine drug should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d338.s8.p0	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a drug fluvoxamine cimetidine diltiazem isoniazide and some macrolide antibiotics 	DDI-mechanism
DDI-DrugBank.d396.s2.p4	the use of mao inhibitors or drug with drug preparations may increase the effect of either the antidepressant or hydrocodone 	DDI-effect
DDI-DrugBank.d175.s1.p0	the possibility of hypotensive effects with drug can be minimized by either discontinuing the drug or increasing the salt intake approximately one week prior to initiation of treatment with captopril captopril tablets usp or initiating therapy with small doses or mg 	DDI-effect
DDI-DrugBank.d481.s0.p0	milk milk products and drug rich foods or drugs may impair the absorption of drug 	DDI-mechanism
DDI-DrugBank.d479.s0.p0	the vasodilating effects of drug may be additive with those of other drug 	DDI-effect
DDI-DrugBank.d60.s12.p26	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local drug procainamide and quinidine 	DDI-effect
DDI-DrugBank.d94.s4.p21	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine drug troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d85.s12.p2	drug naproxen sodium and other nsaids have been reported to reduce the tubular secretion of drug in an animal model possibly increasing the toxicity of methotrexate 	DDI-mechanism
DDI-MedLine.d63.s6.p0	intraventricular injection of drug at doses of to micrograms equally antagonized in a dose dependent manner the tail flick inhibition induced by intraventricular drug and morphine 	DDI-effect
DDI-DrugBank.d500.s2.p4	absorption of drug is impaired by antacids containing aluminum calcium or magnesium and drug containing preparations 	DDI-mechanism
DDI-DrugBank.d220.s9.p0	this appears to be the only clinically relevant interaction of this kind with drug although theoretically coadministration of other drugs known to alter cardiac conduction eg drug or beta adrenergic blocking agents calcium channel blockers antihistamines or h blocking agents tricyclic antidepressants and phenothiazines might also contribute to a prolongation of the qtc interval 	DDI-effect
DDI-DrugBank.d350.s14.p0	when drug is co administered with inducers of drug clearance such as drug nevirapine phenytoin dexamethasone or carbamazepine use of a daily dose of mg of cancidas should be considered	DDI-advise
DDI-DrugBank.d132.s22.p0	therefore drug and drug should not be used concomitantly 	DDI-advise
DDI-DrugBank.d560.s2.p0	this allows drug to open air passages increasing the effectiveness of the drug 	DDI-effect
DDI-DrugBank.d359.s2.p1	a two way interaction between the drug phenytoin and the drug dose s has been suggested	DDI-int
DDI-DrugBank.d359.s2.p1	a two way interaction between the drug phenytoin and the s drug has been suggested	DDI-int
DDI-DrugBank.d359.s2.p1	a two way interaction between drug phenytoin and the drug s has been suggested	DDI-int
DDI-DrugBank.d359.s2.p1	a two way interaction between the drug phenytoin and the drug s has been suggested 	DDI-int
DDI-DrugBank.d166.s2.p0	in particular convulsions have been reported when drug is administered with drug and special care should be taken when the treatment regimen includes both of these drugs 	DDI-effect
DDI-DrugBank.d396.s2.p1	the use of drug or tricyclic antidepressants with drug preparations may increase the effect of either the antidepressant or hydrocodone 	DDI-effect
DDI-DrugBank.d499.s25.p2	it is recommended that plasma lithium levels be monitored when drug is coadministered with drug 	DDI-advise
DDI-DrugBank.d194.s0.p0	caution should be exercised when administering drug with drugs that are known to inhibit phosphatase activities e g drug 	DDI-advise
DDI-DrugBank.d40.s19.p5	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids coumarin digitoxin doxycycline drug furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d431.s5.p0	nonetheless individual patients may require additional titration of their drug dosage when drug is started or stopped to ensure clinically effective blood levels 	DDI-advise
DDI-DrugBank.d373.s8.p3	quinidine immediate release capsules there have been rare reports of an interaction between drug and drug with a decreased plasma level of quinidine 	DDI-mechanism
DDI-DrugBank.d340.s6.p1	drugs that should not be coadministered with drug antiarrhythmics drug quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives antimycobacterial agents rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d144.s1.p14	if treatment with inhibitors of cyp a activity such as ketoconazole intraconazole drug indinavir saquinavir erythromycin etc is indicated reduction of the drug dose should be considered 	DDI-advise
DDI-DrugBank.d60.s12.p24	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate drug salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d113.s2.p2	aspirin concurrent administration of drug may lower drug plasma levels possibly by competing for protein binding sites 	DDI-mechanism
DDI-DrugBank.d200.s0.p0	co administration of drug with drug has been shown to increase the mean half life and the area under the concentration time curve 	DDI-mechanism
DDI-DrugBank.d450.s2.p22	quinidine verapamil drug propafenone indomethacin itraconazole alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d226.s9.p0	as the primary effect of drug is to decrease conduction through the a v node higher degrees of heart block may be produced in the presence of drug 	DDI-effect
DDI-DrugBank.d307.s43.p0	therefore concurrent use of drug with drug may render these contraceptives less effective 	DDI-effect
DDI-DrugBank.d178.s0.p6	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins drug and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d338.s6.p1	consequently drug should be avoided in patients receiving ketoconazole and drug which are very potent inhibitors of cyp a 	DDI-advise
DDI-DrugBank.d250.s2.p20	curariform muscle relaxants eg tubocurarine and other drugs including ether succinylcholine gallamine decamethonium and drug potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug parenteral 	DDI-effect
DDI-DrugBank.d450.s12.p1	although drug or calcium channel blockers and drug may be useful in combination to control atrial fibrillation their additive effects on av node conduction can result in advanced or complete heart block 	DDI-effect
DDI-DrugBank.d104.s0.p0	drug may increase slightly the effect of drug e g guanethidine methyldopa reserpine 	DDI-effect
DDI-MedLine.d93.s9.p0	these results suggest that exposure to environmental drug may alter the biological and behavioral responsiveness of an animal to drug 	DDI-effect
DDI-DrugBank.d45.s0.p0	concurrent administration of drug another tnf blocking agent and drug an interleukin antagonist has been associated with an increased risk of serious infections and increased risk of neutropenia and no additional benefit compared to these medicinal products alone 	DDI-effect
DDI-MedLine.d126.s0.p1	drug induced oxidative stress in rat brain and liver is prevented by vitamin e or drug 	DDI-effect
DDI-DrugBank.d236.s1.p2	drug ammonium chloride sodium acid phosphate etc increase the concentration of the ionized species of the drug molecule thereby increasing urinary excretion 	DDI-mechanism
DDI-DrugBank.d17.s25.p2	in some patients the drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-DrugBank.d508.s1.p14	in addition to bleeding associated with heparin and vitamin k antagonists drugs that alter platelet function such as acetylsalicylic acid dipyridamole and drug may increase the risk of bleeding if administered prior to during or after drug therapy 	DDI-effect
DDI-DrugBank.d48.s13.p5	the use of antacids should be considered in place of h blockers or drug in patients receiving drug therapy 	DDI-advise
DDI-DrugBank.d397.s0.p0	drug use in patients who are receiving high doses of drug may be associated with an increase in serum theophylline levels and potential theophylline toxicity 	DDI-effect
DDI-DrugBank.d413.s4.p18	in patients receiving mercaptopurine purinethol or azathioprine imuran the concomitant administration of mg of drug per day will require a reduction in dose to approximately one third to one fourth of the usual dose of drug or azathioprine 	DDI-advise
DDI-DrugBank.d318.s8.p35	imidazoles e g ketoconazole miconazole clotrimazole fluconazole etc in vitro and animal studies with the combination of amphotericin b and imidazoles suggest that drug may induce fungal resistance to drug 	DDI-effect
DDI-DrugBank.d384.s11.p2	corticosteroids a relationship of functional antagonism exists between drug which promote calcium absorption and drug which inhibit calcium absorption 	DDI-mechanism
DDI-DrugBank.d59.s0.p2	the effects of ergomar may be potentiated by drug which inhibits the metabolism of drug 	DDI-mechanism
DDI-DrugBank.d94.s4.p18	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide drug propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d456.s1.p9	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir drug troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d40.s10.p14	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate drug phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d314.s26.p0	the clearance of drug may be increased with concurrent use of drug 	DDI-mechanism
DDI-DrugBank.d247.s9.p0	drug may antagonize the neuron blockade produced by drug resulting in decreased antihypertensive effect and requiring increased dosage of the latter 	DDI-effect
DDI-MedLine.d63.s4.p0	intrathecal injection of drug at doses of to micrograms caused a dose related blockade of the inhibition of the tail flick response induced by intraventricular injection of drug and a high dose of naloxone micrograms completely blocked the tail flick inhibition induced by intraventricular beta endorphin micrograms 	DDI-effect
DDI-DrugBank.d374.s0.p1	drug should be avoided by patients with a history of serious reaction to any gold medication including drug and myochrysine 	DDI-advise
DDI-DrugBank.d236.s8.p1	drug with desipramine or drug and possibly other tricyclics cause striking and sustained increases in the concentration of d amphetamine in the brain 	DDI-mechanism
DDI-DrugBank.d232.s0.p2	after multiple dosing interferon beta a drug mcg im once weekly reduced drug clearance by approximately 	DDI-mechanism
DDI-DrugBank.d187.s3.p0	it is believed that the toxicity may have resulted from a previously unrecognized interaction between drug and drug and a molecular basis for this interaction has been proposed 	DDI-effect
DDI-DrugBank.d338.s8.p2	the following are examples of drugs known to inhibit the metabolism of other related drug presumably through inhibition of cyp a nefazodone fluvoxamine drug diltiazem isoniazide and some macrolide antibiotics 	DDI-mechanism
DDI-DrugBank.d356.s4.p1	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d509.s11.p0	when concomitant administration of drug with drug occurs aripiprazole dose should be reduced to one half of its normal dose 	DDI-advise
DDI-DrugBank.d170.s5.p26	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids sedatives drug tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d456.s1.p4	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir drug nefazodone nelfinavir ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d409.s2.p0	concurrent use of drug with oral drug may render oral contraceptives less effective 	DDI-effect
DDI-DrugBank.d171.s0.p6	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain drug lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d350.s14.p4	when drug is co administered with inducers of drug clearance such as efavirenz nevirapine phenytoin dexamethasone or drug use of a daily dose of mg of cancidas should be considered	DDI-advise
DDI-MedLine.d128.s15.p1	drug mg kg s c completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of drug 	DDI-effect
DDI-DrugBank.d411.s2.p7	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract drug cholestyramine resin colestipol hydrochloride ferrous sulfate sodium polystyrene sulfonate soybean flour e g infant formula sucralfate 	DDI-mechanism
DDI-DrugBank.d500.s4.p2	drug carbamazepine and phenytoin decrease the half life of drug 	DDI-mechanism
DDI-DrugBank.d487.s4.p0	drug may increase the clearance of chronic high dose drug 	DDI-effect
DDI-DrugBank.d54.s15.p3	tricyclic antidepressants use of drug with drug and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed 	DDI-effect
DDI-DrugBank.d257.s3.p2	although no interaction between mao inhibitors and drug has been observed it is not recommended for use with drug 	DDI-advise
DDI-DrugBank.d422.s15.p1	additionally drug should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine drug and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high 	DDI-advise
DDI-MedLine.d86.s9.p0	because of the pronounced intersubject variability in the extent of the drug drug interaction whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs 	DDI-advise
DDI-DrugBank.d480.s30.p4	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines carbamazepine and type c antiarrhythmics e g drug flecainide and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d386.s12.p0	nevertheless caution is indicated in the co administration of drug with any of the drug and also in switching from one class to the other 	DDI-advise
DDI-DrugBank.d567.s11.p2	danazol the risk of myopathy rhabdomyolysis is increased by concomitant administration of drug particularly with higher doses of drug see warnings myopathy rhabdomyolysis 	DDI-effect
DDI-DrugBank.d74.s0.p1	drug augments the action of non depolarising muscle relaxants and the muscle relaxant effects of drug 	DDI-effect
DDI-DrugBank.d423.s4.p2	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of drug ssris and agents for migraine therapy such as imitrex drug and dihydroergotamine 	DDI-effect
DDI-DrugBank.d237.s5.p0	it is advisable to check coagulation time within the first few days after the start and discontinuation of drug therapy with an appropriate adjustment of the drug dose if necessary 	DDI-advise
DDI-DrugBank.d31.s1.p0	when other potent parental drug such as drug are used in combination with hydralazine patients should be continuously observed for several hours for any excessive fall in blood pressure 	DDI-effect
DDI-DrugBank.d492.s1.p3	drug may have additive effects with alcohol and other cns depressants e g hypnotics drug tranquilizers antianxiety agents 	DDI-effect
DDI-DrugBank.d5.s17.p15	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone drug should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d414.s6.p0	in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of drug 	DDI-effect
DDI-DrugBank.d170.s5.p21	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other opioids sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines drug and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d493.s2.p5	anakinra concurrent administration of anakinra an drug and another drug has been associated with an increased risk of serious infections an increased risk of neutropenia and no additional benefit compared to these medicinal products alone 	DDI-effect
DDI-DrugBank.d31.s7.p0	drug may decrease the hemodynamic effects of drug 	DDI-effect
DDI-DrugBank.d364.s5.p1	concomitant administration of drug and moderate cyp a inhibitors including quinolone antibiotics and drug has not been evaluated but should be avoided unless clinically necessary because of similar potential drug interactions 	DDI-advise
DDI-DrugBank.d60.s12.p16	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g drug tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d485.s17.p12	benzodiazepines combination drug may decrease the clearance of some benzodiazepines alprazolam chlordiazepoxide diazepam and increase the clearance of others drug oxazepam temazepam 	DDI-mechanism
DDI-MedLine.d12.s2.p3	although neither drug nor retinyl acetate affected the proliferation of prostatic epithelium in rpmi containing transferrin alone they modify the mitogenic effect of egf and drug 	DDI-effect
DDI-DrugBank.d397.s6.p1	drug has been reported to decrease the clearance of triazolam and drug and thus may increase the pharmacologic effect of these benzodiazepines 	DDI-mechanism
DDI-MedLine.d67.s5.p0	drug at doses of mg kg and mg kg injected with drug was found to decrease the antinociceptive effect of morphine 	DDI-effect
DDI-DrugBank.d245.s0.p3	the hypoglycemic action of drug may be potentiated by certain drugs including nonsteroidal anti inflammatory agents and other drugs that are highly protein bound salicylates sulfonamides drug probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d130.s2.p0	antagonism between drug and drug in vitro has been demonstrated 	DDI-effect
DDI-DrugBank.d568.s1.p13	alcohol although lexapro did not potentiate the cognitive and motor effects of alcohol in a clinical trial as with other drug the use of alcohol by patients taking drug is not recommended 	DDI-advise
DDI-DrugBank.d20.s6.p8	ace inhibitors and angiotensin ii receptor antagonists hypertension in clinical studies of patients with hypertension the addition of drug to mg to ace inhibitors and drug increased mean serum potassium slightly about meq l 	DDI-effect
DDI-DrugBank.d522.s24.p5	mevacor other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide drug bromocriptine valproate astemizole and fundamental interaction lovastatin	DDI-int
DDI-DrugBank.d522.s24.p5	other dose drug interactions have been reported with concomitant administration of drug and other medications let in cyclosporine hexobarbital carbamazepine alfentanil disopyramide drug bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p5	other drugs drug interactions have been reported with concomitant of drug and medications including hexobarbital carbamazepine disopyramide drug bromocriptine valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p5	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide drug bromocriptine valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d484.s0.p25	nelfinavir restoril drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris jaun gris peg nizoral rifadin sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease medication inhibitors agenerase drug fortovase invirase kaletra norvir toilet viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p25	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and achromycin anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as proteolytic enzyme inhibitors agenerase drug fortovase invirase kaletra norvir nelfinavir morphia astramorph kadian molarity contin butazolidin prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p25	drug may interact with the following clofibrate acetaminophen tylenol antibiotics such as ampicillin and tetracycline vitamin dilantin lipitor tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin prednisolone medications atromid s cyclosporine neoral sandimmune dur drugs rifadin as protease inhibitors agenerase drug fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone phenobarbital prelone classified rifampin st johns wort temazepam theophylline theo hiv and anticonvulsants c	DDI-int
DDI-DrugBank.d484.s0.p25	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase drug fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d123.s16.p5	theophylline as with some other drug concurrent administration of ciprofloxacin with drug may lead to elevated serum concentrations of theophylline and prolongation of its elimination half life 	DDI-mechanism
DDI-DrugBank.d231.s0.p0	drug may increase the ototoxic potential of drug especially in the presence of impaired renal function 	DDI-effect
DDI-DrugBank.d43.s14.p4	interactions with other antiretroviral drugs significant decreases in the auc of drug and indinavir occurred following simultaneous administration of these agents with drug 	DDI-mechanism
DDI-DrugBank.d137.s10.p1	drug and tricyclic anti depressants could exaggerate the prolongation of the qt interval observed with drug 	DDI-effect
DDI-DrugBank.d328.s21.p2	lithium serum concentrations should be monitored closely when initiating or changing therapy with drug in patients receiving drug 	DDI-advise
DDI-DrugBank.d485.s41.p3	drug amitriptyline imipramine nortriptyline metabolism may be inhibited by drug increasing plasma levels of antidepressant 	DDI-mechanism
DDI-DrugBank.d77.s4.p0	drug may potentiate the effects of drug 	DDI-effect
DDI-DrugBank.d488.s2.p29	platelet inhibitors drugs such as acetylsalicylic acid dextran phenylbutazone drug indomethacin dipyridamole hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d565.s30.p0	concomitant administration of drug with drug has been reported to result in elevated serum levels of carbamazepine to increase resulting in toxicity in some cases 	DDI-mechanism
DDI-DrugBank.d198.s35.p0	based on these data drug should not be used in patients on drug therapy 	DDI-advise
DDI-DrugBank.d291.s11.p2	drug or mao inhibitors with hepatotoxic potential must not be administered together with bezalip or drug 	DDI-advise
DDI-DrugBank.d503.s3.p1	avoid the concomitant use of drug and tramadol drug 	DDI-advise
DDI-DrugBank.d561.s7.p9	lithium increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving drug during therapy with drug 	DDI-mechanism
DDI-DrugBank.d340.s30.p4	rifabutin coadministration of drug and drug resulted in a decrease in nelfinavir plasma auc and a increase in rifabutin plasma a c 	DDI-mechanism
DDI-DrugBank.d413.s10.p0	the concomitant administration of drug and drug has been associated with a decrease in the excretion of oxypurines hypoxanthine and xanthine and an increase in urinary uric acid excretion compared with that observed with allopurinol alone 	DDI-mechanism
DDI-DrugBank.d522.s24.p6	other drugs drug interactions dilantin have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin drug valproate early astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p6	other drugs drug interactions have been with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine disopyramide phenytoin drug valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p6	other drugs drug interactions have been reported with sequent presidential term of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin drug valproate astemizole and lovastatin	DDI-int
DDI-DrugBank.d522.s24.p6	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin drug valproate astemizole and lovastatin 	DDI-int
DDI-DrugBank.d378.s1.p1	nephrotoxicity has been reported following concomitant administration of other drug with potent diuretics such as drug 	DDI-effect
DDI-DrugBank.d522.s19.p3	triazolam drug has been reported to decrease the clearance of drug and thus may increase the pharmacologic effect of triazolam 	DDI-mechanism
DDI-DrugBank.d139.s3.p3	cholestyramine concomitant intake of drug and drug may reduce the absorption of vitamin k 	DDI-mechanism
DDI-DrugBank.d434.s1.p4	use in conjunction with other antiepileptic drugs the addition of drug to drug aeds affects the steady state plasma concentrations of aeds 	DDI-mechanism
DDI-MedLine.d131.s0.p1	interaction on the antinociceptive effect between drug and enkephalins or drug 	DDI-effect
DDI-DrugBank.d488.s3.p0	the anticoagulant effect of drug is enhanced by concurrent treatment with drug human in patients with hereditary antithrombin iii deficiency 	DDI-effect
DDI-DrugBank.d94.s4.p15	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine drug niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-MedLine.d30.s7.p1	in both species drug but not nanm antagonized the rate decreasing effects of drug on fi and fr responding 	DDI-effect
DDI-DrugBank.d122.s3.p1	drug has been shown to be antagonistic to beta lactam antibiotics including drug based on in vitro studies and time kill curves with enteric gram negative bacilli 	DDI-effect
DDI-DrugBank.d238.s7.p0	administration of drug has been reported to increase the plasma levels of drug if given concomitantly 	DDI-mechanism
DDI-DrugBank.d325.s4.p0	cardiac effects of drug are antagonized by drug such as propranolol and metoprolol 	DDI-effect
DDI-DrugBank.d325.s8.p3	cyclopropane or drug increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug such as dopamine 	DDI-effect
DDI-DrugBank.d179.s37.p3	antidiabetics oral diabetes medicine you take by mouth use of oral drug with drug may increase the chance of side effects affecting the blood and or the side effects or oral antidiabetics	DDI-effect
DDI-DrugBank.d395.s7.p2	digoxin drug may raise serum drug levels in some individuals 	DDI-mechanism
DDI-DrugBank.d210.s3.p3	aspirin concomitant administration of low dose drug with drug may result in an increased rate of gi ulceration or other complications compared to use of vioxx alone 	DDI-effect
DDI-DrugBank.d266.s0.p0	in vitro studies have shown drug can displace drug s such as warfarin from their protein binding sites 	DDI-mechanism
DDI-DrugBank.d105.s0.p11	anticoagulants including coumarin derivatives indandione derivatives and platelet aggregation inhibitors such as drug nsaids and aspirin may increase the risk of bleeding when administered concomitantly with drug 	DDI-effect
DDI-DrugBank.d450.s0.p0	drug are a major contributing factor to drug toxicity 	DDI-effect
DDI-DrugBank.d475.s3.p1	in patients given very high doses mg of drug daily increases in serum salicylate levels were seen when drug mg b i d was administered concurrently 	DDI-mechanism
DDI-DrugBank.d98.s15.p5	magnesium magnesium containing preparations eg drug may cause hypermagnesemia and should therefore not be taken during therapy with drug by patients on chronic renal dialysis 	DDI-advise
DDI-DrugBank.d48.s1.p8	concomitant use of drug and drugs that inhibit cyp a eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone drug saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d469.s9.p0	the prior administration of drug does not enhance the duration but quickens the onset and may increase the depth of neuromuscular block induced by drug 	DDI-effect
DDI-MedLine.d133.s0.p0	suppression by drug of drug enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats 	DDI-effect
DDI-DrugBank.d323.s0.p1	co administration of drug and aminoglycosides or other agents interfering with neuromuscular transmission e g drug should only be performed with caution as the effect of the toxin may be potentiated 	DDI-advise
DDI-DrugBank.d325.s2.p0	concurrent administration of low dose drug and drug may produce an additive or potentiating effect on urine flow 	DDI-effect
DDI-DrugBank.d3.s19.p5	psychoactive drugs hallucinations have been reported when drug was used in patients taking drug fluoxetine thiothixene alprazolam 	DDI-effect
DDI-DrugBank.d223.s20.p0	therefore drug should be discontinued at least two weeks prior to the cautious initiation of therapy with drug 	DDI-advise
DDI-DrugBank.d269.s11.p5	digoxin digoxin concentrations are increased by about when drug and drug are administered concomitantly 	DDI-mechanism
DDI-DrugBank.d154.s0.p0	the coadministration of drug decreases the biologic half life of drug because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine 	DDI-mechanism
DDI-DrugBank.d423.s4.p6	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of selective serotonin reuptake inhibitors drug and agents for migraine therapy such as imitrex sumatriptan succinate and drug 	DDI-effect
DDI-DrugBank.d5.s17.p4	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine drug fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g propafenone flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d411.s2.p12	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract aluminum hydoxide cholestyramine resin colestipol hydrochloride ferrous sulfate sodium polystyrene sulfonate soybean flour e g infant formula drug 	DDI-mechanism
DDI-DrugBank.d422.s15.p0	additionally drug should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug epinephrine and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high 	DDI-advise
DDI-DrugBank.d76.s12.p14	other potentially important drug interactions benzodiazepines benzodiazepines metabolized by hepatic oxidation e g alprazolam midazolam drug elc should be used with caution because the clearance of these drugs is likely to be reduced by drug 	DDI-mechanism
DDI-DrugBank.d223.s23.p0	serious anticholinergic symptoms i e severe dry mouth urinary retention and blurred vision have been associated with elevations in the serum levels of drug when drug therapy is initiated 	DDI-effect
DDI-DrugBank.d345.s14.p3	particular caution should be observed with digitalis preparations since there are conflicting results for the effect of drug on the availability of drug and digitoxin 	DDI-mechanism
DDI-DrugBank.d105.s0.p13	anticoagulants including coumarin derivatives indandione derivatives and platelet aggregation inhibitors such as nonsteroidal anti inflammatory drugs drug and aspirin may increase the risk of bleeding when administered concomitantly with drug 	DDI-effect
DDI-DrugBank.d484.s0.p4	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and drug anticonvulsants dilantin phenobarbital tegretol trileptal stick with topamax itraconazole felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine sodium thiopental neoral sandimmune hiv drugs classified as protease inhibitors agenerase dose crixivan fortovase invirase kaletra norvir elixophyllin viracept antibiotic drug morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p4	drug may nizoral with the following medications acetaminophen tylenol antibiotics such interact ampicillin and phenobarbital anticonvulsants dilantin drug peg trileptal topamax felbatol invirase gris tegretol as sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase antifungals temazepam norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort kaletra theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p4	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin drug anticonvulsants dilantin trileptal felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune drugs classified as protease inhibitors crixivan fortovase invirase kaletra morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p4	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and drug anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d542.s0.p9	interactions for vitamin b niacin antihypertensive therapy drug may potentiate the effects of drug and vasoactive drugs resulting in postural hypotension 	DDI-effect
DDI-DrugBank.d151.s0.p0	drug in large amounts may counteract the antiepileptic effect of drug phenytoin and primidone and increase the frequency of seizures in susceptible pediatric patients 	DDI-effect
DDI-DrugBank.d304.s0.p3	may interact with the following cholestyramine drug use with drug may prevent the diuretic from working properly 	DDI-effect
DDI-DrugBank.d11.s3.p0	dosage adjustment of drug may be necessary when coadministered with cyp d inhibitors e g drug fluoxetine and quinidine 	DDI-advise
DDI-DrugBank.d289.s29.p0	patients using cyp a metabolized drug should have cholesterol levels monitored after drug is initiated to see whether the statin dose needs adjustment 	DDI-advise
DDI-DrugBank.d165.s7.p0	human pharmacokinetics data indicate that oral drug potently inhibits the metabolism of drug resulting in an eight fold increase in the mean auc of cisapride 	DDI-mechanism
DDI-DrugBank.d521.s1.p3	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate drug salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d431.s3.p0	when drug was administered concomitantly with drug cyp a cyp a a minor increase in the clearance of theophylline was seen 	DDI-mechanism
DDI-DrugBank.d559.s1.p7	drug acetaminophen and caffeine may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as chlordiazepoxide drug or other cns depressants causing increased cns depression 	DDI-effect
DDI-MedLine.d131.s0.p0	interaction on the antinociceptive effect between drug and drug or tuftsin 	DDI-effect
DDI-DrugBank.d395.s3.p0	in a multiple dose study drug caused a dose related increase in the mean elimination half life of drug thereby decreasing the clearance of caffeine by up to and leading to a five fold increase in the auc and the half life of caffeine 	DDI-mechanism
DDI-DrugBank.d267.s5.p1	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g drug tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d162.s12.p6	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop potassium sparing and drug 	DDI-effect
DDI-DrugBank.d115.s6.p0	pretreatment of healthy volunteers with multiple doses of drug followed by a single dose of drug increased gleevec oral dose clearance by fold which significantly p decreased mean cmax and auc 	DDI-mechanism
DDI-DrugBank.d60.s12.p7	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin drug colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d115.s2.p2	there is a significant increase in exposure to imatinib when drug is coadministered with drug cyp a inhibitor 	DDI-mechanism
DDI-DrugBank.d339.s0.p2	carbamazepine elevated drug levels have been reported in postmarketing experience when drug is administered concomitantly 	DDI-mechanism
DDI-DrugBank.d503.s7.p2	exert particular caution in combining drug with other anticholinergic drugs tricyclic antidepressants and drug particularly the elderly may develop delirium high fever severe obstipation even ileus and glaucoma 	DDI-advise
DDI-DrugBank.d162.s5.p4	single doses of either cholestyramine or drug resins bind the drug and reduce its absorption from the gastrointestinal tract by up to and percent respectively 	DDI-mechanism
DDI-DrugBank.d480.s4.p0	given the primary cns effects of drug caution is advised in using it concomitantly with other cns active drugs or drug 	DDI-effect
DDI-DrugBank.d309.s0.p1	additive cns depression may occur when drug are administered concomitantly with other cns depressants including drug tranquilizers and alcohol 	DDI-effect
DDI-DrugBank.d339.s2.p1	drug and anticoagulants increased prothrombin time with or without clinical bleeding has been reported when drug is administered concomitantly 	DDI-effect
DDI-DrugBank.d413.s18.p5	cytotoxic agents enhanced bone marrow suppression by cyclophosphamide and other drug has been reported among patients with neoplastic disease except leukemia in the presence of drug 	DDI-effect
DDI-DrugBank.d315.s1.p0	therefore if drug is administered with drug the clinician should be alert to the possibility of increases in digoxin levels 	DDI-mechanism
DDI-DrugBank.d223.s9.p0	the extent to which drug drug interactions may problems depend on the degree of inhibition and the pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d223.s9.p0	the extent to which and drug interactions may pose clinical problems will depend on the degree of inhibition drug the pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d223.s9.p0	the extent to which drug drug interactions may pose along clinical problems will depend on the degree calculate of inhibition and the pharmacokinetics of the ssri involved	DDI-int
DDI-DrugBank.d223.s9.p0	the extent to which drug drug interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ssri involved 	DDI-int
DDI-DrugBank.d333.s6.p2	although clinical studies have not been performed based on the involvement of the cytochrome p a family in clonazepam metabolism inhibitors of this enzyme system notably oral drug should be used cautiously in patients receiving drug 	DDI-advise
DDI-DrugBank.d291.s3.p4	the action of sulphonylureas and drug may be enhanced by bezalip or drug 	DDI-effect
DDI-DrugBank.d81.s14.p3	fentanyl anesthesia severe hypotension has been reported during drug anesthesia with concomitant use of a drug and a calcium channel blocker 	DDI-effect
DDI-DrugBank.d314.s18.p12	hepatic enzyme inducers inhibitors and substrates drugs which induce cytochrome p a cyp a enzyme activity e g barbiturates phenytoin carbamazepine drug may enhance the metabolism of drug and require that the dosage of the corticosteroid be increased 	DDI-mechanism
DDI-DrugBank.d241.s0.p1	additional reductions in blood pressure may occur when drug is administered with diuretics drug or other vasodilators 	DDI-effect
DDI-DrugBank.d522.s24.p9	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine bromocriptine astemizole alfentanil disopyramide phenytoin hexobarbital valproate carbamazepine and drug	DDI-int
DDI-DrugBank.d522.s24.p9	other do drugs drug interactions have been reported with incidental administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and drug	DDI-int
DDI-DrugBank.d522.s24.p9	other interactions have been with concomitant administration of drug and other medications including hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and drug	DDI-int
DDI-DrugBank.d522.s24.p9	other drugs drug interactions have been reported with concomitant administration of drug and other medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole and drug 	DDI-int
DDI-DrugBank.d263.s16.p0	death due to fulminant pancreatitis possibly related to intravenous drug and drug has been reported 	DDI-effect
DDI-DrugBank.d382.s9.p11	corticosteroids dexamethasone drug when given as a regimen of mg with drug coadministered orally as mg on day and aprepitant when given as mg day with dexamethasone coadministered orally as mg on days through increased the auc of dexamethasone a cyp a substrate by fold on days and 	DDI-mechanism
DDI-DrugBank.d330.s2.p0	oral drug inhibits the gastrointestinal absorption of drug oral vitamin b methotrexate and fluorouracil 	DDI-mechanism
DDI-DrugBank.d338.s4.p4	while no in vivo drug drug interaction studies were conducted between drug and inducers of cyp a compounds that are potent cyp a inducers such as carbamazepine phenytoin rifampin and barbiturates would be expected to decrease drug concentrations 	DDI-mechanism
DDI-DrugBank.d380.s6.p1	drug and suboxone should be prescribed with caution to patients on drug or other drugs that act on the central nervous system regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse 	DDI-advise
DDI-DrugBank.d459.s0.p2	the daily dose of drug should not exceed mg when coadministered with potent cyp a inhibitors e g ketoconazole itraconazole drug nelfinavir clarithromycin and nefazadone 	DDI-advise
DDI-DrugBank.d322.s0.p4	amantadine drug and maois may increase anticholinergic effect of drug 	DDI-effect
DDI-DrugBank.d3.s12.p5	the effect of toradol on plasma lithium has not been studied but cases of increased drug plasma levels during drug therapy have been reported 	DDI-mechanism
DDI-DrugBank.d559.s1.p21	butalbital acetaminophen and drug may enhance the effects of other narcotic analgesics alcohol general anesthetics tranquilizers such as drug sedative hypnotics or other cns depressants causing increased cns depression 	DDI-effect
DDI-DrugBank.d463.s1.p2	there is one report suggesting that the concomitant use of trazodone hydrochloride drug and drug may have caused to fold elevations on sgpt alt in a few patients 	DDI-effect
DDI-DrugBank.d224.s1.p1	although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug ophthalmic solution the possibility of an additive or potentiating effect with cns depressants drug barbiturates opiates sedatives anesthetics should be considered 	DDI-advise
DDI-DrugBank.d476.s1.p1	patients receiving catecholamine depleting drugs such as drug or guanethidine should be closely monitored because the added beta adrenergic blocking action of drug may produce excessive reduction of sympathetic activity 	DDI-effect
DDI-DrugBank.d568.s1.p14	alcohol although lexapro did not potentiate the cognitive and motor effects of alcohol in a clinical trial as with other psychotropic medications the use of drug by patients taking drug is not recommended 	DDI-advise
DDI-DrugBank.d253.s1.p0	drug should be withdrawn at least hours before conducting an drug mediated stress test 	DDI-advise
DDI-DrugBank.d521.s1.p5	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate drug others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d270.s39.p1	a dose increase of drug ritonavir to mg twice daily with food isrecommended in combination with drug 	DDI-advise
DDI-DrugBank.d22.s0.p0	drug may decrease the amount of drug lanoxin lanoxicaps that gets absorbed into your body 	DDI-mechanism
DDI-DrugBank.d78.s10.p5	however because some quinolones have been reported to enhance the effects of warfarin or its derivatives prothrombin time or other suitable anticoagulation test should be monitored closely if a drug is administered with drug or its derivatives 	DDI-advise
DDI-DrugBank.d54.s14.p2	therefore patients without a functioning drug gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen containing oral drug are given 	DDI-advise
DDI-DrugBank.d356.s5.p0	therefore when drug and drug are used concomitantly the patient should be observed closely to determine if the desired effect of the diuretic is obtained 	DDI-advise
DDI-DrugBank.d123.s8.p11	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or drug antacids sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d227.s0.p0	drug potentiates the muscle relaxant effect of all drug most notably nondepolarizing muscle relaxants and mac minimum alveolar concentration is reduced by concomitant administration of n o 	DDI-effect
DDI-DrugBank.d8.s0.p2	both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug is administered in combination with other cns depressants such as barbiturates drug opioids or inhalation general anesthetics 	DDI-effect
DDI-DrugBank.d53.s7.p11	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral drug trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d220.s5.p1	concomitant administration of drug and other related compounds eg quinine drug and chloroquine may produce electrocardiographic abnormalities and increase the risk of convulsions 	DDI-effect
DDI-MedLine.d12.s2.p2	although neither drug nor retinyl acetate affected the proliferation of prostatic epithelium in rpmi containing transferrin alone they modify the mitogenic effect of drug and insulin 	DDI-effect
DDI-DrugBank.d521.s1.p2	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as drug trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d309.s0.p3	additive cns depression may occur when drug are administered concomitantly with other cns depressants including barbiturates tranquilizers and drug 	DDI-effect
DDI-DrugBank.d415.s2.p4	aspirin animal studies wshow that drug given with nonsteroidal anti inflammatory agents including drug yields a net decrease in anti inflammatory activity with lowered blood levels of the non aspirin drug 	DDI-effect
DDI-DrugBank.d217.s5.p4	quinolones including drug may enhance the effects of oral anticoagulants including drug or its derivatives or similar agents 	DDI-effect
DDI-DrugBank.d178.s0.p0	the hypoglycemic action of drug may be potentiated by certain drugs including drug and other drugs that are highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors and beta adrenergic blocking agents 	DDI-effect
DDI-DrugBank.d521.s1.p0	before taking drug tell your doctor if you are taking any of the following medicines drug or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or bismuth subsalicylate pepto bismol 	DDI-advise
DDI-DrugBank.d509.s16.p2	aripiprazole dose should be reduced to one half of its normal dose when concomitant administration of drug with drug occurs 	DDI-advise
DDI-DrugBank.d53.s7.p7	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir drug rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d450.s6.p20	antacids kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs and drug may interfere with intestinal drug absorption resulting in unexpectedly low serum concentrations 	DDI-mechanism
DDI-DrugBank.d499.s22.p4	methotrexate drug like other nsaids may cause changes in the elimination of drug leading to elevated serum levels of the drug and increased toxicity 	DDI-mechanism
DDI-DrugBank.d132.s5.p3	hydrochlorothiazide in normal volunteers concomitant administration of drug and drug resulted in significantly increased plasma levels of hydrochlorothiazide 	DDI-mechanism
DDI-DrugBank.d40.s10.p17	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates drug sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d150.s1.p1	drug may enhance the effects of alcohol drug and other cns depressants 	DDI-effect
DDI-DrugBank.d124.s26.p30	although specific studies have not been performed coadministration with drugs that are mainly metabolized by cyp a eg calcium channel blockers drug disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam and triazolam may have elevated plasma concentrations when coadministered with drug 	DDI-mechanism
DDI-DrugBank.d18.s1.p11	injection lorazepam injection like other injectable drug produces depression of the central nervous system when administered with ethyl alcohol phenothiazines barbiturates drug and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d17.s25.p1	in some patients the drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d106.s3.p0	coadministration of drug with mg drug tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels 	DDI-mechanism
DDI-DrugBank.d324.s29.p0	concomitant administration of drug mg and drug mg produced an increase in the mean cmax and auc of zaleplon 	DDI-mechanism
DDI-DrugBank.d48.s15.p54	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride drug fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d566.s0.p11	drug resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone warfarin thiazide diuretics acidic or propranolol basic as well as tetracycline penicillin g phenobarbital thyroid and thyroxine preparations estrogens and progestins and drug 	DDI-mechanism
DDI-DrugBank.d338.s4.p3	while no in vivo drug drug interaction studies were conducted between drug and inducers of cyp a compounds that are potent cyp a inducers such as carbamazepine phenytoin rifampin and drug would be expected to decrease estazolam concentrations 	DDI-mechanism
DDI-MedLine.d51.s4.p0	however the antagonism of the drug induced anxiogenic effects by drug was only observed in the time spent in the light zone and dpcpx induced anxiogenic effects were neither reversed by cgs nor by cpa 	DDI-effect
DDI-DrugBank.d565.s41.p0	coadministration of drug with drug lowered the diltiazem plasma concentrations to undetectable levels 	DDI-mechanism
DDI-DrugBank.d5.s22.p1	drugs that lower seizure threshold concurrent administration of drug and agents e g antipsychotics other drug theophylline systemic steroids etc that lower seizure threshold should be undertaken only with extreme caution 	DDI-advise
DDI-DrugBank.d72.s3.p0	since the pharmacokinetics of drug were studied in patients treated with drug the clearance of busulfex at the recommended dose may be lower and exposure auc higher in patients not treated with phenytoin 	DDI-mechanism
DDI-DrugBank.d123.s19.p4	warfarin drug have been reported to enhance the effects of the oral anticoagulant drug or its derivatives 	DDI-effect
DDI-DrugBank.d123.s8.p3	multivalent cation containing products concurrent administration of a drug including ciprofloxacin with multivalent cation containing products such as magnesium or aluminum drug sucralfate videx chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d284.s4.p5	the ecg changes and or hypokalemia that may result from the administration of non potassium sparing diuretics such as drug can be acutely worsened by drug especially when the recommended dose of the beta agonist is exceeded 	DDI-effect
DDI-DrugBank.d345.s11.p14	the absorption of tetracycline furosemide penicillin g hydrochlorothiazide and drug was significantly decreased when given simultaneously with drug 	DDI-mechanism
DDI-DrugBank.d464.s0.p3	drug in combination with other narcotic analgesics general anesthetics phenothiazines drug sedative hypnotics or other cns depressants including alcohol has additive depressant effects 	DDI-effect
DDI-DrugBank.d198.s10.p5	hiv protease inhibitors drug mg t i d co administered with drug mg resulted in a fold increase in vardenafil auc a fold increase in vardenafil cmax and a fold increase in vardenafil half life 	DDI-mechanism
DDI-DrugBank.d347.s7.p43	magnesium and or aluminum containing antacids products containing ferrous sulfate iron multivitamin preparations containing zinc or other metal cations or drug didanosine chewable buffered tablets or the pediatric powder for oral solution should not be taken within hours before or hours after drug 	DDI-advise
DDI-DrugBank.d269.s1.p17	poor metabolizers of debrisoquin interactions of carvedilol with strong inhibitors of cyp d such as quinidine drug paroxetine and propafenone have not been studied but these drugs would be expected to increase blood levels of the r enantiomer of drug 	DDI-effect
DDI-DrugBank.d260.s3.p5	nephrotoxic agents concomitant administration of drug and agents with nephrotoxic potential e g intravenous aminoglycosides e g tobramycin gentamicin and amikacin amphotericin b drug intravenous pentamidine vancomycin and non steroidal anti inflammatory agents is contraindicated 	DDI-advise
DDI-DrugBank.d228.s2.p1	reciprocal interactions may occur with concomitant use of drug and drugs that increase or inhibit the cytochrome p system e g phenytoin drug cimetidine ketoconazole though this has not been studied	DDI-mechanism
DDI-DrugBank.d522.s7.p2	the mean qt c interval msec was with terfenadine alone and with drug plus drug 	DDI-effect
DDI-DrugBank.d521.s1.p10	before taking drug tell your doctor if you are taking any of the following medicines aspirin or another salicylate such as magnesium choline salicylate trilisate salsalate disalcid others choline salicylate arthropan magnesium salicylate magan or drug pepto bismol 	DDI-advise
DDI-DrugBank.d150.s1.p0	drug may enhance the effects of drug barbiturates and other cns depressants 	DDI-effect
DDI-DrugBank.d423.s4.p5	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of selective serotonin reuptake inhibitors drug and agents for migraine therapy such as imitrex drug and dihydroergotamine 	DDI-effect
DDI-DrugBank.d5.s17.p14	therefore co administration of drug with drugs that are metabolized by cyp d isoenzyme including certain antidepressants e g nortriptyline imipramine desipramine paroxetine fluoxetine sertraline antipsychotics e g haloperidol risperidone thioridazine beta blockers e g metoprolol and type c antiarrhythmics e g drug flecainide should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication 	DDI-advise
DDI-DrugBank.d358.s1.p1	pharmacokinetic studies have demonstrated that drug and erythromycin significantly increased the systemic exposure of drug and or its major metabolites 	DDI-mechanism
DDI-DrugBank.d88.s3.p4	coumarin anticoagulants altered coagulation parameters and or bleeding have been reported in patients taking drug concomitantly with drug such as warfarin and phenprocoumon 	DDI-effect
DDI-DrugBank.d171.s0.p1	drug apparently through an effect on certain microsomal enzyme systems has been reported to reduce the hepatic metabolism of warfarin type anticoagulants drug propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline and metronidazole thereby delaying elimination and increasing blood levels of these drugs 	DDI-mechanism
DDI-DrugBank.d115.s0.p14	drugs that may alter imatinib plasma concentrations drugs that may increase imatinib plasma concentrations caution is recommended when administering drug with inhibitors of the cyp a family e g ketoconazole itraconazole erythromycin drug 	DDI-advise
DDI-DrugBank.d487.s7.p0	the effect of drug on oral drug is variable 	DDI-effect
DDI-DrugBank.d332.s0.p1	administration of drug to patients who are receiving sympathomimetic or drug may result in an additive pressor effect 	DDI-effect
DDI-DrugBank.d225.s13.p0	the mean percentage increase in the drug auc after drug administration was range to 	DDI-mechanism
DDI-DrugBank.d320.s3.p2	although no clinical studies have been conducted it is likely that the metabolism of drug may be affected by the known cyp a inducers such as phenytoin phenobarbital drug cyp a inhibitors azole antimycotics e g ketoconazole 	DDI-mechanism
DDI-DrugBank.d53.s1.p0	co administration of drug at steady state with a single dose of drug x mg tablets results in increased azithromycin serum concentrations 	DDI-effect
DDI-DrugBank.d5.s8.p2	while not systematically studied certain drugs may induce the metabolism of drug e g carbamazepine phenobarbital drug 	DDI-mechanism
DDI-DrugBank.d548.s9.p4	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline drug and imipramine phenothiazines and type c antiarrhythmics e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d103.s3.p10	monoamine oxidase inhibitors and tricyclic antidepressants drug should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or drug because the action of formoterol on the cardiovascular system may be potentiated by these agents 	DDI-advise
DDI-DrugBank.d170.s5.p14	central nervous system depressants the concomitant use of drug fentanyl transdermal system with other central nervous system depressants including but not limited to other drug sedatives hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d413.s15.p0	although a causal mechanism and a cause and effect relationship have not been established current evidence suggests that renal function should be monitored in patients on drug and drug even in the absence of renal failure and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected 	DDI-advise
DDI-DrugBank.d53.s7.p0	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of drug carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d357.s0.p25	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the ht antagonist class including for example drug granisetron dolasetron palonosetron and alosetron is contraindicated 	DDI-advise
DDI-DrugBank.d171.s4.p0	however a crossover study in healthy subjects receiving either drug mg q i d or mg h s concomitantly with a mg b i d dosage of drug theo dur key pharmaceuticals inc demonstrated less alteration in steady state theophylline peak serum levels with the mg h s regimen particularly in subjects aged years and older 	DDI-mechanism
DDI-DrugBank.d313.s3.p3	drug clonidine lithium salts and alcohol may either potentiate or weaken the blood glucose lowering effect of drug 	DDI-effect
DDI-DrugBank.d440.s1.p6	products containing calcium and other multivalent cations such as drug magnesium iron are likely to interfere with absorption of drug 	DDI-mechanism
DDI-DrugBank.d372.s2.p1	drug diminishes the effect of coumarin and drug 	DDI-effect
DDI-DrugBank.d288.s11.p2	hypersensitivity reactions patients with a history of severe hypersensitivity reactions to products containing cremophor el eg cyclosporin for injection concentrate and drug for injection concentrate should not be treated with drug 	DDI-advise
DDI-DrugBank.d488.s2.p32	platelet inhibitors drugs such as acetylsalicylic acid dextran phenylbutazone ibuprofen drug dipyridamole hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d310.s1.p0	in europe drug was observed to occasionally intensify the effect of drug taken concomitantly by patients suffering from hypertension 	DDI-effect
DDI-MedLine.d113.s3.p1	in addition to this pharmacological interaction this report describes a novel chemical reaction between drug a benzodiazepine and drug under acidic conditions similar to those found in vivo resulting in a ethoxylated product 	DDI-mechanism
DDI-DrugBank.d291.s11.p3	perhexiline hydrogen maleate or drug with hepatotoxic potential must not be administered together with drug or bezalip retard 	DDI-advise
DDI-DrugBank.d18.s1.p3	injection drug injection like other injectable benzodiazepines produces depression of the central nervous system when administered with ethyl alcohol phenothiazines drug mao inhibitors and other antidepressants when scopolamine is used concomitantly with injectable lorazepam an increased incidence of sedation hallucinations and irrational behavior has been observed 	DDI-effect
DDI-DrugBank.d480.s30.p7	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines carbamazepine and type c antiarrhythmics e g propafenone flecainide and encainide or that inhibit this enzyme e g drug should be approached with caution 	DDI-advise
DDI-DrugBank.d372.s0.p0	drug accelerates the metabolism of drug 	DDI-mechanism
DDI-DrugBank.d359.s3.p1	presumably drug acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the drug and increased prothrombin proconvertin concentrations 	DDI-mechanism
DDI-DrugBank.d548.s9.p7	therefore co administration of drug with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index including certain antidepressants tricyclic antidepressants tcas such as nortriptyline amitriptyline and imipramine phenothiazines and drug e g propafenone flecainide should be approached with caution 	DDI-advise
DDI-DrugBank.d382.s23.p8	the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via cyp a drug triazolam should be considered when coadministering these agents with drug 	DDI-advise
DDI-DrugBank.d56.s0.p0	taking drug after drinking drug may worsen side effects and may cause severe hypotension and cardiovascular collapse 	DDI-effect
DDI-DrugBank.d60.s12.p19	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin drug lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d462.s0.p3	aminoglycosides the mixing of drug with an drug in vitro can result in substantial inactivation of the aminoglycoside 	DDI-effect
DDI-DrugBank.d59.s1.p0	the pressor effects of drug and other drug can combine to cause dangerous hypertension 	DDI-effect
DDI-MedLine.d67.s7.p0	drug used at doses of mg kg and mg kg decreased the antinociceptive effect of drug metamizol only in the tail flick test and indomethacin 	DDI-effect
DDI-DrugBank.d488.s6.p8	drugs decreasing heparin effect drug tetracyclines nicotine or antihistamines may partially counteract the anticoagulant action of drug 	DDI-effect
DDI-DrugBank.d356.s6.p0	since drug and drug including midamor may each be associated with increased serum potassium levels the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently 	DDI-effect
DDI-DrugBank.d458.s19.p2	when taken orally imidazole compounds like drug may enhance the anticoagulant effect of drug like drugs 	DDI-effect
DDI-DrugBank.d284.s12.p2	beta adrenergic receptor antagonists drug and drug may interfere with the effect of each other when administered concurrently 	DDI-effect
DDI-DrugBank.d446.s0.p9	dose may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene dose somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p9	drug may interact with antidepressants aspirin whitethorn barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene drug somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p9	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin tamoxifen dantrolene drug somatropin cyclosporine and warfarin	DDI-int
DDI-DrugBank.d446.s0.p9	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene drug somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d450.s2.p7	drug verapamil amiodarone propafenone indomethacin itraconazole alprazolam and spironolactone raise the serum drug concentration due to a reduction in clearance and or in volume of distribution of the drug with the implication that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d43.s4.p7	antacids concomitant administration of drug containing magnesium or aluminum with drug chewable dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the antacid components 	DDI-effect
DDI-DrugBank.d322.s1.p1	drug may decrease the effect of phenothiazines drug and ketoconazole 	DDI-effect
DDI-DrugBank.d411.s2.p9	levothyroxine sodium absorption the following agents may bind and decrease absorption of drug from the gastrointestinal tract aluminum hydoxide cholestyramine resin drug ferrous sulfate sodium polystyrene sulfonate soybean flour e g infant formula sucralfate 	DDI-mechanism
DDI-DrugBank.d488.s2.p20	platelet inhibitors drugs such as acetylsalicylic acid drug phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine and others that interfere with platelet aggregation reactions the main hemostatic defense of heparinized patients may induce bleeding and should be used with caution in patients receiving drug 	DDI-effect
DDI-DrugBank.d495.s7.p1	also due to the potential for additive effects such as bradycardia and av block caution is warranted in patients receiving drug with agents known to affect sinus node function or av nodal conduction e g digitalis drug and beta blockers 	DDI-advise
DDI-DrugBank.d29.s12.p1	therefore drug may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability eg ketoconazole drug salts and digoxin 	DDI-mechanism
DDI-DrugBank.d368.s0.p1	drug modifies phenytoin metabolism with increased serum levels of drug 	DDI-mechanism
DDI-DrugBank.d357.s0.p26	ht antagonists based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron the concomitant use of drug with drugs of the ht antagonist class including for example ondansetron drug dolasetron palonosetron and alosetron is contraindicated 	DDI-advise
DDI-DrugBank.d357.s0.p9	ht antagonists based on reports of profound hypotension and loss of consciousness when drug was administered with drug the concomitant use of apomorphine with drugs of the ht antagonist class including for example ondansetron granisetron dolasetron palonosetron and alosetron is contraindicated 	DDI-effect
DDI-DrugBank.d266.s0.p1	in vitro studies have shown drug can displace coumarin anticoagulants such as drug from their protein binding sites 	DDI-mechanism
DDI-DrugBank.d210.s22.p2	standard monitoring of methotrexate related toxicity should be continued if drug and drug are administered concomitantly 	DDI-advise
DDI-DrugBank.d454.s0.p1	drug may enhance the cns depressive effects of alcohol drug and other sedatives	DDI-effect
DDI-DrugBank.d254.s0.p11	other cns depressant drugs e g barbiturates drug opioids and general anesthetics have additive or potentiating effects with drug 	DDI-effect
DDI-DrugBank.d236.s8.p2	drug with desipramine or protriptyline and possibly other drug cause striking and sustained increases in the concentration of d amphetamine in the brain 	DDI-mechanism
DDI-DrugBank.d334.s8.p0	this interaction should be given consideration in patients taking drug concomitantly with drug 	DDI-advise
DDI-DrugBank.d188.s2.p1	however it adversely affected response duration suggesting that drug should not be administered with hexalen and or drug 	DDI-advise
DDI-DrugBank.d76.s11.p1	consequently it is recommended that drug not be used in combination with either terbinafine drug or cisapride 	DDI-advise
DDI-DrugBank.d428.s1.p0	concomitant use of drug with other cardioactive compounds that could cause heart failure e g drug requires close monitoring of cardiac function throughout treatment 	DDI-advise
DDI-DrugBank.d40.s10.p10	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine drug halothane isoniazid methylphenidate phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d459.s0.p4	the daily dose of drug should not exceed mg when coadministered with potent cyp a inhibitors e g ketoconazole itraconazole ritonavir nelfinavir drug and nefazadone 	DDI-advise
DDI-DrugBank.d502.s0.p0	drug should be used with caution in patients who are receiving a drug orally because of the potential for additive effects on systemic beta blockade 	DDI-advise
DDI-DrugBank.d480.s18.p0	although concomitant use of drug and drug is not recommended it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in clozapine plasma levels 	DDI-advise
DDI-DrugBank.d222.s2.p0	since drug are potentiated by the drug they should be used cautiously in the treatment of convulsions 	DDI-advise
DDI-MedLine.d113.s0.p0	acid catalyzed ethanolysis of drug in anhydrous and aqueous drug solutions 	DDI-mechanism
DDI-DrugBank.d216.s10.p2	drugs that induce cyp a rifampicin racemic drug exposure was decreased by concomitant useof drug a potent inducer of cyp a 	DDI-mechanism
DDI-DrugBank.d139.s5.p3	mineral oil concomitant intake of drug and drug may reduce the absorption of vitamin k 	DDI-mechanism
DDI-DrugBank.d484.s0.p29	drug interact with the following medications acetaminophen tylenol antibiotics such as tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors crixivan fortovase invirase kaletra drug viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p29	drug may interact with the sm following medications acetaminophen tylenol antibiotics such reciprocal ohm as vitamin a ampicillin and tetracycline anticonvulsants dilantin dose phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra drug viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st medication johns wort temazepam sodium thiopental theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p29	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and achromycin anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin lipitor atromid s atromid s cyclosporine neoral sandimmune hiv dose classified as protease inhibitors agenerase crixivan fortovase invirase kaletra drug nelfinavir morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p29	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra drug viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d291.s9.p6	when bezalip or drug is used concurrently with anion exchange resins e g drug an interval of at least hours should be maintained between the two medicines since the absorption of bezalip or bezalip retard is impaired	DDI-advise
DDI-DrugBank.d26.s0.p7	patients receiving other drug s general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants or other cns depressants including alcohol concomitantly with drug may exhibit an additive cns depression 	DDI-effect
DDI-DrugBank.d352.s3.p2	conversely drug may interfere with antihypertensive drugs i e guanethidine drug	DDI-int
DDI-DrugBank.d352.s3.p2	conversely drug may interfere drugs antihypertensive with i e guanethidine drug	DDI-int
DDI-DrugBank.d352.s3.p2	conversely drug may interfere with antihypertensive drugs i tocopherol guanethidine drug	DDI-int
DDI-DrugBank.d352.s3.p2	conversely drug may interfere with antihypertensive drugs i e guanethidine drug 	DDI-int
DDI-DrugBank.d340.s26.p0	therefore drug should be administered with food one hour after or more than two hours before drug 	DDI-advise
DDI-DrugBank.d503.s3.p0	avoid the concomitant use of drug and drug ultram 	DDI-advise
DDI-MedLine.d36.s2.p5	we report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross reactivity of drug with a toxicology screen for drug 	DDI-advise
DDI-DrugBank.d187.s2.p2	acetaminophen a report of severe drug toxicity was reported in a patient receiving drug 	DDI-effect
DDI-DrugBank.d322.s0.p2	drug tricyclic antidepressants and maois may increase anticholinergic effect of drug 	DDI-effect
DDI-DrugBank.d434.s38.p0	drug treatment resulted in a decrease in the drug auc but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol 	DDI-mechanism
DDI-DrugBank.d40.s10.p13	the most commonly occurring drug interactions are listed below drugs that may increase plasma drug concentrations include acute alcohol intake amiodarone chboramphenicol chlordiazepoxide cimetidine diazepam dicumarol disulfiram estrogens ethosuximide fluoxetine h antagonists halothane isoniazid drug phenothiazines phenylbutazone salicylates succinimides sulfonamides tolbutamide trazodone	DDI-mechanism
DDI-DrugBank.d466.s20.p1	drug should not be taken closely in time with aluminum and drug containing antacids 	DDI-advise
DDI-DrugBank.d458.s7.p0	human pharmacokinetics data indicate that oral drug potently inhibits the metabolism of drug resulting in a mean eight fold increase in auc of cisapride 	DDI-mechanism
DDI-DrugBank.d267.s5.p4	other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug include certain antibiotics e g aminoglycosides tetracyclines bacitracin drug lincomycin clindamycin colistin and sodium colistimethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d423.s0.p16	in patients receiving nonselective monoamine oxidase inhibitors maois e g drug in combination with serotoninergic agents e g drug fluvoxamine paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d94.s4.p6	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide azole antifungals cimetidine clarithromycin dalfopristin danazol drug diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d395.s22.p2	theophylline related adverse effects have occurred in patients when drug and drug were coadministered 	DDI-effect
DDI-DrugBank.d561.s12.p1	drug like other ace inhibitors has had less than additive effects with drug presumably because both drugs lower blood pressure by inhibiting parts of the renin angiotensin system	DDI-effect
DDI-DrugBank.d237.s6.p3	antidepressants in vitro data indicate that drug inhibits the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d75.s10.p0	it is known that cyp a is inhibited by several medicinal products including drug and such medicinal products could theoretically adversely influence the clearance of drug 	DDI-mechanism
DDI-DrugBank.d484.s0.p17	drug may interact with astramorph following medications acetaminophen tylenol antibiotics crixivan as ampicillin and tetracycline dur dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin drug clofibrate atromid the cyclosporine neoral sandimmune hiv drugs classified as st inhibitors agenerase such fortovase invirase kaletra norvir viracept morphine s kadian rifampin contin phenylbutazone prednisolone prelone rifadin ms protease johns wort temazepam theophylline theo anticonvulsants and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p17	dose may interact with the following medications acetaminophen tylenol antibiotics such as sk ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral itraconazole atorvastatin dose clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra ritonavir viracept morphia astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p17	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and stick with tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin drug clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra antibiotic drug norvir vitamin a viracept morphine astramorph kadian ms drug contin phenylbutazone prednisolone prelone rifadin sm rifampin st johns wort temazepam theophylline human immunodeficiency virus theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p17	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin drug clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d338.s1.p5	the action of the drug may be potentiated by anticonvulsants antihistamines alcohol barbiturates monoamine oxidase inhibitors drug phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d208.s0.p2	drug may with alcohol blood thinners drug allergy cold and sinus medicines diabetic drugs lithium like aleve or ibuprofen high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p2	drug may interact with alcohol blood thinners drug allergy cold thinner and sinus medicines diabetic drugs lithium norepinephrine nsaids medication like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p2	drug may interact with alcohol blood thinners drug allergy cold and sinus medicines diabetic drugs lithium noradrenaline nsaids like aleve or isobutylphenyl propionic acid and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p2	drug may interact with alcohol blood thinners drug allergy cold and sinus medicines diabetic drugs lithium norepinephrine nsaids like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d153.s0.p8	the administration of local anesthetic solutions containing epinephrine or drug to patients receiving monoamine oxidase inhibitors or drug may produce severe prolonged hypertension 	DDI-effect
DDI-MedLine.d97.s8.p0	among the risk factors studied two appear to increase the risk of are the prescription of drug to treat strongyloidiasis during the drug cure and the bad general clinical conditions of patients 	DDI-effect
DDI-DrugBank.d565.s42.p0	coadministration of drug with drug or any known cyp a inducer should be avoided when possible and alternative therapy considered 	DDI-advise
DDI-DrugBank.d60.s6.p10	isoflurane or enflurane administered with drug oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of drug and decrease the required infusion rate of nimbex 	DDI-effect
DDI-DrugBank.d568.s16.p4	sumatriptan there have been rare postmarketing reports describing patients with weakness hyperreflexia and incoordination following the use of a drug ssri and drug 	DDI-effect
DDI-DrugBank.d485.s32.p13	protease inhibitors amprenavir lopinavir drug and ritonavir have been shown to decrease plasma levels of drug 	DDI-mechanism
DDI-DrugBank.d340.s18.p6	saquinavir coadministration of drug using an experimental soft gelatin capsule formulation of saquinavir mg with drug resulted in an increase in nelfinavir plasma auc and a fold increase in saquinavir plasma a c 	DDI-mechanism
DDI-DrugBank.d43.s9.p2	in eight hiv infected patients the steady state auc of ciprofloxacin was decreased an average of ci when drug was administered hours prior to a marketed chewable dispersible tablet formulation of drug 	DDI-mechanism
DDI-DrugBank.d386.s26.p0	concurrent administration of drug and drug can produce clinically significant increases in the plasma levels of the tricyclic antidepressants 	DDI-mechanism
DDI-DrugBank.d208.s0.p4	drug may interact with alcohol blood thinners drugs drugs allergy cold and sinus lithium diabetic decongestant medicines drug nsaids like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p4	drug may interact with alcohol blood thinners decongestant drugs and sinus medicines drugs lithium drug nsaids like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p4	drug may interact with alcohol blood thinners roue decongestant drugs roue allergy cold and sinus medicines diabetic drugs lithium drug nsaids like aleve or ibuprofen and high blood pressure medications	DDI-int
DDI-DrugBank.d208.s0.p4	drug may interact with alcohol blood thinners decongestant drugs allergy cold and sinus medicines diabetic drugs lithium drug nsaids like aleve or ibuprofen and high blood pressure medications 	DDI-int
DDI-DrugBank.d308.s1.p0	therefore when drug are administered concomitantly with drug their dosage should be reduced 	DDI-advise
DDI-DrugBank.d328.s44.p0	coadministration of drug and drug increased the exposure of norethindrone and ethinyl estradiol by and respectively 	DDI-mechanism
DDI-DrugBank.d359.s4.p0	conversely the drug have been reported to increase the serum levels and prolong the serum half life of drug by inhibiting its metabolism 	DDI-mechanism
DDI-DrugBank.d213.s0.p1	drug or iodine excess may decrease the effect of drug and an iodine deficiency can increase the effect of carbimazole 	DDI-effect
DDI-DrugBank.d325.s10.p0	therefore extreme caution should be exercised when administering drug to patients receiving drug or halogenated hydrocarbon anesthetics 	DDI-advise
DDI-DrugBank.d386.s28.p0	there have been greater than two fold increases of previously stable plasma levels of drug when drug has been administered in combination with these agents 	DDI-mechanism
DDI-DrugBank.d488.s6.p13	drugs decreasing heparin effect digitalis tetracyclines drug or antihistamines may partially counteract the anticoagulant action of drug 	DDI-effect
DDI-DrugBank.d456.s1.p6	caution should be used when administering or taking drug with ketoconazole and other strong cyp a inhibitors such as but not limited to atazanavir clarithromycin indinavir itraconazole nefazodone drug ritonavir saquinavir telithromycin troleandomycin tao and voriconazole 	DDI-advise
DDI-DrugBank.d60.s6.p4	drug or enflurane administered with nitrous oxide oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of nimbex and decrease the required infusion rate of drug 	DDI-effect
DDI-DrugBank.d562.s7.p2	also concomitant administration of drug with products containing iron multivitamins containing drug or videx didanosine chewable buffered tablets or the pediatric powder for oral solution may result in low urine levels 	DDI-mechanism
DDI-DrugBank.d434.s25.p0	increasing the drug dose to mg day increased the steadystate drug cmin to micrograms ml 	DDI-mechanism
DDI-DrugBank.d389.s0.p3	drug may enhance the effects of tricyclic antidepressants barbiturates alcohol and other drug 	DDI-effect
DDI-DrugBank.d53.s7.p5	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz drug indinavir midazolam rifabutin sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d48.s15.p24	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil drug terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids ergotamine dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d153.s4.p2	phenothiazines and drug may reduce or reverse the pressor effect of drug 	DDI-effect
DDI-DrugBank.d448.s3.p9	the antihypertensive effects of methyldopa mecamylamine reserpine and drug may be reduced by drug 	DDI-effect
DDI-DrugBank.d231.s3.p0	patients receiving high doses of drug concomitantly with drug as in rheumatic disease may experience salicylate toxicity at lower doses because of competitive renal excretory sites 	DDI-effect
DDI-DrugBank.d568.s39.p7	concomitant administration with racemic citalopram citalopram since drug is the active isomer of racemic drug celexa the two agents should not be coadministered 	DDI-advise
DDI-DrugBank.d446.s0.p5	do drugs may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements do drugs corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p5	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements drug corticotropin dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p5	drug may interact with dose antidepressants aspirin barbiturates bromocriptine calcium supplements drug corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin	DDI-int
DDI-DrugBank.d446.s0.p5	drug may interact with antidepressants aspirin barbiturates bromocriptine calcium supplements drug corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen and warfarin 	DDI-int
DDI-DrugBank.d310.s3.p2	a study in eight healthy volunteers has shown a increase in mean peak nimodipine plasma concentrations and a increase in mean area under the curve after a one week course of drug at mg day and drug at mg day 	DDI-mechanism
DDI-DrugBank.d484.s0.p10	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal drug felbatol antifungals jaun gris peg nizoral itraconazole atorvastatin atorvastatin clofibrate atromid s cyclosporine neoral sandimmune human immunodeficiency virus drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifadin st johns wort restoril theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p10	drug may interact with fork the following medications acetaminophen toilet tylenol antibiotics such as ampicillin and phenytoin tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal drug felbatol jaun gris antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine separate neoral sandimmune hiv drugs classified fork as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p10	astramorph may interact with the agenerase medications acetaminophen tylenol drug such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal drug felbatol antifungals gris viracept nizoral neoral atorvastatin lipitor clofibrate atromid s cyclosporine sporanox sandimmune hiv drugs classified as protease inhibitors prelone crixivan fortovase invirase kaletra norvir peg morphine antibiotics kadian ms contin phenylbutazone prednisolone following rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p10	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal drug felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-MedLine.d56.s2.p0	in the presence of drug m drug m failed to cause the first contraction 	DDI-effect
DDI-DrugBank.d395.s1.p0	thus concomitant administration of drug and drug should be avoided 	DDI-advise
DDI-DrugBank.d495.s1.p1	drug may enhance the cns depressive effects of alcohol drug or other sedatives 	DDI-effect
DDI-DrugBank.d114.s9.p0	exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of drug and drug including crescentic iga glomerulonephritis oculo bulbar myasthenia gravis inflammatory arthritis thyroiditis bullous pemphigoid and stevens johnson syndrome 	DDI-effect
DDI-MedLine.d12.s7.p3	these results suggest that both drug and retinyl acetate and possibly other glucocorticoids and retinoids may regulate the proliferation of prostate epithelium by a dose dependent modification of the activity of drug and egf 	DDI-effect
DDI-DrugBank.d219.s15.p3	lithium drug have produced an elevation of plasma drug levels and a reduction in renal lithium clearance 	DDI-mechanism
DDI-DrugBank.d60.s12.p5	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin drug lincomycin clindamycin colistin and sodium colistemethate magnesium salts lithium local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d53.s7.p8	when used in therapeutic doses drug had a modest effect on the pharmacokinetics of atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam drug sildenafil theophylline intravenous and oral triazolam trimethoprim sulfamethoxazole or zidovudine 	DDI-mechanism
DDI-DrugBank.d428.s10.p0	drug increased the auc of drug by 	DDI-mechanism
DDI-DrugBank.d424.s4.p0	alternatives to drug should be considered during the course of pcp treatment with drug 	DDI-advise
DDI-DrugBank.d325.s14.p0	it is suggested that in patients receiving drug alternatives to drug should be used if anticonvulsant therapy is needed 	DDI-advise
DDI-DrugBank.d158.s18.p2	norepinephrine drug enhance the adrenergic effect of drug 	DDI-effect
DDI-DrugBank.d480.s30.p5	therefore co administration of drug with other drugs that are metabolized by this isozyme including antidepressants phenothiazines carbamazepine and type c antiarrhythmics e g propafenone drug and encainide or that inhibit this enzyme e g quinidine should be approached with caution 	DDI-advise
DDI-DrugBank.d400.s0.p4	aspirin as with other drug concomitant administration of ponstel and drug is not generally recommended because of the potential of increased adverse effects 	DDI-advise
DDI-DrugBank.d233.s0.p2	use with allopurinol the principal pathway for detoxification of drug is inhibited by drug 	DDI-mechanism
DDI-DrugBank.d537.s0.p11	drug may interact with acetaminophen e constant of gravitation panadol chloramphenicol e constant of gravitation chloromycetin local anesthetics e constant of gravitation ethyl aminobenzoate and lidocaine belem aminobenzoic acid paba containing preparations e constant of gravitation sunscreens and some multivitamins procainamide e constant of gravitation drug sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic addendum use of pancreatic addendum may give imitation test results	DDI-int
DDI-DrugBank.d537.s0.p11	drug may interact with acetaminophen e g chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba preparations e g sunscreens and some multivitamins procainamide e g sulfonamides sulfa medicines thiazide diuretics use of these during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may false test results	DDI-int
DDI-DrugBank.d537.s0.p11	drug may interact with acetaminophen e g acetaminophen tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic multivitamin acid paba containing preparations e g check sunscreens and some multivitamins procainamide e g drug sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic sulpha supplements use use of goods and services of pancreatic supplements may give false test results	DDI-int
DDI-DrugBank.d537.s0.p11	drug may interact with acetaminophen e g tylenol chloramphenicol e g chloromycetin local anesthetics e g benzocaine and lidocaine para aminobenzoic acid paba containing preparations e g sunscreens and some multivitamins procainamide e g drug sulfonamides sulfa medicines thiazide diuretics use of these medicines during the test period will affect the test results and pancreatic supplements use of pancreatic supplements may give false test results 	DDI-int
DDI-MedLine.d56.s5.p0	when drug was applied to the muscle in the presence of drug both first and second contractile responses to ptx were abolished 	DDI-effect
DDI-DrugBank.d415.s5.p5	methotrexate ibuprofen as well as other drug probably reduces the tubular secretion of drug based on in vitro studies in rabbit kidney slices 	DDI-mechanism
DDI-MedLine.d124.s1.p4	previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and drug when administered concomitantly with an intravenous opiate such as drug 	DDI-mechanism
DDI-DrugBank.d237.s7.p10	antifungals in vitro and or in vivo data indicate that fluconazole drug and oral ketoconazole markedly inhibit the metabolism of drug which can result in an increase in plasma cisapride levels and prolongation of the qt interval on the ecg 	DDI-mechanism
DDI-DrugBank.d149.s0.p1	possible drug interactions of or with succinylcholine drug with other drug	DDI-int
DDI-DrugBank.d149.s0.p1	possible drug fundamental interaction interactions of drug with succinylcholine or with other drug	DDI-int
DDI-DrugBank.d149.s0.p1	drug interactions of drug with succinylcholine or other drug	DDI-int
DDI-DrugBank.d149.s0.p1	possible drug interactions of drug with succinylcholine or with other drug 	DDI-int
DDI-DrugBank.d282.s0.p2	drug should not be administered concurrently with d antagonists such as phenothiazines butyrophenones drug or metoclopramide 	DDI-advise
DDI-DrugBank.d86.s0.p10	the concurrent use of two or more drugs with anticholinergic activity such as an antipsychotic drug eg chlorpromazine an drug eg trihexyphenidyl and or a drug eg amitriptyline commonly results in excessive anticholinergic effects including dry mouth and associated dental complications blurred vision and in patients exposed to high temperature and humidity hyperpyrexia 	DDI-effect
DDI-DrugBank.d219.s23.p0	short term pharmacokinetic studies have demonstrated that concomitant administration of drug and drug etodolac capsules and tablets results in reduced protein binding of warfarin but there was no change in the clearance of free warfarin 	DDI-mechanism
DDI-DrugBank.d162.s12.p5	non steroidal anti inflammatory drugs in some patients the administration of a drug can reduce the diuretic natriuretic and antihypertensive effects of loop drug 	DDI-effect
DDI-DrugBank.d5.s8.p1	while not systematically studied certain drugs may induce the metabolism of drug e g carbamazepine drug phenytoin 	DDI-mechanism
DDI-DrugBank.d170.s5.p25	central nervous system depressants the concomitant use of duragesic drug transdermal system with other central nervous system depressants including but not limited to other opioids drug hypnotics tranquilizers e g benzodiazepines general anesthetics phenothiazines skeletal muscle relaxants and alcohol may cause respiratory depression hypotension and profound sedation or potentially result in coma or death 	DDI-effect
DDI-DrugBank.d269.s1.p19	poor metabolizers of debrisoquin interactions of carvedilol with strong inhibitors of cyp d such as quinidine fluoxetine drug and propafenone have not been studied but these drugs would be expected to increase blood levels of the r enantiomer of drug 	DDI-effect
DDI-DrugBank.d443.s3.p3	drug phenylbutazone oxyphenbutazone and possibly dipyrone concomitant administration with drug may increase the risk of gastrointestinal ulceration 	DDI-effect
DDI-DrugBank.d444.s0.p0	the use of drug for injection in combination with drug is not recommended due to the risk of severe pulmonary toxicity 	DDI-advise
DDI-DrugBank.d76.s25.p0	accordingly drug and drug should not ordinarily be co administered 	DDI-advise
DDI-DrugBank.d176.s9.p25	antacids in a clinical pharmacology study coadministration of an antacid aluminum hydroxide drug and simethicone with drug reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone suggesting that antacids may impair absorption of fosinopril 	DDI-mechanism
DDI-DrugBank.d340.s6.p7	drugs that should not be coadministered with drug antiarrhythmics amiodarone quinidine antihistamines astemizole terfenadine antimigraine ergot derivatives drug rifampin benzodiazepines midazolam triazolam gi motility agents cisapride	DDI-advise
DDI-DrugBank.d176.s9.p30	antacids in a clinical pharmacology study coadministration of an antacid aluminum hydroxide magnesium hydroxide and drug with drug reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone suggesting that antacids may impair absorption of fosinopril 	DDI-mechanism
DDI-MedLine.d107.s9.p0	these results suggest that the hepatoxicity of drug in alcoholic beverages is enhanced by interaction with its congeners and drug 	DDI-effect
DDI-DrugBank.d135.s7.p2	ketoconazole in healthy subjects receiving drug a cyp a inhibitor at mg twice daily for days systemic exposure auc to drug was increased to approximately fold of control and half life increased to fold of control 	DDI-mechanism
DDI-DrugBank.d103.s4.p20	corticosteroids methylxanthines and diuretics concomitant treatment with xanthine derivatives steroids or drug may potentiate a possible hypokalemic effect of drug 	DDI-effect
DDI-DrugBank.d60.s12.p11	other drugs which may enhance the neuromuscular blocking action of drug such as nimbex include certain antibiotics e g aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin and sodium colistemethate magnesium salts drug local anesthetics procainamide and quinidine 	DDI-effect
DDI-DrugBank.d552.s0.p2	drug should be administered with caution to patients who are taking other psychoactive drugs or cns depressants including drug barbiturates and narcotic analgesics or to those with a history of psychiatric disorder including manic depressive illness and schizophrenia 	DDI-advise
DDI-DrugBank.d143.s24.p0	on administration of oral drug the need for drug therapy should be reviewed and the dose reduced by approximately or discontinued 	DDI-advise
DDI-DrugBank.d423.s0.p11	in patients receiving nonselective monoamine oxidase inhibitors drug e g selegiline hydrochloride in combination with serotoninergic agents e g fluoxetine drug paroxetine sertraline venlafaxine there have been reports of serious sometimes fatal reactions 	DDI-effect
DDI-DrugBank.d386.s23.p2	if drug is to be combined with other psychotropic agents such as tranquilizers or drug hypnotics careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines e g chlordiazepoxide or diazepam are additive 	DDI-effect
DDI-DrugBank.d249.s5.p4	patients who begin taking drug or who increase their diclofenac dose or any other nsaid while taking digoxin methotrexate or drug may develop toxicity characteristics for these drugs 	DDI-effect
DDI-DrugBank.d484.s0.p9	do drugs may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol do drugs topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune human immunodeficiency virus do drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra ritonavir viracept morphia astramorph kadian ms contin phenylbutazone pediapred prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p9	drug may interact with the following neoral acetaminophen tylenol antibiotics theo as ampicillin and tetracycline clofibrate dilantin phenobarbital tegretol drug sandimmune felbatol antifungals and peg nizoral sporanox atorvastatin lipitor c atromid s cyclosporine medications topamax hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline such dur gris vitamin anticonvulsants	DDI-int
DDI-DrugBank.d484.s0.p9	drug may lipitor interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol drug achromycin topamax felbatol phenytoin antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir principen viracept morphine astramorph kadian ms contin phenylbutazone prednisolone vitamin a prelone rifadin rifampin st johns wort temazepam theophylline theo dur drug and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p9	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol drug topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone prednisolone prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d368.s6.p0	drug may increase the effects of other drug 	DDI-effect
DDI-DrugBank.d359.s3.p0	presumably drug acts as a stimulator of drug metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin proconvertin concentrations 	DDI-mechanism
DDI-DrugBank.d395.s17.p4	antacids containing drug and magnesium hydroxide reduce the oral absorption of drug by 	DDI-mechanism
DDI-DrugBank.d228.s0.p0	oral doses of drug mg kg via alcohol dehydrogenase inhibition significantly reduced the rate of elimination of drug by approximately given to healthy volunteers in moderate doses 	DDI-mechanism
DDI-DrugBank.d43.s6.p3	ganciclovir administration of drug hours prior to or concurrent with oral drug was associated with a increase in the steady state auc of didanosine n 	DDI-mechanism
DDI-DrugBank.d382.s31.p0	consequently concomitant administration of drug with strong cyp a inhibitors e g drug itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir should be approached with caution 	DDI-advise
DDI-DrugBank.d413.s16.p8	ampicillin amoxicillin an increase in the frequency of skin rash has been reported among patients receiving drug or amoxicillin concurrently with drug compared to patients who are not receiving both drugs 	DDI-effect
DDI-DrugBank.d5.s22.p0	drugs that lower seizure threshold concurrent administration of drug and agents e g drug other antidepressants theophylline systemic steroids etc that lower seizure threshold should be undertaken only with extreme caution 	DDI-advise
DDI-DrugBank.d434.s22.p2	valproate drug causes an increase in steady state drug concentrations 	DDI-mechanism
DDI-DrugBank.d289.s19.p0	co administration of drug decreased the plasma concentrations of drug by approximately 	DDI-mechanism
DDI-DrugBank.d450.s3.p15	erythromycin and clarithromycin and possibly other macrolide antibiotics and drug may increase drug absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine so that digitalis intoxication may result 	DDI-mechanism
DDI-DrugBank.d249.s0.p9	aspirin concomitant administration of diclofenac and aspirin is not recommended because drug is displaced from its binding sites during the concomitant administration of drug resulting in lower plasma concentrations peak plasma levels and auc values 	DDI-mechanism
DDI-DrugBank.d299.s6.p17	selective serotonin reuptake inhibitors ssris drug e g fluoxetine fluvoxamine paroxetine sertraline have been rarely reported to cause weakness hyperreflexia and incoordination when coadministered with drug 	DDI-effect
DDI-MedLine.d124.s1.p3	previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and drug when administered concomitantly with an intravenous drug such as morphine 	DDI-mechanism
DDI-DrugBank.d94.s16.p4	additionally anti malarial drugs such as drug and mefloquine may antagonize the activity of drug 	DDI-effect
DDI-MedLine.d126.s7.p0	thus the results suggest that drug exposure of rats results in free radical mediated tissue damage as indicated by elevated cerebral and hepatic lipid peroxidation which was prevented by drug and vitamin e 	DDI-effect
DDI-DrugBank.d471.s1.p0	administration of drug to hypoparathyroid patients who are concurrently being treated with drug may cause hypercalcemia 	DDI-effect
DDI-DrugBank.d40.s19.p2	drugs whose efficacy is impaired by drug include anticoagulants corticosteroids drug digitoxin doxycycline estrogens furosemide oral contraceptives rifampin quinidine theophylline vitamin d 	DDI-effect
DDI-DrugBank.d123.s8.p14	multivalent cation containing products concurrent administration of a quinolone including drug with multivalent cation containing products such as magnesium or aluminum antacids sucralfate drug chewable buffered tablets or pediatric powder or products containing calcium iron or zinc may substantially decrease the absorption of ciprofloxacin resulting in serum and urine levels considerably lower than desired 	DDI-mechanism
DDI-DrugBank.d443.s3.p6	pyrazolone derivatives drug oxyphenbutazone and possibly dipyrone concomitant administration with drug may increase the risk of gastrointestinal ulceration 	DDI-effect
DDI-MedLine.d104.s4.p0	the effects of drug were very strong and completely depressed the drug induced hyperlocomotion 	DDI-effect
DDI-DrugBank.d76.s24.p0	moreover as noted with drug the effect of drug may even be more pronounced when it is administered at higher doses 	DDI-effect
DDI-MedLine.d12.s4.p2	higher concentrations of dexamethasone m or drug x m enhance the mitogenic activity of drug 	DDI-effect
DDI-DrugBank.d395.s17.p5	antacids containing aluminum hydroxide and drug reduce the oral absorption of drug by 	DDI-mechanism
DDI-DrugBank.d372.s2.p0	drug diminishes the effect of drug and warfarin 	DDI-effect
DDI-DrugBank.d413.s22.p2	cyclosporin reports indicate that drug levels may be increased during concomitant treatment with drug for injection 	DDI-mechanism
DDI-DrugBank.d60.s6.p3	drug or enflurane administered with nitrous oxide oxygen to achieve mac minimum alveolar concentration may prolong the clinically effective duration of action of initial and maintenance doses of drug and decrease the required infusion rate of nimbex 	DDI-effect
DDI-DrugBank.d435.s2.p6	co medications that induce cyp a e g rifampicin drug carbamazepine phenobarbital or st john s wort may significantly decrease exposure to drug 	DDI-mechanism
DDI-DrugBank.d48.s1.p0	concomitant use of drug and drugs that inhibit cyp a eg drug itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin may increase exposure to dasatinib and should be avoided 	DDI-mechanism
DDI-DrugBank.d314.s23.p0	in addition drug alone can inhibit adrenal drug synthesis and may cause adrenal insufficiency during corticosteroid withdrawal 	DDI-effect
DDI-DrugBank.d567.s12.p8	amiodarone or verapamil the risk of myopathy rhabdomyolysis is increased when either drug or verapamil is used concomitantly with a closely related member of the drug see warnings myopathy rhabdomyolysis 	DDI-effect
DDI-DrugBank.d543.s7.p0	because drug may interfere with the absorption of drug simultaneous use of these drugs should be avoided 	DDI-mechanism
DDI-DrugBank.d338.s1.p1	the action of the drug may be potentiated by anticonvulsants drug alcohol barbiturates monoamine oxidase inhibitors narcotics phenothiazines psychotropic medications or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d270.s9.p1	the in vitro interaction between drug and the is agent drug antithrombotic complex	DDI-int
DDI-DrugBank.d270.s9.p1	the in vitro interaction between drug and the antithrombotic agent drug is complex	DDI-int
DDI-DrugBank.d270.s9.p1	the in vitro interaction fundamental interaction between drug and the antithrombotic agent drug is complex	DDI-int
DDI-DrugBank.d270.s9.p1	the in vitro interaction between drug and the antithrombotic agent drug is complex 	DDI-int
DDI-DrugBank.d314.s16.p3	ephedrine drug may enhance the metabolic clearance of drug resulting in decreased blood levels and lessened physiologic activity thus requiring an increase in corticosteroid dosage 	DDI-mechanism
DDI-DrugBank.d291.s3.p2	the action of drug and insulin may be enhanced by bezalip or drug 	DDI-effect
DDI-DrugBank.d423.s4.p3	a rare but serious constellation of symptoms termed serotonin syndrome has been reported with the concomitant use of drug ssris and agents for migraine therapy such as imitrex sumatriptan succinate and drug 	DDI-effect
DDI-DrugBank.d398.s2.p1	the use of drug may result in additive cns depressant effects when coadministered with alcohol drug psychotropics or other drugs that produce cns depression 	DDI-effect
DDI-DrugBank.d171.s2.p0	therefore close monitoring of prothrombin time is recommended and adjustment of the drug dose may be necessary when drug is administered concomitantly 	DDI-advise
DDI-DrugBank.d144.s0.p0	concomitant oral administration of drug a known inhibitor of cyp a activity in the liver and in the intestinal mucosa caused an eight fold increase of the systemic exposure to oral drug 	DDI-mechanism
DDI-DrugBank.d82.s33.p1	blunting of the antihypertensive effect of drug by non steroidal antiinflammatory drugs including drug has been reported 	DDI-effect
DDI-DrugBank.d565.s37.p0	in a ten subject study coadministration of drug mg bid with drug resulted in a times increase in mean lovastatin auc and cmax vs lovastatin alone 	DDI-mechanism
DDI-DrugBank.d322.s0.p5	amantadine tricyclic antidepressants and drug may increase anticholinergic effect of drug 	DDI-effect
DDI-DrugBank.d495.s1.p2	drug may enhance the cns depressive effects of alcohol barbiturates or other drug 	DDI-effect
DDI-DrugBank.d552.s0.p3	drug should be administered with caution to patients who are taking other psychoactive drugs or cns depressants including alcohol drug and narcotic analgesics or to those with a history of psychiatric disorder including manic depressive illness and schizophrenia 	DDI-advise
DDI-DrugBank.d94.s4.p1	agents that are cyp a inhibitors that have been found or are expected to increase plasma levels of drug are the following acetazolamide drug cimetidine clarithromycin dalfopristin danazol delavirdine diltiazem erythromycin fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate verapamil zileuton 	DDI-mechanism
DDI-DrugBank.d48.s15.p89	therefore cyp a substrates known to have a narrow therapeutic index such as alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus or ergot alkaloids drug dihydroergotamine should be administered with caution in patients receiving drug 	DDI-advise
DDI-DrugBank.d289.s11.p0	steady state drug plasma concentrations were to fold higher than in the absence of drug 	DDI-mechanism
DDI-DrugBank.d133.s0.p1	co administration of drug and aminoglycosides or other agents interfering with neuromuscular transmission e g drug should only be performed with caution as the effect of the toxin may be potentiated 	DDI-advise
DDI-DrugBank.d331.s7.p3	indomethacin drug blunts the increases in urine volume and sodium excretion seen during drug treatment and inhibits the bumetanide induced increase in plasma renin activity 	DDI-mechanism
DDI-DrugBank.d413.s6.p4	dicumarol it has been reported that drug prolongs the half life of the anticoagulant drug 	DDI-mechanism
DDI-DrugBank.d289.s27.p0	drug is also expected to reduce plasma concentrations of other drug that have significant metabolism by cyp a such as lovastatin and atorvastatin 	DDI-mechanism
DDI-DrugBank.d328.s13.p0	patients already stabilized on drug should be closely monitored for loss of symptom control with drug coadministration 	DDI-advise
DDI-DrugBank.d412.s9.p0	drug blunts the reflex tachycardia produced by drug without preventing its hypotensive effect 	DDI-effect
DDI-DrugBank.d231.s2.p0	drug should not be used concomitantly with drug because of the possibility of ototoxicity 	DDI-advise
DDI-MedLine.d87.s0.p0	drug a trans dimethyl hydroxyphenyl piperidine prevents gastrointestinal effects of intravenous drug without affecting analgesia 	DDI-effect
DDI-DrugBank.d129.s2.p0	concurrent administration of drug and drug may result in elevated serum levels of oxyphenbutazone 	DDI-mechanism
DDI-DrugBank.d415.s7.p0	caution should be used if drug is administered concomitantly with drug 	DDI-advise
DDI-DrugBank.d484.s0.p36	drug may interact with the rimactane following medications acetaminophen tylenol antibiotics such as indinavir ampicillin and tetracycline anticonvulsants sm dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease saquinavir inhibitors agenerase crixivan acetaminophen pediapred fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone drug prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p36	drug may interact with the following medications acetaminophen tylenol antibiotics such as polycillin and tetracycline anticonvulsants diphenylhydantoin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune human immunodeficiency virus drugs classified as protease inhibitors agenerase indinavir fortovase invirase kaletra ritonavir viracept morphine astramorph kadian ms contin phenylbutazone drug prelone rifadin rifampin st johns wort temazepam elixophyllin theo dur and vitamin c	DDI-int
DDI-DrugBank.d484.s0.p36	drug may with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg sporanox lipitor clofibrate s neoral sandimmune hiv drugs classified as protease crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone drug prelone rifadin rifampin st johns wort temazepam theophylline theo and vitamin	DDI-int
DDI-DrugBank.d484.s0.p36	drug may interact with the following medications acetaminophen tylenol antibiotics such as ampicillin and tetracycline anticonvulsants dilantin phenobarbital tegretol trileptal topamax felbatol antifungals gris peg nizoral sporanox atorvastatin lipitor clofibrate atromid s cyclosporine neoral sandimmune hiv drugs classified as protease inhibitors agenerase crixivan fortovase invirase kaletra norvir viracept morphine astramorph kadian ms contin phenylbutazone drug prelone rifadin rifampin st johns wort temazepam theophylline theo dur and vitamin c 	DDI-int
DDI-DrugBank.d531.s39.p0	when drug at an increased dose mg every hours was given with drug mg once daily the indinavir auc and cmin were decreased on average by and respectively compared to when indinavir mg every hours was given alone 	DDI-mechanism
DDI-DrugBank.d64.s90.p17	drugs that reduce the number of blood platelets by causing bone marrow depression such as antineoplastic agents or drugs which inhibit platelet function eg aspirin and other drug dipyridamole hydrochloroquine clofibrate dextran may increase the bleeding tendency produced by drug without altering prothrombin time determinations 	DDI-effect
